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Abstract 
Enzymes that are involved in the synthesis and processing of oligosaccharides, such as 
glycosidases, are important catalysts for the specific assembly of oligosaccharide structures 
on proteins. Design and preparation of selective inhibitors of these enzymes are of high 
interest as these molecules can be used to modulate cellular functions. Moreover, they may 
provide potential drugs in new therapeutic strategies. In particular, swainsonine (Swa), a 
natural inhibitor of Golgi α-mannosidase II, reduces certain tumors and hematological 
dysfunctions. Nevertheless, some side effects resulted in limitations for the development of 
this compound in medicinal treatments.  
 
Recently, our laboratory has developed a new combinatorial methodology for the disclosure 
of glycosidase inhibitors based on the dihydroxypyrrolidine scaffold found in Swa. This 
method allowed the preparation of a new family of selective and competitive α-mannosidase 
inhibitors with inhibitory activities (Ki values) ranging from 3 μM to 135 nM for the best 
congeners toward α-mannosidase from jack bean, a reliable model enzyme for mammalian 
Golgi α-mannosidase II.  
 
The aim of the present work was to design and synthesise optimized inhibitors of α-
mannosidases II based on a 2-aminomethyl-3,4-dihydroxypyrrolidine scaffold and to assess 
their potential as new anti cancer leads.  
 
In a first time, a structural study was carried out through the analysis of x-ray structures of the 
best inhibitors previously developed in our laboratory complexed to Golgi α-mannosidase II 
from Drosophila melanogaster (dGMII), which presents a high sequence identity with the 
human enzyme. The binding mode of these inhibitors could be thus established. This study 
combined with docking experiments allowed us to design inhibitors of α-mannosidase II, with 
improved efficacy. The best congener (3R,4R,5R)-3,4-dihydroxy-5-({[(1R)-2-hydroxy-1-
phenylethyl]amino}methyl)-1-methylpyrrolidin-2-one displayed an enhanced inhibitory 
potency against dGMII (IC50 = 0.5 μM vs 80 μM for the first generation inhibitor). 
Introduction of a polar substituent on the C(5) position of the pyrrolidine ring accounted for 
this improved activity as revealed by the x-ray structure of this new derivative complexed to 
dGMII which displayed additional interactions with active site residues.  
  
In a second time, these new α-mannosidase inhibitors have been evaluated as anti cancer 
agents and their effects were determined on human cancer cells from glioblastoma and 
melanoma, two tumors associated with a high proliferative and invasive potential, multiple 
resistance toward conventional chemotherapeutic agents, and poor prognosis. As these 
compounds were not able to inhibit cellular growth, probably due to a poor cellular uptake, 
derivatization of our inhibitors into more lipophilic esters, ethers and amides derivatives was 
envisaged. In particular, introduction of a 4-bromobenzoate moiety resulted in an 
improvement of cellular uptake, leading to a complete inhibition of cellular growth at 300 μM 
with inhibitors (2R)-2-({[(2R,3R,4S)-3,4-dihydroxypyrrolidin-2-yl]methyl}amino)-2-
phenylethyl 4-bromobenzoate and (2R)-2-({[(2R,3R,4R)-3,4-dihydroxy-1-methyl-5-
oxopyrrolidin-2-yl]methyl}amino)-2-phenylethyl 4-bromobenzoate. Under the same 
conditions, Swa didn’t provide any significant growth inhibition. Moreover, exposure of 
human fibroblasts, as model of healthy cells, to our lead derivatives revealed some selectivity 
toward tumoral cells. It was hypothesized that cellular esterases were able to hydrolyse the 
ester moiety and thus release the more hydrophilic parent inhibitors within the tumoral cells.  
 
Finally, in order to get more insights into the mode of action of our derivatives, their 
inhibitory activity on α-mannosidases from human glioblastoma extracts was determined and 
compared to the activity of Swa. The first generation inhibitor presented a moderate inhibitory 
potency on α-mannosidases whereas the optimized derivative displayed potent inhibitory 
activity on human α-mannosidases (IC50 = 50 μM decreased to 0.5 μM). Nevertheless, Swa 
presented higher potency than our new lead (IC50 = 10-50 nM). It was also determined by gel 
filtration that the cellular α-mannosidases targeted by our pyrrolidine based inhibitors 
displayed apparent molecular weight of about 120 kD. 
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Résumé 
Les enzymes impliquées dans la synthèse des oligosaccharides, telles que les glycosidases, 
sont des catalyseurs biologiques essentiels pour l’assemblage spécifique des structures 
oligosaccharidiques sur les protéines. L’élaboration et la préparation d’inhibiteurs sélectifs de 
ces enzymes présentent un grand intérêt dans la mesure où ces produits peuvent être utilisés 
pour moduler les fonctions cellulaires. De plus, ils pourraient être utilisés dans de nouvelles 
stratégies thérapeutiques. En particulier, la swainsonine (Swa), un inhibiteur naturel de l’α-
mannosidase II de l’appareil de Golgi, a révélé une aptitude à diminuer certaines tumeurs et 
des dysfonctions hématologiques. Malheureusement, les effets secondaires engendrés ont 
limité le développement de la Swa comme agent thérapeutique.   
 
Récemment, notre laboratoire a développé une nouvelle méthode combinatoire pour la 
découverte d’inhibiteurs de glycosidases dont le motif de base est une dihydroxypyrrolidine 
présente dans la Swa. Cette méthode a permis la préparation d’une nouvelle famille 
d’inhibiteurs, sélectifs et compétitifs, d’α-mannosidase avec des constantes d’inhibitions 
(mesure de Ki) qui s’échelonnent de 3 μM à 135 nM pour les meilleurs composés. L’enzyme 
utilisée pour ces mesures est l’α-mannosidase de jack bean, un modèle valable de l’α-
mannosidase de Golgi chez les mammifères.  
 
L’objectif de ce travail a consisté à élaborer et synthétiser de meilleurs inhibiteurs d’α-
mannosidases II basés sur un motif 2-aminomethyl-3,4-dihydroxypyrrolidine. Leur potentiel 
thérapeutique en tant qu’agents anti cancer a aussi été évalué.  
 
Dans un premier temps, une analyse structurale a été effectuée à partir de rayons-x obtenus 
avec les meilleurs inhibiteurs développés précédemment dans nos laboratoires complexés 
dans le site actif de l’α-mannosidase II, golgienne, de Drosophila melanogaster (dGMII) qui 
présente une séquence d’acide-aminés comparable à celle de l’enzyme humaine. Le mode de 
reconnaissance de ces inhibiteurs a ainsi pu être déterminé. Cette étude, combinée à des 
expériences de « docking », nous ont permis d’élaborer de nouveaux inhibiteurs d’α-
mannosidase II. Le meilleur composé, soit la (3R,4R,5R)-3,4-dihydroxy-5-({[(1R)-2-hydroxy-
1-phenylethyl]amino} methyl)-1-methyl pyrrolidin-2-one a montré une activité inhibitrice 
supérieure à celle obtenue avec le composé de la première génération (IC50 = 0.5 μM vs 80 
  
μM pour l’inhibiteur de la première génération sur la dGMII). L’introduction d’un 
groupement polaire sur la position C(5) de la pyrrolidine a contribué à l’amélioration de 
l’activité inhibitrice et a été démontrée par les rayons-x du nouvel inhibiteur dans le site actif 
de la dGMII qui ont ainsi révélés de nouvelles interactions avec les acide aminés de l’enzyme. 
 
Dans un deuxième temps, ces nouveaux inhibiteurs d’α-mannosidases ont été évalués en tant 
qu’agents anti cancéreux. Leurs effets ont été déterminés sur des cellules cancéreuses de 
glioblastome et de mélanome, deux tumeurs hautement invasives et présentant de multiples 
résistances aux agents thérapeutiques conventionnels ainsi qu’à un mauvais pronostic vital. 
Comme ces composés n’étaient pas capables de diminuer la croissance cellulaire de ces 
tumeurs, probablement à cause d’une mauvaise internalisation dans les cellules, il a été 
envisagé de dérivatiser ces composés en esters, éthers et amides qui présentent une plus 
grande lipophilie. L’introduction d’un motif 4-bromobenzyle a particulièrement amélioré 
l’internalisation des composés dans les cellules et a engendré une inhibition complète de la 
croissance cellulaire à 300 μM pour les composés (2R)-2-({[(2R,3R,4S)-3,4-di-
hydroxypyrrolidin-2-yl]methyl}amino)-2-phenylethyl 4-bromobenzoate et (2R)-2-
({[(2R,3R,4R)-3,4-dihydroxy-1-methyl-5-oxopyrrolidin-2-yl]methyl}amino)-2-phenylethyl 4-
bromo benzoate. Dans les mêmes conditions, la Swa n’a montré aucune diminution de la 
croissance cellulaire. De plus, des fibroblastes humains utilisés comme modèles de cellules 
saines ont été moins sensibles que les cellules tumorales révélant ainsi une certaine sélectivité 
de nos inhibiteurs pour les cellules cancéreuses. L’hypothèse a été proposée que des estérases 
cellulaires puissent hydrolyser l’ester et libérer les inhibiteurs hydrophiles correspondants 
dans les cellules tumorales.  
 
Finalement, pour obtenir de plus amples informations sur le mode d’action de nos dérivés, 
leur activité inhibitrice a été évaluée sur des α-mannosidases humaines d’extraits cellulaires 
de glioblastomes, puis comparée à celle de la Swa. L’inhibiteur de première génération a 
présenté une activité inhibitrice modeste alors que le dérivé optimisé a révélé une excellente 
inhibition des α-mannosidases humaines (IC50 = 50 μM améliorée à 0.5 μM). Cependant, la 
Swa demeure plus active que notre meilleur inhibiteur (IC50 = 10-50 nM). De plus, le poids 
moléculaire apparent des α-mannosidases cellulaires ciblées par nos inhibiteurs a été évalué, 
par filtration sur gel, à 120 kD.  
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1. Introduction 
1.1. Biological function of sugars 
Carbohydrates or saccharides (Greek sakcharon: “sugar”) are simple molecules present in all 
living species and display numerous properties such as the storage and transport of energy or 
act as structural components (cellulose in plants or chitin in insects). Additionally, 
carbohydrates and their derivatives play major roles in the activity of the immune system, 
fertilization, cell growth, pathogenesis, blood clotting, inflammation and interactions, 
adhesions.1  
 
Carbohydrates can be found as monosaccharides (monomeric units), oligosaccharides 
(composed of two or more monomeric units) and polysaccharides (composed of several 
hundreds or thousands of monomeric units). Monosaccharides are the simplest carbohydrates 
with a general formula (CH2O)n, with n = 3 to 7, called respectively trioses, tetroses, pentoses, 
hexoses or heptoses. Glucose (Glc, C6H12O6), an example of hexose, is one of the most 
common monosaccharide and as polysaccharide is used to store energy in plant cells (starch) 
or in animal cells (glycogen).  
 
Carbohydrates differ from proteins and nucleic acids in two important characteristics. They 
can be highly branched molecules and their monomeric units may be connected to one 
another by many different linkage types whereas proteins and nucleic acids are almost 
exclusively linear and they only display a single type of linkage. This complexity allows 
carbohydrates to provide almost unlimited variations in their structures. Although 
carbohydrates can be present without being attached to other molecules, the majority of them 
are attached to proteins, lipids or nucleosides. The terminology glycoproteins and glycolipids 
is used to reflect this conjugaison. Lectins are carbohydrate-binding proteins able to recognize 
glycoproteins and/or glycolipids and can consequently mediate many specific biological 
functions such as immune defense (mannose binding protein) and cell-cell adhesion 
(selectins).2 
                                                 
1 a) Alberts, B.; Bray, D.; Lewis, J.; Raff, M.; Roberts, K.; Watson, J. D. Molecular Biology of the Cell , 3rd 
edition, Garland Publishing, 1994. b) Rudd, P. M.; Elliott, T.; Cresswell, P.; Wilson, I. A.; Dwek, R. A. 
Carbohydrate and Glycobiology 2001, 291, 2370-2376. 
2 a) Dwek, R. A Chem Rev. 1996, 96, 683-720. b) Drickamer, K.; Taylor, M. E. Annu. Rev. Cell Biol. 1993, 9, 
237-264. c) Hart, G. W. Curr. Opin. Cell. Biol. 1992, 4, 1017-1023. 
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1.2. Biosynthesis of glycoproteins 
The cell is the smallest functional unity that all living organisms have in common. Delimited 
by a membrane, they contain as major constituents: a nucleus,3 where the genetic information 
is stored, mitochondria,4 to produce energy, the endoplasmic reticulum (ER), where proteins 
are synthesised and the Golgi apparatus for maturation of proteins. Cells are principally made 
of proteins, which constitute more than half of their dry weight. Proteins determine the shape 
and structure of the cell and serve as the main instruments of molecular recognition. They also 
ensure the capacity of cells to effect many kinds of chemical reactions that are needed for 
their growth and survival.  
 
To synthesize a protein, the DNA (deoxyribonucleic acid) strand, contained in the nucleus, is 
transformed into mRNA (messenger ribonucleic acid) through a process called transcription. 
The mRNA is then translocated to the cytosol where ribosomes can read it and bind the 
specific amino acids together to synthesize the protein (Scheme 1). Depending on the 
destination of the protein, the ribosomes are floating in the cytosol (for proteins intended to 
stay in the cell) or attached to the ER (for secreted and membrane proteins). In the first case, 
the protein is directly available in the cytosol after folding through hydrogen and disulphur 
bonds to obtain a functional three-dimensional protein. In the second case, the protein is 
synthesized in the ER and then carried out of the cell. In contrast to cytosolic proteins which 
are rarely glycosylated, most of the soluble and membrane-bound proteins that are synthesised 
in the ER are glycosylated.  
 
 
 
 
 
 
 
 
Scheme 1: Protein synthesis. 
                                                 
3 Felsenfeld, G. Sci. Am. 1985, 253, 58-67. 
4 Bereiter-Hahn, J. Int. Rev. Cytol. 1990, 122, 1-63. 
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1.2.1. Structure and diversity of N-linked and O-linked glycans 
The majority of cell surface and secreted proteins are glycosylated with carbohydrates 
covalently attached through either a nitrogen atom (via the amino group of an asparagine 
residue) or an oxygen atom (via the hydroxyl group of serine or threonine). Glycoproteins are 
thus classified as N-linked or O-linked depending on the nature of the glycosidic bond 
between the protein and the polysaccharide. With a molecular weight up to 3 kDa, the 
oligosaccharide groups in mammalian glycoproteins cover a large fraction of its surface and 
form flexible and hydrated branches that can extend 3 nm or further into the extracellular 
medium. This carbohydrate moiety may thus participate directly in recognition events but it 
may also modify the conformation5 and the stability6 of the protein. 
 
N-linked glycoproteins are widespread due to the importance of their role in biological 
functions. The advances in techniques for oligosaccharide structural analysis have made it 
possible to deduce the complete structure of hundreds of asparagine-linked oligosaccharides 
from a variety of plant and animal sources. When these structures are examined, they fall into 
three main categories7 termed high mannose, hybrid and complex (Scheme 2). They share the 
common structure: Manα1,3(Manα1,6) Manβ1,4 GlcNAcβ1,4 GlcNAc-Asn (boxed area in 
Scheme 2, Man (mannose), GlcNAc (N-acethylglucosamine), Asn (asparagine)). The high 
mannose-type oligosaccharide has typically two to six additional mannose residues linked to 
the pentasaccharide core. The complex-type glycans contain no other mannose residues 
except those of the core but are often multibranched with GlcNac, galactose (Gal) and sialic 
acid residues (SA). The hybrid-type molecules display features of both high-mannose and 
complex-type oligosaccharides: one or two mannose residues are linked to the Manα1,6 arm 
of the core (as in high mannose-type glycans) and usually one or two branches (as found in 
complex-type glycans) are linked to Manα1,3 of the core.  
                                                 
5 Varki, A. Glycobiology 1993, 3, 97-130. 
6 Opdenakker, G.; Rudd, P.M.; Ponting, C.P.; Dwek, R.A. FASEB J. 1993, 7, 1330-1337. 
7 Kornfeld, R.; Kornfeld, S. Annu. Rev. Biochem. 1985, 54, 631-664. 
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Scheme 2: Structures of the major types of asparagine-linked oligosaccharides. The boxed 
area encloses the pentasaccharide core common to all N-linked structures. 
 
1.2.2. Biosynthesis of N-linked oligosaccharides 
The biosynthesis of glycoproteins is a process shared by the ER and the Golgi apparatus. The 
sugars are added to the nascent protein, synthesized in the ER, as a core oligosaccharide unit, 
which is then extensively modified by removal and addition of sugar residues in the ER and 
the Golgi complex.  
 
The core oligosaccharides have a clearly defined structure composed of a branched unit made 
of three glucoses, nine mannoses and two N-acetyl-glucosamines (Glc3Man9GlcNAc2) 
(Scheme 3).8 This “14-saccharide core” unit is assembled as a membrane-bound 
dolicholpyrophosphate precursor by enzymes located on both sides of the ER membrane.9 
The completed core oligosaccharide is transferred by a flipping mechanism from the 
dolichylpyrophosphate carrier to a growing nascent polypeptide chain, and is coupled through 
a N-glycosidic bond to the side chain of an asparagine residue. The oligosaccharyltransferase 
recognizes a specific conformation of the glycosylation sequence (Asn-X-Ser/Thr) formed 
when the polypeptide chain emerges, where X can be any amino acid except proline.10 At this 
stage all glycoproteins bear the same carbohydrate structure in the ER. 
                                                 
8 a) Gahmberg, C. G.; Tolvanen, M. Trends Biochem. Sci. 1996, 21, 308-311. b) Helenius, A.; Aebi, M. Ann. 
Rev. Biochem. 2004, 73, 1019-1049. 
9 Burda, P.; Aebi, M. Biochim. Biophys. Acta 1999, 1426, 239-257. 
10 Knauer, R.; Lehle, L. Biochim. Biophys. Acta 1999, 1426, 259-273. 
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  “14-saccharide core” 
 
 
 
 
 
 
Scheme 3: Structure of the untrimmed N-glycosidic oligosaccharide Glc3Man9GlcNAc2-
protein. This “14-saccharide core” is composed of 14 saccharides: 3 glucoses (Glc), 9 
mannoses (Man) and 2 N-acetylglucosamines (GlcNac).  
 
Then a second phase of ordered trimming of selected monosaccharides by glycosidases and 
addition of others by glycosyltransferases begins in the ER and continues in the Golgi 
apparatus. This enzymatic pathway and the cellular location of the various reactions in that 
sequence are depicted in Scheme 4 and Scheme 5. This oligosaccharide processing is pre-
determined, protein selective and cell-specific, but does not request a template as is necessary 
for the synthesis of DNA, RNA or proteins.  
 
First, α-Glucosidase I (GlcI) and α-glucosidase II (GlcII) remove the external α1,2-Glc and 
α1,3-Glc, respectively, to produce the GlcMan9GlcNAc2-protein, a process associated with 
the calnexin/calreticulin (CNX/CRT) cycle,11 that facilitates the folding of newly-formed 
glycoproteins. Indeed, the monoglucosylated glycoprotein binds two ER-resident lectins: the 
membrane bound calnexin and its soluble homologue calreticulin. These proteins sequester 
the newly synthesized glycopeptide chains and serve as molecular chaperones, preventing 
aggregation and export of the incompletely folded chains from the ER.12 In many cases, they 
also protect the folding intermediates against premature degradation.  
                                                 
11 Parodi, J. Biochem J. 2000, 348, 1-13. 
12 Helenius, A.; Aebi, M. Science 2001, 291, 2364-2369. 
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To release the bound chains from calnexin or calreticulin, GlcII removes the remaining 
glucosyl residue to form the Man9GlcNAc2-protein. The free glycoprotein may subsequently 
be re-glucosylated by the UDP-Glc glycoprotein glucosyltransferase (UDP-Glc, Scheme 4) 
and thus be recognized once again by the CNX/CRT. Deglucosylation/reglucosylation cycles 
catalysed by the opposing activities of GlcII and UDP-Glc only stop when proper folding is 
achieved. Then, still in the ER, the processing enzyme ER α1,2-mannosidase I (ERMI) 
removes a single α1,2-Man to form the Man8GlcNAc2-protein (Scheme 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 4: Detailed glycoprotein processing pathway (first part). 
 
The newly synthesized glycoproteins are next transported to the cis Golgi cisternae by 
vesicles which are believed to bud from the ER and then fuse with the Golgi membrane.13 
This high mannose oligosaccharide can be further trimmed by Class I Golgi α1,2-
mannosidase (GMI) to yield a Man5GlcNAc2-protein.  
                                                 
13 Rothblatt, J.; Novick, P.; Stevens, T. Guidebook to the Secretory Pathway, Oxford University Press, 1994, 
107-109. 
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The Man5GlcNAc2-protein chains destined to become complex-type structures are further 
processed in the medial Golgi where a N-acetylglucosamine transferase I (GlcNAcTI) adds a 
GlcNAc residue from UDP-GlcNAc to the α1,3-Manβ1,4-Man branch (Scheme 5).14 This 
addition is a signal for Golgi α-mannosidase II (GMII) to remove two mannosyl residues 
(α1,3Man and α1,6Man) from the GlcNAcMan5GlcNAc2-protein to form the 
GlcNAcMan3GlcNAc2-protein.15 The prior addition of the single GlcNAc residue by 
GlcNAcTI is a prerequisite, since the activity toward Man5GlcNAc2-protein is reduced by 
more than 10-fold.16 During subsequent terminal glycosylation there is addition of new 
terminal sugars including GlcNAc, galactose, sialic acid and fucose to yield complex or 
hybrid types glycoproteins. 
The hydrolytic steps in the maturation of N-glycans had originally been proposed to occur 
exclusively by the stepwise removal of single sugar residues (called in this introduction 
“traditional pathway”). But an alternative pathway has been identified due to the discovery of 
a processing endomannosidase which is able of cleave an oligosaccharide (Glc3-1Man) from 
the Glc3-1Man9-4GlcNAc2-protein to yield Man8-3GlcNAc2-protein.17 The Man8GlcNAc2-
protein chain formed by the action of this Golgi endomannosidase on Glc1Man9GlcNAc2-
protein is distinct from the one detected in vivo following digestion of Man9GlcNAc2-protein 
by the ERMI (Scheme 4).18 In vitro, the Golgi endomannosidase has been shown to prefer the 
monoglucosylated oligosaccharides with the release of a α1,3-Glcα1,3-Man disaccharide,19 
but has the capacity to process di- and tri-glucosylated species with the excision of Glc2Man 
and Glc3Man, respectively.20 Afterwards, the Man8GlcNAc2-protein chain can further be 
trimmed by the GMI to yield the conventional Man5GlcNAc2-protein. 
                                                 
14 Harpaz, N.; Schachter, H. J. Biol. Chem. 1980, 255, 4894-4902. 
15 a) Tabas, I.; Kornfeld, S. J. Biol. Chem. 1978, 253, 7779-7786. b) Tulsiani, D. R. P.; Hubbar, S. C.; Robbins, 
P. W.; Touster, O. J. Biol. Chem. 1982, 257, 3660-3668. 
16 Moremen, K. W.; Trimble, R. B.; Herscovics, A. Glycobiology 1994, 4, 113-125. 
17 Lubas, W. A.; Spiro, R. G. J. Biol. Chem. 1988, 263, 3990-3998. 
18 Lubas, W. A.; Spiro, R. G. J. Biol. Chem. 1987, 262, 3775-3781. 
19 Fujimoto, K.; Kornfeld, R. J. Biol. Chem. 1991, 266, 3571-3578. 
20 Moore, S. E. H.; Spiro, R. G. J. Biol. Chem. 1990, 265, 13104-13112. 
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A second alternative route to the traditional pathway was discovered in GMII-null mice that 
developed a dyserythropoietic anemia. Cells from GMII-null mice, that lack the GMII 
activity, were found to accumulate hybrid and complex-type oligosaccharides. This finding 
indicates that complex oligosaccharides can be synthesized by a GMII-independent pathway, 
leading to the proposal of an alternative pathway and the prediction of a new α-mannosidase, 
designated α-mannosidase III (GMIII, Scheme 5). GMIII hydrolyzes two α-mannosyl 
residues in Man5GlcNAc2-protein and produces Man3GlcNAc2-protein which is further 
converted to the conventional GlcNAcMan3GlcNAc2-protein by GlcNAcTI.21 This new 
mannosidase might be identical to the mannosidase discovered by Bonay and Hughes in rat 
liver.22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 5: Detailed glycoprotein processing pathway (second part). 
 
 
                                                 
21 Chui, D.; Oh-Eda, M.; Liao, Y.-F.; Penneerselvam, K.; Lal, A.; Marek, K. W.; Freeze, H. H.; Moremen, K. 
W.; Fukuda, M. N.; Marth, J. D. Cell 1997, 90, 157-167. 
22 Bonay, P.; Hughes, C. R.; Eur. J. Biochem. 1991, 197, 229-238. 
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A third alternative route to the traditional pathway was discovered when Fukuda et al. 
screened human-genomic and cDNA libraries by cross-hybridization with human GMII 
cDNA. They identified an α-mannosidase IIx that they called GMX.23 This new enzyme 
composed of 1139 amino-acid residues presents 66% identity with the peptide sequence of 
GMII.24 In the presence of GMX, Man6GlcNAc2-protein was converted to the corresponding 
Man4GlcNAc2-protein after removal of α1,6-Man and α1,3-Man residues (Scheme 5).25 The 
proposed specificity of GMX is analogous to the action of GMII, which removes α1,6-Man 
and α1,3-Man residues from GlcNAcMan5GlcNAc2-protein. After removal of the two 
mannosyl residues by GMX, the substrate Man4GlcNAc2-protein was further converted to 
Man3GlcNAc2-protein by GMI, which is known to be a substrate for GlcNAcTI.26 
 
                                                 
23 Misago, M.; Liao, Y.-F.; Kudo, S.; Eto, S.; Mattei, M.-G.; Moremen, K. W.; Fukuda, M. N. Proc. Natl Acad. 
Sci. USA 1995, 92, 11766-11770. 
24 Ogawa, R.; Misago, M.; Fukuda, M. N.; Kudo, S.; Tsukada, J.; Morimoto, I.; Eto, S. Eur. J. Biochem. 1996, 
242, 446-453. 
25 Oh-eda, M.; Nakagawa, H.; Akama, T. O.; Lowitz, K.; Misago, M.; Moremen, K. W.; Fukuda, M. N. Eur. J. 
Biochem. 2001, 268, 1280-1288. 
26 Nilsson, T.; Warren, G. Curr. Opin. Cell Biol. 1994, 6, 517-521. 
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1.3. Glycosidases 
1.3.1. Introduction to enzymes 
Glycosidases play important roles in biological systems ranging from the degradation of 
polysaccharides to the manipulation of the structures of glycoconjugates at the surface of 
proteins. They are involved in biological processes such as the digestion, the biosynthesis of 
glycoproteins and the catabolism of glycoconjugates.27  
 
The glycosidic bond, between two glucosyl residues in cellulose or starch is on of the most 
stable linkage with a half-live for spontaneous hydrolysis being in the range of 5 million 
years. But hydrolysis carried out by enzyme is accomplished with rate constants up to 1000s-1, 
which make these enzymes some of the most efficient catalysts.28 
1.3.2. Mechanism for enzymatic hydrolysis of glycosides 
Basic mechanisms of the hydrolysis of interglycosidic bonds were proposed in 1953 by 
Kohsland.29 Indeed, hydrolysis of the glycosidic bond can occur with one of two possible 
stereochemical outcomes: inversion or retention of anomeric configuration.30 Both 
mechanisms involve oxocarbenium-ion like transition states and a pair of carboxylic acids in 
the active site of the enzyme.  
 
With inverting β-glycosidases, as described by Kohsland, hydrolysis proceeds via a single-
step mechanism in which the sugar anomeric centre is attacked by a water molecule that acts 
as a nucleophile (Scheme 6). This reaction is catalysed by two carboxylic acid moieties both 
present in the active site. Deprotonation of the water molecule by the carboxylate enhances its 
nucleophilicity and allow it to attack the anomeric position. The glycosidic bond is cleaved 
and released the alcohol which results in the inversion of the anomeric centre of the cleaved 
sugar.  
                                                 
27 de Melo, E. B.; da Silveira Gomes, A.; Carvalho, I. Tetrahedron 2006, 62, 10277-10302. 
28 Wolfenden, R.; Lu, X.; Young, G. J. Am. Chem. Soc. 1998, 120, 6814-6815. 
29 Koshland, D. E. Biol. Rev. 1953, 28, 416-436. 
30 a) Zechel, D. L.; Withers, S. G. Acc. Chem. Res 2000, 33, 11-18. b) Withers, S. G. Carb. Polymers 2001, 44, 
325-327. c) Sinnott, M. L. Chem. Rev. 1990, 90, 1171-1202. 
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Scheme 6: General mechanism of inverting β-glycosidases. 
 
In contrast, retaining β-glycosidases proceed via a double-step mechanism (Scheme 7). The 
first carboxylate attacks the anomeric position and cleaves the glycosidic bond with release of 
an alcohol. A water molecule then attacks the remaining sugar which is bond to the first 
carboxylic acid. This step is catalysed by the second carboxylic acid which deprotonates the 
water molecule so enhancing its nucleophilicity. The reaction affords the cleaved sugar 
without inversion of the anomeric center.31 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 7: General mechanism of retaining β-glycosidases. 
                                                 
31 Vasella, A.; Davies, G. J.; Böhm, M. Curr. Opin. Chem. Biol. 2002, 6, 619-629. 
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Retaining and inverting β-glycosidases differ mainly by the distance separating the two 
carboxylic groups of the active site. This distance is around 5 Å in retaining enzymes and 
around 10 Å in inverting enzymes. The greater span found in inverters is necessary to 
accommodate the nucleophilic water molecule.  
 
The hydrolysis processes have been more thoroughly studied for β-glycosidases. 
Nevertheless, it has been reported that α-glycosidases act through a similar pathway to β-
glycosidases.32 The mechanisms have been evidenced by the isolation of α-linked 
intermediates.33  
 
However, subtle differences, between α- and β-glycosidases seem to exist in the 
oxocarbenium ion character of the transition state.30a For β-glycosidases, the interactions 
involving the nucleophilic carboxyl oxygens, the anomeric center and the alcohol at C(2) 
position support delocalization of the positive charge on the anomeric carbon (Scheme 8B). 
On the other hand, for α-glycosidases, these interactions occur between the carboxyl oxygen, 
the endocyclic oxygen and the anomeric center resulting in the delocalization of the positive 
charge on the anomeric oxygen (Scheme 8A).34  
 
 
Scheme 8: Comparison of the transition states for A) α- and B) β- retaining glycosidases. 
 
                                                 
32 McCarter, J. D.; Withers, S. G J. Am. Chem. Soc. 1996, 118, 241-242. 
33 Uitdehaag, J. C. M.; Mosi, R.; Kalk, K. H.; van der Veen, B. A.; Dijkhuisen, L.; Withers, S. G.; Dijkstra, B. 
W. Nat. Struct. Biol. 1999, 6, 432-436. 
34 Heightman, T. D.; Vasella, A. T. Angew. Chem. Int. Ed. 1999, 38, 750-770. 
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1.3.3. Enzyme kinetics 
1.3.3.1. Michaelis-Menten kinetics 
Michaelis-Menten equation (Eq.1) describes the kinetics of many enzymes: 
 
  
[S])  (K
[S] Vmax   V
M +
⋅=        Eq.1 
where:  V =   velocity of the reaction 
Vmax =  maximum velocity  
[S] =   substrate concentration 
KM =  Michaelis-Menten constant 
 
Graphical analysis of the Michaelis-Menten equation presents the reaction rate (V) vs 
substrate concentration [S] and produces an hyperbolic rate plot (Scheme 9). 
 
 
 
 
 
 
 
Scheme 9: Plot of substrate concentration vs reaction velocity. 
 
 
At high substrate concentrations, the rate of the reaction reaches Vmax which reflects the fact 
that at these concentrations almost all of the enzyme molecules are bound to substrate and the 
rate is virtually independent of substrate. Vmax represents the highest velocity of the enzyme 
for the catalytic reaction. At lower substrate concentrations, the lower reaction velocities 
indicate that at any moment only a portion of the enzyme molecules are bound to the 
substrate. The Michaelis-Menten equation demonstrates that at the substrate concentration 
that produces exactly half of the maximum reaction rate (Vmax/2) the substrate concentration 
is numerically equal to KM. This characteristic value of the enzyme represents its affinity for 
the substrate. 
[S] 
V 
Vmax 
2
Vmax  
KM 
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Lineweaver and Burk introduced an analysis of enzyme kinetics (Eq.2) based on the 
following rearrangement of the Michaelis-Menten equation:  
 
  
Vmax
1  
[S]
1 
Vmax
K
  
V
1 M +⋅=       Eq. 2 
 
Plots of 1/V vs 1/[S] yield straight lines having a slope of KM/Vmax and intercepts the 
ordinate at 1/Vmax and the abscise at -1/KM (Scheme 10).  
 
 
 
 
 
 
Scheme 10: Lineweaver-Burk Plot.35 
 
1.3.3.2. Enzyme inhibitors 
Enzyme inhibitors fall into two broad classes: those causing irreversible inactivation of 
enzymes and those whose inhibitory effects can be reversed.  
 
Inhibitors of the first class usually cause an inactivating, covalent modification of the enzyme 
structure. The kinetic effect of irreversible inhibitors is to decrease the concentration of active 
enzyme. Irreversible inhibitors are usually considered to be poisons and are generally 
unsuitable for therapeutic purposes.  
 
Reversible inhibitors can be divided into three main categories: competitive inhibitors, 
uncompetitive inhibitors and non competitive inhibitors. Competitive inhibition occurs when 
both the substrate and the inhibitor compete for binding to the active site of the enzyme. 
Normally a competitive inhibitor bears some structural similarity to the substrate.  
                                                 
35 Dowd, J. E.; Riggs, D. S. J. Biol. Chem. 1965, 240, 863-869. 
1/[S] 
1/V 
Slope = 
Vmax
K M  Vmax
1  
MK
1 -  
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In the case of a competitive inhibitor, the equation of Michaelis-Menten becomes: 
 
  
[S]  
K
[I]1 K
[S] Vmax   V
i
M +⎟⎟⎠
⎞
⎜⎜⎝
⎛ +
⋅=       Eq.3 
where:  [I] =   inhibitor concentration 
Ki =   inhibition constant = [EI]
[I]  [E] ⋅  
[E]=   enzyme concentration 
[EI] =  complex: enzyme/inhibitor concentration 
 
The velocity equation differs from the usual Michaelis-Menten equation in that the KM term is 
multiplied by the factor ⎟⎟⎠
⎞
⎜⎜⎝
⎛ +
iK
[I]  1 . As [I] increases, KMapp increases. Thus, a competitive 
inhibitor acts only to increase the apparent KM for the substrate. The Vmax remains 
unchanged, but in the presence of a competitive inhibitor a much greater substrate 
concentration is required to attain any given fraction of Vmax.  
 
An expression for the relative velocity or fractional activity in the presence and absence of a 
competitive inhibitor can be derived:  
With  vi = velocity at a given [S] in the presence of inhibitor = 
[S]  
K
[I]   1 K
[S] Vmax 
i
M +⎟⎟⎠
⎞
⎜⎜⎝
⎛ +
⋅  
 vo = velocity at the same [S] in the absence of inhibitor = 
[S]  K
[S] Vmax 
M +
⋅  
Then 
vo
vi = the relative velocity (fractional activity) = 
[S]  
K
[I]   1 K
[S]  K
i
M
M
+⎟⎟⎠
⎞
⎜⎜⎝
⎛ +
+  
 
Relative velocity data are frequently expressed in terms of fractional inhibition (i) or percent 
inhibition (i% = 100 i):  
 i = fractional inhibition = 1 - 
vo
vi  = 
⎟⎟⎠
⎞
⎜⎜⎝
⎛ ++
M
i K
[S]  1 K  [I]
[I]   Eq. 4 
As predicted by equation 4, to obtain 50 % inhibition:  
 [I]0.5 = IC50 = i
M
K  
K
[S]  1 ⋅⎟⎟⎠
⎞
⎜⎜⎝
⎛ +       Eq. 5 
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The degree of inhibition (i) caused by a competitive inhibitor depends on [S], [I], KM, and Ki. 
An increase in [S] at constant [I] decreases the degree of inhibition. An increase in [I] at 
constant [S] increases the degree of inhibition. And the lower the value of Ki, the greater is 
the degree of inhibition at any given [S] and [I].  
 
IC50 is commonly used as a measure of drug effectiveness and represents the concentration of 
inhibitors required for 50% inhibition of the enzyme (Eq. 5). This value is obtained 
experimentally when measuring the percentage of the enzyme activity in function of various 
concentrations of the inhibitor.  
 
The velocity equation for competitive inhibition in reciprocal form is:  
 
  
Vmax
1  
[S]
1  
K
[I]  1  
Vmax
K
  
v
1
i
M +⋅⎟⎟⎠
⎞
⎜⎜⎝
⎛ +⋅=     Eq. 6 
 
Thus, the slope of the plot increases by the factor ⎟⎟⎠
⎞
⎜⎜⎝
⎛ +
iK
[I]  1  (which multiplied KM in the 
original equation), but the 1/V axis intercept remains 1/Vmax. For each inhibitor 
concentration, a new reciprocal plot can by drawn. As [I] increases, the inhibitor curves 
increase in slope pivoting counterclockwise about the point of intersection with the control 
curve (at 1/Vmax on the 1/V axis). As [I] increases, the intercept on the 1/[S] axis moves 
closer to the origin, that is, KMapp continually increases (Scheme 11A).  
 
The inhibition constant (Ki), referring to the dissociation constant between the inhibitor and 
the enzyme, can be calculated from the slope of any reciprocal plot or from any KMapp.  
  MMM K  [I] Ki
K
 K
app
+=       Eq. 7 
 
The behaviour of the curves obtained under these conditions will point to the mode of 
inhibition.36  
                                                 
36 a) Cheng, Y.-C.; Prusoff, W. H. Biochem. Pharmacol. 1973, 22, 3099-3108. b) Segel, I. H. Enzyme Kinetics, 
behavior and analysis of rapid equilibrium and steady-state enzyme systems, Wiley-Interscience Publication, 
1975. 
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A)       B) 
 
 
 
 
 
 
 
Scheme 11: Lineweaver-Burk plots of inhibited enzymes. A) Competitive inhibition. B) non 
competitive inhibition.  
 
 
Uncompetitive inhibition occurs when the inhibitor binds to a position different than the 
active site, which becomes available after the substrate has bound the enzyme, and blocks the 
formation of the products. Apparent Vmax and KM decrease.  
 
Finally, non competitive inhibition occurs when the inhibitor binds at a different place from 
the substrate binding site, causing a modification of the active site and such reduction in the 
catalytic rate. Vmax is decreased proportionally to inhibitor concentration and KM is unaltered 
since non competitive inhibitors do not interfere in the equilibration of the enzyme with the 
substrate (Scheme 11B).37 
 
                                                 
37 a) www.lsbu.ac.uk/biology/enztech/inhibition.html. b) Cortes, A.; Cascante, M.; Cardenas, M. L.; Cornish-
bowden, A. Biochem. J. 2001, 357, 263-268. 
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1.4. Glycosidases as therapeutic targets 
The post-translational glycosylation patterns of proteins in the various cellular compartments 
will determine not only the function, structure, physical and biochemical properties, but also 
the fate of a protein, such as retention in a determined cell compartment, secretion, 
degradation, insertion in the cell membranes or interactions with other molecules and binding 
to membrane receptor. Therefore, inhibition of the activity of selected enzymes involved in 
protein glycosylation, in particular in the latter phases of the biosynthesis process, may alter 
the function of the target protein and its role in important biological processes. Glycosylation 
pathways as drug targets have remained relatively little studied until very recently. 
Nevertheless, the specific inhibition of α-glucosidases and α-mannosidases involved in the 
trimming of glycoproteins represent promising therapeutic options.  
 
As presented in paragraph 1.2.2, the removal of the outer α1,2 glucose is achieved by 
glucosidase I and the two remaining α1,3 glucosyl residues are cleaved by glucosidase II. It is 
such of high interest to find selective inhibitors of these enzymes as they occur at the 
beginning of the N-glycosylation process.  
 
Mannosidases which play key roles in the processing of glycoproteins belong to classes I or 
II. They are genetically, structurally and functionally distinct and have different subcellular 
locations.38 In a general way, α1,2-mannosidases I, localized in the ER or in the Golgi 
apparatus, are inverting enzymes, belong to the glycosylhydrolase family 47 and require Ca2+ 
for their activity. On the other hand, α-mannosidases II are localized either in the lysosome or 
in the Golgi apparatus of the cell. The lysosomal α-mannosidases II which catabolizes 
glycoconjugates and the Golgi α-mannosidases II which hydrolyzes α1,3 and α1,6 linkages, 
are retaining enzymes and belong to the glycosylhydrolase family 38.39  
 
                                                 
38 Daniel, P. F.; Winchester, B.; Warren, C. D. Glycobiology 1994, 4, 551-566. 
39 Rothblatt, J.; Novick, P.; Stevens, T. Guidebook to the Secretory Pathway, Oxford University Press, 1994, 
103-104, 185-188 
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The group of D. Rose has shown that Drosophila melanogaster Golgi α-mannosidase II 
(dGMII) displays 41% sequence identity and 61% similarity, comparable substrate specificity 
and kinetic properties, and the same inhibitor sensitivity than human GMII (hGMII).40 The 
sequence alignment of the human enzyme and its Drosophila homologue is shown in Scheme 
12. Thus, dGMII can be used as a valid model of the structural and functional features of the 
mammalian enzymes. Rose and co-workers analyzed a series of crystal structures of 
dGMII/inhibitor complexes41 providing insight into the structure and the catalytic mechanism 
of dGMII. This enzyme presents a protein fold consisting of a N-terminal α/β domain, a 
three-helical bundle and an all-β C-terminal domain forming a single compact entity, 
connected by five internal disulfide bonds and stabilized by a zinc-binding site. The protein 
discloses a convex N-terminal face and a planar face at its opposite side presenting an 
extended pocket formed primarily by acidic residues. This pocket is the active site and is 
conserved in the human GMII sequence. Moreover, detailed binding studies suggest that a 
putative GlcNAc binding pocket is located near the active site. The hydrolytic process likely 
starts by the cleavage of the α-1,6-linked Man6 followed by rotation of the α-1,3-linked Man7 
residue through the active site pocket for its cleavage. Between these two successive 
hydrolyses, the polypeptide-carbohydrate complex is anchored by the stationary GlcNAc, thus 
preventing its release. Thus, these data opens the door to the design of specific inhibitors of 
GMII.  
 
A reliable model of the mammalian lysosomal α-mannosidase II is the α-mannosidase from 
jack bean which has been shown to be mechanistically similar to the human lysosomal 
enzyme.42 Its amino acid sequence surrounding the catalytic nucleophile, identified as aspartic 
acid, reveals high sequence similarity with the mammalian Golgi α-mannosidase II. 
 
In our study, we will focus on the design of new α-mannosidase II inhibitors for the 
development of anticancer agents using dGMII and jack bean α-mannosidase as model 
enzymes for screening purpose.  
                                                 
40 a) Rabouille, C.; Kuntz, D. A.; Lockyer, A.; Watson, R.; Signorelli, T.; Rose, D. R.; van den Heuvel, M.; 
Roberts, D. B. J. Cell Sci. 1999, 112, 3319-3330. b) van den Elsen, J. M. H.; Kuntz, D. A.; Rose, D. R. Embo 
J. 2001, 20, 3008-3017. 
41 a) Kuntz, D. A.; Ghavami, A.; Johnston, B. D.; Pinto, B. M.; Rose, D. R. Tetrahedron: Assymetry 2005, 16, 
25-32. b) Numao, S.; Kuntz, D. A.; Withers, S, G.; Rose, D. R. J. Biol. Chem. 2003, 278, 48074-48083. c) 
Rose, D. R.; Kuntz, D. A.; van den Elsen, J. M. H. US Pat. Appl. Publ. 2002, US 2002172670. 
42 a) Howard S., Braun C., Biochem. Biophys. Res. Commun. 1997, 238, 896-898. b) Howard, S.; He, S.; 
Withers, S. G. J. Biol. Chem. 1998, 273, 2067-2072. 
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Human           -MKLSRQFTVFGSAIFCVVIFSLYLMLDRGHLDYPRNPRREGSFPQGQLSMLQEKIDHLE 59 
Drosophila      MLRIRRRFALVICSGCLLVFLSLYIILN---FAAPAATQIKPNYEN-----IENKLHELE 52 
                 ::: *:*::. .:   :*::***::*:   :  *  .: : .: :     :::*:..** 
Human           RLLAENNEIISNIRDSVINLSESVEDGPKSSQSNFSQGAGSHLLPSQLSLSVDTADCLFA 119 
Drosophila      NGLQEHGEEMRNLRARLAKTSN--RDDPIRP-------------PLKVARSPRPGQCQDV 97 
                . * *:.* : *:*  : : *:  .*.*  .             * ::: *  ..:*  . 
Human           SQSGSHNSDVQMLDVYSLISFDNPDGGVWKQGFDITYESNEWDTEP-LQVFVVPHSHNDP 178 
Drosophila      VQD-VPNVDVQMLELYDRMSFKDIDGGVWKQGWNIKYDPLKYNAHHKLKVFVVPHSHNDP 156 
                 *.   * *****::*. :**.: ********::*.*:. ::::.  *:*********** 
Human           GWLKTFNDYFRDKTQYIFNNMVLKLKEDSRRKFIWSEISYLSKWWDIIDIQKKDAVKSLI 238 
Drosophila      GWIQTFEEYYQHDTKHILSNALRHLHDNPEMKFIWAEISYFARFYHDLGENKKLQMKSIV 216 
                **::**::*::..*::*:.* : :*:::.. ****:****:::::. :. :**  :**:: 
Human           ENGQLEIVTGGWVMPDEATPHYFALIDQLIEGHQWLENNIGVKPRSGWAIDPFGHSPTMA 298 
Drosophila      KNGQLEFVTGGWVMPDEANSHWRNVLLQLTEGQTWLKQFMNVTPTASWAIDPFGHSPTMP 276 
                :*****:***********..*:  :: ** **: **:: :.*.* :.************. 
Human           YLLNRAGLSHMLIQRVHYAVKKHFALHKTLEFFWRQNWDLGSVTDILCHMMPFYSYDIPH 358 
Drosophila      YILQKSGFKNMLIQRTHYSVKKELAQQRQLEFLWRQIWDNKGDTALFTHMMPFYSYDIPH 336 
                *:*:::*:.:*****.**:***.:* :: ***:*** **  . * :: ************ 
Human           TCGPDPKICCQFDFKRLPGGRFGCPWGVPPETIHPGNVQSRARMLLDQYRKKSKLFRTKV 418 
Drosophila      TCGPDPKVCCQFDFKRMGSFGLSCPWKVPPRTISDQNVAARSDLLVDQWKKKAELYRTNV 396 
                *******:********: .  :.*** ***.**   ** :*: :*:**::**::*:**:* 
Human           LLAPLGDDFRYCEYTEWDLQFKNYQQLFDYMNSQSKFKVKIQFGTLSDFFDALDKADETQ 478 
Drosophila      LLIPLGDDFRFKQNTEWDVQRVNYERLFEHINSQAHFNVQAQFGTLQEYFDAVHQAER-- 454 
                ** *******: : ****:*  **::**:::***::*:*: *****.::***:.:*:.   
Human           RDKGQSMFPVLSGDFFTYADRDDHYWSGYFTSRPFYKRMDRIMESHLRAAEILYYFALRQ 538 
Drosophila      --AGQAEFPTLSGDFFTYADRSDNYWSGYYTSRPYHKRMDRVLMHYVRAAEMLSAWHSWD 512 
                   **: **.***********.*:*****:****::*****::  ::****:*  :   : 
Human           AHKYKINKFLSSSLYTALTEARRNLGLFQHHDAITGTAKDWVVVDYGTRLFHSLMVLEKI 598 
Drosophila      G---------MARIEERLEQARRELSLFQHHDGITGTAKTHVVVDYEQRMQEALKACQMV 563 
                .          : :   * :***:*.******.******  *****  *: .:* . : : 
Human           IGNSAFLLILKDKLTYDSYSPDTFLEMDLKQKSQDSLPQKNIIRLSAEPR---YLVVYNP 655 
Drosophila      MQQSVYRLLTKPSIYSPDFSFSYFTLDDSRWPGSGVEDSRTTIILGEDILPSKHVVMHNT 623 
                : :*.: *: * .:   .:* . *   * :  ...   .:. * *. :     ::*::*. 
Human           LEQDRISLVSVYVSSPTVQVFSASGKPVEVQVSAVWDTAN---------TISETAYEISF 706 
Drosophila      LPHWREQLVDFYVSSPFVSVTDLANNPVEAQVSPVWSWHHDTLTKTIHPQGSTTKYRIIF 683 
                * : * .**..***** *.* . :.:***.***.**.  :           * * *.* * 
Human           RAHIPPLGLKVYKILESASS---NSHLADYVLYKN-KVEDSGIFTIKNMINTEEGITLEN 762 
Drosophila      KARVPPMGLATYVLTISDSKPEHTSYASNLLLRKNPTSLPLGQYPEDVKFGDPREISLRV 743 
                :*::**:** .* :  * *.   .*: :: :* ** .    * :. .  :.  . *:*.  
Human           -SFVLLRFDQTGLMKQMMTKEDGKHHEVNVQFSWYGTTIKRDKSGAYLFLPDGNAKPYVY 821 
Drosophila      GNGPTLAFSEQGLLKSIQLTQDSPHVPVHFKFLKYGVRSHGDRSGAYLFLPNGPASP-VE 802 
                 .   * *.: **:*.:  .:*. *  *:.:*  **.  : *:********:* *.* *  
Human           TTPPFVRVTHGRIYSEVTCFFDHVTHRVRLYHIQGIEGQSVEVSNIVDIRKVYNREIAMK 881 
Drosophila      LGQPVVLVTKGKLESSVSVGLPSVVHQTIMR------GGAPEIRNLVDIGSLDNTEIVMR 856 
                   *.* **:*:: *.*:  :  *.*:. :       * : *: *:*** .: * **.*: 
Human           ISSDIKSQNRFYTDLNGYQIQPRMTLSKLPLQANVYPMTTMAYIQDAKHRLTLLSAQSLG 941 
Drosophila      LETHIDSGDIFYTDLNGLQFIKRRRLDKLPLQANYYPIPSGMFIEDANTRLTLLTGQPLG 916 
                :.:.*.* : ******* *:  *  *.******* **:.:  :*:**: *****:.*.** 
Human           VSSLNSGQIEVIMDRRLMQDDNRGLEQGIQDNKITANLFRILLEKRSAVNTEEEKKSVSY 1001 
Drosophila      GSSLASGELEIMQDRRLASDDERGLGQGVLDNKPVLHIYRLVLEKVNNCVRPSKLHPAGY 976 
                 *** **::*:: **** .**:*** **: *** . :::*::*** .     .: :...* 
Human           PSLLSHITSSLMNHPVIPMANKFSSPTLELQGEFSPLQSSLPCDIHLVNLRTIQSKVGNG 1061 
Drosophila      LTSAAHKASQSLLDPLDKFIFAEN-EWIGAQGQFGGDHPSAREDLDVSVMRRLTKSS--A 1033 
                 :  :* :*. : .*:  :    .   :  **:*.  :.*   *:.:  :* : ..   . 
Human           HSNEAALILHRKGFDCRFSSKGTGLFCSTTQGKILVQKLLNKFIVESLTPSSLSLMHSPP 1121 
Drosophila      KTQRVGYVLHRT------NLMQCGTPEEHTQKLDVCHLLPN---VARCERTTLTFLQNLE 1084 
                :::... :***.      .    *   . **   : : * *   *     ::*::::.   
Human           GTQNISEINLSPMEISTFRIQLR- 1144 
Drosophila      HLDGMVAPEVCPMETAAYVSSHSS 1108 
                  :.:   ::.*** :::  .    
Scheme 12: Sequence alignment of hGMII (AS: NP 002362) and dGMII (AS: CAA 54732). 
ClustalW (http://www.ebi.ac.uk/clustalw/) was used to create the above alignment using the 
default parameters without manual intervention. An alignment score of 2574 was calculated 
by the software.43  
 
                                                 
43 Hoffmann, D. Diploma Thesis, Ontario Cancer Institute, 2006. 
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1.5. Glycosidase Inhibitors 
In addition to natural inhibitors, the disclosure of the function of the active site of 
glycosidases involved in the biosynthesis of glycoproteins has led to the development of 
synthetic inhibitors.  
 
The biosynthesis pathway may be interrupted at different stages of the glycosylation process. 
Representative examples of inhibitors interacting mainly with the α-glucosidases or the α-
mannosidases of the glycoprotein biosynthesis pathway will be presented.44  
1.5.1. Inhibition of the formation of the “14-saccharide core” 
One strategy consists in stopping the biosynthesis of the Glc3Man9GlcNAc2-protein at the 
“14-saccharide core” unit stage (Scheme 3). Inhibition of the transfer of GlcNAc-1-P to the 
lipid carrier by tunicamycin (1, TM, Scheme 13) is an example of this approach. TM was first 
identified and isolated from Streptomyces lysosuperificus by Takatsuki et al., by virtue of the 
fact that it inhibited replication of a number of enveloped viruses. This antibiotic is active 
against animal and plant viruses, Gram-positive bacteria, yeast and fungi.45 TM are composed 
of uracil, two linked sugars and fatty acid side chains (I to X). 
 
Five other antibiotics have been reported to inhibit the formation of N-acetylglucosaminyl-
pyrophosphoryl-dolichol like TM.46 They are structurally related to tunicamycin and are 
known as streptovirudin,47 mycospocidin,48 antibiotic 24010,49 antibiotic MM 1929050 and 
corynetoxin.51 All these compounds share the same general structure of TM but differ in the 
nature of the fatty acid component (Scheme 13).52  
                                                 
44 a) Asano, N. J. Enzyme Inhibition 2000, 15, 215-234. b) Asano, N.; Kato, A.; Watson, A. A. Mini Rev. Med. 
Chem. 2001, 1, 145-154. 
45 Takatsuki, A.; Arima, K.; Tamura, G. J. Antibiot. 1971, 24, 215-223. 
46 a) Elbein, A. D.; Gafford, J.; Kang, M. S. Arch. Biochem. Biophys. 1979, 196, 311-318. b) James, D. W.; 
Elbein, A. D. Plant. Physiol. 1980, 65, 460-464. 
47 Elbein, A. D.; Occolowitz, J. L.; Hamill, R. L.; Eckardt, K. Biochemistry 1981, 20, 4210-4216. 
48 Nakamura, S.; Arai, M.; Karasawa, K.; Yonehara, H. J. Antibiot. 1957, 10, 248-253. 
49 a) Mizuno, M.; Shimojima, Y.; Sugawara, T.; Takeda, I. J. Antibiot. 1971, 24, 896-899. b) Shimojima, Y.; 
Mizuno, M.; Mizuno, Y.; Ooka, T.; Takeda, I. J. Antibiot. 1972, 25, 604-606. 
50 Kenig, M.; Reading, C. J. Antibiot. 1979, 32, 549-554. 
51 Eckardt, K. Nucleoside Antibiot. 1983, 46, 544-550. 
52 Cockrum, P. A.; Edgar, J. A.; J. Chromato. 1983, 268, 245-254. 
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Tunicamycins (TM):  
I  R = -CH=CH(CH2)7CH(CH3)2  
II  R = -CH=CH(CH2)8CH(CH3)2 
III  R = -CH=CH(CH2)10CH3  
IV  R = -CH=CH-C12H25 
V  R = -CH=CH(CH2)9CH(CH3)2  
VI  R = -(CH2)11CH(CH3)2  
VII  R = -CH=CH(CH2)10CH(CH3)2  
VIII  R = -CH=CH(CH2)12CH3 
IX  R = -CH=CH-C14H29 
X  R = -CH=CH(CH2)11CH(CH3)2  
O OH
O
O
HO OH
R(O)CHN
AcNGlc
HO OH
N
H
NO O
 
 
(1) 
   
Streptovirudins Corynetoxins : 
A2 R = -CH=CH(CH2)6CH(CH3)2 H17a  R = -CH2=CHOH-(CH2)10CH(CH3)(CH2-CH3)  
B2 R = -CH=CH(CH2)6CH(CH3)(CH2-CH3) U17a  R = -CH=CH(CH2)10CH(CH3)(CH2-CH3) 
Scheme 13: Structures of Tunicamycin and related antibiotics. 
 
 
The major drawback associated with inhibitors such as tunicamycin is the complete 
prevention of glycosylation and therefore result in the synthesis of nonglycosylated proteins. 
Another approach consists in inhibiting specific enzymes of the trimming process so that 
glycosylation can occur but the N-linked oligosaccharides cannot be modified beyond a 
specific step. The molecules found in the nature or developed for that purpose are defined as 
processing inhibitors.  
 
1.5.2. Inhibitors of α-glucosidases and their biological activities 
Several families of aza-sugars are inhibitors of glucosidases. These molecules belong to five 
different structural classes: polyhydroxylated piperidines, pyrrolidines, indolizidines, 
pyrrolizidines and nortropanes.53 For instance, polyhydroxylated piperidines such as 
nojirimycin (3, NJ, Scheme 14), 1-deoxynojirimycin (4, DNJ, Scheme 15) and N-methyl 1-
deoxynojirimycin (5, Me-DNJ, Scheme 15) are aza-sugar analogues of D-glucose (2, Glc, 
Scheme 14) in which the intracyclic oxygen of the hexose is replaced with a basic nitrogen 
atom. 
                                                 
53 Asano, N.; Nash, R. J.; Molyneux, R. J.; Fleet, G. W. J. Tetrahedron Assymetry 2000, 11, 1645-1680. 
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In 1966, NJ (3), discovered as the first natural glucose mimic, was described as an antibiotic 
produced by Streptomyces roseochromogenes R-468 and S. lavendulae SF-425 and was 
shown to be a potent inhibitor of α- and β-glucosidases of different origins.54 This non 
selectivity was explained by the observations of Inouye et al. who reported that NJ exists in 
aqueous solution in both α- and β- forms in a 6:4 ratio.55 These two forms are able to inhibit 
α- and β-glucosidases, respectively.  
OHO
HO
OH
OH
OH
 
 
Glucose (2, Glc) 
IC50 Enzyme [Ref] 
 0.56 μM α-glucosidase (rat intestinal sucrase) [27] 
 0.76 μM α-glucosidase (rat intestinal glucoamylase) [27] 
 0.89 μM β-glucosidase (sweet almond) [27] 
 
NHHO
HO
OH
OH
OH
 
 
Nojirimycin (3, NJ) 
 0.36 μM β-glucosidase (Aspergillus wentii) [27] 
Scheme 14: Structures of Glucose and Nojirimycin. IC50 toward various enzymes. 
 
Moreover, NJ is relatively unstable since the hydroxyl group at C(1) is prone to elimination. 
The corresponding reduced piperidine, DNJ (4, Scheme 15) was isolated from the roots of 
Morus bombycis (mulberry trees) and called moranoline.56 DNJ, also produced by many 
strains of the genera Bacillus and Streptomyces, was found to be a potent inhibitor of α-
glucosidase I and II. Saunier et al. reported that the inhibitory ability of DNJ is pH dependent 
and that DNJ inhibits glucosidase II more strongly than glucosidase I. For instance, IC50 
values of 2 μM and 20 μM have been reported for α-glucosidase I and α-glucosidase II from 
Saccharomyces cerevisiae, respectively.57 Nevertheless, DNJ proved to be rather non-specific 
and inhibits other α-glucosidases, β-glucosidase and reduces the formation of the “14-
saccharide core” unit.58  
 
                                                 
54 Inouye, S.; Tsurouka, T.; Niida, T. J. Antibiot. 1966, 19, 288-292. 
55 Inouye, S.; Tsurouka, T.; Ito, T.; Niida, T. Tetrahedron 1968, 23, 2125-2144. 
56 Masahiro, Y.; Tatsuhiko, K.; Yoshiaki, A.; Hiromu, M. Nippon Nogei Kagaku Kaishi 1976, 50, 571-572. 
57 Saunier, B.; Kilker, R. D.; Tkacz, J. S.; Quaroni, A. Herscovics, A. J. Biol. Chem. 1982, 257, 14155-14161. 
58 a) Evans, S. V.; Fellows, L. E.; Shing, T. K. M.; Fleet, G. W. J. Phytochemistry 1985, 24, 1953-1955. b) Li, Y. 
K.; Byers, L. D. Biochim. Biophys. Acta 1989, 999, 227-232. c) Ridruejo, J. C.; Munoz, M. D.; Andaluz, E.; 
Larriba, G. Biochim. Biophys. Acta 1989, 993, 179-185. 
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IC50 Enzyme [Ref] 
 20 μM α-glucosidase I (S. cerevisiae) [57] 
 2 μM α-glucosidase II (S. cerevisiae) [57] 
 81 μM β-glucosidase (emulsin) [58a] 
 560 μM anti HIV activity [112] 
NHHO
HO
OH
OH
 
 
1-Deoxynojirimycin (4, DNJ)   
  
 0.3 μM α-glucosidase I (calf liver microsomes) [60] 
 130 μM α-glucosidase II (calf liver microsomes) [60] 
 
NHO
HO
OH
OH Me
 
 
N-methyl 1-deoxynojirimycin  
(5, Me-DNJ) 
  
Scheme 15: Structures of inhibitors of α- and β-glucosidases. IC50 toward various enzymes. 
 
The N-methyl derivative of 1-deoxynojirimycin (5, Scheme 15) isolated from the leaves of 
mulberry trees demonstrated potent inhibition of ER α-glucosidases I and II.59 Indeed, N-
alkylation of compound 4, induces a shift from α-glucosidase II to α-glucosidase I in the 
specific inhibition of purified glucosidases.60 Furthermore, in cell culture, N-alkyl derivatives 
of DNJ are more effective inhibitors of glucosidase I than glucosidase II, since a much larger 
proportion of the oligosaccharides formed in the presence of these inhibitors contains three 
glucose residues.61 
 
The problem with most of these inhibitors is the lack of specificity leading to the inhibition of 
both α-glucosidase I and α-glucosidase II, as well as other α-glucosidases. In 1988, 
homonojirimycin (HNJ, 6, Scheme 16) was isolated from the tropical liana Omphalea 
diandra.62 It was the first report of the isolation of the naturally occurring C(1) branched DNJ 
derivative. Some years later, Zeng et al examined the effect of HNJ and its analogues on the 
activity of the processing glucosidases. It was found that HNJ was a better inhibitor of 
glucosidase II than glucosidase I, while its N-methyl derivative (Me-HNJ, 7, Scheme 16) 
inhibited glucosidase I more effectively than glucosidase II and was also more potent against 
glucosidase I than DNJ.63  
                                                 
59 Asano. N.; Tomioka, E.; Kizu, H.; Matsui, K. Carbohydrate Res. 1994, 253, 235-245. 
60 Hettkamp, H.; Legler, G.; Bause, E. Eur. J. Biochem. 1984, 142, 85-90. 
61 Tan, A.; van den Broek, L.; van Boeckel, S.; Ploegh, H.; Bolscher, J. J. Biol. Chem. 1991, 266, 14504-14510. 
62 Kite, G. C.; Fellows, L. E.; Fleet, G. W. J.; Liu, P. S.; Scofield, A. M.; Smith, N. G. Tetraehdron Lett. 1988, 
29, 6483-6486. 
63 Zeng, Y.; Pan, Y. T.; Asano, N.; Nash, R .J.; Elbein, A.D. Glycobiology 1997, 7, 297-304. 
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IC50 Enzyme [Ref] 
 2.5 μg/ml α-glucosidase I (mung bean seedlings) [63] 
 1 μg/ml α-glucosidase II (mung bean seedlings) [63] 
  
  
NHHO
HO
CH2OH
OH
OH
 
 
Homonojirimycin (6, HNJ) 
  
  
  
 0.25 μg/ml α-glucosidase I (mung bean seedlings) [63] 
 10 μg/ml α-glucosidase II (mung bean seedlings) [63] 
  
  
NHO
HO
CH2OH
OH
OH Me
 
 
N-methyl homonojirimycin (7, Me-HNJ)   
Scheme 16: Structures of Homonojirimycin and one analogue. IC50 toward various enzymes. 
 
 
Castanospermine (8, CST, Scheme 17), another natural glucosidase inhibitor, was isolated in 
1981 from the seeds of Castanospermum australe,64 and later from the dried pods of Alexa 
leiopetala.65 Compound 8 is a polyhydroxylated indolizidine alkaloid which inhibits strongly 
α- and β-glucosidase as well as intestinal sucrase. Experiments indicate that the extent of 
castanospermine inhibition is greatly dependent on the pH with better efficiency at pH 6.5 
than at lower pH.66 CST is a more potent inhibitor of α-glucosidase I than α-glucosidase II. 
Moreover, CST is more active on α-glucosidase I than DNJ.67 Indeed, conformational 
comparison between DNJ and castanospermine suggests that the greater activity of CST 
compared to DNJ may by due to the fixed axial positioning of the O6 atom.68  
                                                 
64 Hohenschutz, L. D.; Bell, E. A.; Jewess, P. J.; Leworthy, D. P.; Pryce, R. J.; Arnold, E.; Clardy, J. Phytochem. 
1981, 20, 811-814. 
65 Nash, R. J.; Fellows, L. E.; Dring, J. V.; Stirton, C. H.; Carter, D.; Hegarty, M. P.; Bell, E. A. Phytochem. 
1988, 27, 1403-1404. 
66 a) Saul, R.; Molyneux, R. J.; Elbein, A. D. Arch. Biochem. Biophys. 1984, 230, 668-675. b) Trugnan, G.; 
Roussett, M.; Zweibaum, A. FEBS Lett. 1986, 195, 28-32. 
67 a) Pan, Y. T.; Hori, H.; Saul, R.; Sanford, B. A.; Molyneux, R. J.; Elbein, A. D. Biochemistry 1983, 22, 3975-
3984. b) Szumilo, T; Kaushak, G. P.; Elbein, A. D. Arch. Biochem. Biophys. 1986, 247, 261-271. 
68 Hempel, A.; Camerman, N.; Mastropaolo, D.; Camerman, A. J. Med. Chem. 1993, 36, 4082-4086. 
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IC50 Enzyme [Ref] 
 < 1 μg/ml (i.e. 1 μM) α-glucosidase I  (mung bean seedlings) [69] 
 0.5 – 1 μg/ml α-glucosidase (amyloglucosidase) [66a] 
 5 μg/ml β-glucosidase, pH = 6.5 (almond emulsin) [66a] 
 20 μg/ml β-glucosidase, pH = 5.0 (almond emulsin) [66a] 
 < 1 μM sucrase [69] 
 < 1 μM maltase [69] 
 29 μM anti HIV activity [112] 
 
N
OHOH
HO
HO
H
 
 
Castanospermine  
(8, CST) 
  
  
 20 μM α-glucosidase I (mung bean seedlings) [69] 
 > 500 μM α-glucosidase II (mung bean seedlings) [69] 
 5.8 μg/ml α-glucosidase (amyloglucosidase) [69] 
 28 μM sucrase [69] 
 35 μM maltase [69] 
 
N
HO
HO H OH
HO  
 
Australine (9)   
Scheme 17: Natural inhibitors of glycosidases from Catanospermum australe. IC50 toward 
various enzymes. 
 
 
In addition to indolizidine alkaloids, C. australe was reported to produce the 
polyhydroxylated pyrrolizidine alkaloid australine (9, Scheme 17). This compound 
demonstrated a strong activity and selectivity toward α-glucosidase I as it poorly inhibited α-
glucosidase II. Australine was the first example of a compound presenting such selectivity but 
is nevertheless less active than CST on α-glucosidase I. Australine demonstrated poor 
inhibitory ability toward β-glucosidase (10 times less active than CST),69 and was not active 
toward α- and β- mannosidases, α- and β-galactosidases, sucrase and maltase, which made 
australine a definitively more selective inhibitor.70 
                                                 
69 Tropea, J. E.; Molyneux, R. J.; Kaushal, G. P.; Pan, Y. T.; Mitchell, M.; Elbein, A. D. Biochemistry 1989, 28, 
2027-2034. 
70 Molyneux, R. J.; Benson, M.; Wong, R. Y J. Nat. Prod. 1988, 51, 1198-1206. 
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1.5.3. Inhibitors of α-mannosidases and their biological activities 
Several alkaloids isolated from plants and microorganisms display inhibitory ability against 
α-mannosidases. For instance, 1-deoxymannonojirimycin (12, DMJ, Scheme 18) was first 
isolated from the seeds of the legume Lonchocarpus sericeus, a native plant of the West 
Indies and tropical America71 and was later isolated from the tropical Omphalea diandra and 
Angylocalyx pynaertii,72 an edible vegetable growing in tropical African forest. In 1979, the 
discovery of DMJ revealed the second example after NJ of a sugar analogue, containing a 
nitrogen atom instead of an oxygen atom in the sugar ring. Compound 12 (DMJ) has been 
found to be a selective inhibitor of rat liver Golgi α-mannosidase I but did not affect ER α-
mannosidase or Golgi α-mannosidase II. Nevertheless high concentrations of this compound 
are necessary for inhibition.73  
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Mannose (10, Man) 
 
NHHO
HO
OH
OH
OH
 
 
Mannonojirimycin (11, MJ) 
 
IC50 Enzyme [Ref] 
1-2 μM Golgi α-mannosidase I (rat liver) [73b] 
n.i. Golgi α-mannosidase II (rat liver) [73b] 
n.i. ER α-mannosidase (rat liver) [73b] 
 
NHHO
HO
OH
OH
 
 
1-Deoxymannonojirimycin  
(12, DMJ)   
n.i. = no inhibition 
Scheme 18: Structures of Mannose, Mannonojirimycin and 1-Deoxymannonojirimycin. IC50 
toward various enzymes. 
                                                 
71 Fellows, L. E.; Bell, E. A.; Lynn, D. G.; Pilkiewicz, F.; Miura, I.; Nakanishi, K. J. Chem. Soc., Chem. 
Commun. 1979, 22, 977-978. 
72 Molyneux, R. J.; Pan, Y. T.; Tropea, J. E.; Elbein, A. D.; Lawyer, C. H.; Hughes, D. J.; Fleet, G. W. J. Nat. 
Prod. 1993, 56, 1356-1364. 
73 a) Fuhrmann, U.; Bause, E.; Legler, G.; Ploegh, H. Nature 1984, 307, 755-758. b) Bischoff, J.; Kornfeld, R. 
Biochim. Biophys. Res. Commun. 1984, 125, 324-331. c) Hardick, D. J.; Hutchinson, D. W.; Trew, S. J.; 
Wellington, E. M. H. Tetrahedron 1992, 48, 6285-6296. 
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Mannostatin A and B (13 and 14, Scheme 19) were discovered by Aoyagi and collaborators in 
1989 and so named because of their highly potent inhibition of α- and β-mannosidase 
activities. They were isolated from the soil microorganism Streptoverticillum verticillus 
during screening of culture broths for mannosidase inhibitors.74 Inhibition by mannostatin A 
and B of α-mannosidases prepared from epididymes of adult rats has been shown to be 
competitive. When tested on various glycosidases, Mannostatin A was inactive toward β-
glucosidase, α- and β-galactosidase, β-mannosidase but was a potent inhibitor of jack bean α-
mannosidase. Mannostatin A also proved to be an effective competitive inhibitor of the 
glycoprotein-processing enzyme α-mannosidase II but was inactive toward α-mannosidase 
I.75 
 
Kifunensine (15, Scheme 19), initially isolated from the culture broth of the actinomycete 
Kitasatosporia kifunensine 9482,76 was reported to be a weak inhibitor of jack bean α-
mannosidase but was a very potent and selective inhibitor of α-mannosidase I from mung 
bean seedlings. Studies with rat liver microsomes indicated that kifunensine selectively 
inhibited Golgi α-mannosidase I but did not inhibit the ER mannosidase. Moreover, 
introduction of kifunensine in cells culture medium at 1 μg/ml or higher concentration 
resulted in the production of Man9GlcNAc2 chains rather than complex structures.77  
                                                 
74 Aoyagi, T.; Yamamoto, T.; Kojiri, K.; Morishima, H.; Nagai, M.; Hamada, M.; Takeuchi, T.; Umezawa, H. J. 
Antibiot. 1989, 42, 883-889. 
75 a) Tropea, J. E.; Kaushal, G. P.; Pastuszak, I.; Mitchell, M.; Aoyagi, T.; Molyneux, R. J.; Elbein, A. D. 
Biochemistry 1990, 29, 10062-10069. b) Berecibar, A.; Grandjean, C.; Siriwardena, A. Chem. Rev. 1999, 99, 
799-844. 
76 Kayakiri, H.; Takase, S.; Shibata, T.; Okamoto, M.; Terano, H.; Hashimoto, M.; Tada, T.; Koda, S. J. Org. 
Chem. 1989, 54, 4015-4016. 
77 Elbein, A. D.; Tropea, J. E.; Mitchell, M.; Kaushal, G. P. J. Biol. Chem. 1990, 265, 15599-15605. 
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IC50 Enzyme [Ref] 
 20 nM α-mannosidase (rat epididymis) [75a] 
 70 nM α-mannosidase (jack bean ) [75a] 
 450 nM α-mannosidase (mung bean) [75a] 
 160 nM α-mannosidase (rat liver lysosomal) [75a] 
 15 nM α-mannosidase II (mung bean seedlings) [75a] 
n.i. α-mannosidase I (mung bean seedlings) [75a] 
 
HO OH
HO SCH3
NH2
 
 
Mannostatin A (13) 
  
  
  
  
 20 nM α-mannosidase (rat epididymis) [74] 
 30 nM α-mannosidase (jack bean ) [75b] 
  
 
HO OH
HO SOCH3
NH2
 
 
Mannostatin B (14) 
  
  
  
 120 μM jack bean [76] 
 20-50 nM mannosidase I (mung bean seedlings) [77] 
n.i. mannosidase II (mung bean seedlings) [77] 
 100 nM Golgi-mannosidase I (rat liver) [77] 
n.i. ER-mannosidase (rat liver) [77] 
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Kifunensine (15) 
  
n.i. = no inhibition 
Scheme 19: Structures of Mannostatin A, B and Kifunensine. IC50 toward various enzymes. 
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Swainsonine (16, Scheme 20), a polyhydroxylated indolizidine alkaloid, discovered in 1978 
by Dorling and al.,78 displayed reversible inhibition of class II α-mannosidases (lysosomal 
and Golgi α-mannosidases). Swa was first isolated in Australia from the plant Swainsona 
canescens,79 which was toxic to livestock. Swa has then been identified as the toxic principle 
of locoism, a syndrome developed by animals ingesting the locoweed infested species 
Astragalus and Oxytropis species,80 and more recently in the poisonous plant Ipomea 
carnea,81 and the fungus Rhizoctonia leguminocola.82 The clinical signs of locoism include 
nervousness, aggression, hyperactivity, increasing miscoodination, head tremors, loss of 
weight, reproductive alterations, weakness and death. These symptoms are attributed to 
lysosomal storage disease which is characterized by cytoplasmic vacuolation of cells of the 
central nervous system. However, purified Swa alone is now known not to be neurotoxic, but 
loco syndrome may be caused by ingestion of a combination of alkaloids found in Swainsona 
canescens or Astragalus.83 
 
Dorling and al. recognized that the lysosomal storage disorder induced in animals grazing 
Swainsona species was biochemically and morphologically similar to the rare genetic 
mannosidosis that occurs in humans. This affection is characterized by accumulation in cells 
and excretion in urine of mannose-rich oligosaccharides, resulting from a deficiency of 
lysosomal α-mannosidase.84 It has been found that Swa concentrates and accumulates in 
lysosomes of normal human fibroblasts and human lymphoblasts in culture, since it is almost 
fully ionized within the acidic environment of this organelle.85 Such accumulation produces 
the inhibition of the intracellular lysosomal α-mannosidase which induces incomplete 
catabolism of the carbohydrate moiety of glycoproteins and storage of the remaining proteins 
which finally leads to disease as a consequence. It is assumed that this mode of action also 
occurs in vivo. Actually, Swa provides a valuable tool for the study of human mannosidosis 
despite the fact it also inhibits Golgi α-mannosidase II. 86  
                                                 
78 Dorling, P. R.; Huxtable, C. R.; Vogel, P. Neuropathol. Appl. Neurobiol. 1978, 4, 285-295. 
79 Colegate, S. M.; Dorling, P. R.; Huxtable, C. R.; Aust. J. Chem. 1979, 32, 2257-2264. 
80 Molyneux, R. J.; James, L. F.; Science 1982, 216, 190-191. 
81 Haraguchi, M.; Gorniak, S. L.; Ikeda, K.; Minami, Y.; Kato, A.; Watson, A. A.; Nash, R. J.; Molyneux, R. J.; 
Asano, N. J. Agric. Food Chem. 2003, 51, 4995-5000. 
82 Schneider, M. J.; Ungemach, F. S.; Broquist, H. P.; Haris, T. M. Tetraheddron 1983, 39, 29-32. 
83 Bowlin, T. L.; Sunkara, P. S. Biochem. Biophys. Res. Commun. 1988, 151, 859-864. 
84 Jolly, R. D.; Winchester, B. G.; Gehler, J.; Dorling, P. R.; Dawson, G. J. Appl. Biochem. 1981, 3, 273-291. 
85 a) Chotai, K.; Jennings, C.; Winchester, B.; Dorling, P.R. J. Cell. Biochem. 1983, 21, 107-117. b) Ikeda, K.; 
Kato, A.; Adachi, I.; Haraguchi, M.; Asano, N. J. Agric. Food Chem. 2003, 51, 7642-7646. 
86 a) Watson, A. A.; Fleet, G. W. J.; Asano, N.; Molyneux, R.; Nash, R. J. Phytochemistry 2001, 56, 265-295. b) 
Cenci di Bello, I.; Dorling, P.R.; Winchester, B.; Biochem. J. 1983, 215, 693-696. 
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Swa was the first compound able to alter glycoprotein processing. It displayed inhibitory 
ability toward jack bean α-mannosidase, rat liver Golgi α-mannosidase II but was without 
effect on Golgi α-mannosidase I.87 In addition, Swa did not inhibit ER α-mannosidase or the 
soluble α-mannosidases of rat liver.88 The selectivity of Swa toward α-mannosidases was 
established against other glycosidases such as α-glucosidase, β-galactosidase and β-
glucoronidase and lysosomal β-mannosidases.85a The pKa of Swa was determined to be 7.4 
which mean that Swa would be fully ionized at pH 4.0.89 Molecular modelling has shown that 
the relative positions of the cationic ammonium center and the three hydroxyl groups mimic 
an intermediate cationic structure of the hydrolysis mediated by α-mannosidases II and thus 
accounts for the apparent specificity of Swa for α-mannosidases II.85b  
 
IC50 Enzyme [Ref] 
 0.4-0.1 μM jack bean  [89, 104a] 
 70 nM α-mannosidase (human liver lysosomal) [87c] 
 20 nM α-mannosidase (rat lysosomal) [85b] 
 40 nM α-mannosidase (human lysosomal) [85b] 
n.i. Golgi mannosidase I (rat liver) [87a] 
 200 nM Golgi mannosidase II (rat liver) [87a] 
 
N
OH
OHH
OH
 
 
Swainsonine (16, Swa) 
 160 nM α-mannosidase (rat liver lysosomal) [75a] 
n.i. = no inhibition 
Scheme 20: Structure of Swainsonine. IC50 toward various enzymes. 
 
Several research groups have developed synthetic pathways to more complex sugar 
mimetics90 hoping to achieve more potent inhibition against selected glycosidases. 
Nevertheless, the inhibition values were generally lower than the activities provided by 
natural azasugars.  
 
                                                 
87 a) Tulsiani, D. P. R.; Harris, T. M.; Touster, O. J. Biol. Chem. 1982, 257, 7936-7939. b) Tulsiani, D. P. R.; 
Broquist, H. P.; James, L. F.; Touster, O. Arch. Biochem. Biophys. 1988, 264, 607-617. c) Cenci di Bello, I.; 
Fleet, G.; Namgoong, S. K.; Tadano, K.-I..; Winchester, B.; Biochem. J. 1989, 259, 855-861. 
88 Bischoff, J.; Kornfeld, R. J. Biol. Chem. 1986, 261, 4758-4765. 
89 Dorling, P. R.; Huxtable, C. R.; Colegate, S. M. Biochem. J. 1980, 191, 649-651. 
90 Robina, I.; Vogel, P. Synthesis 2005, 5, 675-702 and refs cited therein. 
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The development of inhibitors of the recently disclosed endomannosidase,19, 91 has also raised 
interest, as these enzymes are not inhibited by Swa. Spiro and al have shown that Glcα1,3(1-
deoxy)mannonojirimycin (17, Scheme 21) in the presence of castanospermine, inhibited in 
vivo the endomannosidase mediated pathway thus preventing the synthesis of complex N-
linked oligosaccharides.92  
 
NH
OH
OH
HO
OHO
HO
O
OH
OH
 
     (17) 
Scheme 21: Glcα1,3(1-deoxy)mannonojirimycin. 
 
                                                 
91 Hamilton, S. R.; Li, H.; Wischnewski, H.; Prasad, A.; Kerley-Hamilton, J. S.; Mitchell, T.; Walling, A. J.; 
Davidson, R. C.; Wildt, S.; Gerngross, T. U. Glycobiology 2005, 15, 615-624. 
92 a) Hiraizumi, S.; Spohr, U.; Spiro, R. G. J. Biol.Chem. 1993, 268, 9927-9935. b) Rothblatt, J.; Novick, P.; 
Stevens, T. Guidebook to the Secretory Pathway, Oxford University Press, 1994, 188-189. 
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1.6. Therapeutic applications of glycosidase inhibitors 
1.6.1. Therapeutic applications not related to cancer 
Because enzyme-catalyzed carbohydrate hydrolysis is a biologically widespread process, 
glycosidase inhibitors have many potential applications as agrochemicals and as therapeutic 
agents. Inhibition of glycosidases in living material can have profound effects on the quality 
control, maturation, transport, and secretion of glycoproteins, and can alter cell-cell or cell-
pathogens recognition processes suggesting potential use of glycosidase inhibitors against 
viral and bacterial infections and cancer.93 
1.6.1.1. Diabetes treatment 
Since the late 1960s, the Bayer group has searched for inhibitors of intestinal sucrase for 
clinical development in the treatment of type II diabetes (non-insulinodependent). In our diet, 
carbohydrates consist mainly of starch and saccharose. Starch is hydrolyzed into maltose by 
α-amylase released by the pancreas in the small intestine. Saccharose is hydrolyzed into 
glucose and fructose by α-glucosidases by intestinal saccharase. These monosaccharides are 
then directly absorbed by intestinal cells and enter the blood stream. Diabetic patients are 
affected by hyperglycemia. Inhibition of α-glucosidases in the small intestine can slow down 
carbohydrate hydrolysis and thus prevent peaks in the blood sugar levels. The Bayer group 
discovered that the pseudotetrasaccharide acarbose (18, Scheme 22), from the fermentation 
broth of the Actinoplanes strain SE 50,94 competes with saccharose for the binding to the 
active site of the saccharase. The inhibitory ability (IC50) of acarbose toward the porcine 
intestinal saccharase has been measured as 0.5 μg/ml.95 Actually, acarbose is commercialized 
as Glucobay® for the therapy of type II diabetes.96  
                                                 
93 Asano, N. Glycobiology 2003, 13, 93R-104R. 
94 Schmidt, D. D.; Frommer, W.; Junge, B.; Müller, L.; Wingender, W.; Truscheit, E. Naturwissenschaften 1977, 
64, 535-536. 
95 Kwon, Y.-I.; Son, H.-J.; Moon, K. S.; Kim, J. K.; Kim, J.-G.; Chun, H.-S.; Ahn, S. K.; Hong, C. I. J. Antibiot. 
2002, 55, 462-466. 
96 Balfour, J.A.; McTavish, D. Drugs 1993, 46, 1025-1054. 
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A structure similar to acarbose is found in valienamine (19, Scheme 22) and its analogue 
valiolamine (20, Scheme 22) which were isolated from the culture broth of validamycin-
producing organism, Streptomyces hygroscopicus var. limoneus. These compounds exhibit 
strong α-glucosidase inhibitory ability in vivo and in vitro but valiolamine presents a more 
potent α-glucosidase inhibitory activity toward porcine intestinal sucrase, maltase and 
isomaltase than valienamine.97 Horii and co-workers synthesized numerous N-substituted 
valiolamine derivatives in order to enhance the α-glucosidase inhibitory efficacy in vitro. The 
derivative voglibose (21, Scheme 22), obtained by reductive amination of valiolamine with 
dihydroxyacetone, presents IC50 values of 15 nM and 46 nM toward maltase and sucrase, 
respectively.98 Voglibose is now on the market for the therapy of type II diabetes in Japan 
under the name Basen®.  
 
In 1976, DNJ was found to be even more active than acarbose for the inhibition of α-
glucosidase. However, despite its excellent α-glucosidase inhibitory potential in vitro, its 
efficacy in vivo was only moderate.99 Alternative DNJ analogues were then developed and 
hundreds of N-substituted and C-branched derivatives were synthesized and screened for their 
biological activity. The best derivatives were nearly two orders of magnitude more effective 
than acarbose but the N-hydroxyethyl derivative of DNJ (22, Scheme 22) was finally chosen 
for further development and clinical trials. It has been approved for the treatment of type II 
diabetes under the name of Miglitol®.100 
 
Recently, the piperidine alkaloid isofagomine (23, Scheme 22), a strong inhibitor of β-
glucosidase,101 has been reported to inhibit hepatic glycogen phosphorylase with an IC50 value 
of 0.7 μM, and to prevent basal and glucagon-stimulated glycogen hydrolysis in cultured 
hepatocytes with IC50 values of 2-3 μM.102 Inhibitors of glycogen phosphorylase have not yet 
been evaluated for the treatment of type II diabetes but are promising target. 
                                                 
97 Kameda, Y.; Asano, N.; Yoshikawa, M.; Takeuchi, M.; Yamaguchi, T.; Matsui, K.; Horii, S.; Fukase, H. J. 
Antibiot. 1984, 37, 1301-1307. 
98 Horii, S.; Fukase, H.; Matsu, T.; Kameda, Y.; Asano, N.; Matsui, K. J. Med. Chem. 1986, 29, 1038-1046. 
99 Junge, B.; Matzke, M,; Stoltefuss, J. Handbook of Experimental Pharmacology; Kuhlmann, J.; Puls, W. Eds.; 
Springer: Berlin Heiderberg New York, 1996, 119, 411-482. 
100 a) Paulsen, H.; Stütz, A.E Iminosugars as Glycosidase Inhibitors: Nojirimycin and Beyons,Ed. Wiley-VCH, 
Weinheim, 1999, Chapter 1. b) Jacob, G. S. Curr. Opin. Struct. Biol. 1995, 5, 605-611. 
101 Jespersen, T. M.; Dong, W.; Sierks, M. R.; Skrydstrup, T.; Lundt, I.; Bols, M. Angew. Chem. Int. Ed. Engl. 
1994, 33, 1778-1779. 
102 Jakobsen, P.; Lundbeck, J. M.; Kristiansen, M.; Breinholt, J.; Demuth, H.; Pawlas, J.; Torres Candela, M. P.; 
Andersen, B.; Westergaard, N.; Lundgren, K.; Asano, N. Bioorg. Med. Chem. 2001, 9, 733-744. 
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        N-Hydroxyethyl deoxynojirimycin 
        (22, Miglitol®) 
 
             Acarbose (18, Glucobay®) 
       IC50 = 0.5 μg/ml, porcine intestinal sucrase [95] 
 
 
IC50 Enzyme [Ref] 
  
 18 μM α-glucosidase (yeast) [97] 
 53 μM sucrase (porcine intestinal) [97] 
 340 μM maltase (porcine intestinal) [97] 
 1 mM isomaltase (porcine intestinal) [97] 
 
HO
HO
HO
OH
NH2
 
 
Valienamine (19) 
  
  
  
 190 μM α-glucosidase (yeast) [97] 
 49 nM sucrase (porcine intestinal) [97] 
 2.2 μM maltase (porcine intestinal) [97] 
 2.7 μM isomaltase (porcine intestinal) [97] 
  
 
HO
HO
HO
OH
NH2
HO
 
 
Valiolamine (20) 
  
  
  
  
 4.6 nM sucrase (porcine intestinal) [98] 
 15 nM maltase (porcine intestinal) [98] 
  
  
 
HO
HO
HO
OH
N
H
HO
OH
OH
 
 
Voglibose (21, Basen®) 
  
  
  
  
 0.7 μM hepatic glycogen phosphorylase [102] 
 0.11 μM β-glucosidase (almonds) [101] 
  
  
 
NH
HO
HO
HO  
 
Isofagomine (23)   
Scheme 22: Glycosidase inhibitors as anti-diabetic agents. IC50 toward various enzymes. 
OHO
OH
Me
O
OHO
OH
O
OH
OHO
OH
OH
OH
HO
OH
HO N
H
HO
NHO
HO
OH
OH CH2CH2OH
Introduction 
 
 
36 
1.6.1.2. Antiviral treatment 
Glycosidase inhibitors may also provide useful antiviral drugs as viruses carried coat 
glycoproteins which play an important role in their adhesion and their infectivity to cells. 
Thus, compounds that interfere with the glycosylation processes of viral glycoproteins can be 
expected to act as antiviral agents. An example of this strategy is illustrated by TM (1) which 
has been found to reduce transport of influenza viral glycoproteins to the cell surface.103 
Moreover, it has been shown that the absence of the carbohydrate side-chain from the viral 
glycopeptides of Herpes simplex type 1 virus particles grown in the presence of tunicamycin, 
does not affect the overall integrity of the virions but significantly decreases infectivity.104  
 
α-Glucosidase inhibitors, such as DNJ105 (4), N-butyl-deoxynojirimycin106 (24, Bu-DNJ, 
Scheme 24) and CST107 (8) are potent inhibitors of human immunodeficiency virus (HIV) 
replication.108 All sugars mimetics showing anti-HIV activity have the common property to be 
potent inhibitors of processing α-glucosidase I. It is presumed that the anti-HIV activity 
results from the inhibition of processing ER α-glucosidase I, since there is a good correlation 
between the potency of inhibition toward this enzyme and viral control. Treatment of HIV-1-
infected cells with an inhibitor such as Bu-DNJ causes a reduction of the release of infectious 
viruses.109 This reduction is not induced by a decrease in the numbers of viral particles but of 
the modification of the structures of these particles rendering them unable to infect cells. 
Indeed, the process of fusion between the virus and the membrane of CD4 lymphocytes is 
prevented since gp120, the protein which is essential for the binding to CD4 lymphocyte is 
misfolded.110  
                                                 
103 Saito, T.; Yamaguchi, I. J. Vet. Med. Sci. 2000, 62, 575-581. 
104 a) Katz, E.; Margalith, E.; Duksin, D. Antimicrobial Agents Chemotherapy 1980, 17, 1014-1022. b) Elbein, 
A. D. Ann. Rev. Biochem. 1987, 56, 497-534. c) Schwarz, R. T.; Datema, R. Adv. Carbohydrate Chem. 
Biochem. 1982, 40, 287-379. 
105 Sunkara, P. S.; Bowlin, T. L.; Liu, P. S.; Sjoerdsma, A. Biochem. Biophys. Res. Comm. 1987, 148, 206-210. 
106 a) Karlsson, G. B.; Butters, T. D; Dwek, R. A.; Platt, F. M. J. Biol. Chem. 1993, 268, 570-576. b) Dedera, D.; 
Vander Heyen, N.; Ratner, L. AIDS Res. Hum. Retrovirus 1990, 6, 785-794. c) Karpas, A.; Fleet, G. W.; 
Dwek, R. A.; Tetursson, S.; Namgoong, S. K. and al. Proc. Natl. Acad. Sci. USA 1988, 85, 9229-9233. 
107 Walker, B. D.; Kowalski, M.; Goh, W. C.; Kozarsky, K.; Krieger, M.; Rosen, C.; Rohrschneider, L.; 
Haseltine, W. A.; Sodroski, J. Proc. Natl. Acad. Sci. 1987, 84, 8120-8124. 
108 Robina, I.; Moreno-Vargas, A. J.; Carmona, A. T.; Vogel, P. Curr. Drug Metabolism 2004, 5, 329-361. 
109 a) Taylor, D. L.; Nash, R.; Fellows, L. E.; Kang, M. S.; Tyms, A. S. Antiviral Chem. Chemother. 1992, 3, 
273-277. b) Fischer, P. B.; Collin, M.; Karlsson, G. B.; James, W.; Butters, T. D.; Davis, S. J.; Gordon, S.; 
Dwek, R. A.; Platt, F. M. J. Virol. 1995, 69, 5791-5797. 
110 Dwek, R. A.; Butters, T. D.; Platt, F. M.; Zitzmann, N. Nat. Rev. Drug Discov. 2002, 1, 65-75. 
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Side effects such as diarrhea and problems in achieving therapeutic serum concentrations of 
Bu-DNJ needed to inhibit α-glucosidase I in humans may limit the practical use of this drug 
as an anti-HIV agent.111  
 
Clinical trials combining Bu-DNJ (24) and zidovudine a nucleotide analogue (25, AZT, 
Scheme 23)112 in a double-blind, randomized, multi-site Phase II study of 118 patients 
suggested that Bu-DNJ presents an anti-HIV activity. Nevertheless, diarrhea limited the 
maximum dose tolerated and precluded its use as an anti-HIV agent. To avoid this problem, 
the Bu-DNJ tetrabutanoate commercialized under the name glycovir (27, Scheme 24) was 
developed as a candidate for the treatment of AIDS (acquired immune deficiency syndrome). 
This prodrug is thought to be converted into the active Bu-DNJ after its passage through the 
intestine, thus avoiding diarrhea.113 Other prodrug forms of Bu-DNJ, such as perbutyrylated 
ester, have been prepared to reduce gastrointestinal toxicity.114  
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N-Butyl-deoxynojirimycin (24, Bu-DNJ) 
IC50 = 56 μM, anti HIV activity [112] 
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Zidovudine (25, AZT®) 
IC50 = 0.1 μM, anti HIV activity [112] 
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6-O-Butanoylcastanospermine (26, Bu-Cast) 
IC50 = 1.1 μM, anti HIV activity [112] 
NHO
HO
OC(O)CH2CH2CH3
OH Bu
 
(27, Glycovir®) 
Scheme 23: Structures of anti-HIV agents. 
 
Another α-glucosidase inhibitor, currently undergoing Phase I clinical trials against HIV is 6-
O-butanoylcastanospermine (26, Bu-Cast, Scheme 23). Its activity was compared with other 
inhibitors of glycoprotein-processing enzyme such as DNJ (4), Bu-DNJ (24) and CST (9), and 
                                                 
111 Mehta, A.; Zitzmann, N.; Rudd, P. M.; Block, T. M.; Dwek, R. A. FESB Lett. 1998, 430, 17-22. 
112 Taylor, D. L.; Sunkara, P. S.; Liu, P. S.; Kang, M. S.; Bowlin, T. L.; Tyms, A. S. AIDS 1991, 5, 693-698. 
113 Cook, C. S.; Karabatsos, P. J.; Schoenhard, G. L.; Karim, A. Pharm. Res. 1995, 12, 1158-1164. 
114 Fischl, M. A.; Resnick, L.; Coombs, R.; Kremer, A. B.; Pottage, J. C.; Fass, R. J.; Fife, K. H.; Powderly, W. 
G.; Collier, A. C.; Aspinall, R. L. J. Acquir. Immun. Defic. Syndr. 1994, 7, 139-147. 
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compound 26 was the most potent against HIV.112 An additional study reported that Bu-Cast 
was about 30 fold more potent than the parent CST for the inhibition of HIV replication in 
CD4+ T lymphocytes and for the inhibition of glycoprotein processing. This improved 
activity in vitro is probably the result of enhanced cellular uptake, suggesting that Bu-Cast 
may be hydrolyzed intracellularly to castanospermine through the action of cellular 
esterases.115  
 
The treatment of the influenza virus can be achieved by zanamivir (28, Relenza®, Scheme 24) 
and oseltamivir (29, Tamiflu®, Scheme 24) which are neuraminidase inhibitors. After 
replication of the virus in the host cell, the virus binds to an inside cell-membrane 
glycoprotein containing a sialic acid (SA). The viral neuraminidase, found on the surface of 
the virus, cleaves this SA residue and enables the progeny virion to leave the infected cells. 
Thus, by blocking the release of the newly formed viral particles, neuraminidase inhibitors 
prevent further spread of the virus.116 Both compounds 28 and 29 have been found to be 
highly potent inhibitors of the influenza neuraminidase and to inhibit influenza A and B virus 
infection in humans for both prophylactic and therapeutic treatments.117 Zanamivir has low 
bioavailability and is administrated by inhalation, which can cause problems in patients with 
underlying respiratory disease. In contrast, the more lipophilic prodrug oseltamivir has a very 
high oral bioavailability and is readily absorbed from the gastrointestinal tract, converted by 
hepatic esterase to the active form of the compound and is finally distributed in the body. 118 
Presently, the only potential drug for the pandemic threat of H5N1 influenza is oseltamivir, 
administrated in capsule.119  
 
O
NHCOCH3
N
OHO
NH2
NH2
OH
OH
OH
 
(28, Zanamivir, Relenza®) 
< 1ng/ml, Influenza A, B, neuraminidase [117] 
 
NHCOCH3
O NH2
OEtO  
(29, Oseltamivir, Tamiflu®) 
< 1ng/ml, Influenza A,B, neuraminidase [117] 
Scheme 24: Neuraminidase inhibitors as antiviral agents.  
                                                 
115 Taylor, D. L.; Kang, M. S.; Brennan, T. M.; Bridges, C. G.; Sunkara, P. S.; Tyms, A. S. Antimicrob. Agents 
Chemotherapy 1994, 38, 1780-1787. 
116 Moscona, A. N. Engl. J. Med. 2005, 353, 1363-1373. 
117 de Clercq, E. Nature Rev. Drug Discovery 2006, 5, 1015-1025. 
118 Farina, V.; Brown, J. D. Ange. Chem. Int. 2006, 45, 7330-7334. 
119 Wei, D.-Q.; Du, Q.-S.; Sun, H.; Chou, K.-C. Bio. Biophys. Res. Comm. 2006, 344, 1048-1055. 
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1.6.2. Therapeutic applications related to cancer treatment 
1.6.2.1. Glycosylation and cancer 
Glycosylation has been documented for human cancer, and it has been found that both 
catabolic and glycoprotein-processing glycosidases are involved in the transformation of 
normal cells to cancer cells. Glycans expressed by diseased cells are displayed at different 
levels or with different structures than by normal cells.120 Many tumor cells display aberrant 
glycosylation due to an altered expression of glycosyltransferases.121 It has also been known 
for a long time that the levels of glycosidases are elevated in the serum of many patients with 
various tumors,122 and some secreted glycosidases are involved in the degradation of the 
extracellular matrix in tumor cell invasion.123 Consequently, these enzymes constitute 
valuable targets for cancer treatment. In addition, alteration in the protein folding in tumor 
cells results in the destabilization of the tertiary structure, defects in glycoprotein recognition 
and thus elimination by the cell quality control.124 This mechanism can be detrimental for the 
tumor cell and induce its elimination by the organism or beneficial and promote tumor 
progression.  
 
Glycans are involved in many steps of the metastasis which is the primary cause of morbidity 
and mortality in cancer patients. For metastasis to occur, a number of highly specialized 
events must happen, including detachment from the original tumor, invasion through the 
extracellular matrix (ECM) and into the vascular or lymphatic system, extravasation from the 
vessel into the host tissue, and proliferation to a secondary site (Scheme 25).125 Several 
critical steps in this metastatic cascade depend on cell-to-cell or cell-to-matrix interactions 
that involve cell surface molecules. Consequently, changes in oligosaccharides structures on 
the cell surface may have a strong influence on the behaviour of malignant cells.126  
                                                 
120 Dube, D. H.; Bertozzi, C. R. Nat. Rev. Drug Discov. 2005, 4, 477-488. 
121 Hakomori, S.-I. Cancer Res. 1985, 45, 2405-2414. 
122 Woollen, J. W.; Turner, P.; Clin. Chim. Acta 1965, 12, 671-683. 
123 Bernacki, R. J.; Niedbala, M. J.; Korytnyk, W.; Cancer Metastasis Rev. 1985, 4, 81-101. 
124 Dennis, J. W.; Granovski, M.; Warren, C. E. BioEssays 1999, 21, 412-421. 
125 Fuster, M. M.; Esko, J. D.; Nat. Rev. Drug Discov. 2005, 5, 526-542. 
126 a) Hakomori, S.-I. Cancer Res. 1996, 56, 5309-5318. b) Roberts, J. D.; Klein, J.-L. D.; Palmantier, R.; 
Dhume, S. T.; George, M. D.; Olden, K. Canc. Detect. Prev. 1998, 22, 455-462. 
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Scheme 25: Metastasis cascade. 
 
Most classes of glycans exist as membrane-bound glycoconjugates or as secreted molecules, 
which can become integral parts of the ECM. These locations place glycans in a position to 
mediate cell adhesion and motility, as well as intracellular signalling events.127  
 
In the tumor environment, changes in glycosylation allow neoplastic cells to mimic many of 
the events that occur during the development which allows tumor cells to invade and spread 
throughout the organism.128 Examples of the importance of glycans are described below 
according to the main stages of tumor progression.  
 
During tumor invasion, tumor cells detach one from another and from the ECM and migrate 
through neighbouring tissue.129 Tumors also generate glycoconjugates that appear to serve a 
repulsive role, physically facilitating the detachment of invasive cells from the primary tumor. 
Indeed, tumor cells tend to produce increased levels of glycoconjugates containing sialic acid, 
an acidic sugar that imparts a negative charge to the glycans chains. The formation and the 
                                                 
127 Varki, A.; Cummings, R.; Esko, J.; Freeze, H.; Hart, G.; Marth, J. Essentials of Glycobiology, Published by 
Cold Spring Harbor Laboratory Press, 1999, 515-536. 
128 Varki, A.; Cummings, R.; Esko, J.; Freeze, H.; Hart, G.; Marth, J. Essentials of Glycobiology, Published by 
Cold Spring Harbor Laboratory Press, 1999, 537-549. 
129 Nicolson, G. Cancer Metastasis Rev. 1988, 7, 143-188. 
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overexpression of polysialic acid occur in some tumor cells.130 Enhanced sialic acid 
expression might promote cell detachment from the tumor mass through charge repulsion, 
which physically inhibits cell-cell apposition. Polysialylation is often associated with the 
increased invasive potential of tumor cells and its expression correlates with poor prognosis. 
Inhibitors of specific enzymes of the tumor cell glycosylation pathways could avoid this 
polysialylation and thus prevent detachment of tumor cells. 
 
Invasion by tumor cells also involves the alteration of cell-matrix interactions, which are 
mediated by adhesion molecules present on the tumor cells that bind to ECM components. 
Malignant cells commonly exhibit increased expression of complex β1,6-branched N-linked 
glycans on their surface, caused by an increase in the expression of the enzyme N-
acetylglucosamine transferase V (GlcNAcTV).131 In the Golgi, this enzyme transfers a 
GlcNAc residue onto growing N-linked glycans so that subsequent glycosylation results in 
“multi-antennary” chains.132 In tumor cells, the presence of such complex β1,6-glycans on E-
cadherin, an adhesion molecule that mediates cell aggregation, reduces tumor cell-cell 
adhesion.133 Therefore, increased expression of this enzyme by tumor cells promotes 
detachment and invasion. The same strategy occurs with integrins. The biological role of 
these adhesion molecules is modified by tumor cells through an altered glycosylation. 
Integrins represent a crucial class of cell-surface adhesion receptors that mediate attachment 
to important ECM protein ligands such as fibronectin and laminin. Increased GlNAcTV 
expression results in increased β1,6-glycans on integrins which disrupts the ability of 
integrins to bind ECM proteins. This alteration also increases tumor motility through the 
ECM as well as invasion across basement membranes.134 Alteration of this abnormal 
glycosylation process with inhibitors of glycosidases that may act before the GlNAcTV would 
prevent the invasion of tumor cells and thus control cancer progression.  
                                                 
130 a) Seidenfaden, R.; Krauter, A.; Schertzinger, F.; Gerardy-Schahn, R.; Hildebrandt, H. Mol. Cell. Biol. 2003, 
23, 5908-5918. b) Dennis, J. W.; Pawling, J.; Cheung, P.; Partridge, E.; Demetriou, M. Biochim. Biophys. 
Acta 2002, 1573, 414-422. 
131 Dennis, J. W.; Granovsky, M.; Warren, C. E. Biochim. Biophys. Acta 1999, 1473, 21-34. 
132 a) Goss, P. E.; Baker, M. A.; Carver, J. P.; Dennis, J. W. Clin. Cancer Res. 1995, 1, 935-944. b) Varki, A.; 
Cummings, R.; Esko, J.; Freeze, H.; Hart, G.; Marth, J. Essentials of Glycobiology, Published by Cold Spring 
Harbor Laboratory Press, 1999, 85-100. 
133 Yoshimura, M.; Ihara,Y.; Matsuzawa, Y.; Taniguchi, N. J. Biol. Chem. 1996, 271, 13811-13815. 
134 Guo, H. B.; Lee, I.; Kamar, M.; Aklyama, S. K.; Pierce, M. Cancer Res. 2002, 62, 6837-6845. 
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1.6.2.2. Glycosidase inhibitors as potent anti-cancer agents  
Therapeutic targeting of the altered glycosylation pathways of tumor cells should be 
considered as anti-proliferative approaches. For example, the blockage of tumor N-
glycosylation through the inhibition of GlcNAcTV and the blockage of sialylation pathways 
might offer promising strategies.135 Nevertheless, there have been no specific inhibitors of 
GlcNATV reported so far. On the other hand, isoenzymes ST8SiaII and ST8SiaIV that 
catalyses the synthesis of polysialic acid in mammalian cells can be inhibited using synthetic 
sialic acid precursors.136 But the use of these agents in vivo has not been reported yet. These 
two strategies still need further investigation to be validated.  
 
However, the use of glycosidase inhibitors has recently appeared as a promising approach to 
treat cancers.137 Transferases, α-glucosidases and α-mannosidases are the most relevant 
targets in the field of cancer for the development of cellular glycosidases inhibitors.  
 
Tunicamycin (1), which inhibits the first step of N-oligosaccharides biosynthesis, has been 
shown to exhibit antimetastatic activity by reducing the adhesion of tumor cells to the 
vascular endothelium.138 Moreover, TM significantly enhanced in vitro the sensitivity of head 
and neck carcinoma cells to cisplatin (cis-diaminedichloroplatinum(II)) a drug widely used to 
treat different cancers including testicular, head and neck, bladder and lung cancer. 
Furthermore, in vivo administration of TM in combination with cisplatin significantly 
inhibited local tumor growth and increased apoptosis of cisplatin-resistant tumor cells as 
compared to cisplatin alone.139  
                                                 
135 Granovsky, M.; Fata, J.; Pawling, J.; Muller, W. J.; Khokha, R.; Dennis, J. W. Nature Med. 2000, 6, 306-312. 
136 Horstkorte, R.; Mühlenhoff, M.; Reutter, W.; Nöhring, S.; Zimmermann-Kordmann, M.; Gerardy-Schahn, R. 
Exp. Cell. Res. 2004, 298, 268-274. 
137 Humphries, M. J.; Olden, K. Pharmac. Ther. 1989, 44, 85-105. 
138 Humphries, M. J.; Matsumoto, K.; White, S. L.; Olden, K. Cancer Res. 1986, 46, 5215-5222. 
139 Noda, I.; Fujieda, S.; Seki, M.; Tanaka, N.; Sunaga, H.; Ohtsubo, T.; Tsuzuki, H.; Fan, G.-K.; Saito, H. Int. J. 
Cancer 1999, 80, 279-284. 
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Castanospermine (8), which is a potent inhibitor of α-glucosidase I, was tested for its potency 
to inhibit the ability of metastatic cells to cause platelet aggregation. Spearman and al. 
developed a series of T24-H-ras-transformed 10T1/2 fibroblasts, which display varying 
metastatic potential to form lung tumors when injected into the tail vein of syngeneic mice. 
When grown in the presence of CST (50 μM) and injected in mice, a significant reduction in 
their ability to aggregate platelets was observed and correlated with the ability of CST to 
inhibit tumor lung colonization by the treated cells.140 
 
Other in vivo experiments with CST resulted in significant inhibition of tumor growth in nude 
mice. Indeed, tumor growth inhibition in animals treated with CST was about 50% less than 
in control animals when measured 13 days after treatment. However, little or no regression 
was observed when animals, treated with CST, were bearing large tumors (> 1cm). Since 
angiogenesis is an important contributor to tumor growth, the effect of CST on 
neovascularisation in vivo was assessed. Control animals exhibited a strong angiogenic 
response with abundant vessels while CST-treated animals showed significantly less 
vascularisation when injected with 50 mg CST/mouse/day. Moreover, in endothelial cells 
grown in vitro, CST or Me-DNJ (5) prevented capillary-like structure formation. Indeed, the 
ability of endothelial cells to adhere to extracellular matrix proteins was retained but CST- or 
Me-DNJ-treated cells exhibited increased cell aggregation and reduced cell migration, thus 
preventing their alignment and organization to form tubular structures. These results suggest 
that CST and Me-DNJ increased cell-cell adhesion by glycoside-dependent interactions 
resulting in the blockage of the reorganization of cells into capillary-like networks.141  
 
Analogues of the natural ester Sintenin (30, Scheme 26), displaying moderate inhibitory 
activity toward α-glucosidase, exhibited significant cytoxicity toward human tumor cell lines 
from hepatocellular, nasopharyngeal, lung, prostate and cervical (adeno)carcinoma.142  
 
                                                 
140 Spearman, M. A.; Ballon, J. M.; Gerrard, J. M.; Greenberg, A. H. Wright, J. A. Cancer Lett. 1991, 60, 185-
191. 
141 Pili, R.; Chang, J.; Partis, R. A.; Mueller, R. A.; Chrest, F. J.; Passaniti, A. Cancer Res. 1995, 55, 2920-2926. 
142 Hu, L. H.; Zou, H. B.; Gong, J. X.; Li, H. B.; Yang, L. X.; Cheng, W.; Zhou, C. X.; Bai, H.; Guéritte, F.; 
Zhao, Y. J. Nat. Prod. 2005, 68, 342-348. 
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Streptozotocin (31, STZ, Scheme 26), a β-glycosidase inhibitor increased median survival of 
patients with metastatic pancreatic carcinoma of 64 weeks in combination with 5-fluorouracil. 
In combination with 5-fluorouracil and mitomycin, 31 increased median survival for 10 
months.143 STZ has been approved by the FDA (U.S. Food and Drug Administration) for 
treating metastatic cancer of pancreatic islet cells. Since the drug caries a substantial risk of 
side effects, due its toxicity against the insulin-producing beta cells of the pancreas, its use is 
generally limited to patients that can not be treated by other drugs.144  
 
 
 R1 R2 R3 IC50 Enzyme [Ref] 
 OMe OMe OMe  110 μM α-glucosidase [142] 
 H OH H  65 μM α-glucosidase [142] 
 OH OH H  97 μM α-glucosidase [142] 
O
O
R3
R3
R3R1
R2
R3
 
 
Analogues of Sintenin (30)       
 
    
    
    
    
OHO
HO
HN
OH
ON
N
Me
O
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Streptozotocin (31) 
    
Scheme 26: Anti-cancer agents based on glycosidase inhibition. 
 
 
Although a number of polyhydroxylated alkaloids have been reported to show anti cancer 
activity, research has concentrated on the development of Swa (16, Scheme 20) as a drug 
candidate for the management of human malignancies. Experiments have shown that Swa has 
a complex mode of action such as inhibiting the growth of tumor cells, preventing the 
dissemination of malignant cells from the primary tumor to secondary sites and stimulating 
effect of the immune system.145 Theses point will be discussed more in details below.  
 
                                                 
143 Bukowski, R. M.; Schacter, L. P.; Groppe, C. W.; Hewlett, J. S.; Weick, J. K.; Livingston, R. B. Cancer 
1982, 50, 197-200. 
144 Schnedl, W. J.; Ferber, S.; Johnson, J. H.; Newgard, C. B. Diabetes 1994, 43, 1326-1333. 
145 Olden, K.; Breton, P.; Grzegorzewski, K,; Yasuda, Y.; Gause, B. L.; Oredipe, O. A.; Newton, S. A.; White, S. 
L. Pharmacol. Ther. 1991, 50, 285-290. 
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The effect of Swa on different human cancer cell lines was evaluated. Treatment of human 
hepatoma cells with Swa resulted in an accelerated secretion of hybrid forms of the 
glycoproteins transferin, ceruloplasmin, α2-macroglobulin and α1-antitrypsin, whereas the 
secretion of non-glycoproteins was not affect. Moreover, the transport of these hybrid 
glycoproteins through the Golgi apparatus was faster than the transport of normal 
glycoproteins.146 These results highlight the capacity of Swa to modify the metabolism of 
glycoproteins and thus their biological activity.  
 
The decrease of tumor cell proliferation by Swa seems to be related to its activity on the 
inhibition of the processing of asparagine-linked oligosaccharides. Indeed, neoplastic 
transformation in both human and rodent tumor cells is often accompanied by increasing 
expression of β-1,6-branched oligosaccharides.147 Swa is known to block the expression of 
complex-type oligosaccharides in malignant cells by its ability to inhibit Golgi α-
mannosidase II.15b It seems that loss or truncation of β-1,6-branched oligosaccharides in 
metastatic tumor cells reduces cell motility by increasing cell adhesion.148 In vitro, Swa 
increased the adhesion of bladder cancer cells to laminin, collagen IV and fibronectin.149 
Consequently, Swa reduced their capacity to invade other tissues and also reduced solid tumor 
growth.  
 
Using Swa, Humphries and al. tested the hypothesis that specific glycans structures are 
required for pulmonary colonization by tumor cells. B16-F10 murine melanoma cells were 
treated with Swa in growth medium and then injected intravenously into syngeneic C57BL/6 
mice. This treatment resulted in dramatic inhibition of colonization, but it had no effect on 
B16-F10 viability or tumorigenicity after subcutaneous implantation. Swa-treated 
radiolabeled B16-F10 cells were cleared from the lungs at a greater rate than control cells, 
suggesting that one effect of the treatment is to alter tumor cell retention in the target organ. 
These results implicate specific glycans structures in pulmonary colonization involved in 
tumor cell-organ recognition during metastasis.150 Similarly, both the lymphoid tumor cell 
line MDAY-D2 and B16-F10 melanoma cells were less metastatic when grown in Swa (0.3 
μg/ml) for 48 hours prior to injection of the cells into the lateral tail veins of mice. 
                                                 
146 Yeo, T.-K.; Yeo, K.-T.; Parent, J. B.; Olden, K. J. Biol. Chem. 1985, 260, 2565-2569. 
147 Pierce, M.; Arango, J. J. Biol. Chem. 1986, 261, 10772-10777. 
148 Dennis, J. W.; Koch, K.; Yousefi, S.; VanderElst, I. Cancer Res. 1990, 50, 1867-1872. 
149 Przybylo, M.; Litynska, A.; Pochec, E. Biochimie 2005, 87, 133-142. 
150 Humphries, M. J.; Matsumoto, K.; White, S. L.; Olden, K. Proc. Natl. Acad. Sci. USA 1986, 83, 1752-1756. 
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Furthermore, the addition of Swa (2.5 μg/ml) to the drinking water of the mice further 
reduced the incidence of lung colonization by B16-F10 melanoma cells.151 In experimental 
murine cancer models, administration of Swa in drinking water, before or after surgical 
excision of the primary tumor, inhibited by 95 and 88% the formation of spontaneous 
metastases to the liver and lungs of the highly invasive M5076 murine reticulosarcoma or 
B16-F10 murine melanoma cells.145  
 
There is also considerable evidence that Swa enhances the natural antitumor defences of the 
body.152 This information comes from the ability of Swa to activate immune effector cells 
such as natural killer cells,153 T-lymphocytes and macrophages.154 It seems that the anti-tumor 
properties of these cells are apparent only after they have been activated. Swa can also induce 
tumouricidal activity in resident tissue macrophages of both the lung and spleen, their 
activation being both time- and dose-dependent.154b This is relevant to the clinical 
management of metastatic diseases since visceral organs are common sites of metastasis.  
 
Since all cellular glycoproteins which normally express complex-type oligosaccharides are 
affected by Swa treatment, investigations were carried out to determine whether the effects of 
Swa on cellular proliferation could be widespread amongst non-transformed tissues in the 
body. These studies showed that the effects of this compound would appear to be cell-
specific, since it does not equally affect the processing of all glycoproteins.155 Moreover, the 
systemic administration of high doses of Swa to sheep induces mannosidosis.156 However, no 
evidence of an overt toxic reaction was observed when Swa was administrated orally to 
rodents157 so it was considered that the mannosidosis induced by Swa could be species- or 
tissue specific phenomena.158  
                                                 
151 Dennis, J. W. Cancer Resarch 1986, 46, 5131-5136. 
152 Kino, T.; Inamura, N.; Nakahara, K.; Kiyoto, S.; Goto, T.; Terano, H.; Kohsaka, M.; Aoki, H.; Imanaka, H. J. 
Antibiot. 1985, 38, 936-940. 
153 Humphries, M. J.; Matsumoto, K.; White, S. L.; Molyneux, R. J.; Olden, K. Cancer Res. 1988, 48, 1410-
1415. 
154 a) White, S. L.; Nagai, T.; Akiyama, S. K.; Reeves, E. J.; Grzegorzewski, K.; Olden, K. Cancer commun. 
1991, 3, 83-91. b) Das, P. C.; Roberts, J. D.; White, S.; Olden, K. Oncology research 1995, 7, 425-433. 
155 Spearman, M. A.; Damen, J. E.; Kolodka, T.; Greenberg, A. H.; Jamieson, J. C.; Wright, J. A.; Cancer Lett. 
1991, 57, 7-13. 
156 Huxtable, C. R.; Dorling, P. R. Am. Assoc. Pathol. 1982, 107, 124-126. 
157 Huxtable, C. R.; Dorling, P. R. Acta Neuropathol. 1985, 68, 65-73. 
158 Tulsiani, D. R. P.; Touster, O. J. Biol. Chem. 1987, 262, 6506-6514. 
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These results were so encouraging that the efficacy of Swa was examined in phase I clinical 
trials in humans with advanced malignancies. In the first study, Swa was administrated to 
nineteen terminally-ill cancer patients with leukemia, breast, colon, lung, pancreatic, or head 
and neck cancers by continuous intravenous infusion over 5 days in the dose range from 50 to 
550 μg/kg/day, repeated at once 28 days intervals. The serum concentrations of this drug 
reached 3 to 11.8 mg/l which is 100 to 400 times greater than the 50% inhibitory 
concentration for Golgi α-mannosidase II and lysosomal α-mannosidase.159 Nevertheless, the 
patients had elevated levels of the liver enzyme aspartate aminotransferase in the serum that 
was indicative of hepatic toxicity and they also suffered from pulmonary and peripheral 
oedema. However, the patients with head and neck cancer presented a decrease of the tumor 
progression and two others showed symptomatic improvement.160 A second clinical trial was 
undertaken to evaluate Swa by oral administration twice a week (dose range 50 to 600 μg/kg) 
to sixteen patients with advanced malignancies. Serum drug levels peaked 3 to 4 hours 
following a single oral dose. The maximum dose tolerated was found to be 300 μg/kg/day due 
to an increased level of aspartate aminotransferase in the serum and dyspnea similar to that 
observed in the previous trial.161 Other side effects were observed included fatigue, anorexia, 
abdominal pain and neurological symptoms.  
 
Seventeen patients with locally advanced or metastatic kidney carcinoma were enrolled in a 
phase II trial to assess the efficacy of oral chronic administration of GD0039 (Hydrochloride 
salt of Swa). Unfortunately, no evidence of anti-tumor activity of GD0039 was seen in this 
study and the seventeen patients discontinued the treatment due to toxicity.162 Adverse events 
such as fatigue, anorexia, nausea and diarrhea were also observed.  
 
In order to avoid these side effects, analogues of Swa with substituents at C(3) position have 
been synthesized in order to improve the selectivity for Golgi α-mannosidase II over 
lysosomal α-mannosidase (32-35, Scheme 27) which are class II retaining enzymes with high 
sequence homology.163 These new derivatives, with α-oriented substituents (32, 34), were 
more potent inhibitors than the corresponding β-analogues (33, 35), which is consistent with 
                                                 
159 Baptista, J. A.; Goss, P.; Nghiem, M.; Krepinsky, J. J.; Baker, M.; Dennis, J. W. Clin. Chem. 1994, 40, 426-
430.  
160 Goss, P. E.; Baptiste J.; Fernandes, B.; Baker, M.; Dennis, J. W. Cancer Res. 1994, 54, 1450-1457. 
161 Goss, P. E.; Reid, C. L.; Bailey, D.; Dennis, J. W. Clin. Cancer. Res. 1997, 3, 1077-1986. 
162 Shaheen, P. E.; Stadler, W.; Elson, P.; Knox, J.; Winquist, E.; Bukowski, R. M. Invest. New Drugs 2005, 23, 
577-581. 
163 Liao, Y.-F.; Lal, A.; Moremen, K. W. J. Biol.Chem. 1996, 271, 28348-28358. 
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the hypothesis that the C(3) substituent mimics the α-oriented carbohydrate that should be 
hydrolyzed by the α-mannosidase.164  
 
Inhibitors with small substituents at C(3) position were not as potent as Swa, however 
derivatives 32 presented interesting biological properties toward jack bean α-mannosidase as 
they were more potent inhibitors of this enzyme than Swa. On the other hand, ring-expanded 
analogues165 of Swa or derivatives of Swa166 with substituents at C(6) and C(7) were not 
active toward the α-mannosidase from jack bean (structures not shown). 
 
N
OH
OHH
OH
CH2OCH2Ar  
(32) 
N
OH
OHH
OH
CH2OCH2Ar  
 
(33) 
 Ar IC50  (jack bean) [164b] IC50 (jack bean) [164b] 
 Ph  0.39 μM  100 μM 
 2-naphtyl  0.11 μM  17 μM 
 4-Ph-Ph  0.08 μM  200 μM 
 4-tBu-Ph  0.05 μM  > 200 μM 
 
N
OH
OHH
OH
CH2OH  
(34) 
IC50 (jack bean) = 1.2 μM [164a] 
 
N
OH
OHH
OH
CH2OH  
(35) 
IC50 (jack bean) = 45 μM [164a] 
Scheme 27: Analogues of Swa with substituents at the C(3) position. IC50 toward jack bean 
α-mannosidase vs Swa IC50 = 0.4-0.1 μM. 
                                                 
164 a) Hembre, E. J.; Pearson, W. H. Tetrahedron 1997, 53, 11021-11032. b) Pearson, W. H.; Guo, L. 
Tetrahedron Lett. 2001, 42, 8267-8271. 
165 Pearson, W. H.; Hembre, E. J. J. Org. Chem. 1996, 61, 5537-5545. 
166 Pearson, W. H.; Hembre, E. J. Tetrahedron Lett. 2001, 42, 8273-8276. 
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Esters analogues of Swa have been synthesized to improve the specificity for Golgi α-
mannosidase II and/or improve pharmacokinetics in order to enhance anti-tumoral effects and 
immune stimulatory activity. The results revealed that carbonoyloxy esters of Swa with 
substitutions at the alcohols on position C(2) and C(8) were 2-3 orders of magnitude less 
active than Swa as α-mannosidase inhibitors toward jack bean α-mannosidase. In vivo, 
among the various carbonoyloxy analogues of Swa, the 2-octanoyloxy-derivative 39 induced 
the highest increased rate of survival of mice 28 days after injection, which is similar to the 
rate obtained with Swa, suggesting that cellular esterases may convert this analogue into Swa 
inside the cells.167  
 
N
O
OHH
OR2
R1
O  
 R1 R2 IC50 (jack bean) [167] 
Swa (16) H H  0.1 – 0.4 μM 
2-benzoyloxy-Swa (36) Bn H  350 μM 
2-toluoyloxy-Swa (47) Bn-CH3 H  350 μM 
2-p-nitrobenzoyloxy-Swa (38) Bn-NO2 H  123 μM 
2-octanoyloxy-Swa (39) (CH2)6CH3 H  123 μM 
2-butanoyloxy-Swa (40) (CH2)2CH3 H  123 μM 
8-palmitoyloxy-Swa (41) H (CH2)14CH3  240 μM 
8-myristinoyloxy-Swa (42) H (CH2)12CH3  > 500 μM 
Scheme 28: Analogues of Swa. IC50 toward jack bean  α-mannosidase.  
                                                 
167 Dennis, J. W.; White, S. L.; Freer, A. M.; Dime, D. Biochem. Pharmacol. 1993, 46, 1459-1466. 
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The following table (Table 1) summarizes the different inhibitors of glycosidases which have 
been studied and have shown interesting properties for the treatment of cancer.168  
 
Compound 
(n°) [Ref] 
Targeted 
glycosidase Type of cancer 
In vitro/ 
In vivo Results 
Inhibition of the 
biosynthesis of 
“14 core unit”  
Squamous cell 
carcinoma of head and 
neck  
In vitro Increased sensitivity of carcinoma cells to cis-platin 
TM 
(1) [139] 
 Cis-platin resistant mouse model In vivo 
Inhibition of local tumor growth by 
administration of TM and cis-platin 
Me-DNJ 
(5) [141] 
α-glucosidase I 
α-glucosidase II Endothelial cells In vitro 
Increased cell aggregation and reduced 
cell migration 
Sintenin 
analogues 
(30) [142] 
α-glucosidase I 
α-glucosidase II 
Hepatocellular, 
Nasopharyngeal,  
Lung,  
Prostate,  
Cervical carcinoma cells 
In vitro Inhibition of growth 
α-glucosidase I Lung In vivo Inhibition of platelets aggregation and tumor lung colonization 
CST (8) 
[140,141] 
 Prostate In vivo Reduction of tumor growth, decrease of blood vessel infiltration 
Golgi  
α-mannosidase II 
Melanoma,  
Reticulocarcinoma,  In vivo 
Inhibition of lung colonization, 
inhibition of metastases formation after 
excision of the primary tumor 
 Bladder cells In vitro 
Increased adhesion of tumor cells to 
laminin, collagen IV and fibronectin. 
Decreased migratory ability 
Swa (16) 
[53, 161] 
[145, 146] 
[149] 
 Advanced tumors Phase I Reduction of tumor mass 
2-carbonoyl-
Swa (38-40) 
[167] 
Poor inhibition of 
α-mannosidases Melanoma In vivo 
Increased rate of survival 28 days after 
injection of treated cancer cells 
Reduction of  
β-glycosidase 
activities in kidney 
Carcinoid tumors Clinical use In combination with 5-florouracil: increased median survival of 64 weeks. 
STZ 
(31) [143] 
 Pancreatic tumors Clinical use 
In combination with 5-florouracil and 
mitomycin: increased median survival of 
10 months. 
Table 1: Glycosidase Inhibitors as Potential Anti-cancer agents. 
 
                                                 
168 Gerber-Lemaire, S.; Juillerat-Jeanneret, L. Mini-Rev. Medicinal Chem. 2006, 6, 1043-1052. 
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Recently the Vogel’s group has initiated a search for new potent inhibitors of α-mannosidase 
II with the hope to uncover a new anti-cancer lead. A combinatorial method was developed 
for the rapid discovery of inhibitors of α-mannosidase from jack bean (Scheme 29).169  
 
N
H
OHHO
NH2 + RCHO
N
H
OHHO
N
Measurement of
the inhibitory
activity
H2O + R
fast
 
 43       44 
Scheme 29: Combinatorial methodology. 
 
 
In this approach, amine 43 was mixed with a panel of commercially available aldehydes, in 
water and at low concentration, then the jack bean α-mannosidase was added to the 
corresponding imines (44) allowing direct measurement of the inhibitory ability of these 
imines. The equilibrium constant for imine formation from these partners was particularly 
high, due to an intramolecular promoting effect of the secondary β-amino moiety. It was also 
established that the imines were valid models of the corresponding diamines for the inhibitory 
ability.  
 
Thus, this study allowed the determination of the more appropriate side chains to be 
introduced on the (2R,3R,4S)-2-aminomethylpyrrolidine 3,4-diol core to produce potent 
inhibitors of α-mannosidase from jack bean. Based on this approach, a new family of 
selective and competitive inhibitors of α-mannosidases was disclosed with Ki values ranging 
from 3 μM to 135 nM for the best congeners (45-47, Scheme 30).170  
                                                 
169 Gerber-Lemaire, S.; Popowycz, F.; Rodriguez-Garcia, E.; Carmona Asenjo, A.T.; Robina, I.; Vogel, P. 
ChemBioChem. 2002, 3, 466-470. 
170 a) Popowycz, F.; Gerber-Lemaire, S.; Rodríguez-García, E.; Schütz, C.; Vogel, P. Helv. Chim. Acta 2003, 86, 
1914-1948. b) Popowycz, F.; Gerber-Lemaire, S.; Schütz, C.; Vogel, P. Helv. Chim. Acta 2004, 87, 800-810. 
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IC50 = 6.2 μM IC50 = 17 μM IC50 = 700 nM 
Ki = 1.2 μM Ki = 2.3 μM Ki = 135 nM 
Scheme 30: Dihydroxypyrrolidine derivatives as potent α-mannosidase inhibitors. IC50 
toward α-mannosidase from jack bean. 
 
 
Five membered iminocyclitols bearing hydroxyl groups have been shown to be potent 
inhibitors of α-mannosidases. The dihydroxypyrrolidine moiety is thought to mimic the shape 
and charge of the transition state of the reacting sugar moiety (49, Scheme 31). This 
pyrrolidine ring is similar to the oxocarbenium ion-like intermediate (48, Scheme 31) but is 
not hydrolysable due to the stability conferred by the nitrogen atom and thus knocks down the 
enzyme activity.171 Furthermore, the five-membered ring confers an additional similitude with 
the oxocarbenium ion-like intermediate where the region around the cation is planar in 
contrast with the chair conformation of the sugar. The (3R,4S) configuration of the hydroxyl 
groups ensures selectivity towards mannosidases because of their similar orientation in space 
with mannose. On the other hand, a (3S,4R) configuration for example would lead to a 
selective inhibition of glucosidases. 
 
 
                                                 
171 Popowycz, F.; Gerber-Lemaire, S.; Demange, R.; Rodríguez-García, E.; Carmona Asenjo, A. T.; Robina, I.; 
Vogel, P. Bioorg. Med. Chem. Lett. 2001, 11, 2489-2493. 
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         48               49 
Scheme 31: Supposed interaction of the natural substrate and the inhibitor in the active site of 
a glycosidase. 
 
 
Moreover, it has been suggested that the binding of a polyhydroxylated alkaloid to the active 
site of a glycosidase, protonation of the compound leads to the formation of an ion pair 
between the inhibitor and a carboxylate anion in the active site of the enzyme. The protonated 
inhibitor closely resembles the transition state of the natural substrate and hence the enzyme 
has a high affinity for the molecule. However, the strength of the binding and consequently 
the effectiveness of the inhibition depend on the ionization state of the inhibitor, dictated by 
its pKa, and the optimal pH of the enzyme.172 
                                                 
172 Lalegerie, P.; Legler, G.; Yon, J. M. Biochimie 1982, 64, 977-1000. 
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2. Aim of the project 
In view of the promising inhibitory activities obtained with compound 47 and analogues on α-
mannosidase from jack bean and the anticancer properties of Swa, our project aimed at the 
development of a new family of anticancer agents based on the inhibition of α-mannosidases 
II.  
 
We were first interested in performing structural analyses with Drosophila melanogaster 
Golgi α-mannosidase II, a reliable model of the human Golgi α-mannosidase II. These data 
will allow us to understand the binding mode of the first lead inhibitor 47 into the active site 
of the enzyme and open the door to a docking study to determine adequate computer tools for 
the prediction of the binding of inhibitors to α-mannosidases II. These analyses will focus our 
attention on various modifications that can be performed in order to improve the inhibitory 
activity of pyrrolidine derivatives previously disclosed in Vogel’s group. Several chemical 
transformations such as the introduction of additional substituents on the pyrrolidine ring and 
derivatization of the primary alcohol will be envisaged (Scheme 32).  
 
 
 
 
 
 
 
Scheme 32: Functionalization of pyrrolidine 47. 
 
 
After these structural modifications, the newly designed derivatives will be evaluated as 
inhibitors of model and human α-mannosidases II. The most active congeners will be further 
assessed for their potential anti cancer properties. Various tumoral cells lines will be tested 
such as glioblastoma (LNZ308 and LN18) and melanoma cells (Me237, Me275). 
Glioblastomas are associated with a high proliferative and invasive potential, multiple 
resistance toward conventional chemotherapeutic agents, and poor prognosis. It is thus of high 
interest to find new molecules that could inhibit the proliferation of these tumours.  
N
H
OHHO
N
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H
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Transformations into : 
- ethers 
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The effect of the pyrrolidine derivatives on the growth of cancer cells will be first measured 
with the MTT ((3,4,5-dimethylthiazol-yl)-2,5-diphenyl tetrazolium) assay, which determines 
the number of metabolically active cells. For the best inhibitors, we will also determine DNA 
synthesis inhibition and protein synthesis inhibition by [3H]-thymidine and [3H]-leucine 
incorporation measurements, respectively. Comparative measurements on healthy cell lines 
from primary fibroblasts (PO05, PG95) will allow us to determine the selectivity of our 
derivatives.  
 
3. Results and Discussion 
3.1. Binding mode of dGMII:47 complex 
In order to determine the different chemical modifications that could enhance the inhibitory 
ability of pyrrolidine derivative 47, elucidation of the binding mode of this compound to α-
mannosidase II represented the first aim of this study. As previously described, dGMII is a 
valid model of the structural and functional features of mammalian Golgi α-mannosidase II. 
In collaboration with the group of Prof. D. Rose (University of Toronto, Canada), we 
investigated the x-ray structure of the dGMII: 47 complex.173  
 
Resolution of the synchrotron collected data at 1.30 Å allowed accurate analysis of the 
binding mode of 47 to the active site of dGMII as depicted in Scheme 33. 
 
 
Scheme 33: Crystal structure of compound 47 complexed to dGMII. Interactions closer than 
3.2 Ǻ are indicated. The interactions with the zinc atom are drawn in magenta, water 
molecules appear as orange balls. Distances are presented in Table 3, page 63. The figure was 
generated with PyMOL. 
                                                 
173 Measurements performed by Dr. D. Kuntz, University of Toronto, Canada.  
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The binding of inhibitor 47 in the active site of dGMII is illustrated in Scheme 33 and a list of 
interactions distance less than 3.2 Å is given in Table 3, page 63. These data revealed tight 
interactions between the hydroxyl groups at C(3) and C(4) positions of the pyrrolidine ring 
and the active site zinc which made additional interactions with His90, Asp92, Asp204 and 
His471. Furthermore, interactions were also revealed between the exocyclic N7 atom in the 
“tail” region of 47 and Asp341 and Tyr269. Trp95 made two important interactions with the 
inhibitors: (i) a T-shaped interaction between the aromatic ring of the inhibitor and the indole 
moiety of Trp95, the two planes being at near right angles of each other and (ii) Trp95 also 
made π-stacking hydrophobic interactions with the pyrrolidine ring, a common feature of 
dGMII complexes.  
 
Comparison of dGMII: 47 structure with dGMII:Swa (dGMII:16) complex revealed that 
major changes of the binding modes of these two inhibitors occurred in the interactions of the 
terminal hydroxyl group (OH-9) of 47 with the active site of dGMII. Furthermore, in the case 
of Swa, an hydroxyl moiety was engaged in tight interactions with Asp472 and Tyr727. In the 
case of 47, the absence of an alcohol group in this region of the active site resulted in a shift 
of 0.6 Å of the hydroxyl moiety of Tyr727 (Tyr727 OH) toward the hydroxyl moiety of 
Asp472 OD1 (Table 3, page 63).  
 
This analysis revealed that the inhibitor 47 made numerous interactions with dGMII active 
site. Nevertheless, the region between Asp472 and Tyr727 should be able to accommodate 
additional substituents on the C(5) position of the pyrrolidine ring. We thus envisaged the 
introduction of a methyl group at this position.  
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3.2. Synthesis and Enzymatic test of 5-methylpyrrolidine-3,4-diol derivatives 
The synthetic pathway started from L-5-trityloxymethyl-2-pyrroldinone (50) which was 
converted into the protected diol 51 in five steps following Ikota’s methodology174 with 20% 
overall yield (Scheme 34). Lactam 51 was treated through a sequence of Grignard addition 
followed by reduction of the resulting methyl ketone moiety and cyclization in basic medium 
to afford pyrrolidines 52 and 53, as a 1:1 mixture of diastereoisomers separable by flash 
chromatography. On both isomers, the trityl protecting group was removed through Birch 
reduction,175 allowing subsequent oxidation of the primary alcohol under Swern176 or Ley’s177 
conditions. The resulting carbaldehydes 54 and 56 were then engaged in a reductive 
amination procedure in the presence of D-(α)-phenylglycinol and NaBH(OAc)3 for in situ 
reduction of the intermediate imines. Acidic removal of acetonide and carbamate protecting 
groups afforded 55 and 57 in 73% and 39% yield, respectively (2 steps). 
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2. (COCl)2, DMSO,
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Scheme 34: Synthesis of 5-methylpyrrolidine-3,4diol derivatives. 
                                                 
174 Ikota, N.; Hanaki, A. Chem. Pharm. Bull. 1989, 4, 1087-1089. 
175 Birch, A. J.; Nasipuri, D. Tetrahedron 1959, 6, 148-153. 
176 Mancuso, A. J.; Swern, D. Synthesis 1981, 3, 165-185. 
177 Ley, S. V.; Norman, J.; Griffith, W. P.; Marsden, S.P. Synthesis 1994, 7, 639-666. 
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The inhibitory ability of 55 and 57 was evaluated on dGMII178 and on 16 commercially 
available glycosidases:179 α-L-fucosidase (bovine kidney), two α-galactosidases (coffee beans 
and Escherichia coli), three β-galactosidases (Escherichia coli, bovine liver and Aspergillus 
orizae), two α-glucosidases (yeast and rice), two amyloglucosidases (Aspergillus niger and 
Rhizopus mold), β-glucosidase (almonds), α-mannosidase (jack beans), β-mannosidase (Helix 
promatia), β-xylosidase (Aspergillus niger) and two β-N-acetylglucosaminidases (jack beans 
and bovine kidney) at the optimal pH value of each enzyme. The collected data were 
compared to the inhibitory ability of compound 47 (Table 2).  
 
  47180 55 57 
β-glucosidase (almonds) Inhibition (%) at 1mM 93% n.i. 94% 
 IC50  46 μM n.d.  40 μM 
 Ki  9.5 μM n.d. n.d. 
α-mannosidase (jack bean) Inhibition (%) at 1mM 100% n.i. 80% 
 IC50  700 nM n.d.  134 μM 
 Ki  135 nM n.d.  53 μM 
α-mannosidase (dGMII) IC50  80 μM 2-3 mM  1mM 
n.i. = no inhibition  n.d. = not determined 
Table 2: Inhibitory ability of derivatives 47, 56 and 57. 
 
 
Pyrrolidine derivative 55 did not display any inhibitory ability toward all the tested 
glycosidases. The other isomer 57 displayed about 200 times less inhibitory ability against α-
mannosidase from jack bean than compound 47 (IC50 = 134 μM for 57 vs 0.7 μM for 47) and 
was also less efficient toward dGMII (IC50 = 1 mM for 57 vs 0.08 mM for 47). The 
introduction of a methyl group at C(5) position of the pyrrolidine ring was thus highly 
detrimental for the inhibition of α-mannosidases. As for compound 47, the other enzymes 
were not affected by 57 except β-glucosidase from almonds (IC50 = 40 μM).  
 
                                                 
178 Enzymatic assays performed according to the procedure described in Kuntz, D. A.; Ghavami, A.; Johnston, B. 
D.; Pinto, B. M.; Rose, D. R. Tetrahedron: Assymetry 2005, 16, 25-32. 
179 Enzymatic assays performed by Catherine Schütz, EPFL. 
180 Popowycz, F. These de doctorat n° 2866, EPFL, 2003. 
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3.3. X-ray analysis of substituted pyrrolidine derivatives 
This new substituted pyrrolidine derivative was also complexed to dGMII and the resulting 
crystal structure was analyzed by x-ray. A similar study was carried out on compound 58, a 
stereoisomer of compound 47. 
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IC50 dGMII (μM):  80 720 1000 
    
B) 
 
   
PDB code:   2F18 2F1A 2F1B 
Resolution (Å):  1.30 1.45 1.45 
Scheme 35: A) Structures of the three hydroxypyrrolidines crystallized in the active site of 
dGMII and their inhibitory ability (IC50) toward dGMII. B) Electron density representation of 
the inhibitors, PDB code and Resolution. The active site zinc ion is represented by the 
magenta ball.  
 
Scheme 35 shows the accuracy of the electron density around the bound pyrrolidine 
inhibitors. The density of 47 and 57 was much cleaner in the “tail” region of the aromatic ring 
than the similar region for inhibitor 58. Indeed, the tail region of 58 was not clearly defined in 
the electron density which means that this region is an unfavourable location, and may be 
oscillating between several positions. Furthermore, this lack of good density correlated well 
with the lowest inhibitory ability of 58 (IC50 = 720 μM vs 80 μM for 47).  
Results and discussion 
 
 
62 
Inhibitors 47 and 57 exhibited virtually identical binding modes in the active site of dGMII 
with the exception of the methyl group on C(5) of the pyrrolidine ring. An overlay of the 
binding mode of compounds 47 and 57, Scheme 36, revealed that the active site region was 
opened up in the structure of 57 compared to structure of 47 whereas the Phe206 and Tyr727 
were pushed away from the inhibitor. The distance between C2 in the inhibitors and CZ of 
Phe206 was 4.8 Å in the dGMII:57 complex, while it was 4.3 Å in the dGMII:47 adduct. The 
Tyr727 OH was shifted 0.4 Å away from C2. The additional methyl group in 57 was in a 
position normally occupied by a polar hydroxyl in other inhibitors; the conformational stress 
put on the enzyme to accommodate its binding might be a reason for the low affinity of 57 
relative to 47 (IC50 = 1000 μM for 57 vs 80 μM for 47). 
 
 
 
 
 
 
 
 
 
 
 
Scheme 36: Overlay of the conformations of the active site residues in the complexes of 47 
(ligand green, protein grey) and 57 (ligand and protein orange) with dGMII. The zinc atoms 
appear as magenta balls. Distances are presented in Table 3, page 63. The figure was 
generated with PyMOL. 
 
 
In the dGMII:47 complex, the terminal oxygen of the inhibitor 47 (OH-9) made numerous 
hydrogen bonds. It was 2.7 Å from Asp340 OD1, 2.8 Å from a water molecule, 3.3 Å from 
Tyr269 OH and 3.5 Å from Asp341 OD1. An almost identical bonding pattern was seen for 
inhibitor 57, although the interaction distances were slightly longer. The oxygen of compound 
57 (OH-9) was 2.7 Å from Asp340 OD1, 2.8 Å from a water molecule, 3.5 Å from Tyr269 
OH and 3.7 Å from Asp341 OD1 (Table 3). 
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Because of the different stereochemistry of the inhibitor 58, the primary oxygen of compound 
58 (OH-9) was placed in a different location and was now 4.8 Å from Asp340 OD1 and 4.5 Å 
from Asp341 OD1. Nevertheless, there were still interactions with Tyr269 and two water 
molecules (Table 3). 
 
Zinc Interactions 
Compound Swa (16) 47 58 57 
PDB 1HWW 2F18 2F1A 2F1B 
Protein or Inhibitor Atom Distance (Å) Distance (Å) Distance (Å) Distance (Å) 
His90   NE2 2.10 2.12 2.11 2.14 
Asp92   OD1 2.24 2.13 2.16 2.17 
Asp204 OD1 2.17 2.09 2.08 2.11 
His471 NE2 2.09 2.11 2.09 2.13 
OH-1 (16) or OH-3 (47, 58, 57) 2.20 2.18 2.20 2.20 
OH-2 or OH-4 2.13 2.26 2.35 2.31 
Protein/ligand Interactions 
Compound Swa (16) 47 58 57 
PDB 1HWW 2F18 2F1A 2F1B 
Protein 
Atom 
Atom Distance 
(Å) 
Atom Distance 
(Å) 
Atom Distance 
(Å) 
Atom Distance 
(Å) 
Asp92   OD1 OH-1 3.03 OH-3 2.99 OH-3 2.98 OH-3 3.03 
 OH-2 2.92 OH-4 3.11 OH-4 3.18 OH-2 3.12 
Asp92   OD2 OH-2 2.54 OH-4 2.69 OH-4 2.61 OH-2 2.59 
Asp204 OD1 OH-1 2.83 OH-3 2.76 OH-3 2.81 OH-3 2.77 
 OH-2 2.97 OH-4 2.93 OH-4 2.96 OH-4 2.98 
 N-4 2.75 N-1 2.81 N-1 2.88 N-1 2.81 
Asp204 OD2 N-4 3.45 N-1 3.34 N-1 3.36 N-1 3.38 
N-7 3.00 N-7 2.88 N-7 3.14 
Tyr269 OH   
 
 OH-9 3.30 OH-9 2.97 OH-9 3.52 
Asp340 OD1   OH -9 2.67 OH -9 4.82 OH -9 2.66 
Asp341 OD1 OH-9 3.49 OH-9 4.48 OH-9 3.70 
Asp341 OD2 N-7 2.78 N-7 2.85 N-7 2.80 
 
 
 
 
 
OH-4 3.42 OH-4 3.49 OH-4 3.45 
Asp472 OD1 OH-8 2.56 - - - - - - 
Asp472 OD2 OH-1 2.60 OH-3 2.49 OH-3 2.46 OH-3 2.59 
Tyr727 OH OH-8 2.64 - - - - - - 
OH-9 2.78 OH-9 2.63 OH-9 2.78 
WATERS   
N-1 2.91 N-1 2.94 N 2.96 
Table 3: Summary of interatomic distances (Å) between the inhibitors and dGMII. 
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3.4. Docking studies 
Our goal, in collaboration with the group of Prof. N. Moitessier (McGill University, Montreal, 
Canada), was to determine, through a comparative evaluation of several docking programs, 
the most accurate computational tool for the design of α-mannosidase inhibitors.  
 
3.4.1. Selection of the model enzyme and associated structures 
Since we have obtained three x-ray structures of our inhibitors in the dGMII, we used these 
dGMII:inhibitor complexes as the starting point for computer-assisted design of new potent 
and selective inhibitors of α-mannosidases. No other models nearer the human enzyme, was 
available to perform this study. Indeed, mammalian mannosidases are difficult to purify in 
suitable quantities to be used for crystallization and thus x-ray assays. And only a single 
structure of bovine lysosomal mannosidase is available from the Protein Data Bank (PDB 
107D) with a suboptimal resolution of 2.70 Å which hinders the possibility of performing 
accurate docking experiments on it.  
 
To the three structures of dGMII:inhibitors described in paragraph 3.3 was added seven 
supplementary complexes selected from available crystal structures in the Protein Data Bank 
(Scheme 37). The ligands were selected to represent a large range of inhibitory activity 
against dGMII ranging from 20 nM to 7.5 mM . The PDB codes retained were: 1HWW 
(Swa), 1HXK (DMJ), 1PS3 (Kifunensine), 1R33, 1R34, 1TQS (Salacinol) and 
1TQT.40b,178,181,182 The structures with ligands that were not competitive inhibitors or 
structures with resolution worse than 2 Å were discarded. 
                                                 
181 Shah, N.; Kuntz, D. A.; Rose, D. R. Biochemistry 2003, 42, 13812-13816. 
182 Kavlekar, L. M.; Kuntz, D. A.; Wen, X.; Johnston, B. D.; Svensson, B.; Rose, D. R.; Pinto, B. M. 
Tetrahedron: Assymetry 2005, 16, 1035-1046. 
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 Name PDB code Resolution (Å) IC50 dGMII (μM) 
16 Swainsonine (Swa) 1HWW 1.87 0.02 
12 Deoxymannojirimycine (DMJ) 1HXK 1.50 400 
15 Kifunensine 1PS3 1.80 1000 
59  1R33 1.80 70 
60  1R34 1.95 900 
61 Salacinol 1TQS 1.30 7500 
62  1TQT 1.90 7500 
Scheme 37: Structures of seven dGMII:inhibitor complexes. 
 
3.4.2. General considerations 
For the last two decades, computational methods for structure-based drug design have evolved 
significantly. Their increasing accuracy has been followed with growing interest by the 
pharmaceutical industry. Among these methods, docking techniques have been extensively 
investigated and exploited in medicinal chemistry projects.  
 
Computational molecular docking is a research technique for predicting whether one ligand 
will bind a target protein. Protein-ligand docking is done by modelling the interactions 
between the protein and the ligand. The success of a docking study depends on two 
mathematic tools: the search algorithm and the scoring function.  
 
The search algorithm is the first mathematic tool used by the docking program to search all 
possible conformations of the ligand paired to the protein, which are called “poses”. The 
scoring function is the second mathematic tool of the program and is used to predict the 
affinity of the ligand for the protein in order to rank various inhibitors in function of their 
inhibitory ability.  
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3.4.3. Docking of dGMII inhibitors 
3.4.3.1. Challenges for the docking on dGMII 
A close look at the selected crystal structures revealed challenges for the accurate docking of 
GMII inhibitors. First, a zinc atom was involved in the catalytic activity of the enzyme and 
was strongly bound to the inhibitors. Second, some solvent-exposed moieties of the largest 
and more hydrophilic inhibitors were not completely inserted into the active site. Third, bound 
water molecules made important interactions with some inhibitors. Nevertheless, as none of 
the water molecules were conserved throughout the set of the 10 dGMII:inhibitor complexes, 
they were not considered for the docking study. Indeed, it would have been impossible to 
keep water molecules without biasing the self-docking of an inhibitor to its natural solvated 
receptor.  
3.4.3.2. Selection of the docking program 
Despite the extensive investigations that have been pursued during the last decade on docking 
techniques, no universal method applicable to any protein target has been discovered. Thus, 
the choice of the software has to be done wisely. A set of docking programs (Glide, GOLD, 
FlexX, AutoDock, eHiTs and FITTED) was used in order to identify the optimal software for 
the design of Golgi mannosidase II (GMII) inhibitors.183 This study performed with Pablo 
Englebienne at McGill University was not intended to fully evaluate these docking programs 
but only to find the best one in the context of the α-mannosidase II inhibition.  
 
The assessed programs covered a variety of conformational search methods in order to predict 
the binding mode of the inhibitor into the active site of the enzyme. GOLD, AutoDock and 
FITTED used a genetic algorithms, FlexX an incremental construction, eHiTs a rigid 
fragment docking and linking and finally Glide a multi-level search. Moreover, a large panel 
of scoring functions (e.g. ChemScore, GlideScore, GoldScore, AutoDock scoring function) 
were tested to evaluate their accuracy to predict the inhibitory ability of the inhibitors for the 
enzyme.  
 
                                                 
183 Englebienne, P.; Fiaux, H.; Kuntz, D. A.; Corbeil, C. R.; Gerber-Lemaire, S.; Rose, D. R.; Moitessier, N. 
Proteins, 2007, paper in press. 
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Some of the evaluated programs came with an interface that was used to prepare the protein 
structures, the ligands and some of the initial keyword files. However, in order to obtain the 
best performance from each docking program, the standalone versions with optimized 
parameters were used.  
 
Glide, which I have personally tested in this comparative study, will be discussed in details.  
 
3.4.3.3. Evaluation of Glide 
Specificities of Glide: 
Glide uses a funnel-type approach to search the conformational space. The best poses are then 
scored using the scoring function GlideScore.184 Among the many terms of this scoring 
function is a term accounting for metal-ligand interactions that might have been well suited 
for the Zn-inhibitor interactions. However, this term is restricted to anionic ligands and single 
atom ligation. It thus does not account for the geometry of metal-ligands complexes. The 
selected ligands were neutral and the metal ligation would therefore be modelled as purely 
electrostatic.  
 
Moreover, Glide proposes the use of constraints to force specific interactions. The user-
defined constraints add an additional filter to the hierarchical filtering of the funnel. In order 
to evaluate the impact of constraints on accuracy, two studies (with and without constraints) 
were carried out. Unexpectedly, the addition of a constraint did not significantly increase the 
accuracy of the binding mode prediction.  
 
The catalytic site, including two histidines (His90, His471), two aspartates (Asp92, Asp204) 
and a zinc ion, was studied in details. The formal charge of the zinc atom is +2, although it is 
clear that this charge was delocalized onto the chelating residues. Thus, the charges for the 
catalytic site residues and for the zinc atom were derived from density functional theory 
(DFT) calculations of a truncated binding site.  
                                                 
184 Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; 
Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. J. Med. Chem. 2004, 47, 1739-
1749. 
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Principle of Glide: 
Prior to the docking experiments, several operations are required by Glide to prepare the 
proteins and the ligands. Indeed, after addition of the hydrogen atoms, the ligands were 
separated from the protein to work in an independent way. The proteins were charged and 
prepared through minimization calculation and the ligands were prepared separately and 
optimized since, in a real drug design scenario, the final structure is not known (Scheme 
38A). Then, the prepared proteins were used for computing grids, with and without 
constraints. Finally, the docking study was performed with the ten selected ligands which 
were docked to the ten protein structures for a total of 100 docking runs (10 self-docking runs 
where the ligands were docked-back to their own protein and 90 cross-docking runs, where 
the ligands were docked in the nine other x-ray structures of dGMII, Scheme 38B).  
 
A) B) 
 
Scheme 38: A) Steps for the preparation of the proteins and ligands for docking studies. B) 
Representation of the 10 self-docking runs and 90 cross-docking runs. 
 
 
Once the program has docked the ligand into the protein, the “poses” which are the simulated 
conformations of the ligand in the protein were examined and compared to the x-ray structure 
through a RMSD (Root mean square deviation) calculation. This value is thus an evaluation 
of the accuracy of the program to dock an inhibitor into the protein.  
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Results obtained with Glide on dGMII: 
With Glide, the ligands were docked with RMSD’s below 1.0 Å in 40% of the cases (Scheme 
39A, dashed arrow) and below 2.0 Å in 48% (Scheme 39A, bold arrow). The other programs 
assessed were less accurate. 
 
A) B)
 
Scheme 39: Accuracy for Glide to dock the 10 ligands to the 10 protein structures. A) 
Deviation of the docked poses relatively to the crystal structure binding mode. B) Metal 
binding atoms.  
 
The computed RMSD’s indicated better accuracy for the self-docking of the smaller ligands 
which were docked back to their protein structure with RMSD’s below 1.1 Å (data not 
shown). This observation was consistent with the results reported in the original Glide 
publication by Friesner and co-workers.184 They observed that about 50% of the compounds 
were docked back with RMSD’s below 1.0 Å. In the same study, about a third of the 
compounds were docked with RMSD between 1.0 Å and 2.0 Å. Nevertheless, in our study, 
ligands 47, 57 and 58 were self-docked with RMSD values higher than 2.5 Å. To further 
evaluate the apparent poor docking accuracy observed for ligands 47, 57 and 58 a closer 
inspection of the poses around the zinc atom was carried out and the docked conformations 
were inspected and compared to the experimental x-ray structures.  
 
First, it was noticed that the experimentally observed zinc chelation by the diol or alcohol 
moieties was correctly predicted in most of the one hundred complexes. Indeed, in 54% of the 
cases the chelating alcohols or diols are predicted at 0.5 Ǻ to the observed x-ray structure 
(Scheme 39B, dashed arrow) and 91% of the cases are located at 1.0 Ǻ (Scheme 39B, bold 
arrow).  
Results and discussion 
 
 
70 
Second, a close look at the docked structures indicated that the docked pose was for the most 
part correct in many cases. The main deviation came from the solvent-exposed moieties and 
the orientation of the aromatic groups.  
 
For instance, compound 47’s phenyl group was predicted to interact with Arg228 through π 
interactions, while in the crystal structure it was interacting with Trp95 through a T-shaped π 
interaction (Scheme 40). In fact, Glide and the other programs were not able to predict this T-
shaped interaction which is probably due to the poor description of this type of interaction by 
the commonly used scoring functions. Nevertheless, the pyrrolidine ring was perfectly 
orientated in all poses.  
 
 
 
 
 
 
 
 
 
Scheme 40: Glide docked vs observed binding mode of compound 47. The crystal structure 
appears in grey and the docked structure in green.  
 
 
It is worth noting that the geometry of the ligands was optimized prior to docking. As a 
consequence, the ring conformation in the input file was already different from the crystal 
structure and thus contributed to a small part of the RMSD (< 0.3 Ǻ).  
 
So, the apparent poor accuracy of 48% should be considered with circumspection as most of 
the compounds were docked properly. The main deviation could be attributed to the solvent 
exposed moieties. When these moieties were not considered accuracies higher than 91% were 
calculated (Scheme 39). The other programs of the comparative study poorly predicted both 
the metal ligation and the location of the solvent exposed groups.  
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Despite the good docking accuracy of Glide, the scores obtained with the scoring function 
GlideScore (GScore) did not correlate well with the experimental biological activities 
(Scheme 41). The scores are negative and predict the inhibiting ability of the inhibitor for 
dGMII. More the score is negative, more efficient should be the inhibitor. But, Swa the most 
active compound (16, 1HWW, IC50 = 20 nM toward dGMII) was predicted to be one of the 
poorest active inhibitors of the set with a GScore of -10.78. Whereas 57 (2F1B, IC50 = 1mM 
toward dGMII) was predicted to be one of the most active compounds with a GScore 
evaluated at -12.83.  
 
 
Scheme 41: Accuracy for Glide to predict the inhibitory activities. Correlation between the 
scores calculated with the scoring function GlideScore (GScore) and the inhibitory activities 
(IC50) toward dGMII.  
 
 
This study revealed that Glide could accurately discriminate the different poses and thus 
predict reasonable binding modes but the scoring function of the program was not able to 
predict the inhibitory activities of compounds with different affinities.  
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3.5. Functionalization of inhibitor 47 with polar substituents 
As it was not possible to design relevant chemical modifications of our lead inhibitor 47 
through computational methods, the x-ray structures of dGMII:47, dGMII:57 and dGMII:58 
served as the basis for further functionalizations. In particular, comparison of the binding of 
47 with Swa suggested that the introduction of polar groups at C(5) position of the pyrrolidine 
could enhance the affinity of the inhibitor for the enzyme. Additional interactions with the 
Asp472 and Tyr727 should thus provide more potent inhibition toward dGMII (Scheme 42).  
 
 
 
 
 
 
 
 
 
Scheme 42: Overlays of the binding of compound 47 with Swa (16). Molecule 47 is drawn in 
green, Swa in grey and the atom of zinc in purple. 
 
 
3.5.1. Synthesis of 3,4,5-trihydroxypyrrolidine derivatives 
Introduction of an hydroxyl group at the C(5) position of the pyrrolidine ring was first 
envisaged.185 Starting from the intermediate 51, reduction of the carbamate moiety in 
presence of sodium borohydride followed by subsequent protection of the resulting alcohol as 
methyloxymethyl ether afforded 63 as a mixture of two diastereoisomers, with 80% overall 
yield (2 steps). Birch reduction of the trityl moiety and oxidation of the resulting alcohol 
under Swern conditions provided aldehyde 64 (1:1 mixture of diastereoisomers, 75% yield). 
Reductive amination with D-(α)-phenylglycinol afforded diamine 65 with 46% yield.  
                                                 
185 Steiner, C. Diploma work, EPFL, 2005. 
Interactions with: 
Asp472 and Tyr727 
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Several assays to remove the protecting groups in acidic medium (CF3COOH/H2O 4/1, 1M 
HCl) failed to afford the expected hemiaminal 66, due mainly to decomposition. Indeed, the 
acidic conditions required for deprotection may lead to mixture of compounds including 
imines and dimmer. Defoin and al. have shown that simple 2-hydroxypyrrolidines could be 
obtained as equilibrium mixtures of the corresponding imine, 2-aminoalcohol and dimmer. 
The composition of these mixtures depended on the pH value of the medium and on the 
nature of ionic species in the buffers.  
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Scheme 43: Synthesis of 3,4,5-trihydroxypyrrolidine derivatives. 
 
 
In order to prevent water elimination from the hemiaminal to form the corresponding imine, 
introduction of a methyl group on the amine of the pyrrolidine ring was envisaged. 
Methylation of L-5-trityloxymethyl-2-pyrroldinone 50 followed by introduction of the C(3), 
C(4) diol moiety according to the procedure of Ikota provided N-methyllactam 68 (Scheme 
43). Reduction of the carbonyl moiety of 68 was then attempted under several conditions 
(Table 4). In the presence of NaBH4, LiBH4 or LiBH(Et)3, only starting material was 
recovered. The use of stronger reducing agents (entries 5-7) afforded a compound which was 
not further analyzed, but may be the corresponding N-methylpyrrolidine.  
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 Hydride Eq. Solvent Temp (°C) Result 
1 NaBH4 1.5 MeOH 0°C to 25°C Starting Material 
2 NaBH4 5.0 MeOH 25°C to reflux Starting Material 
3 LiBH4 1.0 THF -78°C to 25°C Starting Material 
4 LiBH(Et)3 1.0 THF -78°C to 25°C Starting Material 
5 LiAlH4 1.0 THF -20°C to 25°C N-Methylpyrrolidine 
6 DIBAL-H 1.0 + 1.2 CH2Cl2 -78°C to 25°C N-Methylpyrrolidine 
7 K-Selectride 1.0 + 2.0 THF -78°C to 25°C N-Methylpyrrolidine 
Table 4: Conditions for the reduction of lactam 68. 
 
 
As a carbamate protecting group was necessary to achieve reduction of the lactam, 
introduction of a benzylcarbamate was chosen (Scheme 44) as this group can be removed 
under non-acidic conditions after reduction of the carbonyl moiety. Further methylation of the 
pyrrolidine nitrogen will prevent imine formation during final deprotection. L-5-
trityloxymethyl-2-pyrroldinone 50 was converted into carbamate 69 in 91% yield.186 Ikota’s 
procedure then provided the protected lactam 70 in poor yield. Reduction of the carbonyl 
group was achieved with lithium borohydride in almost quantitative yield. But protection of 
the alcohol as a methyloxymethyl ether followed by the cleavage of the carbamate released a 
complex mixture of non-separable compounds that could not be identified by NMR (nuclear 
magnetic reasonance). 
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Scheme 44: Synthesis with a benzylcarbamate protecting group.  
                                                 
186 Hannessian, S.; Kornienko, A.; Swayze, E. E. Tetrahedron 2003, 59, 995-1007. 
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As introduction of an hydroxyl group at C(5) position of the pyrrolidine ring was 
unsuccessful, fluorination of this position was also attempted (Scheme 45). However, neither 
treatment of hydroxycarbamate 72 with DAST, nor transformation into the corresponding 
triflate or mesylate for further displacement with fluoride anion afforded the targeted 
derivative.  
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Scheme 45: Attempt of fluorination at C(5) position of the pyrrolidine ring. 
 
 
Consequently, we wondered whether a pyrrolidinone instead of a pyrrolidine scaffold could 
provide additional interactions with Asp472 and Tyr727 residues of the active site of dGMII 
and if modifications on the phenylglycinol moiety could improve the biological activities 
toward α-mannosidases.  
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3.5.2. Synthesis of dihydroxypyrrolidinone derivatives 
As removal of trityl moiety required strong basic conditions, we decided to replace it with a 
silyl ether. 5-oxo-L-proline 73 was converted into the primary alcohol 74 with 84% yield. 
Protection as a tert-butyldimethylsilyl ether followed by introduction of a tert-butyl carbamate 
(75) or a methyl group (81) on the nitrogen atom afforded lactams in good yields. Ikota’s 
procedure provided diols 76 and 82 in 43% and 41% yield, respectively. Protection of the diol 
moieties as acetonides (77 and 83) followed by cleavage of the silyl ether in presence of 
tetrabutylammonium fluoride allowed oxidation of the resulting primary alcohol with Dess-
Martin periodinane.187 Other oxidative reagents (Swern, PCC) failed to afford reasonable 
yield of the expected aldehydes 79 and 85. Reductive amination with D-(α)-phenylglycinol 
provided protected lactam intermediates that were treated under acidic conditions to afford 
3,4-dihydroxypyrrolidinone derivatives 80 and 86 in 12% and 28% yield, respectively 
(Scheme 46). 
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Scheme 46: Synthesis of 3,4-dihydroxypyrrolidinone derivatives. 
                                                 
187 Dess, D. B.; Martin, J. C. J. Org. Chem. 1983, 48, 4155-4156. 
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3.5.3. Modification of the phenylglycinol moiety 
In the frame of our study, modification of the phenylglycinol moiety was also envisaged to 
modulate the inhibitory ability of our pyrrolidine-based inhibitors. Elongation of the aromatic 
chain to produce compound 89 was achieved by coupling carbaldehyde 87,188 with D-(α)-
phenylalaninol 88 followed by acidic removal of the protecting groups (Scheme 47). 
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Scheme 47: Functionalization of the phenyl group. 
                                                 
188 Fleet, G. W. J.; Son, J. C. Tetrahedron 1988, 44, 2637-2647. 
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Functionalization of the aromatic moiety of phenylglycinol with polar groups that may 
influence the solubility of the corresponding inhibitors in physiologic medium was initiated. 
For that purpose, 4-hydroxyphenylglycine 90 was protected as tert-butylcarbamate and treated 
with methyliodide in basic medium to afford 91 and 92 in 28% and 62% yield, respectively 
(Scheme 46).189 Deprotection of the amine under acidic conditions followed by reductive 
amination with aldehyde 85 provided the methyloxyphenyl derivative 95 in moderate yield. 
Phenol 93 did not react under these conditions. Our attempt to reduce the methyl ester moiety 
failed to give the expected primary alcohol. Thus, reduction of the methyl ester was 
performed on compounds 91 and 92 with lithium aluminium hydride. Deprotection of the 
amine allowed reductive amination with aldehyde 85. The phenol derivative 96 was not 
reactive toward the reductive amination whereas the methyloxyphenyl intermediate 97 led to 
a very low yield of the corresponding pyrrolidinone. Further acidic cleavage of acetonide 
protecting group afforded 98 with good yield and purity. Until now, optimization of this 
synthetic route was not assessed.   
3.5.4. Inhibition of jack bean α-mannosidase and dGMII 
The inhibitory potential of compounds 58, 80, 86, 89 and 98 toward α-mannosidase from jack 
bean and dGMII was determined and compared to the activity of our lead inhibitor 47 and of 
Swa (16) as a reference inhibitor of α-mannosidase II.  
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Scheme 48: Overview of pyrrolidine and pyrrolidinone compounds for enzymatic tests. 
                                                 
189 Chen, Y. T.; Seto, C. T. J. Med. Chem. 2002, 45, 3946-3952. 
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 α-mannosidase from jack bean dGMII 
Swa (16) IC50 398 nM   30 nM 
 Ki 155 nM (C) n.d. 
47 IC50 705 nM   80 μM 
 Ki 135 nM (C) n.d. 
58 IC50 90 μM   720 μM 
 Ki 173 μM (C) n.d. 
80 IC50 4.5 μM   7 μM 
 Ki 4.0 μM (C) n.d. 
86 IC50 150 nM   500 nM 
 Ki 206 nM (C) n.d. 
89 IC50 1 mM  n.d. 
98 IC50 30 nM  n.d. 
(C) = competitive inhibition n.d. = not determined 
Table 5: Inhibitory activities toward α-mannosidase from jack bean and dGMII.  
 
 
The configuration of the phenylglycinol moiety was clearly determinant in the inhibition of 
both enzymes as 58 was a poor inhibitor (IC50 = 720 μM for 58 vs 80 μM for 47 toward 
dGMII). Homologation of the aromatic chain by one methylene group also resulted in a 
dramatic loss of inhibitory potency against α-mannosidase from jack bean (IC50 = 1mM for 
89 vs 705 nM for 47). Replacement of the pyrrolidine moiety by a pyrrolidinone system also 
resulted in a significant decrease of the inhibitory potency toward α-mannosidase from jack 
bean (80). On the other hand substitution of the lactam moiety by a methyl group induced an 
improvement of the IC50 toward this enzyme (IC50 = 150 nM for 86 vs 750 nM for 47) and 
compound 86 appeared to be as potent as Swa (Ki = 206 nM for 86 vs 155 nM for 16). The 
anisole analogue 98 was even more potent with an IC50 of 30 nM against α-mannosidase from 
jack bean. However, the very little quantities obtained thus far did not allow further 
investigations on this derivative.  
 
The inhibition of dGMII by pyrrolidine 47 was very modest while transformation into a 
pyrrolidinone system led to a net improvement of the inhibitory ability. In particular, 
derivative 86 presented an IC50 of 500 nM toward dGMII which make it one of the best 
inhibitor of this enzyme. Nevertheless, it remained 15 times less active than Swa on dGMII.  
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3.5.5. X-ray structure of dGMII:86 complex 
Compound 86 was co-crystallized in the active site of dGMII in order to evaluate its binding 
mode (Scheme 49). In comparison with our lead 47, the carbonyl group of the N-methyl-
pyrrolidinone inhibitor made additional interactions with Tyr727 and Asp472 which may 
account for the increased inhibition of 86 toward dGMII (IC50 = 500 nM for 86 vs 80 μM for 
47). The stacking interactions with Trp95 (Scheme 50) and the polar interactions with the zinc 
atom and Asp340, Asp341 and Tyr269 are similar for the both inhibitors 47 and 86.  
 
A 3.23 Å long hydrogen bond between the O-2 of compound 86 and the NE1 of Trp95 
assumingly stabilizes the observed stacking between this residue and the inhibitor. A further 
new interaction of 86 that has neither been observed with Swa nor with 47 is a hydrogen bond 
between NE2 of His471 and the 3-hydroxyl group of 86 which apparently causes additional 
improvement in binding affinity and stabilization of the compound in the active site (Table 6). 
Introduction of a methyl substituent on the nitrogen center of the pyrrolidinone ring was 
fundamental to allow a global shift of the inhibitor into the active site. Indeed, the inhibitory 
ability of the free lactam 80 was significantly lower than the activity of the N-methyl 
substituted analogue 86 (IC50 = 7 μM for 80 vs 500 nM for 86).  
 
 
Scheme 49: Crystal structure of dGMII:86 complex. Interactions closer than 3.5 Ǻ are 
indicated and the interactions with the zinc atom are drawn in magenta. Distances are 
presented in Table 6. The figure was generated with Molscript.  
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Scheme 50: Electron density map of dGMII:86 complex. The active site zinc ion is presented 
by a magenta ball and the inhibitor in white. 
 
 
Superimposition of the binding modes of compounds 86 and of Swa, Scheme 51, revealed 
that the hydroxyl moiety (OH-8) of Swa pointed out in the same direction than the carbonyl 
moiety of inhibitor 86. It is noteworthy that the distance between the carbonyl oxygen O-2 of 
86 and the hydroxyl group of Tyr727 is almost equal to the distance between the hydroxyl 
group (OH-8) of Swa and the same residue (2.65 Å for 86 vs 2.64 Å for Swa). For the 
interactions with Asp472, the same observation was made (d(O-2, Asp472 OD1) = 2.47 Å for 
86 vs d(OH-8, Asp472 OD1) = 2.56 Å for Swa). Table 6 summarized the distances of 
interaction between these two inhibitors with the amino acids groups of dGMII. 
 
Scheme 51: Superimposition of the structures dGMII:86 and dGMII:Swa complexes. The 
zinc atom is presented in grey, Swa in pink and compound 86 in yellow.  
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Zinc Interactions 
Compound Swa (16) 86 
Protein or Inhibitor Atom Distance (Å) Distance (Å) 
His90   NE2 2.10 2.05 
Asp92   OD1 2.24 2.20 
Asp204 OD1 2.17 2.09 
His471 NE2 2.09 2.14 
OH-1 (16) / OH-3 (86) 2.20 2.24 
OH-2 or OH-4 2.13 2.42 
Protein/ligand Interactions 
Compound Swa (16) 86 
Protein Atom Atom Distance (Å) Atom Distance (Å) 
Asp92   OD1 OH-1 3.03 OH-3 2.92 
 OH-2 2.92 OH-4 3.29 
Asp92   OD2 OH-2 2.54 OH-4 2.55 
Trp95   NE1 - - O-2 3.23 
Asp204 OD1 OH-1 2.83 OH-3 2.86 
 OH-2 2.97 OH-4 2.97 
 N-4 2.75 N-1 4.37 
Asp204 OD2 N-4 3.45 N-1 3.61 
N-7 3.01 
Tyr269 OH - - 
OH-9 3.13 
Asp340 OD1 - - OH -9 2.75 
Asp341 OD1 OH-9 3.34 
Asp341 OD2 N-7 2.81 
 
- - 
OH-4 3.27 
His471 NE2 - - OH-3 3.16 
Asp472 OD1 OH-8 2.56 O-2 2.47 
Asp472 OD2 OH-1 2.60 OH-3 2.59 
Tyr727 OH OH-8 2.64 O-2 2.65 
Table 6: Comparison of interatomic distances (Å) between inhibitors Swa or 86 and dGMII. 
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3.6. Biological Assays 
We next evaluated, in vitro, the activity of pyrrolidine and pyrrolidinone derivatives that 
displayed potent inhibitory properties against α-mannosidases, on tumor cells in collaboration 
with the group of Dr. L. Juillerat (CHUV, Lausanne).  
 
Biological assays were performed on different human cancer cell lines derived from 
melanoma,190 and glioblastoma,191 which are tumors associated with a high proliferative and 
invasive potential, multiple resistance toward conventional chemotherapeutics agents and 
poor prognosis. Human cerebral endothelial cells (HCEC),192 were also included in the study 
and human fibroblasts were used as models for non tumoral cells.  
 
3.6.1. MTT assay 
To study cell viability, the MTT assay was selected.  
3.6.1.1. Principle of MTT assay 
Metabolically active cells reduce the tetrazolium salt MTT ((3,4,5-dimethylthiazol-yl)-2,5-
diphenyl tetrazolium) to afford a formazan dye which can be quantified in a multiwell plate 
reader at 540 nm (Scheme 52).  
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Scheme 52: Metabolization of MTT to a formazan salt by viable cells. 
                                                 
190 Bullani, R. R.; Wehrli, P.; Viard-Leveugle, I.; Rimoldi, D.; Cerottini, J.-C.; Saurat, J.-H.; Tschopp, J.; French, 
L. E. Melanoma Res. 2002, 12, 263-270. 
191 Dieserens, A. C.; de Tribolet, N.; Martin-Achard, A.; Gaide, A. C.; Schnegg, J. F.; Carrel, S. Acta 
Neuropathol. 1981, 53, 21-28. 
192 Muruganandam, A.; Herx, L. M.; Monette, R.; Durkin, J. P.; Stanimirovic, D. B. FASEB J. 1997, 11, 1187-
1197. 
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3.6.1.2. Preliminary results of the MTT assay 
First, the effects of compound 47, 86 and Swa, as a reference, were determined in human 
LN18 and LNZ308 glioblastoma cells using the MTT assay (Scheme 53). None of these 
potent inhibitors of α-mannosidase from jack bean and dGMII displayed significant inhibition 
of glioblastoma cells growth.  
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Scheme 53: First compounds tested on glioblastoma cells. 
 
As the hydrophilic character of these molecules may hinder their transport across cell 
membranes, a series of more lipophilic derivatives of our lead 47 was synthesized. Indeed, 
derivative 47 was transformed into more lipophilic compounds such as ethers, esters and 
amides in order to allow internalization by human cancer cells.  
 
3.6.1.3. Introduction of lipophilic groups  
D-(α)-phenylglycinol 99 was transformed into diallylamine 100 (79%) allowing protection of 
the primary alcohol as simple ethers (benzyl and methyl ethers) with good to quantitative 
yields.180 Substituted benzyl ethers were also introduced. Palladium promoted cleavage of the 
allyl moieties in the presence of 2-mercaptobenzoic acid as an allyl scavenger,193 followed by 
a reductive amination with carbaldehyde 87 led to diamines 103 and 106, after deprotection in 
acidic medium. Deallylation of the 3-fluorobenzyl ether 107 resulted in a poor yield of the 
corresponding amine 108 while the 4-fluorobenzyl ether 110 decomposed during the reaction. 
Amine 108 was then submitted to reductive amination and acidic deprotection to provide the 
functionalized pyrrolidine 109 (Scheme 54).  
 
                                                 
193 Lemaire-Audoire, S.; Savignac, M.; Genet, J.-P. Tetrahedron Lett. 1995, 36, 1267-1270. 
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Scheme 54: Derivatization into ethers. 
 
 
Introduction of ester moieties on the primary hydroxyl group of derivative 47 was also carried 
out (Scheme 55). D-(α)-phenylglycinol (99) was protected as a tert-butyl carbamate 111, 
allowing acylation of the primary alcohol with aliphatic and substituted aromatic acyl 
chlorides. After acidic treatment, the resulting amines 112-122 were engaged in a reductive 
amination procedure with pyrrolidine carbaldehyde 87 to provide compounds 123-133 after 
quantitative cleavage of the Boc and acetonide protecting groups.194  
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Scheme 55: Derivatization into aliphatic and aromatic esters. 
                                                 
194 Fiaux, H.; Schütz, C.; Vogel, P.; Juillerat-Jeanneret, L.; Gerber-Lemaire Chimia 2006, 60, 185-189. 
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In order to evaluate the influence of the configuration of the phenylglycinol moiety, 
compound 134 (Scheme 57) was synthesized according to the same procedure starting from 
L-(α)-phenylglycinol. 
 
Intermediate 111 was also converted into the corresponding primary amine 135 and used to 
introduce amide groups on the lateral side chain of the pyrrolidine (Scheme 56).195 Reaction 
with 3-bromobenzoyl chloride followed by acidic treatment afforded the corresponding 
aminoamide 136. Subsequent reductive amination with carbaldehyde 87 and sodium 
triacetoxyborohydride, followed by acid-catalyzed removal of acetonide and Boc moieties 
provided the targeted pyrrolidine 137 in 74% yield (2 steps).  
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Scheme 56: Derivatization into aromatic amide.196 
 
 
The effects of these derivatives on human glioblastoma cells were determined using the MTT 
assay after 24 hours of exposure. The data are summarized in Table 7. 
                                                 
195 Favre, S.; Fiaux, H.; Schütz, C.; Vogel, P.; Juillerat-Jeanneret, L.; Gerber-Lemaire, S. Heterocycles 2006, 69, 
179-192. 
196 Favre, S. Diploma work, EPFL, 2005 
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3.6.1.4. Results of the MTT assay 
Scheme 57 summarized all the products tested on tumoral cells lines: 
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Scheme 57: Overview of the products tested on tumoral cells lines.  
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  100 μM 200 μM 300 μM 
 LN18  7  18  13 Swa (16)  LNZ308  25  24  16 
 LN18  13  19  22 47  LNZ308  0  8  26 
 LN18  0  17  7 58  LNZ308  0  4  28 
 LN18  0  0  0 80  LNZ308  0  0  1 
 LN18  1  0  0 86  LNZ308  3  5  10 
Ether  LN18  2  19  27 
109  LNZ308  2  14  34 
Ester aliphatic  LN18  5  0  11 
123  LNZ308  3  9  17 
 LN18  21  7  22 124  LNZ308  17  11  20 
 LN18  6  38  38 125  LNZ308  16  17  25 
 LN18  6  9  16 126  LNZ308  11  15  7 
 LN18  6  7  14 127  LNZ308  12  6  20 
 LN18  4  0  20 128  LNZ308  3  0  22 
Ester aromatic  LN18  0  17  26 
129  LNZ308  0  18  23 
 LN18  9  22  20 130  LNZ308  4  16  21 
 LN18  8  10  16 131  LNZ308  5  5  17 
 LN18  5  67  92 132  LNZ308  11  60  87 
 LN18  0  12  11 133  LNZ308  4  15  27 
 LN18  0  25  32 134  LNZ308  0  6  26 
Amide  LN18  15  30  52 
137  LNZ308  2  20  50 
Table 7: Growth inhibition of glioblastoma cells by functionalized pyrrolidines. Cells were 
exposed for 24 hours to 0, 100, 200 or 300 μM of the various synthetic derivatives then the 
MTT assay was performed for the last 2 hours of incubation. The % of residual mitochondrial 
activity was calculated as the ratio of absorbance of treated to control cells. 
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Introduction of an ether moiety slightly decreased the growth of glioblastoma cells. The 
aliphatic ester groups did not significantly increased the anti-proliferative activity. Among the 
aromatic ester derivatives, the 4-bromobenzoate (132) demonstrated a concentration-
dependant inhibition of growth with almost complete inhibition at 300 μM. Replacement of 
the bromo substituent by a fluoro group or placing the halide substituent in meta position of 
the aromatic ring resulted in the loss of antiproliferative properties. The use of an amide bond 
rather than an ester linkage (137) also decreased the efficacy. As for the inhibition of α-
mannosidase from jack bean and dGMII, inversion of the configuration of the phenylglycinol 
moiety (134) decreased the anti-proliferative properties toward glioblastoma cells.  
 
Neither 4-bromobenzoïc acid, nor ethyl 4-bromobenzoate, which may result from the 
hydrolysis of 132 by cell esterases, affected glioblastoma cell growth (data not shown), which 
excludes an effect of the aromatic substituent.  
 
Since derivatization into 4-bromobenzoate promoted the antiproliferative properties of α-
mannosidase inhibitor 47, the same transformation was carried out on the second generation 
inhibitors 80 and 86 to afford 138 and 139 (Scheme 58).  
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Scheme 58: Pyrrolidinone derivative from aromatic phenylglycinol esters. 
 
 
These ester derivatives 138 and 139 were evaluated on the growth of glioblastoma LN18 and 
LNZ308 cells after exposition for 24, 48 or 72 hours, and were compared to 132 (Table 8).  
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  LN18 LNZ308 
 Conc 24h 48h 72h 24h 48h 72h 
100 μM  5  17  31  11  15  24 
200 μM  67  48  68  60  33  56 132 
300 μM  92  95  97  87  78  96 
100 μM  24  -  -  0  -  - 
200 μM  52  -  -  16  -  - 138 
300 μM  59  -  -  51  -  - 
100 μM  4  52 -  6  15 - 
200 μM  49  89 -  50  61 - 139 
300 μM  92  95 -  98  99 - 
Table 8: Time-course of growth inhibition of glioblastoma cells. Cells were exposed for 24, 
48 or 72 hours to 0, 100, 200 or 300 μM of the various synthetic derivatives, then the MTT 
assay was performed for the last 2 hours of incubation. The % of residual mitochondrial 
activity was calculated as the ratio of absorbance of treated to control cells. 
 
 
Increasing the time of exposure led to a significant improvement of growth inhibition, 
especially at low concentration of compounds. The N-methylpyrrolidinone derivative 139 
displayed comparable anti-proliferative activity as its pyrrolidine analogue 132 whereas its 
inhibitory potency against α-mannosidase from jack bean and dGMII was higher. The non-
substituted pyrrolidinone 138 was ineffective on inhibiting glioblastoma cell growth.  
 
A dose-response evaluation (300 μM to 100 μM, 24 hours of exposure to the inhibitors) of the 
antiproliferative effects of the best derivatives 132 and 139 was carried out on both 
glioblastoma cell lines and on HCEC cells to compare the profile of inhibition (Scheme 59).  
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A) 
 
B) 
 
Scheme 59: Growth inhibition of human glioblastoma and HCEC cells by 132 and 139 after 
24 hours of incubation. A) LN18 glioblastoma cells B) HCEC cells. Results are shown as 
means ± SD of triplicate wells of one representative experiment out of three. 
 
 
Comparison of the inhibition profile on LN18 and LNZ308 cells revealed a slightly improved 
efficiency for the pyrrolidine derivative 132 (IC50 = 130 μM and 120 μM for 132 vs 200 μM 
and 200 μM for 139 toward LN18 and LNZ308 cells, respectively). Growth inhibition of 
LN18 is presented in Scheme 59A. The same experiment on HCEC cells showed similar 
growth inhibition for both derivative 132 and 139 (IC50 = 130 μM for 132 vs 120 μM for 139 
toward HCEC cells) (Scheme 59B).  
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These data demonstrated that 4-bromobenzoate derivatives of α-mannosidases inhibitors 132 
and 139 have the ability to inhibit glioblastoma cell growth, whereas Swa was ineffective 
under the same conditions. The aromatic ester promoted likely, the transport of the inhibitors 
across cells membrane and was probably cleaved by cellular esterases to release the more 
hydrophilic derivative 47 and 86, respectively.  
 
In view of these promising results, the mode of action of derivative 132 was studied in more 
detail.  
 
3.6.2. Inhibition of DNA and proteins synthesis 
3.6.2.1. Principle of incorporation of [3H]-thymidine and [3H]-leucine 
Metabolic incorporation of tritiated thymidine ([3H]-thymidine) into cellular DNA and 
tritiated leucine ([3H]-leucine) into protein are widely used protocols to monitor rates of DNA 
synthesis and protein synthesis, respectively.  
 
The cells are incubated in the presence of the inhibitor and then [3H]-thymidine is added. 
During each cell division, the cells incorporate [3H]-thymidine into its DNA. The 
incorporation of the labelled thymidine is thus proportional to the multiplication of the cells. 
Then, the amount of radioactivity is counted in a scintillation counter.  
 
The same strategy is used with tritiated leucine. Indeed, during each cell division, the cells 
incorporate the labelled leucine into their proteins, which allow a quantification of the 
proteins newly synthesized.  
 
3.6.2.2. Results of the inhibition of DNA and Protein synthesis 
We evaluated whether 132 had the potential to diminish cell growth by inhibiting the 
synthesis of DNA and of proteins by glioblastoma cells. The evaluation of the incorporation 
of [3H]-thymidine and [3H]-leucine, after 6 hours of exposure of the cells to compound 132, 
demonstrated that 132 inhibited thymidine incorporation (DNA synthesis) (Scheme 60A) at 
slightly lower concentration and to a higher extent than leucine incorporation (protein 
synthesis) (Scheme 60B). These results suggested that this derivative acted initially by 
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inhibiting DNA synthesis (93% inhibition at 300 μM in LN18) which then led to a decrease of 
protein synthesis (82% at 300 μM in LN18) and ultimately resulted in diminished cell 
survival.  
 
A) 
 
B) 
 
Scheme 60: Inhibition of DNA and protein synthesis by 132 in human glioblastoma cells: 
LN18 are represented with light gray bars and LNZ308 with dark gray bars. Cells were 
exposed for 6 hours to increasing concentrations of 132. The incorporation of either A) 
radioactive thymidine (3HT) or B) radioactive leucine (3H-Leu) was performed for the last 2 
hours. Results are shown as means ± SD of triplicate wells of one representative experiment 
out of three.  
 
 
3.6.3. Evaluation of 132 toward melanoma and fibroblasts cells 
We further evaluated whether compound 132 was able to inhibit DNA and protein syntheses 
and survival in human cancer cells originating from a tumor different from glioblastoma, the 
melanoma cells (Me237 and Me275).  
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A) 
 
B) 
 
C) 
 
Scheme 61: Inhibition by 132 of DNA synthesis (A), protein synthesis (B) and growth (C) in 
human melanoma cells: Me237 are represented with light gray bars and Me275 with dark 
gray bars. Cells were exposed to increasing concentrations of 132. The incorporation of 
radioactive thymidine (3HT) or radioactive leucine (3H-Leu) were performed for the last 2 
hours after 6 hours of incubation of 132. MTT assay was performed after 24 hours of 
incubation of 132. Results are shown as means ± SD of triplicate wells of one representative 
experiment out of three.  
 
Exposure of human Me237 and Me275 melanoma cells for 6 hours to 132 resulted in a 
blockage of DNA (Scheme 61A) and protein syntheses (Scheme 61B). After 24 hours, the 
number of metabolically active melanoma cells decreased as determined by the MTT assay 
(Scheme 61C). 
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Finally, the sensitivity of human fibroblasts, a model of non-tumoral cells, was evaluated with 
increased concentration of 132 (Scheme 62).  
A) 
B) 
Scheme 62: Comparison of the growth inhibition induced by 132 in human primary 
fibroblasts (PG98/5 and PO08) and human tumor cells (LNZ308 glioblastoma and Me237 
melanoma cells). Cells were exposed to increasing concentrations of 132. A) Incorporation of 
radioactive thymidine (3HT) was performed for the last 2 hours after 6 hours of incubation of 
132 and B) the MTT assay was performed after 24 hours of incubation of 132. Results are 
shown as means ± SD of triplicate wells of one representative experiment out of three. 
 
 
Fibroblasts were less sensitive to 132 than glioblastoma and melanoma cells for the inhibition 
of DNA synthesis after 6 hours of exposure (Scheme 62A) or survival after 24 hours of 
incubation (Scheme 62B) suggesting some cell selectivity of 132 between tumoral and 
nontumoral cells.  
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3.6.4. Physicochemical parameters of compounds 47, 86, 132 and 139 
In view of the different activities of the esters 132 and 139 compared to their parent alcohols 
47 and 86, evaluation of their physicochemical parameters was performed in collaboration 
with Dr. B. Faller at NOVARTIS, Basel. Data were collected for: solubility, pKa, 
permeability,197and LogPo/w,198 the octanol-water partition coefficient which measures the 
hydrophobicity and/or hydrophilicity of the substance. Table 9 summarizes the collected data. 
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LopPo/w, Permeability and Solubility 
 47 86 132 139 
LogPo/wa) 2.4 n.d. 3.3 3.5 
Permeabilityb) n.d. n.d. H H 
Solubility (μg/ml) pH 1.0 n.d. n.d. 449 450 
 pH 6.8 n.d. n.d. 289 299 
n.d. = not determined 
a) Range of LogPo/w is measured between [-2;7] 
 LogPo/w > 5 = product toxic, due to a high lipophilicity 
b) L=low; M=Medium; H=High 
c) pKa values of the conjugate acids 
d) calculation program : ACD/pKa DB release version 9.04 
 
Table 9: LogPo/w, pKa, solubility and permeability across artificial membrane of compounds 
47, 86, 132 and 139.199 
                                                 
197 Wohnsland, F.; Faller, B. J. Med. Chem. 2001, 44, 923-930. 
198 Faller, B.; Grimm, H. P.; Loeuillet-Ritzler, F.; Arnold, S.; Briand, X. J. Med. Chem. 2005, 48, 2571-2576. 
199 Measurement performed by Xavier Briand, Novartis, Basel.  
4.29 (5.83) 
8.15 (8.73) 
4.98 (6.55) 
5.75 (7.57) 4.75 (6.85)
8.17 (8.75) 
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In accordance with the previous data on growth inhibition of tumor cells, ester derivatives 132 
and 139 are more lipophilic than the parent alcohols (LogPo/w = 3.3 for 132 vs 2.4 for 47). 
LogPo/w of 86 was not obtained because of low absorbance intensity. The high permeability 
of compounds 132 and 139 place them as potential candidates for drug development.  
 
Discrepancies were noticed between the calculated and the experimental pKa values for the 
amino group on the lateral chain (two pKa units for all compounds). The stronger acidity of 
this ammonium group compared with the expected value may result from a poor solvatation 
due to the presence of the aromatic ring. These experimental data for pKa values could 
account for the difference of solubility observed between derivatives 132 and 139 in pH 7 
buffer, which corresponds to the conditions used in the MTT assay. Indeed, 132 in its 
ammonium form seemed to be more soluble than its neutral pyrrolidinone analogue 139.  
 
In summary, a series of functionalized pyrrolidine and pyrrolidinone inhibitors of α-
mannosidases have been prepared and evaluated. Derivatives 47 and 86 are potent, selective 
and competitive inhibitors of α-mannosidase from jack bean and dGMII. However, they did 
not inhibit the growth of human cancer cells. It was postulated that their hydrophilic character 
prevented their internalization by cells. In support of this hypothesis, the more lipophilic 
esters 132 and 139 inhibited the growth of human glioblastoma and HCEC cells more 
efficiently than Swa, a potential antitumoral agent (Scheme 59). Moreover, compound 132 
inhibited the growth of glioblastoma and melanoma cells more than the growth of fibroblasts, 
as models of non-tumoral cells (Scheme 62). Measurements of the lipophilicity supported 
these observations as the LogPo/w values were higher for the ester derivatives than for the 
parent alcohols (Table 9).  
 
In order to get more insights into the mode of action of our lead compounds 47 and 86, 
evaluation of their inhibitory activities on cellular α-mannosidases was envisaged.  
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3.6.5. Human α-mannosidases 
3.6.5.1. Various human α-mannosidases 
As already presented in the introduction, there are several cellular α-mannosidases II that 
display similar molecular weight and sequences at their active sites.  
 
These α-mannosidases II can be separated into three groups: 
(i) The acidic/lysosomal (MAN2B1, EC 3.2.1.24) α-mannosidases with the human lysosomal 
α-mannosidase II widely distributed and active at pH 4-4.5. The single chain precursor has a 
molecular weight of 110kD, which is processed to 3 fragments of 70, 42 and 15 kD.200 
Increased expression of this enzyme has been previously demonstrated in extracts of 
glioblastoma and correlated with malignancy.201  
 
(ii) The intermediate/Golgi (MAN2A1, EC 3.2.1.114) α-mannosidases with the human Golgi 
α-mannosidase II, active at pH 5.5-6, with a molecular weight of 130 kD and with its gene 
located to chromosome 5.202  
 
(iii) Neutral/cytosolic (MAN2C1/6A8) α-mannosidases with the human cytosol α-
mannosidase II recently cloned as the 6A8-mab-reactive protein, active at neutral pH. Its 
molecular weight has been evaluated at 120 kD.203 This enzyme is inhibited by Swa with less 
efficiency than Golgi α-mannosidase with IC50 of 20 μM vs 20 nM for Golgi α-mannosidase 
II.  
                                                 
200 Beccari, T.; Stinchi, S.; Orlacchio, A. Bioscience Reports 1999, 19, 157-162. 
201 Wielgat, P.; Walczut, U.; Szajda, S.; Bien, M.; Zimnoch, L.; Mariak, Z.; Zwierz, K. J. Neurooncol. 2006, 80, 
243-249. 
202 Moremen, K. W.; Robbins, P. W.; J. Cell. Biol. 1991, 115, 1521-1534. 
203 Li, B.; Wang, Z. Z.; Ma, F. R.; Shi, G. X.; Zhang, L. X.; Zeng, X.; Liu, Y.; Zhao, F. T.; Zhu, L. P. Eur. J. 
Biochem. 2000, 267, 7176-7183. 
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3.6.5.2. Inhibitory activities toward human α-mannosidases 
The inhibitory potency of compounds 47 and 86 on α-mannosidases extracts from human 
glioblastoma and HCEC was determined and compared to the inhibitory ability of Swa.204  
 
A first set of measurements was performed for derivatives 47, 86 and Swa on glioblastoma 
cell lines LNZ308, LN18 and HCEC cells at three different pH values, with a pre-incubation 
time of 10 minutes of inhibitor in cell extracts at 25°C (Table 10).  
IC50 (μΜ) 
 LNZ308 LN18 HCEC 
 pH 5.0 pH 6.5 pH 7.3 pH 5.0 pH 6.5 pH 7.3 pH 5.0 pH 6.5 pH 7.3 
Swa(16)      0.03  4  4  25  4  4      0.05  4  4 
47  30  1000  500  1000 > 1000  750  75  500  350 
86   < 2.5  500  >1000  500  750 > 1000       2.5  750 > 1000 
Table 10: Inhibitory ability of Swa (16), compounds 47 and 86 on human α-mannosidases 
from glioblastoma and HCEC extracts at three different pH values. Pre-incubation of inhibitor 
in cell extracts: 10 minutes at 25°C. 
 
 
For all cell lines, a decrease of the pH resulted in a higher inhibition. The pH for further 
experiments was thus fixed at 5.0 and it was also anticipated that increasing the pre-
incubation time to 30 minutes and the temperature to 37°C could result in improved inhibition 
(Table 11). 
 
The first generation inhibitor 47 presented a moderate inhibitory potency on α-mannosidases 
from both glioblastoma cell lines (IC50 = 50 μM) and HCEC (IC50 = 25 μM, Table 11). As 
observed for the inhibition of the model enzymes (jack bean α-mannosidase and dGMII), the 
homologated analog 89 was much less active on enzymes of all extracts. Introduction of an 
oxo moiety at the C(5) position of the five membered ring did not afford significant 
improvement of the inhibition (80). However, the N-methyl pyrrolidinone 86 displayed potent 
inhibitory ability on α-mannosidases from LNZ308 and LN18 (IC50 = 500 nM and 2.0 μM, 
respectively) and from HCEC (IC50 = 500 nM).  
                                                 
204 Fiaux, H.; Kuntz, D. A.; Hoffman, D.; Janzer, R. C.; Gerber-Lemaire, S.; Rose, D. R.; Juillerat-Jeanneret, L. ; 
Functionalized pyrrolidine inhibitors of human α-mannosidase II in cancer: optimizing the fit to the active 
site, paper in preparation. 
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 IC50 
Compounds LNZ308 LN18 HCEC 
Swa (16) 20 nM 50 nM 10 nM 
47 50 μM 50 μM 25 μM 
89 500 μM 750 μM 200 μM 
80 50 μM 350 μM 75 μM 
86 500 nM 2.0 μM 500 nM 
Ethyl 4-bromobenzoate n.i. n.i. n.i. 
Acid 4-bromobenzoate n.i. n.i. n.i. 
128 300 μM n.d. n.d. 
130 250 μM n.d. n.d. 
131 350 μM n.d. n.d. 
132 75 μM 200 μM 75 μM 
133 > 1 mM > 1 mM > 1 mM 
134 150 μM 750 μM 75 μM 
137 300 μM n.d. n.d. 
139 7.5 μM 75 μM 750 nM 
n.i. = no inhibition n.d. = not determined 
Table 11: Inhibitory ability (IC50) on human α-mannosidases from glioblastoma and HCEC 
extracts at pH 5.0. Pre-incubation of inhibitors in cell extracts: 30 minutes at 37°C.  
 
Amide 137 or ester derivatives 128, 130, 131 and 133 as well as the corresponding 4-
bromobenzoate ester 132, 134 and 139 presented a decreased inhibitory ability on 
glioblastoma cell extracts. These data were expected as the loss of interactions between the 
primary alcohol and residues of the active site of the enzyme decreased the affinity of the 
inhibitors for the enzyme. Nevertheless, a moderate inhibition was maintained for compound 
139 (IC50 = 7.5 μM and 75 μM on LNZ308 and LN18 extracts, respectively) strengthening 
the hypothesis that the ester linkage is cleaved by cellular esterases to release the free primary 
alcohol. Within the incubation time, this process may only be partial, resulting in a higher 
IC50 values than for the parent inhibitors 47, 80 and 86. Interestingly, in HCEC cells this 
hydrolytic process seemed to be more rapid as the activity of the 4-bromobenzoate derivatives 
was similar to the inhibition induced by the parent alcohols (IC50 = 75, 75 and 0.75 μM for 
132, 138 and 139 vs 25, 75 and 0.50 μM for 47, 80 and 86). 
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These data correlated with the inhibitory abilities measured on dGMII, a reliable model of 
human α-mannosidases II. The additional interactions with the active site of dGMII observed 
for derivative 86 may account for the improved inhibitory potency on dGMII and human α-
mannosidase in comparison with the lead inhibitor 47. However, Swa presented higher 
potency than our derivatives.  
 
Nevertheless the pyrrolidinone derivatives 86 revealed an improved efficacy in comparison 
with our first generation inhibitor 47 and thus constitute new promising scaffolds for the 
inhibition of human cellular α-mannosidases. Furthermore and for the first time in our group, 
it was shown to be active toward human enzymes. 
3.6.5.3. Property of human α-mannosidases 
In order to get additional information on the nature of the cellular targets of our derivatives, 
gel-filtration chromatography was performed on cellular extracts from glioblastoma and 
HCEC cells.  
 
Principle of gel-filtration: 
The principle of this experiment was to separate proteins inversely to their apparent molecular 
weight. As sepharose 4B allows fractioning in the range of 60 to 20’000 kD, this gel was 
selected as stationary phase (Scheme 63).   
 
 
Scheme 63: Principle of gel-filtration. 
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Results for gel-filtration: 
Scheme 64 represents the results obtained for LNZ308 cells line extracted with a detergent. 
The other cells displayed the same elution profile. For all tested cell lines (LN18, LNZ308 
and HCEC) the main enzymatic activity was easily extracted in the presence as well as in the 
absence of detergent and migrated as a protein of apparent molecular weight of about 120 kD. 
 
The molecular weight value obtained from this experiment is in accordance with the 
molecular weights reported in the literature for α-mannosidases II (3.6.5.1). Nevertheless, it 
was not possible to distinguish between lysosomal, cytosolic or Golgi α-mannosidases II.  
 
The main peak displayed an optimum activity at neutral pH and was inhibited by our lead 
molecule 86 (IC50 = 500 μM, pH 6.5) in agreement with the values obtained in cellular 
extracts (Table 10, page 99).  
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Scheme 64: Gel-filtration on Sepharose 4B of LNZ308 glioblastoma cells extracts in presence 
of detergent. Absorbance of blue dextran (2’000 kD) and Haemoglobin (60 kD) was measured 
at 620 and 405 nm, respectively. Kinetic measurement was performed during 30 min, at 3 
different pH values (5.0; 6.5 and 7.3), with α-mannoside-4-methyl-umbelliferyl as substrate.  
4. Conclusions and Perspectives 
The first lead compound 47 was co-crystallized in the active site of Golgi α-mannosidase II 
from Drosophila melanogaster which presents a high sequence homology with the human 
enzyme. The x-ray structure revealed a zinc-binding site and the interactions between the 
inhibitor and specific amino acids of the active site.  
 
This study combined with docking experiments allowed us to design new inhibitors by 
introducing polar substituents on the C(5) position of the pyrrolidine ring to form the 
pyrrolidinone derivative 86 with an additional methyl group on the amine of the ring. The x-
ray structure of dGMII:86 complex revealed two additional interactions between the carbonyl 
group of the pyrrolidinone ring and Asp472 and Tyr267 residues of the protein which can 
account for the higher affinity of this new lead (IC50 = 80 μM for 47 vs 500 nm for 86).  
 
The two leads have been evaluated as anti cancer agents and their effects were determined on 
human glioblastoma cells using the MTT assay, which determines the number of 
metabolically active cells. Unfortunately, these compounds were not able to inhibit cellular 
growth. As the hydrophilic character of these molecules may hinder their transport across cell 
membranes, we prepared analogues that could improve cell penetration. Different lipophilic 
groups have been introduced and we have discovered that introduction of a 4-bromobenzoyl 
moiety resulted in an improvement of cellular uptake, leading to growth inhibition of cancer 
cells. A dose-response evaluation (100 μM to 300 μM) of the anti-proliferative effects on 
glioblastoma cells demonstrated that (2R)-2-({[(2R,3R,4S)-3,4-dihydroxypyrrolidin-2-
yl]methyl}amino)-2-phenylethyl 4-bromobenzoate 132 and (2R)-2-({[(2R,3R,4R)-3,4-
dihydroxy-1-methyl-5-oxopyrrolidin-2-yl]methyl}amino)-2-phenylethyl 4-bromobenzoate 
139 induced complete cellular death at 300 μM concentration. The physicochemical profile of 
these derivatives revealed that the ionization state, at the pH used for the biological assay, 
may not be the same which can account for the slight difference of inhibition profile. 
Furthermore, melanoma cells, another tumoral cells, HCEC cells, an immortal non-tumoral 
cells line and fibroblasts, a model for non tumoral cells were also exposed to these derivatized 
inhibitors. Evaluation of the inhibition of incorporation of [3H]-leucine and [3H]-thymidine 
revealed that the synthesis of DNA was stopped before the synthesis of new proteins.  
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The exposure of tumor cells to ester derivatives results in two advantages: first, the hydrolysis 
of the ester could release molecules more active toward mannosidases (47 and 86) than the 
corresponding prodrugs (132 and 139) and secondly, the hydrophilic character of the active 
molecules following their intracellular hydrolysis by esterases can prevent their passive 
diffusion out of the cells. Therefore, functionalized pyrrolidine represent promising lead 
agents able to control the progression of human glioblastoma and melanoma, to inhibit DNA 
and protein synthesis and to display some selectivity toward tumoral cells compared to non-
tumoral cells.  
 
The inhibitory potency of our new derivatives on α-mannosidases from human glioblastoma 
and HCEC extracts was determined and compared to the activity of Swa. For all cell lines, a 
decrease of the pH of the medium resulted in a higher inhibitory activity. The first generation 
inhibitor 47 presented a moderate inhibitory potency on α-mannosidases from both tumoral 
cells whereas introduction of an oxo moiety at C(5) position and a methyl group on the 
pyrrolidinone system (86) resulting in potent inhibitory activity on human α-mannosidases 
(IC50 = 50 μM toward LNZ308 glioblastoma or HCEC cells for 47 vs 500 nM for 86). 
 
Migration of the α-mannosidases extracted from human glioblastoma cells (LNZ308 and 
LN18) and HCEC cells demonstrated an apparent molecular weight of about 120 kD by gel 
filtration. Nevertheless, further experiments will be required to determine the precise cellular 
target of our derivatives (Golgi α-mannosidase II, cytosolic α-mannosidase or lysosomal α-
mannosidase). 
 
Additional investigations will be performed to determine the localisation (i.e. lysosome, 
Golgi, or cytosol) of the α-mannosidases II inhibited by our derivatives and other cancer cell 
lines will be tested. Furthermore, lectin arrays recently became commercially available 
(Qproteome, Quiagen) to determine glycosylation state of eukaryotic proteins, based on lectin 
spotting on array slides. Preliminary results205 using micro-arrays donated by Quiagen, in the 
context of a field test, have given promising information but this study is still under 
investigation. The modifications of the glycosylation pattern of cellular target proteins may be 
estimated using commercially available carbohydrate-selective biotin-labelled lectins after 
                                                 
205 Measurements performed in collaboration with C. Chapuis, CHUV, 2006.  
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separation of the cellular proteins in polyacrylamide gels and transfer onto a nylon membrane 
that will be the object of future studies.  
 
Improving the cell selectivity of these derivatives by conjugation to targeting moieties may 
also be of high interest in the context of this study.  
 
Conclusions and Perspectives 
 
 
106 
 
 
 
5. Experimental Part 
5.1. General Methods 
5.1.1. Crystallography 
Crystallization, data collection and structural refinement were carried out essentially as 
outlined by Kuntz et al.41a with the exceptions noted below. 
 
Crystals of dGMII were grown overnight, washed with phosphate buffered solution,181 and 
soaked with 10 mM of inhibitors for at least 3 hours. In case of 57, crystals were soaked in 
Tris-buffered reservoir solution without phosphate washing. Data were collected on Beamline 
191D at the Advanced Photon Source for crystals of 47 and 62 and at Beamline A1 at the 
Cornell High Energy Synchrotron Source for 57 and 86. 400 Frames with 0.5 degree 
oscillation/frame were collected. To obtain a data set with good completeness, data on 2 
crystals of 47 were collected and the data merged with Scalepack. 
5.1.2. Preparation of structures and parametrization of Glide 
The 10 structures were retrieved from the PDB (PDB codes: 1HWW, 1HXK, 1PS3, 1R33, 
1R34, 1TQS, 1TQT, as well as the newly determined 2F18, 2F1A, 2F1B) and prepared using 
Maestro 7.0206 from Schrödinger.  
 
Water molecules were removed from the x-ray structures and the resulting proteins were 
aligned based on the α-carbon trace. Hydrogen atoms were added to both protein and ligands 
and bonds between amino acids and the zinc atom were broken. Charges and atom types were 
assigned automatically with Macromodel/OPLS2003 to the protein and the ligands. Neutral 
zones (as defined in Glide) of 10-20 Å around the ligands were defined and the 
inhibitor/proteins were refined using the local optimization procedure proposed in Glide. 
Then, charges of the catalytic site residues were corrected following a DFT207 calculation at 
the B3LYP/6-31G** level of theory (using Jaguar 6.0208) carried out on a truncated site 
consisting of His90, His471, Asp92, Asp204 and Zn. The zinc parameters, obtained from the 
                                                 
206 Maestro 70, Schrödinger LLC: Portland OR 2004 http://www.schrodinger.com. 
207 DFT calculation = Density Functional Theory calculation. 
208 Jaguar 60, Schrödinger LLC: Portland OR 2004 http://www.schrodinger.com. 
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literature,209 were added to the OPLS2003 force field definition and the specific charge, 
obtained with the DFT calculation, was assigned to the zinc atom. Finally, the structures of 
the ligands were all optimized through energy minimization (Tripos force field) prior to the 
docking.  
 
At this stage, the proteins and ligands were ready for docking. Grids were prepared for each 
protein with the exact same center and size of 40 Å around the zinc atom. Moreover, a 
constraint that forced the interaction with the metal ion was included. During the grid 
preparation, a specific keyword (CMAE) has to be employed to maintain the partial charges 
computed from DFT. Four hours per protein were needed to do the preparation, refinement 
and grid calculation on an SGI R16K. The ligands were minimized using the OPS2003 
forcefield and submitted to Glide for docking. 25 runs were performed for each inhibitors in 
one protein. In order to ensure convergence, the following parameters were used and fixed to 
their mamimum values: ligvdwscale factor 1.0; maxkeep 50,000; maxconf 10,000; nreport 
5,000; maxref 4,000; scorecut 100. Using these parameters, the docking of the ten inhibitors 
on a single receptor was performed in an average time of 44 minutes on an SGI R16K. During 
the docking, a specific keyword (reference) was needed to report the RMSD values. 
5.1.3. Biological Evaluation 
5.1.3.1. Inhibition of purified plant glycosidases 
The experiments were performed essentially as previously described by Brandi et al.210 
Briefly, 0.01 to 0.5 units/ml of enzyme (Aldrich, 1 unit = 1 enzyme unit liberates 1 μmol of 
glycoside per minute from p-nitrophenyl glycoside) and various concentrations of inhibitor 
were pre-incubated for 10 or 30 min at 37°C. The kinetic reaction, measured at 37°C, started 
by addition of the appropriate p-nitrophenyl glycoside substrate (Sigma) buffered to the 
optimum pH of the enzyme. The reaction was stopped by addition of 2.5 volumes of 0.2 M 
sodium borate buffer (pH 9.8). The p-nitrophenolate formed was quantified at 410 nm and 
IC50 were calc. or double-reciprocal plots (Lineweaver and Burk) were used to determine the 
inhibition kinetics values. 
                                                 
209 Tiraboschi, G.; Gresh, N.; Giessner-Prettre, C.; Pedersen, L. G.; Deerfield, D. W. J. Comp. Chem. 2000, 21, 
1011-1039. 
210 Brandi, A.; Cicchi, S,; Cordero, F. M.; Frignoli, B.; Goti, A.; Picasso, S.; Vogel, P. J. Org. Chem. 1995, 60, 
6806-6812. 
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5.1.3.2. Cell culture and Treatments.  
Human LN18 and LNZ308 glioblastoma cell lines (a kind gift of A. C. Diserens, 
Neurosurgery Department, CHUV, Lausanne, Switzerland) were routinely maintained in 
Dulbecco’s Modified Eagle Medium (DMEM, Gibco, Invitrogen, Basel, Switzerland) 
containing 4.5 g/l glucose, 5% foetal calf serum (FCS, Gibco) and antibiotics. Human Me237 
and Me275 melanoma cell lines (a kind gift of D. Rimoldi, Ludwig Institute, Lausanne, 
Switzerland) were grown in RPMI medium (Gibco) containing 10% FCS and antibiotics. 
Human primary fibroblasts were prepared from surgical skin (PG 98/5, a kind gift of M. 
Benattan, Dermatology Department, CHUV, Lausanne, Switzerland) or lung (PO 08, a kind 
gift of J.-D. Aubert, Pneumology Department, CHUV, Lausanne, Switzerland) biopsies 
derived in the CHUV using the explant technique, and were grown in DMEM medium 
containing 4.5 g/l glucose, 10% FCS and antibiotics. HCEC cells are immortalized human 
brain-derived endothelial cells (a kind gift of D. Stanimirovic, Ottawa, Canada) and were 
grown in DMEM medium containing 4.5 g/l glucose, 10% FCS and antibiotics. 
 
For the experiments, cells were grown in 48-wells plates (Costar, Corning, NY) for 24 to 72 
hours in presence of FCS until 60-75% confluence, then exposed for the indicated time to 
increasing concentrations of the synthetic derivatives (from 0 to 300 μM, stock solutions in 
methanol/PBS 1/20) in fresh complete medium. Then either metabolically active cells were 
quantified using the MTT assay, or DNA synthesis or protein synthesis as evaluated using 
[
3
H]-Thymidine or [
3
H]-leucine incorporation. Experiments were performed in triplicate wells 
and were repeated at least three times. Means + sd have been calculated. 
 
5.1.3.3. Evaluation of Cell Proliferation by the MTT Assay 
MTT ((3,4,5-dimethylthiazol-yl)-2,5-diphenyl tetrazolium, Sigma, Buchs, Switzerland) was 
used to quantify the number of metabolically active cells. Following treatment with 
pyrrolidine derivatives, the cells were exposed to 0.2 mg/ml MTT in DMEM medium for 2 
hours. The supernatant was aspirated and the precipitated formazan was dissolved in HCl 0.1 
N in 2-propanol and quantified at 540 nm in a multiwell plate reader (iEMS Reader MF, 
Labsystems, Bioconcepts, Switzerland). 
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5.1.3.4. Evaluation of DNA and Protein Synthesis 
Thymidine and leucine incorporation were used to assess DNA and protein syntheses, 
respectively. [3H]-Thymidine (Amersham-Pharmacia, Dübendorf, Switzerland, 400 
nCi/puit/ml) or [3H]-Leucine (American Radiolabeled Chemicals, St-Louis MO, USA, 400 
nCi/puit/ml) were added to treated or control cells for the last 2 hours of incubation with the 
pyrrolidine derivatives. The cell layer was washed, precipitated with 10% trichloracetic acid 
and the precipitate was dissolved in 1% SDS in NaOH 0.1 N. Then 5 ml of scintillation 
cocktail (Optiphase, Wallac, Regensdorf, Switzerland) was added, and the radioactivity was 
measured in a β-counter (WinSpectral, Wallac). 
5.1.3.5. Evaluation of molecular weight of α-mannosidases  
Confluent layers of cells grown on a plate of Petri (9 cm, FalconL) were washed with PBS 
(Phosphate buffer saline, pH 7.3) and extracted in 0.55 ml of PBS-0.1% Triton X-100 (Fluka, 
Switzerland). After centrifugation at 800 g for 5 min, 2.5 mg Blue Dextran (2000 kD, 
Pharmacia, gel filtration kit, Switzerland) and 2.1 mg bovine haemoglobin (67 kD, Fluka, 
Switzerland) were added to 0.5 ml of the cell extract supernatant. The solution was applied to 
a 0.9 cm x 115 cm Sepharose 4B column (Pharmacia, Amersham, Genf, Switzerland) in PBS-
0.1% Triton at 4°C. Collected fractions (350 μl) were measured at 620 nm (Blue Dextran) and 
405 nm (Haemoglobin) and assayed for enzymatic activities at three different pH values (5.0, 
6.5 and 7.3) using the fluororogenic substrate 4-Methyl-Umbelliferyl-α-D-mannopyranoside 
(Fluka) by measuring the fluorescence increase in a multiwell plate reader (Cytofluor, 
PerSeptive BioSystems) thermostated at 37 °C, λex = 360 nm; λem = 460 nm, for 30 min. 
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5.2. Synthesis 
5.2.1. Reagents and Solvents 
All commercially available reagents (Fluka, Aldrich, Acros) were used without further 
purification.  
 
Technical solvents were used for extraction without any purification. For reactions requiring 
anhydrous conditions, dry solvents were bought (Fluka) or filtered prior to use (Innovative 
Technology).  
 
In absence of any particular notification, experiments were carried out under argon 
atmosphere. 
5.2.2. Chromatography techniques 
Reactions were monitored by thin layer chromatography (Merck silica gel 60F254 plates). 
Revelation was carried out by UV light (254nm) and KMnO4 [3g of KMnO4, 20g of K2CO3, 
0.25 ml of AcOH and 300 ml of H2O] or Pancaldi [21g of (NH4)6Mo4, 1g of Ce(SO4)2, 31  ml 
of H2SO4 and 470 ml of H2O] reagents. Purifications were performed by flash 
chromatography (Fluka silica gel 60, 230-400 mesh, 0.04-0.063mm). 
 
Analytical high-performance liquid chromatography (HPLC) was performed on a Waters 600 
apparatus, equipped with a Waters absorbance detector set at 214 nm and C4, C8 and C18 
Grace Vydac columns. Elution was performed using the following gradient over 30 min, 
100% (0.9% CF3COOH in H2O) to 100% (0.9% CF3COOH in MeCN). 
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5.2.3. Analysis 
1H-NMR spectra were recorded on Bruker ARX-400 and DPX-400 spectrometers at 400 
MHz. Chemical shifts δ(H) were assigned relatively to the reference solvent peak in ppm 
(MeOD: δ(H) = 3.34; CDCl3: δ(H) = 7.27). Coupling constants J are given in Hz.  
Multiplicity: s = singlet, d = doublet, t = triplet, b = broad. 
 
13C-NMR spectra were recorded on Bruker ARX-400 and DPX-400 spectrometers at 101 
MHz. References for solvent used in ppm (MeOD: δ(C) = 49.0; CDCl3: δ(C) = 77.0). 
 
IR spectra were recorded on a Perkin Elmer Paragon 1000 FT-IR spectrometer. 
 
UV spectra were recorded on a Kontron Uvikon 810 CW spectrophotometer.  
 
Optical rotations were recorded at 25°C on a Jasco P-1020 polarimeter. [α] values are given 
in units of 10-1deg cm2g-1.  
 
Mass spectra were recorded on a GC-MS spectrometer (Nermag R-10-10C in chemical 
ionisation mode with NH3), on a MALDI-TOF spectrometer (Axima-CFR+, Kratos, 
Manchester), on a ESI-Q spectrometer (Finnigan SSQ 710C, Thermoquest, UK) and on a 
ESI-QT of Ultima spectrometer (Micromass, Manchester).  
 
Microanalyses were performed by Ilse Beetz Laboratory (Kronach, Germany).  
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5.2.4. Synthesis Procedures 
Procedure 1: General method for the reductive amination 
 
To a solution of aldehyde RCHO (1.0 eq) in anhydrous 1,2-dichloroethane were added a 
primary amine R’NH2 (1.0 - 1.5 eq) and sodium triacetoxyborohydride (1.4 eq) portionwise. 
The mixture was stirred at 25°C for 12 hours. After complete consumption of starting 
aldehyde (tlc monitoring), the solution was poured into a saturated aqueous solution of 
NaHCO3. The aqueous layer was extracted 3 times with EtOAc and the combined organic 
extracts were dried over MgSO4. Solvent evaporation in vacuo and flash chromatography on 
silica gel afforded pure diamines.  
 
 
Procedure 2: General method for deprotection of Boc and acetonide groups 
 
Procedure 2a: A 5-10 % solution of protected diamine in CF3COOH/H2O (4/1) was stirred at 
25°C for 1-12 hours. After evaporation in vacuo, the residue was purified by flash 
chromatography on silica gel (CH2Cl2/MeOH or MeCN/NH4OH).  
 
Procedure 2b: A 5-10 % solution of diamine in 4M HClaq was stirred at 25°C for 1-12 hours. 
After evaporation in vacuo, the residue was purified by flash chromatography on silica gel 
(CH2Cl2/MeOH or MeCN/NH4OH).  
 
 
Procedure 3: General method for preparation of phenyl glycinol esters 
To a solution of primary alcohol (1.0 eq) in anhydrous CH2Cl2, at 0°C, were added NEt3 (4.0 
eq), R’’C(O)Cl (1.4 - 2.0 eq) and DMAP (0.2 eq). The mixture was allowed to warm up to 
25°C and was stirred until consumption of starting alcohol. The resulting mixture was poured 
into a saturated aqueous solution of NaHCO3 and the aqueous layer was extracted with 
CH2Cl2 (10 ml, 3 times). The combined organic extracts were washed with a saturated 
aqueous solution of NH4Cl (10 ml) and brine (10 ml), dried over MgSO4, filtered and 
concentrated in vacuo. Purification by flash chromatography on silica gel afforded pure ester 
derivatives.  
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Tert-butyl (3aS,4R,6R,6aR)-2,2,4-trimethyl-6-{[(triphenylmethyl)oxy]methyl}tetrahydro-
5H-[1,3]dioxolo[4,5-c]pyrrole-5-carboxylate ((-)-53) 
 
N
Boc
OTr
Me
O O
5
64
2
3a 6a
1'
 
 
To a solution of 51174 (3.7 g, 6.9 mmol, 1.0 eq) in anhydrous THF (35 ml), cooled to -50°C, 
was added MeMgBr (3.5 ml of a 3M solution in Et2O, 10.4 mmol, 1.5 eq) dropwise. The 
reaction mixture was stirred at -40°C for 30 minutes. The mixture was poured into a saturated 
aqueous solution of NH4Cl (50 ml), water was added (30 ml) and the aqueous layer was 
extracted with EtOAc (25 ml, 3 times). The combined organic extracts were dried over 
MgSO4, filtered and concentrated in vacuo. Flash chromatography on silica gel 
(pentane/EtOAc 3/1) afforded an intermediate amide (3.4 g, 87 %) as a yellow oil.  
 
To a solution of this amide (1.3 g, 2.4 mmol, 1.0 eq) in anhydrous MeOH (24 ml), cooled to 
0°C, was added NaBH4 (371 mg, 9.8 mmol, 4.0 eq) portionwise. The mixture was warmed up 
to 25°C and stirred for 45 minutes. The resulting mixture was poured into brine (30 ml) and 
the aqueous layer was extracted with EtOAc (20 ml, 3 times). The combined organic extracts 
were dried over MgSO4, filtered and concentrated in vacuo to afford a mixture of two 
diastereoisomeric alcohols (1.2 g) as a white foam.  
 
To a solution of this crude mixture (1.2 g, 2.5 mmol, 1.0 eq) in anhydrous CH2Cl2 (24 ml), 
cooled to 0°C, were added NEt3 (512 μl, 3.7 mmol, 1.5 eq) and MsCl (285 μl, 3.7 mmol, 1.5 
eq) dropwise.  The mixture was stirred at 0°C for 30 minutes. The resulting solution was 
poured into a saturated aqueous solution of NaHCO3 (20 ml) and the aqueous layer was 
extracted with EtOAc (15 ml, 3 times). The combined organic extracts were dried over 
MgSO4, filtered and concentrated in vacuo to afford a crude mesylate (1.5 g) as a white foam.  
 
To a solution of this mesylate (1.5g, 2.5 mmol, 1.0 eq), in anhydrous THF (25 ml), cooled to 
0°C, was added tBuOK (688 mg, 6.1 mmol, 2.5 eq) and the mixture was stirred at 0°C for 30 
minutes. The resulting mixture was poured into brine (20 ml) and the aqueous layer was 
extracted with EtOAc (15 ml, 3 times). The combined organic extracts were dried over 
MgSO4, filtered and concentrated in vacuo. Flash chromatography on silica gel 
(pentane/EtOAc 17/1) afforded 52 (455 mg, 35 %, 3steps) and 53 (517 mg, 40 %, 3steps) as 
pale yellow oils. 
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Data for 53, mixture of rotamers (α/β 1/1.6): 
 
[α] 58925  = -59, [α] 25577  = -62, [α] 43525  = -117, [α] 40525  = -136 (c = 0.41, CHCl3). 
 
IR (film): 3455, 2980, 2935, 1695, 1375, 1170, 1080, 1030, 755, 700 cm-1. 
 
1H-NMR (400 MHz, MeOD):  
7.39-7.11 (m, 15Harom); 4.84 (m, 1H, H-C(3aα)); 4.76 (m, 1H, H-C(3aβ)); 4.46 (m, 1H, H-
C(6aβ)); 4.41 (m, 1H, H-C(6aα)); 4.18-4.11 (m, 3H, H-C(4α), H-C(4β), H-C(6α)); 4.05 (m, 1H, 
H-C(6β)); 3.85 (bd, 1H, 2Jgem = 8.9, H-C(1’α)); 3.45 (dd, 1H, 3J(H-C(1’β), H-C(6β)) = 2.5, 
2Jgem = 8.9, H-C(1’β)); 3.07 (bd, 1H, 2Jgem = 8.9, H-C(1’β)); 2.95 (bd, 1H, 2Jgem = 8.9, H-
C(1’α)); 1.54 (s, 9H, Me3Cα); 1.51 (s, 3H, Me); 1.44 (d, 3H, 3J(Me, H-C(4)) = 6.5, Meβ-C(4)); 
1.38 (d, 3H, 3J(Me, H-C(4)) = 5.6, Meα-C(4)); 1.34 (s, 9H, Me3Cβ); 1.32 (s, 3H, Me). 
 
13C-NMR (101 MHz, MeOD):  
154.2 (s, NC(O)O); 143.6 (s, 3Carom); 128.6 (d, 1J(C,H) = 159, 6Carom); 127.9 (d, 1J(C,H) = 
160, 6Carom); 127.1 (d, 1J(C,H) = 161, 3Carom); 110.9 (s, OCMe2); 87.1 (s, OCPh3); 81.8 (d, 
1J(C,H) = 158, C(6aβ)); 81.4 (d, 1J(C,H) = 159, C(6aα)); 81.3 (d, 1J(C,H) = 159, C(3aα)); 80.6 
(d, 1J(C,H) = 158, C(3aβ)); 79.8 (s, OCMe3α); 79.4 (s, OCMe3β); 63.5 (t, 1J(C,H) = 143, 
C(1’α)); 62.7 (C(1’β), C(6α), C(6β)); 58.0 (d, 1J(C,H) = 140, C(4α)); 57.7 (d, 1J(C,H) = 140, 
C(4β)); 28.6 (q, 1J(C,H) = 130, Me3C); 28.4 (q, 1J(C,H) = 130, Me3C); 25.8 (q, 1J(C,H) = 128, 
Me-C(2)); 25.0 (q, 1J(C,H) = 128, Me-C(2)); 16.9 (q, 1J(C,H) = 128, Meα-C(4)); 15.5 (q, 
1J(C,H) = 128, Meβ-C(4)). 
 
ESI-MS: 552.30 (M+Na)+. 
HRMS (C33H39NO5 + Na): calc. 552.2726; found 552.2781. 
 
 
The other isomer 52 was not fully characterized but directly engaged in the next step.  
Experimental Part 
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(2R,3R,4S,5R)-2-({[1R]-2-Hydroxy-1-phenylethyl]amino}methyl) -5-methylpyrrolidine -
3,4-diol ((-)-57) 
N
H
NH OH
Me
HO OH
2
34
5
1'
1''
2''
1
 
 
Metallic sodium chips (387 mg, 16.9 mmol, 15.0 eq) were added to liquid NH3 (55 ml, 
condensed at -78°C) and a solution of 53 (596 mg, 1.1 mmol, 1.0 eq) in anhydrous THF (10 
ml) was added dropwise. After stirring at –78°C for 50 minutes, solid NH4Cl was added until 
complete decoloration of the blue mixture. The solution was allowed to warm up to 25°C and 
stirred to the end of gas evolution. The residue was diluted with EtOAc and water, filtered on 
a pad of Celite and concentrated in vacuo. Purification by flash chromatography on silica gel 
(pentane/EtOAc 1/1) afforded an intermediate primary alcohol (295 mg, 91 %) as a colourless 
oil.  
 
To a solution of this primary alcohol (219 mg, 0.76 mmol, 1.0 eq) in anhydrous CH2Cl2 (8 
ml), were added 4Å molecular sieves (380 mg), NMO (124 mg, 0.92 mmol, 1.2 eq) and 
Pr4NRuO4 (27 mg, 0.08 mmol, 0.1 eq). The mixture was stirred at 25°C for 1 hour, filtered on 
a pad of Celite and concentrated in vacuo. Purification by flash chromatography on silica gel 
(pentane/EtOAc 3/1) afforded the aldehyde 56 (46 mg, 21 %) as a colourless oil.  
 
Procedure 1. D-(-)-α-phenylglycinol (99) (26 mg, 0.19 mmol, 1.2 eq), aldehyde 56 (46 mg, 
0.16 mmol, 1.0 eq), NaBH(OAc)3 (46 mg, 0.22 mmol, 1.4 eq), Cl(CH2)2Cl (2 ml). Flash 
chromatography (CH2Cl2/MeOH 9/1) afforded 59 mg (0.15 mmol, 92 %, colourless oil) of the 
fully protected compound which was directly engaged in procedure 2b. Purification by flash 
chromatography (MeCN/NH4OH 8/1) afforded 57 (16 mg, 42 %) as a brown oil. 
 
[α] 58925  = -5, [α] 43525  = -7, [α] 40525  = -8 (c = 0.20, CHCl3). 
 
IR (film): 3415, 3020, 2930, 1645, 1455, 1215, 1140, 755 cm-1. 
 
1H-NMR (400 MHz, MeOD):  
7.41-7.21 (m, 5Harom); 4.03-4.01 (m, 2H, H-C(3), H-C(1’’)); 3.84 (m, 1H, H-C(4)); 3.72-3.64 
(m, 3H, H-C(5), 2H-C(2’’)); 3.45 (m, 1H, H-C(2)); 2.95 (dd, 1H, 3J(H-C(1’), H-C(2)) = 3.8, 
2Jgem = 13.2, H-C(1’)); 2.80 (dd, 1H, 3J(H-C(1’), H-C(2)) = 9.4, 2Jgem = 13.2, H-C(1’)); 1.42 
(d, 3H, 3J(Me, H-C(5)) = 6.6, Me-C(5)). 
 
13C-NMR (101 MHz, MeOD):  
141.5 (s, 1Carom); 129.7 (d, 1J(C,H) = 160, 2Carom); 128.8 (d, 1J(C,H) = 160, 1Carom); 128.6 (d, 
1J(C,H) = 158, 2Carom); 75.6 (d, 1J(C,H) = 144, C(3)); 73.3 (d, 1J(C,H) = 153, C(1’’)); 67.3 (t, 
1J(C,H) = 144, C(2’’)); 66.6 (d, 1J(C,H) = 143, C(4)); 63.0 (d, 1J(C,H) = 146, C(2)); 58.2 (d, 
1J(C,H) = 141 , C(5)); 48.0 (t, 1J(C,H) = 136, C(1’)); 12.1 (q, 1J(C,H) = 129, Me-C(5)). 
 
MALDI-TOF: 267.12 (M+H)+. 
HRMS (C14H22N2O3 + H): calc. 267.1709; found 267.1748. 
Experimental Part 
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1H-NMR spectrum of 53 
 
 
 
 
 
1H-NMR spectrum of 57 
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(2R,3R,4S,5S)-2-({[1R]-2-Hydroxy-1-phenylethyl]amino}methyl) -5-methylpyrrolidine-
3,4-diol ((-)-55) 
 
 
N
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Metallic sodium chips (296 mg, 12.9 mmol, 15.0 eq) were added to liquid NH3 (42 ml, 
condensed at –78°C) and a solution of 52 (455 mg, 0.86 mmol, 1.0 eq) in anhydrous THF (8 
ml) was added dropwise. After stirring at –78°C for 50 minutes, solid NH4Cl was added until 
complete decoloration of the blue mixture. The solution was allowed to warm up to 25°C and 
stirred to the end of gas evolution. The residue was diluted with EtOAc and water, filtered on 
a pad of Celite and concentrated in vacuo. Purification by flash chromatography on silica gel 
(pentane/EtOAc 1/1) afforded an intermediate primary alcohol (222 mg, 90 %) as a colourless 
oil.  
 
To a solution of oxalyl chloride (79 μl, 0.93 mmol, 1.2 eq) in anhydrous CH2Cl2 (6 ml), 
cooled to -78°C, was added DMSO (132 μl, 1.9 mmol, 2.4 eq). After 20 minutes, the 
intermediate primary alcohol (222 mg, 0.77 mmol, 1.0 eq), in solution in anhydrous CH2Cl2 
(2 ml), was added dropwise. After 20 minutes, NEt3 (539 μl, 3.87 mmol, 5.0 eq) was added 
and the mixture was warmed to -30°C for 20 minutes. The mixture was poured into water (30 
ml) and extracted with EtOAc (15 ml, 3 times). The combined organic layers were washed 
with brine (20 ml), dried over MgSO4, filtered and concentrated in vacuo to afford aldehyde 
54 (140 mg, 63 %).  
 
Procedure 1. D-(-)-α-phenylglycinol (99) (40 mg, 0.29 mmol, 1.2 eq), aldehyde 54 (70 mg, 
0.24 mmol, 1.0 eq), NaBH(OAc)3 (72 mg, 0.34 mmol, 1.4 eq), Cl(CH2)2Cl (2.5 ml). Flash 
chromatography (CH2Cl2/MeOH 11/1) afforded 73 mg (0.18 mmol, 74 %) of the fully 
protected compound which was directly engaged in procedure 2b. Purification by flash 
chromatography (MeCN/NH4OH 8/1) afforded 55 (48 mg, 98 %) as a brown oil. 
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[α] 58925  = -4, [α] 25577  = -7, [α] 43525  = -9 (c = 0.17, CHCl3). 
 
IR (film): 3055, 1670, 1445, 1200, 1140, 840, 800, 725 cm-1. 
 
1H-NMR (400 MHz, MeOD):  
7.53 (m, 2Harom); 7.46 (m, 3Harom); 4.34 (t, 1H, 3J(H-C(1’’), H-C(2’’)) = 5.9, H-C(1’’)); 4.10 
(dd, 1H, 3J(H-C(3), H-C(4)) = 5.2, 3J(H-C(3), H-C(2)) = 7.0, H-C(3)); 3.95 (d, 2H, 3J(H-
C(2’’), H-C(1’’)) = 5.9, H-C(2’’)); 3.90 (dd, 1H, 3J(H-C(4), H-C(5)) = 4.9, 3J(H-C(4), H-
C(3)) = 5.2, H-C(4)); 3.77 (ddd, 1H, 3J(H-C(2), H-C(1’)) = 4.8, 3J(H-C(2), H-C(3)) = 7.0, 
3J(H-C(2), H-C(1’)) = 8.9, H-C(2)); 3.65 (qd, 1H, 3J(H-C(5), H-C(4)) = 4.9, 3J(H-C(5)), Me = 
7.0, H-C(5)); 3.42 (dd, 1H, 3J(H-C(1’), H-C(2)) = 8.9, 2Jgem = 13.6, H-C(1’)); 3.26 (dd, 1H, 
3J(H-C(1’), H-C(2)) = 4.8, 2Jgem = 13.6, H-C(1’)); 1.45 (d, 3H, 3J(Me, H-C(5)) = 7.0, Me-
C(5)). 
 
13C-NMR (101 MHz, MeOD):  
135.7 (s, 1Carom); 130.5 (d, 1J(C,H) = 161, 1Carom); 130.3 (d, 1J(C,H) = 161, 2Carom); 129.4 (d, 
1J(C,H) = 159, 2Carom); 75.4 (d, 1J(C,H) = 149, C(4)); 73.5 (d, 1J(C,H) = 146, C(3)); 66.3 (d, 
1J(C,H) = 142, C(1’’)); 64.3 (t, 1J(C,H) = 145, C(2’’)); 61.7 (d, 1J(C,H) = 147, C(5)); 61.4 (d, 
1J(C,H) = 147, C(2)); 47.0 (t, 1J(C,H) = 143, C(1’)); 16.0 (q, 1J(C,H) = 128, Me-C(5)). 
 
MALDI-TOF: 267.04 (M+H)+. 
HRMS (C14H22N2O3): calc. 266.1630; found 266.1629. 
 
 
 
1H-NMR spectrum of 55 
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Tert-butyl (3aR,6R,6aR)-4-hydroxy-2,2-dimethyl-6-[(trityloxy)methyl]tetrahydro-5H-
[1,3]dioxolo[4,5-c]pyrrole-5-carboxylate ((-)-72) 
 
N
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To a solution of 51174 (1.54 g, 2.91 mmol, 1.0 eq) in anhydrous MeOH (30 ml) at 0°C was 
added sodium borohydride (0.17 g, 4.37 mmol, 1.5 eq) and the solution was stirred at 0°C for 
15 min. The resulting mixture was diluted with EtOAc (30 ml), poured into a saturated 
aqueous solution of NaHCO3 (30 ml). The aqueous layer was extracted with EtOAc (10 ml, 3 
times). The combined organic extracts were dried over MgSO4, filtered and concentrated in 
vacuo. Flash chromatography on silica gel (EtOAc/pentane 1/6) afforded alcohol 72 (1.44 g, 
93%) as a white foam. 
 
[α] 58925  = -57, [α] 25577  = -57, [α] 43525  = -108, [α] 25405  = -128 (c = 0.32, CH2Cl2). 
 
UV (MeCN) : 260 (1500), 217 (11500), 196 (5500). 
 
IR (film) : 3470, 2985, 2940, 2880, 1690, 1430, 1365, 1260, 1215, 1170, 1130, 1080, 780, 
765, 755, 705 cm-1. 
 
1H-NMR (400MHz, CDCl3): 
7.38-7.25 (m, 15Harom) ; 5.64 (bs, 1H, H-C(4maj)) ; 5.52 (bs, 1H, H-C(4min)) ; 4.84 (dd, 1H, 3J 
= 5.8, 3J = 5.8, H-C(3a)) ; 4.32 (d, 1H, 3J(H-C(6a), H-C(3a)) = 5.1, H-C(6a)) ; 4.13 (d, 1H, 3J 
(H-C(6), H-C(1’)) = 3.8, H-C(6min)) ; 4.04 (s, 1H, H-C(6maj)) ; 3.90 (d, 1H, 2Jgem = 8.3, H-
C(1’min)) ; 3.59 (d, 1H, 2Jgem = 9.3, H-C(1’maj)) ; 2.98 (d, 1H, 2Jgem = 9.2, H-C(1’maj)) ; 2.90 (d, 
1H, 2Jgem = 8.6, H-C(1’min)) ; 1.58 (s, 6H, 2CH3-C(2)maj) ; 1.40 (s, 9H, Me3C) ; 1.34 (s, 6H, 
2CH3-C(2)min). 
 
13C-NMR (101MHz, CDCl3): 
154.8 (s, NC(O)Oα) ; 154.3 (s, NC(O)Oβ) ; 143.4 (s, 1Carom) ; 128.5 (d, 1J(C-H) = 159, 2Carom) 
; 128.0 (d, 1J(C-H) = 160, 2Carom) ; 127.2 (d, 1J(C-H) = 161, 1Carom) ; 112.1 (s, OCMe2) ; 87.3 
(s, OCPh3) ; 81.6 (d, 1J(C-H) = 171, C(6a)) ; 81.3 (s, OCMe3) ; 80.9 (d, 1J(C-H) = 167, C(4)) ; 
77.8 (d, 1J(C-H) = 161, C(3a)) ; 63.0 (t, 1J(C-H) = 145, C(1’)) ; 60.3 (d, 1J(C-H) = 147, C(6)) 
; 28.4 (q, 1J(C-H) = 131, Me3C) ; 25.7 (q, 1J(C-H) = 124, 2CH3-C(2)maj) ; 25.2 (s, 1J(C-H) = 
125, 2CH3-C(2)min). 
 
MALDI-TOF: 570.12 (M+K)+·, 554.17 (M+Na)+. 
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Tert-butyl (3aR,6R,6aR)-4-(methoxymethoxy)-2,2-dimethyl-6-[(trityloxy)methyl]tetra-
hydro-5H-[1,3]dioxolo[4,5-c]pyrrole-5-carboxylate ((-)-63) 
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To a solution of alcohol 72 (2.13 g, 4.00 mmol, 1.0 eq) in anhydrous THF (50ml) at 0°C were 
added N-ethyl diisopropylamine (5.47 ml, 31.99 mmol, 8.0 eq), chloromethyl methyl ether 
(1.82 ml, 23.99 mmol, 6.0 eq) and a catalytic amount of tetrabutylammonium iodide. The 
mixture was stirred at reflux for 12 hours. The resulting mixture was diluted with EtOAc (70 
ml), poured into a saturated aqueous solution of NaHCO3 (50 ml) and the aqueous layer was 
extracted with EtOAc (20 ml, 3 times). The combined organic extracts were dried over 
MgSO4, filtered and concentrated in vacuo. Flash chromatography on silica gel 
(EtOAc/pentane 1/8) afforded 63 (1.32 g, 58%), as a light yellow foam and the starting 
material (0.94 g, 44%). 
 
[α] 58925  = -38, [α] 25577  = -39, [α] 43525  = -72, [α] 25405  = -85 (c = 0.91, MeOH). 
 
UV (MeCN): 260 (1500), 233 (7500), 226 (1000). 
 
IR (film): 2925, 1705, 1365, 1215, 1160, 1025, 865, 800, 750 cm-1. 
 
1H-NMR (400MHz, CDCl3): 
7.37-7.25 (m, 15Harom) ; 5.42 (d, 1H, 3J(H-C(4), H-C(3a)) = 5.4, H-C(4maj)) ; 5.33 (d, 1H, 
3J(H-C(4), H-C(3a)) = 5.0, H-C(4min)) ; 5.10-5.01 (m, 1H, 1OCH2O) ; 4.79 (bs, 1H, 
1OCH2O) ; 4.79 (bs, 1H, 3J(H-C(3a), H-C(6a)) = 4.7, H-C(3a)) ; 4.29 (d, 1H, 3J(H-C(6a), H-
C(3a)) = 4.7, H-C(6amaj)) ; 4.20 (d, 1H, 3J(H-C(6a), H-C(3a)) = 4.7, H-C(6amin)) ; 4.14 (s, 1H, 
H-C(6min)) ; 4.08 (s, 1H, H-C(6maj)) ; 4.00 (d, 1H, 2Jgem = 9.1, H-C(1’min)) ; 3.59 (d, 1H, 2Jgem 
= 9.1, H-C(1’maj)) ; 3.52 (s, 3H, OCH3) ; 3.08 (d, 1H, 2Jgem = 9.1, H-C(1’maj)) ; 2.94 (d, 1H, 
2Jgem = 9.1, H-C(1’min)) ; 1.60, 1.61 (2s, 6H, 2CH3-C(2)maj) ; 1.56 (s, 9H, Me3Cβ) ; 1.35 (s, 9H, 
Me3Cα) ; 1.31, 1.22 (2s, 6H, 2CH3-C(2)min). 
 
13C-NMR (101MHz, CDCl3): 
153.8 (s, NC(O)O) ; 143.7 (s, 1Carom min) ; 143.5 (s, 1Carom maj) ; 128.6 (d, 1J(C-H) = 159, 
2Carom) ; 128.0 (d, 1J(C-H) = 160, 2Carom) ; 127.2 (d, 1J(C-H) = 161, 1Carom) ; 112.4 (s, 
OCMe2) ; 97.2 (t, 1J(C-H) = 165, OCH2O) ; 86.9 (s, OCPh3) ; 86.5 (d, 1J(C-H) = 164, C(4min)) 
; 85.8 (d, 1J(C-H) = 162, C(4maj)) ; 81.9 (d, 1J(C-H) = 160, C(6amaj)) ; 81.4 (d, 1J(C-H) = 164, 
C(6amin)) ; 80.9 (s, OCMe3) ; 79.2 (d, 1J(C-H) = 155, C(3amin)) ; 78.2 (d, 1J(C-H) = 155, 
C(3amaj)) ; 62.8 (t, 1J(C-H) = 145, C(1’maj)) ; 61.4 (t, 1J(C-H) = 145, C(1’min)) ; 59.7 (d, 1J(C-
H) = 141, C(6min)) ; 59.4 (d, 1J(C-H) = 141, C(6maj)) ; 56.7 (q, 1J(C-H) = 141, OCH3min) ; 56.3 
(q, 1J(C-H) = 141, OCH3maj) ; 29.6 (q, 1J(C-H) = 127, Me3Cβ) ; 29.3 (q, 1J(C-H) = 127, 
Me3Cα) ; 25.7 (q, 1J(C-H) = 128, 2CH3-C(2)min) ; 25.3 (q, 1J(C-H) = 126, 2CH3-C(2)maj). 
 
MALDI-TOF: 614.06 (M+K)+, 598.10 (M+Na)+; 574.79 (M+). 
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1H-NMR spectrum of 72 
 
 
 
 
 
 
1H-NMR spectrum of 63 
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Tert-butyl (3aR,4S,6aR)-4-formyl-6-(methoxymethoxy)-2,2-dimethyltetrahydro-5H-[1,3] 
dioxolo[4,5-c]pyrrole-5-carboxylate ((-)-64) 
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Metallic sodium chips (0.77 g, 33.59 mmol, 15.0 eq) were added to liquid NH3 (130 ml, 
condensed at -78°C) and a solution of 63 (1.29 g, 2.24 mmol, 1.0 eq) in anhydrous THF (25 
ml) was added dropwise. After stirring at –78°C for 50 minutes, solid NH4Cl was added until 
complete decoloration of the blue mixture. The solution was allowed to warm up to 25°C and 
stirred to the end of gas evolution. The residue was diluted with EtOAc and water, filtered on 
a pad of Celite and concentrated in vacuo. Purification by flash chromatography on silica gel 
(pentane/EtOAc 1/1) afforded an intermediate primary alcohol (0.61 g, 82 %) as a pale yellow 
transparent solid. 
 
To a solution of oxalyl chloride (0.28 g, 2.21 mmol, 1.2 eq) in anhydrous CH2Cl2 (6 ml), 
cooled to -78°C, was added DMSO (315 μl, 4.42 mmol, 2.4 eq). After 20 minutes, the 
intermediate primary alcohol (0.61 g, 1.84 mmol, 1.0 eq), in solution in anhydrous CH2Cl2 (6 
ml), was added dropwise. After 20 minutes, NEt3 (1.28 ml, 9.22 mmol, 5.0 eq) was added and 
the mixture was warmed to -30°C for 20 minutes. The mixture was poured into water (50 ml) 
and extracted with EtOAc (20 ml, 3 times). The combined organic layers were washed with 
brine (20 ml), dried over MgSO4, filtered and concentrated in vacuo. Purification by flash 
chromatography on silica gel (pentane/EtOAc 2/1) afforded aldehyde 64 (0.56 g, 91%) as a 
white foam.  
 
[α] 58925  = -71, [α] 25577  = -72, [α] 43525  = -148, [α] 25405  = -183 (c = 0.30, CH2Cl2). 
 
UV (MeCN): 294 (10500), 282 (10000), 234 (9500). 
 
IR (KBr): 2985, 2365, 2945, 1735, 1675, 1405, 1380, 1370, 1210, 1150, 1110, 1085, 1015, 
970, 920, 855, 775 cm-1. 
 
1H-NMR (400MHz, CDCl3): 
9.65 (s, 1H, H-C(1’min)) ; 9.56 (s, 1H, H-C(1’maj)) ; 5.46 (d, 1H, 3J(H-C(6), H-C(6a)) = 5.4, H-
C(6maj)) ; 5.31 (d, 1H, 3J(H-C(6), H-C(6a)) = 5.3, H-C(6min)) ; 5.03-4.75 (m, 2H, OCH2O) ; 
4.68-4.56 (m, 2H, H-C(6a), H-C(3a)) ; 4.57 (s, 1H, H-C(4maj)) ; 4.52 (s, 1H, H-C(4min)) ; 3.47 
(s, 3H, OCH3) ; 1.68, 1.61 (2s, 6H, 2CH3-C(2)min) ; 1.55, 1.46 (2s, 9H, Me3C) ; 1.42, 1.31 (2s, 
6H, 2CH3-C(2)maj). 
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13C-NMR (101MHz, CDCl3): 
197.4 (d, 1J(C-H) = 191, C(1’)) ; 154.0 (s, NC(O)Oβ) ; 153.1 (s, NC(O)Oα) ; 114.0 (s, 
OCMe2) ; 96.6 (t, 1J(C-H) = 166, COCH2O) ; 84.7 (d, 1J(C-H) = 165, C(6min)) ; 84.4 (d, 1J(C-
H) = 164, C(6maj)) ; 82.3 (s, OCMe3min) ; 82.1 (s, OCMe3maj) ; 79.1 (d, 1J(C-H) = 156, 
C(6amaj)) ; 78.9 (d, 1J(C-H) = 155, C(6amin)) ; 78.0 (d, 1J(C-H) = 152, C(3a)) ; 67.6 (d, 1J(C-
H) = 176, C(4maj)) ; 67.1 (d, 1J(C-H) = 176, C(4maj)) ; 56.5 (q, 1J(C-H) = 141, OCH3min) ; 56.2 
(q, 1J(C-H) = 142, OCH3maj) ; 28.0 (q, 1J(C-H) = 127, Me3C) ; 25.7 (q, 1J(C-H) = 126, 2CH3-
C(2)maj) ; 25.3 (q, 1J(C-H) = 127, 2CH3-C(2)min). 
 
MALDI-TOF: 370.13 (M+K)+, 354.17 (M+Na)+. 
 
 
1H-NMR spectrum of 64 
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Tert-butyl (3aR,4R,6aR)-4-({[(1R)-2-hydroxy-1-phenylethyl]amino}methyl)-6-(methoxy-
methoxy)-2,2-dimethyltetrahydro-5H-[1,3]dioxolo[4,5-c]pyrrole-5-carboxylate ((-)-65) 
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Procedure 1. D-(-)-α-phenylglycinol (99) (50 mg, 0.37 mmol, 1.2 eq), aldehyde 64 (100 mg, 
0.31 mmol, 1.0 eq), NaBH(OAc)3 (100 mg, 0.46 mmol, 1.5 eq), Cl(CH2)2Cl (4 ml). Flash 
chromatography (CH2Cl2/MeOH 30/1) afforded 65 (60 mg, 46%) as a colourless oil. 
 
[α] 58925  = -82, [α] 25577  = -83, [α] 43525  = -165, [α] 25405  = -198 (c = 0.20, CH2Cl2). 
 
UV (MeCN): 295 (8500), 290 (8500), 235 (7500). 
 
IR (film): 3455, 2930, 2360, 1700, 1455, 1370, 1245, 1215, 1160, 1110, 1025, 920, 755 cm-1. 
 
1H-NMR (400MHz, MeOD): 
7.37-7.25 (m, 5Harom) ; 5.19 (bs, 1H, H-C(6maj)) ; 5.06 (bs, 1H, H-C(6min)) ; 4.99 (bs, 1H, 
1OCH2Omaj) ; 4.89 (bs, 1H, 1OCH2Omin) ; 4.77-4.63 (m, 3H, 1OCH2O, H-C(3a), H-C(6a)) ; 
3.97 (bs, 1H, H-C(3’)) ; 3.73-3.70 (m, 1H, H-C(4)) ; 3.63 (dd, 1H, 2Jgem = 10.9, 3J(H-C(1’), 
H-C(4)) = 4.5, H-C(1’)) ; 3.54 (dd, 1H, 2Jgem = 10.8, 3J(H-C(1’), H-C(4)) = 8.4, H-C(1’)) ; 
3.47 (s, 3H, OCH3) ; 2.75 (d, 1H, 2Jgem = 10.9, H-C(4’)) ; 2.60 (bs, 1H, H-C(4’)) ; 1.58 (s, 6H, 
2CH3-C(2)min) ; 1.53 (s, 9H, Me3Cα) ; 1.39 (s, 6H, 2CH3-C(2)maj) ; 1.31 (s, 3H, Me3Cβ). 
 
13C-NMR (101MHz, MeOD): 
155.5 (s, NC(O)O) ; 142.4 (s, 1Carom) ; 129.6 (d, 1J(C-H) = 159, 2Carom) ; 128.6 (d, 1J(C-H) = 
156, 2Carom) ; 113.6 (s, OCMe2) ; 98.4 (t, 1J(C-H) = 165, OCH2Omin) ; 98.0 (t, 1J(C-H) = 165, 
OCH2Omaj) ; 87.8 (d, 1J(C-H) = 164, C(6min)) ; 87.2 (d, 1J(C-H) = 168, C(6maj)) ; 83.3 (d, 1J(C-
H) = 160, C(3amaj)) ; 82.6 (d, 1J(C-H) = 160, C(3amin)) ; 81.6 (s, OCMe3) ; 80.0 (d, 1J(C-H) = 
155, C(6amin)) ; 79.3 (d, 1J(C-H) = 156, C(6amaj)) ; 67.9 (t, 1J(C-H) = 141, C(1’)) ; 66.6 (d, 
1J(C-H) = 135, C(4)) ; 61.4 (d, 1J(C-H) = 147, C(3’)) ; 57.0 (q, 1J(C-H) = 139, OCH3min) ; 
56.7 (q, 1J(C-H) = 142, OCH3maj) ; 28.6 (q, 1J(C-H) = 127, Me3C) ; 26.1 (q, 1J(C-H) = 126, 
2CH3-C(2)maj) ; 25.7 (q, 1J(C-H) = 126, 2CH3-C(2)min). 
 
MALDI-TOF: 454.03 (M+H)+, 453.05 (M+). 
 
 
Experimental Part 
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1H-NMR spectrum of 65 
 
 
 
 
 
 
 
(5S)-1-methyl-5-[(trityloxy)methyl]pyrrolidin-2-one ((-)-67) 
 
 
 
 
 
 
 
 
To a solution of L-(5)-trityloxymethyl-2-pyrrolidinone (50) (500 mg, 1.4 mmol, 1.0 eq) in 
anhydrous THF (3 ml), cooled to 0°C, was added sodium hydride (183 mg, 4.2 mmol, 3.0 eq 
55 % in oil) and the mixture was stirred at 0°C for 5 minutes. Methyl iodide (611 μl, 9.8 
mmol, 7.0 eq) was added and the mixture was allowed to warm up to 25°C. After 4 hours, 
water was added carefully. The resulting mixture was poured into a saturated aqueous 
solution of NH4Cl (15 ml) and the aqueous layer was extracted with EtOAc (15 ml, 3 times). 
The combined organic extracts were dried over MgSO4, filtered and concentrated in vacuo. 
Flash chromatography on silica gel (pentane/EtOAc 4/5) afforded 67 (347 mg, 67 %) as a pale 
yellow solid.  
 
N
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[α] 58925  = -3, [α] 25577  = -6 (c = 0.47, CHCl3). 
 
IR (film): 3450, 3060, 2920, 1685, 1485, 1445, 1400, 1295, 1250, 1220, 1155, 1075, 1035, 
995, 755, 705 cm-1. 
 
1H-NMR (400 MHz, CDCl3):  
7.64-7.07 (m, 15Harom); 3.62 (m, 1H, H-C(5)); 3.31 (dd, 1H, 3J(H-C(1’), H-C(5)) = 3.7, 2Jgem 
= 10.0, H-C(1’)); 3.17 (dd, 1H, 3J(H-C(1’), H-C(5)) = 4.5, 2Jgem = 10.0, H-C(1’)); 2.79 (s, 3H, 
Me-N); 2.55 (m, 1H, H-C(3)); 2.34 (ddd, 1H, 3J(H-C(3), H-C(4)) = 4.7, 3J(H-C(3), H-C(4)) = 
4.8, 2Jgem = 10.1, H-C(3)); 2.12 (m, 1H, H-C(4)); 1.87 (m, 1H, 2Jgem = 9.4, H-C(4)).  
 
13C-NMR (101 MHz, CDCl3):  
175.4 (s, C(2)); 143.6 (s, 3Carom); 128.6 (d, 1J(C,H) = 159, 6Carom); 127.9 (d, 1J(C,H) = 160, 
6Carom); 127.2 (d, 1J(C,H) = 161, 3Carom); 86.9 (s, OCPh3); 64.2 (t, 1J(C,H) = 142, C(1’)); 60.0 
(d, 1J(C,H) = 144, C(5)); 30.2 (t, 1J(C,H) = 133, C(3)); 28.4 (q, 1J(C,H) = 138, Me); 21.6 (t, 
1J(C,H) = 133, C(4)). 
 
MALDI-TOF: 372.15 (M+H)+. 
Anal. for C25H25NO2 (371.48): calc. C 80.83, H 6.78, N 3.77; found C 80.75, H 6.82, N 3.83. 
M.P: 115-117°C. 
 
 
1H-NMR spectrum of 67 
 
 
 
 
Experimental Part 
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(3aR,6R,6aR)-2,2,5-trimethyl-6-[(trityloxy)methyl]tetrahydro-4H-[1,3]dioxolo[4,5-c] 
pyrrol-4-one ((-)-68) 
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Butyllithium (2.2 eq, 1.6 M in hexane, 40.8 mmol, 25 ml) was added to a solution of 
diisopropylamine (5.7 ml, 40.8 mmol, 2.2 eq) in anhydrous THF (41 ml) at –78°C. The 
mixture was stirred at –78°C for 10 minutes, followed by addition of a solution of 67 (6.9 g, 
18.5 mmol, 1.0 eq) in anhydrous THF (25 ml). The mixture was stirred at –78°C for 10 
minutes, at –30°C for 10 minutes and then at –78°C for 15 minutes. After addition of a 
solution of PhSeBr (5.3 g, 22.3 mmol, 1.2 eq) in anhydrous THF (25 ml), the mixture was 
stirred at –78°C for 30 minutes. The solution was dissolved in EtOAc (35 ml) and washed 
with a saturated aqueous solution of NH4Cl (50 ml). The organic layer was dried over MgSO4, 
filtered and concentrated in vacuo at 20°C to give the corresponding 3-selenopyrroldinone 
which was directly engaged in the next step.  
 
This 3-selenopyrrolidinone (18.5 mmol, 1.0 eq) was dissolved in a mixture of EtOAc/H2O2 
(3/1, 160 ml) and cooled to 0°C. After stirring for 1 hour, water and EtOAc were added. The 
organic layer was washed with a saturated aqueous solution of NaHCO3, NH4Cl and brine to 
reach neutral pH. Drying over MgSO4 and concentration in vacuo afforded a crude enone as a 
yellow foam.  
 
This crude enone (18.5 mmol, 1.0 eq), OsO4 (0.1 eq, 0.1 M in H2O, 1.85 mmol, 18.5 ml) and 
NMO monohydrate (3.76 g, 27.8 mmol, 1.5 eq) in a mixture of acetone/H2O (7/3, 160 ml) 
were stirred at 25°C for 12 hours. After addition of sodium pyrosulfite (2.5 g) at 0°C, the 
aqueous layer was extracted with EtOAc (30 ml, 3 times). The combined organic extracts 
were dried over MgSO4 and concentrated in vacuo. Flash chromatography on silica gel 
(CH2Cl2/MeOH 97/3) afforded an intermediate diol (3.34 g, 45 %, 3 steps) as a yellow foam. 
 
To a solution of this diol (140 mg, 0.35 mmol, 1.0 eq) in a mixture of acetone/2,2-
dimethoxypropane (3/1, 3.5 ml), cooled to 0°C, was added a catalytic amount of p-TsOH. The 
solution was stirred at 0°C for 1 hour. After dilution with EtOAc (10 ml), the mixture was 
washed with a saturated aqueous solution of NaHCO3 (15 ml) and H2O (15 ml), dried over 
MgSO4, filtered and concentrated in vacuo. Flash chromatography on silica gel 
(pentane/EtOAc 7/3) afforded 68 (130 mg, 83 %) as a pale yellow solid. 
 
Experimental Part 
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[α] 58925  = -32, [α] 25577  = -37, [α] 43525  = -63, [α] 40525  = -74 (c = 0.46, CHCl3). 
 
IR (film): 2990, 2930, 1705, 1490, 1450, 1380, 1220, 1075, 1000, 755, 705 cm-1. 
 
1H-NMR (400 MHz, CDCl3):  
7.39-7.25 (m, 15Harom); 4.89 (d, 1H, 3J(H-C(3a), H-C(6a)) = 5.7, H-C(3a)); 3.48 (d, 1H, 3J(H-
C(6a), H-C(3a)) = 5.7, H-C(6a)); 3.57 (bs, 1H, H-C(6)) 3.48 (dd, 1H, 3J(H-C(1’), H-C(6)) = 
2.5, 2Jgem = 10.3, H-C(1’)); 3.22 (dd, 1H, 3J(H-C(1’), H-C(6)) = 2.4, 2Jgem = 10.3, H-C(1’)); 
2.77 (s, 3H, Me-N); 1.44 (s, 3H, Me-C(2)); 1.39 (s, 3H, Me-C(2)). 
 
13C-NMR (101 MHz, CDCl3):  
171.7 (s, C(4)); 143.0 (s, 3Carom); 128.4 (d, 1J(C,H) = 159, 6Carom); 128.0 (d, 1J(C,H) = 160, 
6Carom); 127.4 (d, 1J(C,H) = 161, 3Carom); 111.9 (s, C(2)); 87.2 (s, OCPh3); 77.8 (d, 1J(C,H) = 
158, C(3a)); 76.3 (d, 1J(C,H) = 160, C(6a)); 63.9 (d, 1J(C,H) = 144, C(6)); 60.1 (t, 1J(C,H) = 
143, C(1’)); 28.1 (q, 1J(C,H) = 139, Me-N); 27.2 (q, 1J(C,H) = 128, Me-C(2)); 25.8 (q, 
1J(C,H) = 128, Me-C(2)). 
 
MALDI-TOF: 482.14 (M+K)+, 466.16 (M+Na)+, 444.19 (M+H)+. 
Anal. for C28H29NO4 (443.54): calc. C 75.82, H 6.59, N 3.16; found C 75.79, H 6.64, N 3.05. 
M.P: 150-155°C. 
 
 
1H-NMR spectrum of 68 
 
Experimental Part 
 
 
130 
Phenylmethyl (5S)-2-oxo-5-{[(triphenylmethyl)oxy]methyl}pyrrolidine-1-carboxylate  
((-)-69) 
 
 
 
 
 
 
 
 
 
 
To a solution of L-(5)-trityloxymethyl-2-pyrrolidinone (50) (200 mg, 0.56 mmol, 1.0 eq) in 
anhydrous THF (5 ml), cooled to -78°C, was added a solution of LiHMDS (1.1 eq, 1M in 
THF, 500 μl). After 30 minutes, CbzCl (79 μl, 0.56 mmol, 1.0 eq) was added dropwise. The 
mixture was allowed to warm up to 25°C and was stirred for 2 hours. After dilution with 
EtOAc (3 ml), the mixture was washed with NH4Cl (10 ml) and the aqueous layer was 
extracted with EtOAc (15 ml, 3 times). The combined organic extracts were dried over 
MgSO4, filtered and concentrated in vacuo. Flash chromatography on silica gel 
(pentane/EtOAc 3/1) afforded 69 (250 mg, 91 %) as a pale yellow foam.  
 
 
 
[α] 58925  = -48, [α] 25577  = -49, [α] 43525  = -96, [α] 40525  = -115 (c = 0.63, CHCl3). 
 
IR (film): 3025, 2955, 2880, 1785, 1750, 1720, 1490, 1450, 1380, 1290, 1220, 1080, 1035, 
755, 705 cm-1. 
 
1H-NMR (400 MHz, CDCl3):  
7.43-7.24 (m, 15Harom); 5.22 (2H, AB, OCH2Ph); 4.32 (m, 1H, H-C(5)); 3.54 (dd, 1H, 3J(H-
C(1’), H-C(5)) = 4.2, 2Jgem = 9.6, H-C(1’)); 3.22 (dd, 1H, 3J(H-C(1’), H-C(5)) = 2.0, 2Jgem = 
9.6, H-C(1’)); 2.88 (m, 1H, H-C(3)); 2.47 (m, 1H, H-C(3)); 2.13 (m, 1H, H-C(4)); 2.00 
(m,1H, H-C(4)).  
 
13C-NMR (101 MHz, CDCl3):  
174.5 (s, C(2)); 150.9 (s, NC(O)O); 143.4 (s, 3Carom); 135.1 (s, 1Carom); 128.5 (d, 1J(C,H) = 
159, 2Carom); 128.4 (d, 1J(C,H) = 159, 6Carom); 128.2 (d, 1J(C,H) = 159, 1Carom); 128.0 (d, 
1J(C,H) = 159, 2Carom); 127.8 (d, 1J(C,H) = 161, 6Carom); 127.0 (d, 1J(C,H) = 160, 3Carom); 
87.0 (s, OCPh3); 67.7 (t, 1J(C,H) = 148, OCH2Ph); 64.1 (t, 1J(C,H) = 144, C(1’)); 57.4 (d, 
1J(C,H) = 148, C(5)); 32.0 (t, 1J(C,H) = 135, C(3)); 21.2 (t, 1J(C,H) = 134, C(4)). 
 
HRMS (C32H29NO4 + Na): calc. 514.1994; found 514.1957. 
Anal. for C32H29NO4 (491.59): calc. C 78.19, H 5.95, N 2.85; found C 78.14, H 5.97, N 2.76. 
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1H-NMR spectrum of 69 
 
 
 
 
 
 
Phenylmethyl (3aR,6R,6aR)-2,2-dimethyl-4-oxo-6-{[(triphenylmethyl)oxy]methyl}tetra-
hydro-5H-[1,3]dioxolo[4,5-c]pyrrole-5-carboxylate ((-)-70) 
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Butyllithium (2.2 eq, 1.6 M in hexane, 9.1 mmol, 5.7 ml) was added to a solution of 
diisopropylamine (1.3 ml, 9.1 mmol, 2.2 eq) in anhydrous THF (9 ml) at –78°C. The mixture 
was stirred at –78°C for 10 minutes, followed by addition of a solution of 69 (2.0 g, 4.1 
mmol, 1.0 eq) in anhydrous THF (20 ml). The mixture was stirred at –78°C for 10 minutes, at 
–30°C for 10 minutes and then at –78°C for 15 minutes. After addition of a solution of 
PhSeBr (1.17 g, 4.95 mmol, 1.2 eq) in anhydrous THF (6 ml), the mixture was stirred at 
-78°C for 30 minutes. The solution was dissolved in EtOAc (15 ml) and washed with a 
saturated aqueous solution of NH4Cl (20 ml). The organic layer was dried over MgSO4, 
filtered and concentrated in vacuo at 20°C to give the corresponding 3-selenopyrroldinone 
which was directly engaged in the next step.  
Experimental Part 
 
 
132 
This 3-selenopyrrolidinone (4.1 mmol, 1.0 eq) was dissolved in a mixture of EtOAc/H2O2 
(3/1, 32 ml), at 0°C. After stirring for 1 hour, water and EtOAc were added. The organic layer 
was successively washed with a saturated aqueous solution of NaHCO3, NH4Cl and brine to 
reach neutral pH, dried over MgSO4 and concentrated in vacuo to afford a crude enone. 
 
This crude enone (4.1 mmol, 1.0 eq), OsO4 (0.1 eq, 0.1 M in H2O, 0.41 mmol, 4.1 ml) and 
NMO monohydrate (836 mg, 6.2 mmol, 1.5 eq) in a mixture of acetone/H2O (7/3, 40 ml) were 
stirred at 25°C for 12 hours. After addition of sodium pyrosulfite (250 mg) at 0°C, the 
aqueous layer was extracted with EtOAc (25 ml, 3 times). The combined organic extracts 
were dried over MgSO4 and concentrated in vacuo. Flash chromatography on silica gel 
(CH2Cl2/MeOH 97/3) afforded an intermediate diol (609 mg, 28 %, 3 steps) as a white foam. 
 
To a solution of this diol (609 mg, 1.16 mmol, 1.0 eq) in a mixture of acetone/2,2-
dimethoxypropane (3/1, 10 ml), cooled to 0°C, was added a catalytic amount of p-TsOH. The 
solution was stirred at 0°C for 1 hour. After dilution with EtOAc (20 ml), the mixture was 
washed with a saturated aqueous solution of NaHCO3 (20 ml) and water (20 ml), dried over 
MgSO4, filtered and concentrated in vacuo. Flash chromatography on silica gel 
(pentane/EtOAc 7/3) afforded 70 (354 mg, 54 %) as a white solid. 
 
 
 
 [α] 58925  = -58, [α] 25577  = -60, [α] 43525  = -116, [α] 40525  = -158 (c = 0.56, CHCl3). 
 
IR (film): 3060, 3025, 2985, 2885, 1795, 1765, 1725, 1490, 1450, 1380, 1290, 1220, 1155, 
1090, 1000, 750, 705 cm-1. 
 
1H-NMR (400 MHz, CDCl3):  
7.51-7.08 (m, 20Harom); 5.25 (2H, AB, OCH2Ph); 4.97 (d, 1H, 3J(H-C(3a), H-C(6a)) = 5.3, H-
C(3a)); 4.38 (d, 1H, 3J(H-C(6a), H-C(3a)) = 5.3, H-C(6a)); 4.29 (bs, 1H, H-C(6)); 3.74 (dd, 
1H, 3J(H-C(1’), H-C(6)) = 2.4, 2Jgem = 10.2, H-C(1’)); 3.22 (dd, 1H, 3J(H-C(1’), H-C(6)) = 
1.3, 2Jgem = 10.2, H-C(1’)); 1.45 (s, 3H, Me-C(2)); 1.37 (s, 3H, Me-C(2)).  
 
13C-NMR (101 MHz, CDCl3):  
171.1 (s, C(4)); 151.1 (s, NC(O)O); 143.0 (s, 3Carom); 134.9 (s, 1Carom); 128.6 (d, 1J(C,H) = 
160, 1Carom); 128.4 (d, 1J(C,H) = 158, 8Carom); 128.1 (d, 1J(C,H) = 160, 8Carom); 127.3 (d, 
1J(C,H) = 161, 3Carom); 112.2 (s, C(2)); 87.7 (s, OCPh3); 78.1 (d, 1J(C,H) = 160, C(3a)); 75.7 
(d, 1J(C,H) = 161, C(6a)); 68.3 (t, 1J(C,H) = 150, OCH2Ph); 61.8 (t, 1J(C,H) = 145, C(1’)); 
60.6 (d, 1J(C,H) = 149, C(6)); 27.2 (q, 1J(C,H) = 127, Me-C(2)); 25.7 (q, 1J(C,H) = 127, Me-
C(2)). 
 
HRMS (C35H33NO6 + Na): calc. 586.2206; found 586.2238.  
Anal. for C35H33NO6 (563.65): calc. C 74.58, H 5.90, N 2.48; found C 74.59, H 5.96, N 2.55. 
M.P: 191-196°C. 
 
Experimental Part 
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1H-NMR spectrum of 70 
 
 
 
 
 
 
Tert-butyl (2S)-2-({[(1,1-dimethylethyl)(dimethyl)silyl]oxy}methyl)-5-oxopyrrolidine-1-
carboxylate ((-)-75) 
 
 
 
 
 
 
 
To a solution of (S)-5-(hydroxymethyl)-2-pyrrolidinone (74) (200 mg, 1.74 mmol, 1.0 eq) 
in DMF (15 ml), cooled to 0°C, were added imidazole (296 mg, 4.35 mmol, 2.5 eq) and 
TBDMSCl (393 mg, 2.61 mmol, 1.5 eq). The solution was stirred at 0°C for 1 hour. After 
concentration in vacuo, the residue was diluted with EtOAc (5 ml) and washed with a 
saturated aqueous solution of NaHCO3 (10 ml, 3 times). The organic layer was dried over 
MgSO4, filtered and concentrated in vacuo. Flash chromatography on silica gel 
(CH2Cl2/MeOH 97/3) afforded the protected alcohol (339 mg, 85 %) as a yellow oil. 
 
To a solution of this protected alcohol (2.8 g, 12.5 mmol, 1.0 eq) in pyridine (50 ml) were 
added Boc2O (3.0 g, 13.8 mmol, 1.1 eq) and a catalytic amount of DMAP. The reaction 
mixture was stirred at 25°C for 12 hours and then concentrated in vacuo. The residue was 
dissolved in EtOAc (35 ml) and washed with a saturated aqueous solution of NH4Cl (20 ml) 
and a saturated aqueous solution of NaHCO3 (20 ml). The organic layer was dried over 
MgSO4, filtered and concentrated in vacuo. Flash chromatography on silica gel 
(CH2Cl2/MeOH 97/3) afforded 75 (3.7 g, 89 %) as a brown oil. 
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[α] 58925  = -57, [α] 25577  = -60, [α] 43525  = -120, (c = 0.41, CHCl3). 
 
IR (film): 3415, 2955, 2935, 2890, 2860, 1785, 1750, 1710, 1465, 1365, 1310, 1255, 1160, 
1110, 1030, 840, 780 cm-1. 
 
1H-NMR (400 MHz, CDCl3):  
4.17 (m, 1H, H-C(2)); 3.92 (dd, 1H, 3J(H-C(1’), H-C(2)) = 3.8, 2Jgem = 10.6, H-C(1’)); 3.69 
(dd, 1H, 3J(H-C(1’), H-C(2)) = 2.2, 2Jgem = 10.6, H-C(1’)); 2.70 (ddd, 1H, 3J(H-C(4), H-C(3)) 
= 10.2, 3J(H-C(4), H-C(3)) = 10.7, 2Jgem = 17.7, H-C(4)); 2.40 (ddd, 1H, 3J(H-C(4), H-C(3)) = 
2.2, 3J(H-C(4), H-C(3)) = 9.7, 2Jgem = 17.7, H-C(4)); 2.10-2.03 (m, 2H, H-C(3)); 1.54 (s, 9H, 
Me3C); 0.88 (s, 9H, Me3CSi); 0.05, 0.04 (2s, 6H, Me2Si).  
 
13C-NMR (101 MHz, CDCl3):  
174.9 (s, C(5)); 150.1 (s, NC(O)O); 82.7 (s, OCMe3); 64.3 (t, 1J(C,H) = 142, C(1’)); 58.9 (d, 
1J(C,H) = 145, C(2)); 32.3 (t, 1J(C,H) = 132, C(4)); 28.1 (q, 1J(C,H) = 127, Me3C); 25.8 (q, 
1J(C,H) = 125, Me3CSi); 21.1 (t, 1J(C,H) = 134, C(3)); 18.2 (s, Me3CSi); -5.55, -5.60 (2q, 
1J(C,H) = 118, Me2Si). 
 
ESI-MS: 330.38 (M+H)+. 
Anal. for C16H31NO4Si (329.51): calc. C 58.32, H 9.48, N 4.25, Si 8.52; found C 58.43, H 
9.43, N 4.30 Si 8.44. 
 
 
1H-NMR spectrum of 75 
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Tert-butyl (2R,3R,4R)-2-({[(1,1-dimethylethyl)(dimethyl)silyl]oxy}methyl)-3,4-
dihydroxy-5-oxopyrrolidine-1-carboxylate ((-)-76) 
 
 
 
 
 
 
 
 
 
 
 
 
Butyllithium (2.4 eq, 1.6 M in hexane, 25.5 mmol, 16 ml) was added to a solution of 
diisopropylamine (3.6 ml, 25.5 mmol, 2.4 eq) in anhydrous THF (25 ml) at –78°C. The 
mixture was stirred at –78°C for 10 minutes, followed by addition of a solution of 75 (3.5 g, 
10.6 mmol, 1.0 eq) in anhydrous THF (35 ml). The mixture was stirred at –78°C for 10 
minutes, at –30°C for 10 minutes and then at –78°C for 15 minutes. After addition of a 
solution of PhSeBr (3.0 g, 12.7 mmol, 1.2 eq) in anhydrous THF (20 ml), the mixture was 
stirred at –78°C for 30 minutes. The solution was dissolved in EtOAc (35 ml) and washed 
with a saturated aqueous solution of NH4Cl (20 ml). The organic layer was dried over MgSO4, 
filtered and concentrated in vacuo at 20°C to give the corresponding 3-selenopyrroldinone 
which was directly engaged in the next step.  
 
This 3-selenopyrrolidinone (10.6 mmol, 1.0 eq) was dissolved in a mixture of EtOAc/H2O2 
(3/1 80 ml), at 0°C. After stirring for 1 hour, water and EtOAc were added. The organic layer 
was washed with a saturated aqueous solution of NaHCO3, NH4Cl and brine to reach neutral 
pH, dried over MgSO4 and concentrated in vacuo to afford a crude enone. 
 
This crude enone (10.6 mmol, 1.0 eq), OsO4 (0.1 eq, 0.1 M in H2O, 1.06 mmol, 10.6 ml) and 
NMO monohydrate (2.15 g, 15.9 mmol, 1.5 eq) in a mixture of acetone/H2O (7/3 80 ml) were 
stirred at 25°C for 12 hours. After addition of sodium pyrosulfite at 0°C, the aqueous layer 
was extracted with EtOAc (30 ml, 3 times). The combined organic extracts were dried over 
MgSO4 and concentrated in vacuo. Purification by flash chromatography on silica gel 
(CH2Cl2/MeOH 95/5) afforded 76 as a white foam (1.18 g, 43 %, 3 steps). 
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[α] 58925  = -12, [α] 25577  = -12, [α] 43525  = -24, [α] 40525  = -30 (c = 0.36, CHCl3). 
 
IR (film): 3440, 2955, 2885, 2860, 1780, 1465, 1370, 1300, 1255, 1155, 995, 945, 835, 755 
cm-1. 
 
1H-NMR (400 MHz, CDCl3):  
4.57 (d, 1H, 3J(H-C(4), H-C(3)) = 4.8, H-C(4)); 4.36 (d, 1H, 3J(H-C(3), H-C(4)) = 4.8, H-
C(3)); 4.12 (m, 1H, H-C(2)); 3.99 (dd, 1H, 3J(H-C(1’), H-C(2)) = 2.9, 2Jgem = 10.9, H-C(1’)); 
3.83 (dd, 1H, 3J(H-C(1’), H-C(2)) = 1.6, 2Jgem = 10.9, H-C(1’)); 1.55 (s, 9H, Me3C); 0.87 (s, 
9H, Me3CSi); 0.04, 0.03 (2s, 6H, Me2Si).  
 
13C-NMR (101 MHz, CDCl3):  
173.6 (s, C(5)); 149.6 (s, NC(O)O); 83.8 (s, OCMe3); 71.5 (d, 1J(C,H) = 154, C(4)); 69.2 (d, 
1J(C,H) = 167, C(3)); 64.7 (d, 1J(C,H) = 150, C(2)); 61.7 (t, 1J(C,H) = 145, C(1’)); 28.0 (q, 
1J(C,H) = 127, Me3C); 25.8 (q, 1J(C,H) = 125, Me3CSi); 18.2 (s, Me3CSi); -5.64, -5.65 (2q, 
1J(C,H) = 118, Me2Si). 
 
HRMS (C16H31NO6Si + Na): calc. 384.1818; found 384.1822. 
Anal. for C16H31NO6Si (361.51): calc. C 53.16, H 8.64, N 3.87, Si 7.77; found C 53.20, H 
8.64. 
 
 
 
1H-NMR spectrum of 76 
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Tert-butyl (3aR,4R,6aR)-4-({[(1,1-dimethylethyl)(dimethyl)silyl]oxy}methyl)2,2-dimethyl 
-6-oxotetrahydro-5H-[1,3]dioxolo[4,5-c]pyrrole-5-carboxylate ((-)-77) 
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To a solution of diol 76 (1.18g, 3.28 mmol, 1.0 eq) in a mixture of acetone/2,2-
dimethoxypropane (3/1 35 ml), cooled to 0°C, was added a catalytic amount of p-TsOH. The 
solution was stirred at 0°C for 3 hours. After dilution with EtOAc (15 ml), the mixture was 
washed with a saturated aqueous solution of NaHCO3 (15 ml) and water (15 ml), dried over 
MgSO4, filtered and concentrated in vacuo. Flash chromatography on silica gel 
(pentane/EtOAc 9/1) afforded 77 (1.1 g, 89 %) as a brown oil. 
 
 
 
 
 [α] 58925  = -78, [α] 25577  = -81, [α] 43525  = -159, [α] 40525  = -192 (c = 0.56, CHCl3). 
 
IR (film): 3425, 3020, 1640, 1520, 1475, 1425, 1375, 1305, 1215, 1155, 1045, 925, 760 cm-1. 
 
1H-NMR (400 MHz, CDCl3):  
4.65 (d, 1H, 3J(H-C(6a), H-C(3a)) = 5.4, H-C(6a)); 4.52 (d, 1H, 3J(H-C(3a), H-C(6a)) = 5.4, 
H-C(3a)); 4.23 (m, 1H, H-C(4)); 4.00 (dd, 1H, 3J(H-C(1’), H-C(4)) = 2.2, 2Jgem = 10.9, H-
C(1’)); 3.78 (dd, 1H, 3J(H-C(1’), H-C(4)) = 1.3, 2Jgem = 10.9, H-C(1’)); 1.54 (s, 9H, Me3C); 
1.46 (s, 3H, Me-C(2)); 1.38 (s, 3H, Me-C(2)); 0.86 (s, 9H, Me3CSi); 0.03, 0.02 (2s, 6H, 
Me2Si).  
 
13C-NMR (101 MHz, CDCl3):  
170.9 (s, C(6)); 150.0 (s, NC(O)O); 111.8 (s, C(2)); 83.5 (s, OCMe3); 78.2 (d, 1J(C,H) = 160, 
C(6a)); 75.7 (d, 1J(C,H) = 161, C(3a)); 62.0 (t, 1J(C,H) = 144, C(1’)); 61.8 (d, 1J(C,H) = 148, 
C(4)); 28.0 (q, 1J(C,H) = 127, Me3C); 27.1 (q, 1J(C,H) = 125, Me-C(2)); 25.8 (q, 1J(C,H) = 
125, Me3CSi); 25.6 (q, 1J(C,H) = 126, Me-C(2)); 18.2 (s, Me3CSi); -5.64, -5.75 (2q, 1J(C,H) = 
118, Me2Si). 
 
MALDI-TOF: 424.16 (M+Na)+. 
Anal. for C19H35NO6Si (401.58): calc. C 56.83, H 8.78, N 3.49, Si 6.99; found C 56.81, H 
8.72. 
 
Experimental Part 
 
 
138 
1H-NMR spectrum of 77 
 
 
 
 
 
Tert-butyl (3aR,6aR)-4-(hydroxymethyl)-2,2-dimethyl-6-oxotetrahydro-5H-[1,3]dioxolo 
[4,5-c]pyrrole-5-carboxylate ((-)-78) 
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TBAF (2.0 eq, 1 M in THF, 1.0 mmol, 1.0 ml) was added to a solution of 77 (200 mg, 0.5 
mmol, 1.0 eq) in anhydrous THF (5 ml) at 0°C. The mixture was stirred at 0°C for 1 hour and 
then concentrated in vacuo. The residue was purified by flash chromatography on silica gel 
(CH2Cl2/MeOH 96/4) to afford 78 (105 mg, 73 %) as a white foam. 
 
 
Experimental Part 
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[α] 58925  = -56 (c = 0.43, CHCl3). 
 
IR (film): 3495, 2985, 2360, 1780, 1720, 1460, 1370, 1305, 1240, 1155, 1095, 985, 845, 755 
cm-1. 
 
1H-NMR (400 MHz, CDCl3):  
4.77 (d, 1H, 3J(H-C(6a), H-C(3a)) = 5.4, H-C(6a)); 4.60 (d, 1H, 3J(H-C(3a), H-C(6a)) = 5.4, 
H-C(3a)); 4.23 (m, 1H, H-C(4)); 3.97 (ddd, 1H, 3J(H-C(1’), H-C(4)) = 2.2, 3J(H-C(1’), OH) = 
4.8, 2Jgem = 11.5, H-C(1’)); 3.80 (ddd, 1H, 3J(H-C(1’), H-C(4)) = 1.9, 3J(H-C(1’), OH) = 6.1, 
2Jgem = 11.5, H-C(1’)); 2.98 (dd, 1H, 3J(OH, H-C(1’)) = 4.8, 3J(OH, H-C(1’)) = 6.1, OH-
C(1’)); 1.53 (s, 9H, Me3C); 1.45(s, 3H, Me-C(2)); 1.37 (s, 3H, Me-C(2)).  
 
13C-NMR (101 MHz, CDCl3):  
172.2 (s, C(6)); 149.8 (s, NC(O)O); 111.8 (s, C(2)); 83.9 (s, OCMe3); 78.0 (d, 1J(C,H) = 160, 
C(6a)); 75.4 (d, 1J(C,H) = 162, C(3a)); 62.1 (d, 1J(C,H) = 149, C(4)); 61.3 (t, 1J(C,H) = 144, 
C(1’)); 28.0 (q, 1J(C,H) = 127, Me3C); 27.0 (q, 1J(C,H) = 127, Me-C(2)); 25.5 (q, 1J(C,H) = 
127, Me-C(2)). 
 
ESI-MS: 288.32 (M+H)+. 
HRMS (C13H21NO6 + Na): calc. 310.1267; found 310.1273. 
 
 
 
1H-NMR spectrum of 78 
 
Experimental Part 
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(3R,4R,5R)-3,4-Dihydroxy-5-({[(1R)-2-hydroxy-1-phenylethyl]amino}methyl)pyrrolidin-
2-one ((-)-80) 
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To a solution of oxalyl chloride (70 μl, 0.83 mmol, 1.2 eq) in anhydrous CH2Cl2 (6 ml), 
cooled to -78°C, was added DMSO (118 μl, 1.66 mmol, 2.4 eq). After 15 minutes, alcohol 78 
(199 mg, 0.69 mmol, 1.0 eq) in solution in anhydrous CH2Cl2 (1 ml) was added dropwise. 
After 30 minutes, NEt3 (483 μl, 3.47 mmol, 5.0 eq) was added and the mixture was warmed to 
–30°C for 20 minutes. The mixture was poured into water (10 ml) and extracted with EtOAc 
(10 ml, 3 times). The combined organic extracts were washed with brine (20 ml), dried over 
MgSO4, filtered and concentrated in vacuo to afford the corresponding aldehyde 79 as a white 
foam. 
 
Procedure 1. D-(-)-α-phenylglycinol (99) (49 mg, 0.36 mmol, 1.0 eq), aldehyde 79 (103 mg, 
0.36 mmol, 1.0 eq), NaBH(OAc)3 (107 mg, 0.5 mmol, 1.4 eq), Cl(CH2)2Cl (4 ml). Flash 
chromatography (CH2Cl2/MeOH 96/4) afforded 29 mg (0.07 mmol, 19 %, 2 steps, colourless 
oil) of the fully protected compound which was directly engaged in procedure 2b. 
Purification by flash chromatography (MeCN/NH4OH 6/1) afforded 80 (12 mg, 63 %) as a 
brown oil.  
 
[α] 58925  = -8 (c = 0.56, MeOH). 
 
IR (film): 3320, 3020, 2925, 1695, 1450, 1215, 1125, 1050, 760 cm-1. 
 
1H-NMR (400 MHz, MeOD):  
7.39-7.34 (m, 4Harom); 7.31-7.26 (m, 1Harom); 4.22 (d, 1H, 3J(H-C(3), H-C(4)) = 5.4, H-C(3)); 
4.10 (dd, 1H, 3J(H-C(4), H-C(5)) = 1.4, 3J(H-C(4), H-C(3)) = 5.4, H-C(4)); 3.78 (dd, 1H, 
3J(H-C(1’’), H-C(2’’)) = 4.4, 3J(H-C(1’’), H-C(2’’)) = 8.1, H-C(1’’)); 3.66 (dd, 1H, 3J(H-
C(2’’), H-C(1’’)) = 4.4, 2Jgem = 10.9, H-C(2’’)); 3.58 (dd, 1H, 3J(H-C(2’’), H-C(1’’)) = 8.1, 
2Jgem = 10.9, H-C(2’’)); 3.50 (ddd, 1H, 3J(H-C(5), H-C(4)) = 1.4, 3J(H-C(5), H-C(1’)) = 6.1, 
3J(H-C(5), H-C(1’)) = 6.1, H-C(5)); 2.59 (d, 2H, 3J(H-C(1’), H-C(5)) = 6.1, 2H-C(1’)). 
 
13C-NMR (101 MHz, MeOD):  
177.8 (s, C(2)); 141.9 (s, Carom); 129.6 (d, 1J(C,H) = 160, 2Carom); 128.7 (d, 1J(C,H) = 158, 
2Carom); 128.6 (d, 1J(C,H) = 161, Carom); 72.2 (d, 1J(C,H) = 153, C(4)); 71.2 (d, 1J(C,H) = 144, 
C(3)); 67.7 (t, 1J(C,H) = 143, C(2’’)); 66.6 (d, 1J(C,H) = 134, C(1’’)); 61.6 (d, 1J(C,H) = 145, 
C(5)); 50.8 (t, 1J(C,H) = 136, C(1’)). 
 
MALDI-TOF: 267.13 (M+H)+. 
HRMS (C13H18N2O4 + H): calc. 267.1345; found 267.1347. 
 
Experimental Part 
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(5S)-5-({[(1,1-Dimethylethyl)(dimethyl)silyl]oxy}methyl)-1-methylpyrrolidin-2-one  
((+)-81) 
 
 
 
 
 
 
 
To a solution of (S)-5-(hydroxymethyl)-2-pyrrolidinone (74) (200 mg, 1.74 mmol, 1.0 eq) 
in DMF (15 ml), cooled to 0°C, were added imidazole (296 mg, 4.35 mmol, 2.5 eq) and 
TBDMSCl (393 mg, 2.61 mmol, 1.5 eq). The solution was stirred at 0°C for 1 hour. After 
concentration in vacuo, the residue was diluted with EtOAc (5 ml) and washed with a 
saturated aqueous solution of NaHCO3 (10 ml, 3 times). The organic layer was dried over 
MgSO4, filtered and concentrated in vacuo. Flash chromatography on silica gel 
(CH2Cl2/MeOH 97/3) afforded the protected alcohol (339 mg, 85 %) as a yellow oil. 
 
To a solution of this protected alcohol (100 mg, 0.44 mmol, 1.0 eq) in anhydrous THF (4 ml), 
cooled to 0°C, was added sodium hydride (26 mg, 1.1 mmol, 2.5 eq, 55 % in oil). After 
stirring for 5 minutes, methyl iodide (190 μl, 3.1 mmol, 7.0 eq) was added and the mixture 
was allowed to warm up to 25°C. After 1.5 hours, water was added carefully, the resulting 
mixture was poured into a saturated aqueous solution of NH4Cl (15 ml) and the aqueous layer 
was extracted with EtOAc (15 ml, 3 times). The combined organic extracts were dried over 
MgSO4, filtered and concentrated in vacuo. Flash chromatography on silica gel 
(pentane/EtOAc 1/1) afforded 81 (177 mg, 83 %) as a yellow oil.  
 
 
[α] 58925  = 2, [α] 25577  = 2, [α] 43525  = 10, [α] 40525  = 13 (c = 0.40, CHCl3). 
 
IR (film): 3445, 1650, 1465, 1400, 1255, 1110, 1030, 940, 775 cm-1. 
 
1H-NMR (400 MHz, CDCl3):  
3.74 (dd, 1H, 3J(H-C(1’), H-C(5)) = 3.5, 2Jgem = 10.2, H-C(1’)); 3.64-3.53 (dd and m, 2H, 
3J(H-C(1’), H-C(5)) = 4.2, 2Jgem = 10.2, H-C(1’) and H-C(5)); 2.86 (s, 3H, Me-N); 2.45 (m, 
1H, H-C(3)); 2.31 (ddd, 1H, 3J(H-C(3), H-C(4)) = 5.1, 3J(H-C(3), H-C(4)) = 10.2, 2Jgem = 
16.6, H-C(3)); 2.09 (m, 1H, H-C(4)); 1.85 (ddd, 1H, 3J(H-C(4), H-C(3)) = 5.1, 3J(H-C(4), H-
C(3)) = 10.2, 2Jgem = 17.6, H-C(4)); 0.89 (s, 9H, Me3CSi); 0.07, 0.06 (2s, 6H, Me2Si).  
 
13C-NMR (101 MHz, CDCl3):  
175.4 (s, C(2)); 63.8 (t, 1J(C,H) = 141, C(1’)); 61.3 (d, 1J(C,H) = 141, C(5)); 30.2 (t, 1J(C,H) 
= 135, C(3)); 28.2 (q, 1J(C,H) = 137, Me-N); 25.7 (q, 1J(C,H) = 125, Me3CSi); 21.1 (t, 
1J(C,H) = 131, C(4)); 18.1 (s, Me3CSi); -5.52 (q, 1J(C,H) = 118, Me2Si).  
 
HRMS (C12H25NO2Si + Na): calc. 266.1552; found 266.1554. 
Anal. for C12H25NO2Si (243.42): calc. C 59.21, H 10.35, N 5.75, Si 11.54; found C 59.33, H 
10.23, N 5.72 Si 11.40. 
N
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1H-NMR spectrum of 80 
 
 
1H-NMR spectrum of 81 
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(3aR,6R,6aR)-6-({[(1,1-Dimethylethyl)(dimethyl)silyl]oxy}methyl)-2,2,5-trimethyltetra-
hydro-4H-[1,3]dioxolo[4,5-c]pyrrol-4-one ((-)-83) 
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Butyllithium (2.4 eq, 2.5 M in hexane, 100.6 mmol, 40 ml) was added to a solution of 
diisopropylamine (14.1 ml, 100.6 mmol, 2.4 eq) in anhydrous THF (100 ml) at  -78°C. The 
mixture was stirred at –78°C for 10 minutes, followed by addition of a solution of 81 (10.2 g, 
41.9 mmol, 1.0 eq) in anhydrous THF (40 ml). The mixture was stirred at -78°C for 10 
minutes, at –30°C for 10 minutes and then at –78°C for 15 minutes. After addition of a 
solution of PhSeBr (11.9 g, 50.3 mmol, 1.2 eq) in anhydrous THF (30 ml) at -78°C, the 
mixture was stirred for 30 minutes. The solution was dissolved in EtOAc (40 ml) and washed 
with a saturated aqueous solution of NH4Cl (40 ml). The organic extract was dried over 
MgSO4, filtered and concentrated in vacuo at 20°C to give the corresponding 3-
selenopyrroldinone which was directly engaged in the next step.  
 
This 3-selenopyrrolidinone (41.9 mmol, 1.0 eq) was dissolved in a mixture of EtOAc/H2O2 
(3/1, 240 ml) and cooled at 0°C. After stirring for 1 hour, water and EtOAc were added. The 
organic layer was washed with a saturated aqueous solution of NaHCO3, NH4Cl and brine to 
reach neutral pH, dried over MgSO4 and concentrated in vacuo to afford a crude enone. 
 
This crude enone (41.9 mmol, 1.0 eq), OsO4 (0.1 eq, 0.1 M in H2O, 4.2 mmol, 42 ml) and 
NMO monohydrate (8.5 g, 62.9 mmol, 1.5 eq) in a mixture of acetone/H2O (7/3 235 ml) was 
stirred at 25°C for 12 hours. After addition of sodium pyrosulfite (2.5 g) at 0°C, the aqueous 
layer was extracted with EtOAc (50 ml, 3 times). The combined organic extracts were dried 
over MgSO4 and concentrated in vacuo. Purification by flash chromatography on silica gel 
(CH2Cl2/MeOH 97/3) afforded 82 (4.7 g, 41 %, 3 steps) as a white foam. 
 
To a solution of diol 82 (4.7 g, 17.1 mmol, 1.0 eq) in a mixture of acetone/2,2-
dimethoxypropane (3/1, 170 ml), cooled to 0°C, was added a catalytic amount of p-TsOH. 
The solution was stirred at 0°C for 3 hours. After dilution with EtOAc (40 ml), the mixture 
was washed with a saturated aqueous solution of NaHCO3 (25 ml) and H2O (25 ml), dried 
over MgSO4, filtered and concentrated in vacuo. Flash chromatography on silica gel 
(pentane/EtOAc 7/3) afforded 83 (3.14 g, 59 %) as a white solid. 
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[α] 58925  = -33, [α] 25577  = -34, [α] 43525  = -60, [α] 40525  = -71 (c = 0.35, CHCl3). 
 
IR (film): 3450, 2935, 1645, 1465, 1380, 1255, 1220, 1125, 1075, 835, 775 cm-1. 
 
1H-NMR (400 MHz, MeOD):  
4.61 (d, 1H, 3J(H-C(3a), H-C(6a)) = 5.9, H-C(3a)); 4.52 (d, 1H, 3J(H-C(6a), H-C(3a)) = 5.9, 
H-C(6a)); 3.81 (dd, 1H, 3J(H-C(1’), H-C(6)) = 1.9, 2Jgem = 10.8, H-C(1’)); 3.72 (dd, 1H, 3J(H-
C(1’), H-C(6)) = 1.5, 2Jgem = 10.8, H-C(1’)); 3.57 (m, 1H, H-C(6)); 2.86 (s, 3H, Me-N); 1.43 
(s, 3H, Me-C(2)); 1.39 (s, 3H, Me-C(2)); 0.88 (s, 9H, Me3CSi); 0.07, 0.05 (2s, 6H, Me2Si).  
 
13C-NMR (101 MHz, CDCl3):  
171.7 (s, C(4)); 111.8 (s, C(2)); 77.8 (d, 1J(C,H) = 158, C(3a)); 76.5 (d, 1J(C,H) = 160, 
C(6a)); 65.3 (d, 1J(C,H) = 142, C(6)); 60.4 (t, 1J(C,H) = 142, C(1’)); 27.9 (q, 1J(C,H) = 139, 
Me-N); 27.2 (q, 1J(C,H) = 128, Me); 25.8 (q, 1J(C,H) = 127, Me); 25.8 (q, 1J(C,H) = 126, 
Me3CSi); 18.1 (s, Me3CSi); -5.58, -5.64 (2q, 1J(C,H) = 118, Me2Si). 
 
HRMS (C15H29NO4Si + H): calc. 316.1944; found 316.1945.  
Anal. for C15H29NO4Si (315.49): calc. C 57.11, H 9.27, N 4.44, Si 8.90; found C 57.15, H 
9.24, N 4.46, Si 8.88. 
 
M.P: 93-97°C. 
 
 
1H-NMR spectrum of 83 
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(3R,4R,5R)-3,4-Dihydroxy-5-({[(1R)-2-hydroxy-1-phenylethyl]amino}methyl)-1-methyl 
pyrrolidin-2-one ((-)-86) 
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TBAF (1.7 eq, 1 M in THF, 9.0 mmol, 9.0 ml) was added to a solution of 83 (1.68 g, 5.3 
mmol, 1.0 eq) in anhydrous THF (40 ml) at 0°C. The mixture was stirred at 0°C for 1 hour 
and then concentrated in vacuo. The crude product was directly purified by flash 
chromatography on silica gel (CH2Cl2/MeOH 94/6) to afford an intermediate primary alcohol 
84 (1.06 g, 99 %).  
 
To a solution of this primary alcohol 84 (60 mg, 0.29 mmol, 1.0 eq) in anhydrous CH2Cl2 (2.5 
ml) was added Dess-Martin periodinane (189 mg, 0.45 mmol, 1.5 eq). The mixture was stirred 
at 25°C for 1 hour and was directly purified by flash chromatography on silica gel 
(CH2Cl2/MeOH 95/5) to afford aldehyde 85.  
 
Procedure 1. D-(-)-α-phenylglycinol (99) (45 mg, 0.33 mmol, 1.1 eq), aldehyde 85 (59 mg, 
0.29 mmol, 1.0 eq), NaBH(OAc)3 (88 mg, 0.42 mmol, 1.4 eq), Cl(CH2)2Cl (3 ml). Flash 
chromatography (CH2Cl2/MeOH 95/5) afforded 33 mg (0.10 mmol, 36 %, 2 steps, colourless 
oil) of the fully protected compound which was directly engaged in procedure 2b. 
Purification by flash chromatography (MeCN/NH4OH 10/1) afforded 86 (22 mg, 78 %) as a 
colourless oil.  
 
[α] 58925  = -9, [α] 25577  = -25 (c = 0.25, MeOH). 
 
IR (film): 3145, 3040, 1675, 1405, 1200, 1135, 1075, 755, 700 cm-1. 
 
1H-NMR (400 MHz, MeOD):  
7.38-7.26 (m, 5Harom); 4.39 (d, 1H, 3J(H-C(3), H-C(4)) = 5.4, H-C(3)); 4.26 (d, 1H, 3J(H-C(4), 
H-C(3)) = 5.4, H-C(4)); 3.76 (dd, 1H, 3J(H-C(1’’), H-C(2’’)) = 4.4, 3J(H-C(1’’), H-C(2’’)) = 
8.5, H-C(1’’)); 3.63 (dd, 1H, 3J(H-C(2’’), H-C(1’’)) = 4.4, 2Jgem = 10.9, H-C(2’’)); 3.55 (dd, 
1H, 3J(H-C(2’’), H-C(1’’)) = 8.5, 2Jgem = 10.9, H-C(2’’)); 3.38 (dd, 1H, 3J(H-C(5), H-C(1’)) = 
3.4, 3J(H-C(5), H-C(1’)) = 6.1, H-C(5)); 2.84 (dd, 1H, 3J(H-C(1’), H-C(5)) = 3.4, 2Jgem = 13.0, 
H-C(1’)); 2.66 (s, 3H, Me-N); 2.51 (dd, 1H, 3J(H-C(1’), H-C(5)) = 6.1, 2Jgem = 13.0, H-C(1’)). 
 
13C-NMR (101 MHz, MeOD):  
175.4 (s, C(2)); 142.0 (s, Carom); 129.6 (d, 1J(C,H) = 160, 2Carom); 128.9 (d, 1J(C,H) = 160, 
2Carom); 128.7 (d, 1J(C,H) = 160, Carom); 71.7 (d, 1J(C,H) = 145, C(3)); 70.8 (d, 1J(C,H) = 154, 
C(4)); 68.2 (d, 1J(C,H) = 155, C(5)); 67.7 (t, 1J(C,H) = 143, C(2’’)); 66.6 (d, 1J(C,H) = 135, 
C(1’’)); 46.7 (t, 1J(C,H) = 134, C(1’)); 28.7 (q, 1J(C,H) = 138, Me-N). 
 
ESI-MS: 281.33 (M+H)+. 
HRMS (C14H20N2O4 + H): calc. 281.1501; found 281.1491.  
Experimental Part 
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1H-NMR spectrum of 86 
 
 
 
 
 
 
(2R,3R,4S)-2-[{(1R)-1-Hydroxymethyl-2-phenyl-ethylamino}-methyl]-pyrrolidine-3,4-
diol ((+)-89) 
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Procedure 1. D-α-phenylalaninol (99) (168 mg, 1.11 mmol, 1.0 eq), 87 (300 mg, 1.11 
mmol, 1.0 eq), NaBH(OAc)3 (328 mg, 1.55 mmol, 1.4 eq), Cl(CH2)2Cl (11 ml). Flash 
chromatography (CH2Cl2/MeOH 12/1) afforded 239 mg (0.59 mmol, 53 %, brown oil) of the 
fully protected compound which was directly engaged in procedure 2b. Purification by flash 
chromatography (CH2Cl2/MeOH 12/1 to 10/4) afforded 89 (133 mg, 85 %) as a pale yellow 
solid after lyophilisation.  
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[α] 58925  = 2 (c = 0.17, CHCl3). 
 
UV (MeCN): 229 (500), 213 (200). 
 
IR (film): 3020, 1680, 1215, 755, 670 cm-1. 
 
1H-NMR (400 MHz, MeOD):  
7.35-7.29 (m, 5Harom); 4.22 (ddd, 1H, 3J(H-C(4), H-C(3)) = 7.6, 3J(H-C(4), H-C(5)) = 4.2, 
3J(H-C(4), H-C(5)) = 2.3, H-C(4)); 3.90 (dd, 1H, 3J(H-C(3), H-C(4)) = 7.6, 3J(H-C(3), H-
C(2)) = 4.3, H-C(3)); 3.62 (dd, 1H, 3J(H-C(2’’), H-C(1’’)) = 4.0, 2Jgem = 11.1, H-C(2’’)); 3.44 
(dd, 1H, 3J(H-C(2’’), H-C(1’’)) = 6.0, 2Jgem = 11.1, H-C(2’’)); 3.38 (m, 1H, H-C(2)); 3.28 (dd, 
1H, 3J(H-C(5), H-C(4)) = 4.2, 2Jgem = 12.4, H-C(5)); 3.12 (dd, 1H, 3J(H-C(5), H-C(4)) = 2.3, 
2Jgem = 12.4, H-C(5)); 3.08 (dd, 1H, 3J(H-C(1’), H-C(2)) = 4.4, 2Jgem = 13.1, H-C(1’)); 2.93 
(m, 1H, H-C(1’’)); 2.84 (dd, 1H, 3J(H-C(1’), H-C(2)) = 8.2, 2Jgem = 13.1, H-C(1’)); 2.79 (m, 
2H, H-C(1’’’)). 
 
13C-NMR (101 MHz, MeOD):  
140.2 (s, 1Carom); 130.4 (d, 1J(C,H) = 162, 2Carom); 129.6 (d, 1J(C,H) = 160, 2Carom); 127.5 (d, 
1J(C,H) = 161, 1Carom); 75.2 (d, 1J(C,H) = 144, C(3)); 71.7 (d, 1J(C,H) = 152, C(4)); 63.6 (t, 
1J(C,H) = 153, C(2’’)); 62.7 (d, 1J(C,H) = 142, C(2)); 62.5 (d, 1J(C,H) = 134, C(1’’)); 51.1 (t, 
1J(C,H) = 143 , C(5)); 47.5 (t, 1J(C,H) = 134, C(1’)); 38.6 (t, 1J(C,H) = 112, C(1’’’)). 
 
MALDI-TOF: 267.46 (M+H)+. 
HRMS (C14H22N2O3): calc. 266.1630; found 266.1631.  
M.P: 89-93°C. 
 
1H-NMR spectrum of 89 
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(2R)-2-Amino-2-[4-(methyloxy)phenyl]ethanol ((-)-97) 
 
 
 
 
 
 
 
 
 
 
 
 
To a solution of 4-Hydroxy-D-phenylglycine211 (90) (3.0 g, 18.0 mmol, 1.0 eq) in a mixture 
of H2O/Dioxane/1M NaOH (1/2/1 72 ml) was added (Boc)2O (4.3 g, 19.8 mmol, 1.1 eq). The 
mixture was stirred at 25°C for 4 hours and dioxane was evaporated in vacuo. The aqueous 
layer was washed with Et2O (25 ml, 2 times), acidified with KHSO4 and extracted with 
EtOAc (25 ml, 3 times). The combined organic extracts were dried over MgSO4, evaporated 
in vacuo to afford the corresponding carbamate (4.9 g, 98 %) as a white foam.  
 
To a solution of this carbamate (1.0 g, 3.74 mmol, 1.0 eq) in DMF (35 ml), cooled to 0°C, 
were added K2CO3 (2.6 g, 18.71 mmol, 5.0 eq) portionwise and, after 5 minutes, MeI (0.9 ml, 
14.96 mmol, 4.0 eq) dropwise. The solution was stirred for 1 hour at 0°C and the resulting 
mixture, diluted with Et2O (15 ml), was poured into a saturated aqueous solution of NaHCO3 
(15 ml). The aqueous layer was extracted with Et2O (15 ml, 3 times). The combined organic 
extracts were dried over MgSO4, filtered and concentrated in vacuo. Flash chromatography on 
silica gel (pentane/EtOAc 2/1) afforded an intermediate methyl ester 92 (680 mg, 62 %) as a 
colourless oil.  
 
To a solution of this methyl ester 92 (200 mg, 0.68 mmol, 1.0 eq) in anhydrous THF (4 ml), 
cooled to 0°C, was added LiAlH4 (39 mg, 1.02 mmol, 1.5 eq) portionwise. The mixture was 
stirred at 0°C for 1 hour. After addition of water (1 ml), the mixture was filtered through a pad 
of Celite and concentrated in vacuo. The resulting primary alcohol was directly engaged in 
procedure 2b. Purification by flash chromatography (MeCN/NH4OH 10/1) afforded 97 (73 
mg, 64 %, 2 steps) as a pale yellow solid. 
 
 
                                                 
211 Salituro, G.M.; Townsend, C.A., Jacs 1990, 112, 760-770. 
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[α] 58925  = -17, [α] 43525  = -30, [α] 40525  = -34 (c = 0.27, MeOH). 
 
IR (film): 3415, 1650, 1515, 1465, 1250, 1180, 1030, 830 cm-1. 
 
1H-NMR (400 MHz, MeOD):  
7.30 (d, 3J=8.5, 2Harom); 6.93 (d, 3J=8.5, 2Harom); 3.95 (dd, 1H, 3J(H-C(1), H-C(2)) = 4.4, 
3J(H-C(1), H-C(2)) = 8.1, H-C(1)); 3.81 (s, 3H, OMe); 3.67 (dd, 1H, 3J(H-C(2), H-C(1)) = 
4.4, 2Jgem = 10.9, H-C(2)); 3.56 (dd, 1H, 3J(H-C(2), H-C(1)) = 8.1, 2Jgem = 10.9, H-C(2)). 
 
13C-NMR (101 MHz, MeOD):  
160.6 (s, Carom); 134.7 (s, Carom); 129.1 (d, 1J(C,H) = 156, 2Carom); 114.9 (d, 1J(C,H) = 159, 
2Carom); 68.6 (t, 1J(C,H) = 143, C(2)); 58.1 (d, 1J(C,H) = 134, C(1)); 55.7 (q, 1J(C,H) = 144, 
OMe). 
 
ESI-MS: 168.36 (M+H)+. 
CI-MS (NH3): 168 (M+H+, 44), 151 (100), 136 (40). 
HRMS (C9H13NO2 + H): calc. 168.1024; found 168.1025.  
M.P: 122-125°C. 
 
 
1H-NMR spectrum of 97 
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(3R,4R,5S)-3,4-Dihydroxy-5-[({(1R)-2-hydroxy-1-[4-(methyloxy)phenyl]ethyl}amino) 
methyl]-1-methylpyrrolidin-2-one ((-)-98) 
 
 
N
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Procedure 1. Amine 97 (65 mg, 0.39 mmol, 1.0 eq), aldehyde 85 (78 mg, 0.39 mmol, 1.0 eq), 
NaBH(OAc)3 (116 mg, 0.55 mmol, 1.4 eq), Cl(CH2)2Cl (4.5 ml). Flash chromatography 
(CH2Cl2/MeOH 96/4) afforded 9.6 mg (0.03 mmol, 7 %, 2 steps) of the fully protected 
compound which was directly engaged in procedure 2b. Purification by flash 
chromatography (MeCN/NH4OH 12/1) afforded 98 (6.8 mg, 80 %) as a pale yellow oil.  
 
 
1H-NMR (400 MHz, MeOD):  
7.28 (d, 3J=8.5, 2Harom); 6.94 (d, 3J=8.5, 2Harom); 4.36 (d, 1H, 3J(H-C(3), H-C(4)) = 5.4, H-
C(3)); 4.23 (d, 1H, 3J(H-C(4), H-C(3)) = 5.4, H-C(4)); 3.81 (m, 4H, OMe and H-C(1’’)); 3.64 
(dd, 1H, 3J(H-C(2’’), H-C(1’’)) = 4.4, 2Jgem = 10.9, H-C(2’’)); 3.60 (dd, 1H, 3J(H-C(2’’), H-
C(1’’)) = 8.5, 2Jgem = 10.9, H-C(2’’)); 3.41 (dd, 1H, 3J(H-C(5), H-C(1’)) = 3.4, 3J(H-C(5), H-
C(1’)) = 7.1, H-C(5)); 2.88 (dd, 1H, 3J(H-C(1’), H-C(5)) = 3.4, 2Jgem = 13.2, H-C(1’)); 2.68 (s, 
3H, Me-N); 2.56 (dd, 1H, 3J(H-C(1’), H-C(5)) = 7.1, 2Jgem = 13.2, H-C(1’)). 
 
13C-NMR (101 MHz, MeOD):  
175.2 (s, C(2)); 161.3 (s, Carom); 130.2 (d, 1J(C,H) = 156, 2Carom); 115.3 (d, 1J(C,H) = 159, 
2Carom); 115.2 (s, Carom); 71.4 (d, 1J(C,H) = 143, C(3)); 70.7 (d, 1J(C,H) = 154, C(4)); 66.8 (d, 
1J(C,H) = 146, C(5)); 66.4 (t, 1J(C,H) = 146, C(2’’)); 65.8 (d, 1J(C,H) = 135, C(1’’)); 55.8 (q, 
1J(C,H) = 144, OMe); 46.0 (t, 1J(C,H) = 137, C(1’)); 28.8 (q, 1J(C,H) = 140, Me-N). 
 
ESI-MS: 311.35 (M+H)+. 
HRMS (C15H22N2O5 + H): calc. 311.1607; found 311.1610. 
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1H-NMR spectrum of 98 
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(2R)-2-(Diallylamino)-2-phenylethanol ((-)-100) 
 
 
 
 
 
 
 
 
 
To a solution of D-(-)-α-phenylglycinol (99) (2.0 g, 14.6 mmol, 1.0 eq) in THF/DMSO (4/1 
50 ml), were added NaHCO3 (2.4 g, 29.2 mmol, 2.0 eq) and allyl bromide (5.1 ml, 58.3 mmol, 
4.0 eq). A catalytic amount of Bu4NI (1.62 g, 4.38 mmol, 0.3 eq) was added and the reaction 
mixture was stirred at 60°C for 3 hours. After cooling to 25°C, water (30 ml) was added. The 
reaction mixture was extracted with CH2Cl2 (30 ml, 3 times). The combined organic extracts 
were dried over MgSO4, filtered and concentrated in vacuo. The residue was purified by flash 
chromatography (PE/EtOAc 5/1) to afford 100 (2.5 g, 79 %) as a light yellow oil.  
 
 
[α] 58925  = -84, [α] 57725 = -92, [α] 54625  = -102, [α] 43525  = -186, [α] 40525  = -230 (c = 0.39, CH2Cl2). 
 
UV (MeCN): 260 (1000), 211 (9500). 
 
IR (film): 3440, 3080, 2930, 2885, 2820, 1640, 1495, 1455, 1420, 1350, 1265, 1220, 1030, 
920, 760, 705 cm-1. 
 
1H-NMR (400 MHz, MeOD): 
7.39-7.30 (m, 3Harom); 7.22-7.20 (m, 2Harom); 5.82 (dddd, 2 H, 3J(H-C(2’), H-C(1’)) = 4.5, 
3J(H-C(2’), H-C(1’)) = 8.2, 3J(H-C(2’), H-C(3’)) = 10.2, 3J(H-C(2’), H-C(3’)) = 14.2, H-
C(2’)); 5.19 (m, 4 H, H-C(3’)); 4.01 (m, 2H, H-C(1), H-C(2)); 3.63 (dd, 1H, 3J(H-C(1), H-
C(2)) = 4.1, 2Jgem = 9.6, H-C(1)); 3.40 (m, 2H, H-C(1’)); 2.73 (dd, 2H, 3J(H-C(1’), H-C(2’)) = 
8.2, 2Jgem = 14.2, H-C(1’)). 
 
13C-NMR (101 MHz, MeOD): 
136.4 (d, 1J(C,H) = 152, C(2’)); 135.7 (s, Carom); 129.0 (d, 1J(C,H) = 158, 2Carom); 128.3 (d, 
1J(C,H) = 160, 2Carom); 127.8 (d, 1J(C,H) = 160, Carom); 117.7 (t, 1J(C,H) = 153, C(3’)); 63.4 
(d, 1J(C,H) = 137, C(2)); 60.4 (t, 1J(C,H) = 145, C(1)); 52.4 (t, 1J(C,H) = 133, C(1’)). 
 
CI-MS (NH3): 218 (M+H+, 100), 186 (32), 98 (4). 
 
 
 
 
N
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N,N-Diallyl-N-[(1R)-2-((3-fluorobenzyl)oxy)-1-phenylethyl]amine ((-)-107) 
 
 
 
 
 
 
 
 
 
 
 
 
Diallylamine 100 (300 mg, 1.38 mmol, 1.0 eq) was dissolved in anhydrous THF (10 ml) and 
the temperature was cooled to 0°C. Sodium hydride (73 mg, 1.66 mmol, 1.2 eq, 55 % in oil) 
was added and the reaction mixture was stirred at 0°C for 10 minutes. 3-fluorobenzyl bromide 
(365 mg, 1.93 mmol, 1.4 eq) was added portionwise and the mixture was warmed to 60°C for 
6 hours. The resulting mixture was poured into a saturated aqueous solution of NaHCO3 (15 
ml) and the aqueous layer was extracted with EtOAc (20 ml, 3 times). The combined organic 
extracts were dried over MgSO4, filtered and concentrated in vacuo. Flash chromatography on 
silica gel (EtOAc/PE 1/10) afforded 107 (449 mg, 100 %) as a brown oil. 
 
 
UV (MeCN): 218 (6000). 
 
IR (film): 3585, 3070, 2925, 2855, 2360, 1590, 1490, 1450, 1360, 1260, 1140, 1105, 920, 
785, 690 cm-1. 
 
1H-NMR (400 MHz, CDCl3): 
7.39-7.25 (m, 5Harom); 7.13 (m, 1Harom); 7.03-6.93 (m, 3Harom); 5.91-5.81 (m, 2H, H-C(2’)); 
5.19-5.12 (m, 4H, H-C(3’)); 4.52 (s, 2H, OCH2Ar); 4.08 (dd, 1H, 3J(H-C(1), H-C(2)) = 6.1, 
3J(H-C(1), H-C(2)) = 6.4, H-C(1)); 3.89 (dd, 1H, 3J(H-C(2), H-C(1)) = 6.1, 2Jgem = 9.7, H-
C(2)); 3.79 (dd, 1H, 3J(H-C(2), H-C(1)) = 6.4, 2Jgem = 9.7, H-C(2)); 3.27 (dd, 2H, 3J(H-C(1’), 
H-C(2’)) = 5.2, 2Jgem = 14.4, H-C(1’)); 3.01 (dd, 2H, 3J(H-C(1’), H-C(2’)) = 6.8, 2Jgem = 14.4, 
H-C(1’)). 
 
13C-NMR (101 MHz, CDCl3): 
164.1, 140.1, 139.5 (3s, 3Carom); 136.5 (d, 1J(C,H) = 154, C(2’)); 129.7 (d, 1J(C,H) = 168, 
1Carom); 128.5 (d, 1J(C,H) = 164, 2Carom); 128.1 (d, 1J(C,H) = 158, 2Carom); 127.1 (d, 1J(C,H) 
= 139, 1Carom); 122.8 (d, 1J(C,H) = 161, 1Carom); 116.9 (t, 1J(C,H) = 155, C(3’)); 114.4 (d, 
1J(C,H) = 183, 1Carom); 114.2 (d, 1J(C,H) = 183, 1Carom); 72.3 (t, 1J(C,H) = 142, OCH2Ar); 
71.4 (t, 1J(C,H) = 141, C(2)); 62.9 (d, 1J(C,H) = 134, C(1)); 53.2 (t, 1J(C,H) = 134, C(1’)). 
 
MALDI-TOF: 326.52 (M+H)+. 
HRMS (C21H24FNO + H): calc. 326.1920; found 326.1920. 
O
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1H-NMR spectrum of 100 
 
 
 
 
 
 
 
1H-NMR spectrum of 107 
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(1R)-2-((3-Methylbenzyl)oxy)-1-phenylethanamine ((-)-108) 
 
 
 
 
 
 
 
 
 
 
 
To a solution of ether 107 (225 mg, 0.69 mmol, 1.0 eq) and 2-mercaptobenzoic acid (234 mg, 
1.52 mmol, 2.2 eq) in anhydrous THF were added Pd(dba)2 (79 mg, 0.14 mmol, 0.2 eq) and 
DPPB (47 mg, 0.11 mmol, 0.16 eq). The mixture was warmed to 80°C and stirred for 6 hours. 
The solution was diluted with EtOAc (15 ml) and extracted with 1M HClaq (15 ml, 3 times). 
The combined aqueous layers were basified with 2.5M NaOH and extracted with EtOAc (15 
ml, 3 times). The combined organic extracts were dried over MgSO4, filtered and 
concentrated in vacuo. Flash chromatography on silica gel (CH2Cl2/MeOH 30/1) afforded 108 
(30 mg, 18 %) as a brown oil. 
 
 
1H-NMR (400 MHz, MeOD):  
7.40-7.26 (m, 6Harom); 7.13 (m, 1Harom); 7.07 (m, 1Harom); 7.01 (m, 1Harom); 4.57 (s, 2H, 
OCH2Ar); 4.16 (m, 1H, H-C(1)); 3.66-3.55 (m, 2H, H-C(2)). 
 
13C-NMR (101 MHz, MeOD):  
164.0, 144.0, 143.6 (3s, 3Carom); 132.0 (d, 1J(C,H) = 163, 1Carom); 130.4 (d, 1J(C,H) = 160, 
2Carom); 129.4 (d, 1J(C,H) = 144, 1Carom); 128.9 (d, 1J(C,H) = 160, 2Carom); 125.1 (d, 1J(C,H) 
= 159, 1Carom); 116.2 (d, 1J(C,H) = 158, 1Carom); 116.0 (d, 1J(C,H) = 168, 1Carom); 78.0 (7, 
1J(C,H) = 143, C(2)); 74.2 (t, 1J(C,H) = 143, OCH2Ar); 57.4 (d, 1J(C,H) = 138, C(1)). 
 
CI-MS (NH3): 246 (M+H+, 5), 149 (10), 106 (100). 
HRMS (C15H16FNO + H): calc. 246.1294; found 246.1296. 
 
 
(2R,3S,4R)-2-({[(1R)-2-(3-Fluorophenoxy)-1-phenylethyl]amino}methyl)pyrrolidin-3,4 
diol ((-)-109) 
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Procedure 1. Amine 108 (30 mg, 0.12 mmol, 1.0 eq), 87 (33.1 mg, 0.12 mmol, 1.0 eq), 
NaBH(OAc)3 (36.2 mg, 0.17 mmol, 1.4 eq), Cl(CH2)2Cl (4 ml). The crude product was 
directly engaged in procedure 2b. Purification by flash chromatography (MeCN/NH4OH 
10/1) afforded 109 (9 mg, 19 %) as a brown foam after lyophilisation.  
 
 
1H-NMR (400 MHz, MeOD):  
7.40 (m, 6Harom); 7.16 (m, 2Harom); 7.07 (m, 1Harom); 4.57 (s, 2H, OCH2Ar); 3.98 (m, 2H, H-
C(4), H-C(1’’)); 3.98 (m, 3H, 2H-C(2’’), H-C(3)); 3.11 (m, 2H, H-C(5), H-C(2)); 2.84 (m, 
1H, H-C(5)); 2.66 (m, 1H, H-C(1’)); 2.56 (m, 1H, H-C(1’)).  
 
13C-NMR (101 MHz, MeOD):  
142.6, 141.6, 131.9 (3s, 3Carom); 129.6, 129.4, 128.9, 128.8, 124.3, 115.4, 115.1 (7d, 9Carom); 
76.9 (d, 1J(C,H) = 149, C(3)); 76.1 (t, 1J(C,H) = 144, C(2’’)); 73.3 (d, 1J(C,H) = 144, C(4)) ; 
72.5 (t, 1J(C,H) = 149, OCH2Ar); 64.4 (d, 1J(C,H) = 137, C(1’’)); 62.7 (d, 1J(C,H) = 139, 
C(2)); 52.2 (t, 1J(C,H) = 140, C(5)); 50.8 (t, C(1’)). 
 
HRMS (C20H25FN2O3 + H): calc. 361.1927; found 361.1929. 
Purity measured by HPLC (C18, C8, C4 columns): 92%, 100%, 100%.  
 
 
1H-NMR spectrum of 109 
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Tert-butyl ((1R)-2-hydroxy-1-phenylethyl) carbamate ((-)-111) 
 
 
Boc
NH OH
 
 
 
To a solution of D-(-)-α-phenylglycinol (99) (5.0 g, 36.5 mmol, 1.0 eq) in anhydrous CH2Cl2 
(350 ml) were added pyridine (5.9 ml, 73 mmol, 2.0 eq), (Boc)2O (8.0 g, 36.5 mmol, 1.0 eq) 
and a catalytic amount of DMAP. The mixture was stirred at 0°C for 1 hour and poured into a 
saturated aqueous solution of NaHCO3 (150 ml). The aqueous layer was extracted with 
CH2Cl2 (80 ml, 2 times). The combined organic extracts were dried over MgSO4 and 
concentrated in vacuo. The residue was purified by flash chromatography (CH2Cl2/MeOH 
20/1) to afford 111 (7.6 g, 88 %) as a pale yellow solid. 
 
 
[α] 58925  = -49, [α] 25577  = -50, [α] 43525  = -107, [α] 40525  = -134 (c = 0.515, CH2Cl2). 
 
UV (MeCN): 215 (4000). 
 
IR (film): 3310, 3240, 3060, 2980, 2930, 2900, 2300, 1955, 1875, 1750, 1670, 1560, 1490, 
1365, 1265, 1170, 1055, 840, 730, 700 cm-1. 
 
1H-NMR (400 MHz, CDCl3):  
7.38-7.23 (m, 5Harom); 4.73 (m, 1H, H-C(2)); 3.80 (m, 2H, H-C(1)); 1.40 (s, 9H, Me3C). 
 
13C-NMR (101 MHz, CDCl3):  
156.1 (s, NC(O)O); 139.4 (s, 1Carom); 128.7 (d, 1J(C,H) = 161, 2Carom); 127.7 (d, 1J(C,H) = 
154, 1Carom); 126.5 (d, 1J(C,H) = 158, 2Carom); 72.5 (s, OCMe3); 66.9 (t, 1J(C,H) = 148, C(1)); 
56.3 (d, 1J(C,H) = 143, C(2)); 28.3 (q, 1J(C,H) = 127, Me3C). 
 
MALDI-TOF: 276.44 (M+K)+, 260.47 (M+Na)+. 
HRMS (C13H19NO3 + Na): calc. 260.1263; found 260.1266. 
 
M.P: 120-126°C. 
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(2R)-2-Amino-2-phenylethyl acetate (112) 
 
 
 
 
 
 
 
 
 
 
Procedure 3. Primary alcohol 111 (300 mg, 1.26 mmol, 1.0 eq), NEt3 (705 μl, 5.06 mmol, 4.0 
eq), acetyl chloride (180 μl, 2.53 mmol, 2.0 eq), DMAP (cat), CH2Cl2 (13 ml), 4.5 hours. 
Flash chromatography (pentane/EtOAc 4/1) afforded 230 mg (0.82 mmol, 65 %, white solid) 
of the N-protected intermediate which was directly engaged in procedure 2b to provide 112 
(147 mg, quantitative) as a brown oil without any purification. 
 
 
1H-NMR (400 MHz, MeOD):  
7.50 (m, 5Harom); 4.66 (dd, 1H, 3J(H-C(2’), H-C(1’)) = 8.3, 3J(H-C(2’), H-C(1’)) = 4.4, H-
C(2’)); 4.44 (m, 2H, 2H-C(1’)); 2.14 (s, 3H, C(O)Me). 
 
13C-NMR (101 MHz, MeOD):  
171.9 (s, C=O); 134.9 (s, 1Carom); 130.8 (d, 1J(C,H) = 165, 1Carom); 130.5 (d, 1J(C,H) = 164, 
2Carom); 128.4 (d, 1J(C,H) = 158, 2Carom); 65.7 (7, 1J(C,H) = 151, C(1’)); 55.2 (d, 1J(C,H) = 
145, C(2’)); 20.5 (q, 1J(C,H) =130, C(O)Me). 
 
MALDI-TOF: 180.31 (M+H)+. 
HRMS (C10H13NO2 + H): calc. 180.1024; found 180.1022. 
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(2R)-2-Amino-2-phenylethyl propionate (113) 
 
 
 
 
 
 
 
 
 
 
Procedure 3. Primary alcohol 111 (300 mg, 1.26 mmol, 1.0 eq), NEt3 (705 μl, 5.06 mmol, 4.0 
eq), propionyl chloride (221 μl, 2.53 mmol, 2.0 eq), DMAP (cat), CH2Cl2 (13 ml), 3 hours. 
Flash chromatography (pentane/EtOAc 9/1) afforded 297 mg (1.02 mmol, 80 %, white solid) 
of the N-protected derivative which was directly engaged in procedure 2b to provide 113 
(196 mg, quantitative) as a brown oil without any purification. 
 
 
1H-NMR (400 MHz, MeOD):  
7.51 (m, 5Harom); 4.67 (dd, 1H, 3J(H-C(2’), H-C(1’)) = 7.4, 3J(H-C(2’), H-C(1’)) = 4.5, H-
C(2’)); 4.47 (m, 2H, 2H-C(1’)); 2.47 (q, 2H, 3J(H-C(2), H-C(3)) = 7.5, H-C(2)); 1.16 (t, 3H, 
3J(H-C(3), H-C(2)) = 7.5, H-C(3)). 
 
13C-NMR (101 MHz, MeOD):  
175.2 (s, C=O); 134.9 (s, 1Carom); 130.9 (d, 1J(C,H) = 164, 1Carom); 130.5 (d, 1J(C,H) = 162, 
2Carom); 128.4 (d, 1J(C,H) = 159, 2Carom); 65.6 (t, 1J(C,H) = 148, C(1’)); 55.3 (d, 1J(C,H) = 
144, C(2’)); 27.9 (t, 1J(C,H) =126, C(2)); 9.2 (q, 1J(C,H) =128, C(3)). 
 
MALDI-TOF: 194.26 (M+H)+. 
HRMS (C11H15NO2 + H): calc. 194.1181; found 194.1183. 
 
H2N
O
O
Experimental Part 
 
 
160 
(2R)-2-Amino-2-phenylethyl butyrate (114) 
 
 
 
 
 
 
 
 
 
 
 
 
Procedure 3. Primary alcohol 111 (300 mg, 1.26 mmol, 1.0 eq), NEt3 (705 μl, 5.06 mmol, 4.0 
eq), butyryl chloride (265 μl, 2.53 mmol, 2.0 eq), DMAP (cat), CH2Cl2 (13 ml), 8 hours. 
Flash chromatography (pentane/EtOAc 9/1) afforded 296 mg (0.96 mmol, 76 %, white solid) 
of the N-protected intermediate which was directly engaged in procedure 2b to provide 114 
(198 mg, quantitative) as a brown oil without any purification. 
 
 
1H-NMR (400 MHz, MeOD):  
7.50 (m, 5Harom); 4.67 (dd, 1H, 3J(H-C(2’), H-C(1’)) = 7.9, 3J(H-C(2’), H-C(1’)) = 4.7, H-
C(2’)); 3.50 (m, 2H, 2H-C(1’)); 2.42 (t, 2H, 3J(H-C(2), H-C(3)) = 7.4, H-C(2)); 1.66 (tq, 2H, 
3J(H-C(3), H-C(4)) = 7.4, 3J(H-C(3), H-C(2)) = 7.4, H-C(3)); 0.96 (t, 3H, 3J(H-C(4), H-C(3)) 
= 7.4, H-C(4)). 
 
13C-NMR (101 MHz, MeOD):  
174.4 (s, C=O); 135.0 (s, 1Carom); 130.7 (d, 1J(C,H) = 162, 1Carom); 130.4 (d, 1J(C,H) = 160, 
2Carom); 128.4 (d, 1J(C,H) = 165, 2Carom); 65.5 (t, 1J(C,H) = 148, C(1’)); 55.2 (d, 1J(C,H) = 
143, C(2’)); 36.4 (t, 1J(C,H) =128, C(2)); 19.1 (t, 1J(C,H) =128, C(3)); 13.9 (q, 1J(C,H) =125, 
C(4)). 
 
MALDI-TOF: 208.36 (M+H)+. 
HRMS (C12H17NO2 + H): calc. 208.1337; found 208.1339. 
 
H2N
O
O
Experimental Part 
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(2R)-2-Amino-2-phenylethyl pentanoate (115) 
 
 
 
 
 
 
 
 
 
 
 
 
Procedure 3. Primary alcohol 111 (300 mg, 1.26 mmol, 1.0 eq), NEt3 (705 μl, 5.06 mmol, 4.0 
eq), valeroyl chloride (215 μl, 1.77 mmol, 1.4 eq), DMAP (cat), CH2Cl2 (10 ml), 4 hours. 
Flash chromatography (pentane/EtOAc 9/1) afforded 249 mg (0.77 mmol, 62 %, colourless 
oil) of the N-protected intermediate which was directly engaged in procedure 2b to provide 
115 (170 mg, quantitative) as a pale yellow oil without any purification. 
 
 
1H-NMR (400 MHz, MeOD):  
7.51 (m, 5Harom); 4.67 (dd, 1H, 3J(H-C(2’), H-C(1’)) = 7.1, 3J(H-C(2’), H-C(1’)) = 4.7, H-
C(2’)); 4.45 (m, 2H, 2H-C(1’)); 2.45 (t, 2H, 3J(H-C(2), H-C(3)) = 7.4, H-C(2)); 1.63 (tt, 2H, 
3J(H-C(3), H-C(2)) = 7.4, 3J(H-C(3), H-C(4)) = 7.6, H-C(3)); 1.37 (m, 2H, 3J(H-C(4), H-
C(3)) = 7.6, 3J(H-C(4), H-C(5)) = 7.3, H-C(4)); 0.95 (t, 3H, 3J(H-C(5), H-C(4)) = 7.3, H-
C(5)). 
 
13C-NMR (101 MHz, MeOD):  
174.5 (s, C=O); 135.0 (s, 1Carom); 130.8 (d, 1J(C,H) = 162, 1Carom); 130.4 (d, 1J(C,H) = 168, 
2Carom); 128.4 (d, 1J(C,H) = 163, 2Carom); 65.5 (t, 1J(C,H) = 150, C(1’)); 55.2 (d, 1J(C,H) = 
145, C(2’)); 34.3 (t, 1J(C,H) =128, C(2)); 27.9 (t, 1J(C,H) =130, C(3)); 23.2 (t, 1J(C,H) =122, 
C(4)); 14.0 (q, 1J(C,H) =125, C(5)). 
 
MALDI-TOF: 243.48 (M+Na)+, 222.46 (M+H)+. 
HRMS (C13H19NO2 + H): calc. 222.1494; found 222.1495. 
 
H2N
O
O
Experimental Part 
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(2R)-2-Amino-2-phenylethyl-2-methylpropionate (116) 
 
 
 
 
 
 
 
 
 
 
Procedure 3. Primary alcohol 111 (300 mg, 1.26 mmol, 1.0 eq), NEt3 (705 μl, 5.06 mmol, 4.0 
eq), isobutyryl chloride (186 μl, 1.77 mmol, 1.4 eq), DMAP (cat), CH2Cl2 (12 ml), 5 hours. 
Flash chromatography (pentane/EtOAc 9/1) afforded 285 mg (1.19 mmol, 94 %, white solid) 
of the N-protected intermediate which was directly engaged in procedure 2b to provide 116 
(246 mg, quantitative) as a brown oil without any purification. 
 
 
1H-NMR (400 MHz, MeOD):  
7.54-7.47 (m, 5Harom); 4.68 (dd, 1H, 3J(H-C(2’’), H-C(1’’)) = 7.5, 3J(H-C(2’’), H-C(1’’)) = 
5.1, H-C(2’’)); 4.45 (m, 2H, 2H-C(1’’)); 2.68 (qq, 1H, 3J(H-C(2), H-C(3)) = 7.0, 3J(H-C(2), 
H-C(1’)) = 7.0, H-C(2)); 1.19 (d, 3H, 3J(H-C(3), H-C(2)) = 7.0, H-C(3)); 1.18 (d, 3H, 3J(H-
C(1’), H-C(2)) = 7.0, H-C(1’)). 
 
13C-NMR (101 MHz, MeOD):  
177.9 (s, C=O); 135.0 (s, 1Carom); 130.7 (d, 1J(C,H) = 161, 1Carom); 130.4 (d, 1J(C,H) = 163, 
2Carom); 128.4 (d, 1J(C,H) = 159, 2Carom); 65.6 (t, 1J(C,H) = 148, C(1’’)); 55.1 (d, 1J(C,H) = 
145, C(2’’)); 34.8 (d, 1J(C,H) =131, C(2)); 19.2 (q, 1J(C,H) =128, C(3)); 19.1 (q, 1J(C,H) 
=128, C(1’)). 
 
MALDI-TOF: 208.63 (M+H)+. 
HRMS (C12H17NO2 + H): calc. 208.1337; found 208.1338. 
 
H2N
O
O
Experimental Part 
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(2R)-2-Amino-2-phenylethyl-3-methylbutanoate (117) 
 
 
 
 
 
 
 
 
 
 
 
 
Procedure 3. Primary alcohol 111 (300 mg, 1.26 mmol, 1.0 eq), NEt3 (705 μl, 5.06 mmol, 4.0 
eq), isovaleroyl chloride (217 μl, 1.77 mmol, 1.4 eq), DMAP (cat), CH2Cl2 (10 ml), 6 hours. 
Flash chromatography (pentane/EtOAc 7/3) afforded 297 mg (0.92 mmol, 73 %, white solid) 
of the N-protected intermediate which was directly engaged in procedure 2b to provide 117 
(203 mg, quantitative) as a brown oil without any purification.  
 
 
1H-NMR (400 MHz, MeOD):  
7.51 (m, 5Harom); 4.67 (dd, 1H, 3J(H-C(2’’), H-C(1’’)) = 6.1, 3J(H-C(2’’), H-C(1’’)) = 4.8, H-
C(2’’)); 4.46 (m, 2H, 2H-C(1’’)); 2.32 (d, 2H, 3J(H-C(2), H-C(3)) = 7.1, H-C(2)); 2.10 (m, 
1H, 3J(H-C(3), H-C(2)) = 7.1, 3J(H-C(3), Me) = 6.6, H-C(3)); 0.97 (d, 6H, 3J(Me, H-C(3)) = 
6.6, 2xMe(iPr)). 
 
13C-NMR (101 MHz, MeOD):  
173.7 (s, C=O); 135.0 (s, 1Carom); 130.8 (d, 1J(C,H) = 162, 1Carom); 130.6 (d, 1J(C,H) = 161, 
2Carom); 128.4 (d, 1J(C,H) = 156, 2Carom); 65.4 (t, 1J(C,H) = 149, C(1’’)); 55.2 (d, 1J(C,H) = 
145, C(2’’)); 43.6 (t, 1J(C,H) =126, C(2)); 26.6 (d, 1J(C,H) =129, C(3)); 22.6 (q, 1J(C,H) 
=125, 2xMe(iPr)). 
 
MALDI-TOF: 222.30 (M+H)+. 
HRMS (C13H19NO2 + H): calc. 222.1494; found 222.1496. 
 
H2N
O
O
Experimental Part 
 
 
164 
Atom numbering according to the international union of pure and applied chemistry 
(IUPAC) names for compounds:  
 
((-)-123); (124); ((-)-125); ((-)-126); ((-)-129); ((+)-130); ((-)-131); ((-)-132); ((+)-133); ((+)-
134) and ((+)-137) 
 
 
N
H
NH X
OHO OH
R
X = O, NH
1
2'
1''1'''
2'''
3'''4'''
5'''
1'
 
 
 
Experimental Part 
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(2R)-2-({[(2R,3R,4S)-3,4-Dihydroxypyrrolidin-2-yl]methyl}amino)-2-phenylethyl acetate 
((-)-123) 
 
 
N
H
NH O
OHO OH
 
 
 
 
Procedure 1. Amine 112 (147 mg, 0.82 mmol, 1.5 eq), 87 (150 mg, 0.55 mmol, 1.0 eq), 
NaBH(OAc)3 (164 mg, 0.77 mmol, 1.4 eq), Cl(CH2)2Cl (6 ml). Flash chromatography 
(pentane/EtOAc 3/2) afforded 133 mg (0.31 mmol, 55 %, colourless oil) of the fully protected 
compound which was directly engaged in procedure 2b. Purification by flash 
chromatography (MeCN/NH4OH 7/1) afforded 123 (84 mg, 94 %) as a white foam.  
 
 
For atom numbering, see page 162. 
 
[α] 58925  = -5, [α] 43525  = -9, [α] 40525  = -10 (c = 0.50, MeOH). 
 
UV (MeCN): 260 (250), 228 (250), 213 (150). 
 
IR (film): 3015, 1680, 1435, 1210, 840, 760, 670 cm-1. 
 
1H-NMR (400 MHz, MeOD): 
7.51-7.36 (m, 4Harom); 7.31 (m, 1Harom); 4.24 (m, 1H, H-C(3’’’)); 4.19 (m, 1H, H-C(4’’’)); 
4.09 (m, 1H, H-C(2’)); 3.85 (m, 2H, 2H-C(1’)); 3.75 (m, 1H, 3J(H-C(2’’’), H-C(1’’)) = 9.0, 
H-C(2’’’)); 3.48 (dd, 1H, 3J(H-C(5’’’), H-C(4’’’)) = 3.9, 2Jgem = 12.9, H-C(5’’’)); 3.30 (m, 
1H, H-C(5’’’)); 3.24 (m, 2H, H-C(1’’)); 2.35 (s, 3H, H-C(2)). 
 
13C-NMR (101 MHz, MeOD):  
176.7 (s, C=O); 137.8 (s, 1Carom); 130.2 (d, 1J(C,H) = 161, 2Carom); 129.4 (d, 1J(C,H) = 161, 
1Carom); 128.1 (d, 1J(C,H) = 157, 2Carom); 75.2 (d, 1J(C,H) = 146, C(4’’’)); 70.0 (d, 1J(C,H) = 
153, C(3’’’)); 64.6 (d, 1J(C,H) =141, C(2’)); 63.6 (d, 1J(C,H) =149, C(2’’’)); 61.7 (t, 1J(C,H) 
=143, C(1’)); 51.3 (t, 1J(C,H) =145, C(5’’’)); 44.3 (t, 1J(C,H) =138, C(1’’)); 22.0 (q, 1J(C,H) 
=129, C(2)). 
 
MALDI-TOF: 295.51 (M+H)+. 
HRMS (C15H22N2O4 + H): calc. 295.1658; found 295.1660. 
 
Experimental Part 
 
 
166 
(2R)-2-({[(2R,3R,4S)-3,4-Dihydroxypyrrolidin-2-yl]methyl}amino)-2-phenylethyl 
propionate (124) 
 
N
H
NH O
OHO OH
 
 
 
Procedure 1. Amine 113 (149 mg, 0.77 mmol, 1.4 eq), 87 (150 mg, 0.55 mmol, 1.0 eq), 
NaBH(OAc)3 (164 mg, 0.77 mmol, 1.4 eq), Cl(CH2)2Cl (6 ml). Flash chromatography 
(pentane/EtOAc 4/1) afforded 103 mg (0.23 mmol, 42 %, brown oil) of the fully protected 
compound which was directly engaged in procedure 2b. Purification by flash 
chromatography (MeCN/NH4OH 7/1) afforded 124 (22 mg, 31 %) as a brown oil.  
 
 
For atom numbering, see page 162. 
 
1H-NMR (400 MHz, MeOD): 
7.44-7.37 (m, 4Harom); 7.32 (m, 1Harom); 4.26-4.23 (m, 3H, H-C(4’’’) and 2H-C(1’)); 3.99 (t, 
1H, 3J(H-C(2’), H-C(1’)) = 6.2, H-C(2’)); 3.94 (dd, 1H, 3J(H-C(3’’’), H-C(4’’’)) = 8.4, 3J(H-
C(3’’’), H-C(2’’’)) = 4.1, H-C(3’’’)); 3.45 (ddd ,1H, 3J(H-C(2’’’), H-C(3’’’)) = 4.1, 3J(H-
C(2’’’), H-C(1’’)) = 4.3, 3J(H-C(2’’’), H-C(1’’)) = 8.8, H-C(2’’’)); 3.42 (dd, 1H, 3J(H-C(5’’’), 
H-C(4’’’)) = 4.1, 2Jgem = 12.5, H-C(5’’’)); 3.22 (dd, 1H, 3J(H-C(5’’’), H-C(4’’’)) = 2.1, 2Jgem 
= 12.5, H-C(5’’’)); 2.92 (dd, 1H, 3J(H-C(1’’), H-C(2’’’)) = 4.3, 2Jgem = 13.2, H-C(1’’)); 2.71 
(dd, 1H, 3J(H-C(1’’), H-C(2’’’)) = 8.8, 2Jgem = 13.2, H-C(1’’)); 2.34 (q, 2H, 3J(H-C(2), H-
C(3)) = 7.6, H-C(2)); 1.09 (t, 3H, 3J(H-C(3), H-C(2)) = 7.6, H-C(3)). 
 
13C-NMR (101 MHz, MeOD):  
175.9 (s, C=O); 141.3 (s, 1Carom); 129.8 (d, 1J(C,H) = 160, 2Carom); 129.0 (d, 1J(C,H) = 161, 
1Carom); 128.6 (d, 1J(C,H) = 157, 2Carom); 74.9 (d, 1J(C,H) = 143, C(4’’’)); 71.2 (d, 1J(C,H) = 
148, C(3’’’)); 68.9 (t, 1J(C,H) =151, C(1’)); 63.3 (d, 1J(C,H) =138, C(2’)); 62.6 (d, 1J(C,H) 
=146, C(2’’’)); 50.7 (t, 1J(C,H) =145, C(5’’’)); 47.7 (t, 1J(C,H) =139, C(1’’)); 28.2 (t, 1J(C,H) 
=128, C(2)); 9.3 (q, 1J(C,H) =128, C(3)). 
 
MALDI-TOF: 309.45 (M+H)+  
HRMS (C16H24N2O4 + H): calc. 309.1814; found 309.1817. 
 
Experimental Part 
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1H-NMR spectrum of 123 
 
 
 
1H-NMR spectrum of 124 
 
 
 
Experimental Part 
 
 
168 
(2R)-2-({[(2R,3R,4S)-3,4-Dihydroxypyrrolidin-2-yl]methyl}amino)-2-phenylethyl 
butyrate ((-)-125) 
 
N
H
NH O
OHO OH
 
 
Procedure 1. Amine 114 (118 mg, 0.57 mmol, 1.0 eq), 87 (155 mg, 0.57 mmol, 1.0 eq), 
NaBH(OAc)3 (169 mg, 0.80 mmol, 1.4 eq), Cl(CH2)2Cl (6 ml). Flash chromatography 
(pentane/EtOAc 7/3) afforded 112 mg (0.24 mmol, 42 %, yellow oil) of the fully protected 
compound which was directly engaged in procedure 2b. Purification by flash 
chromatography (MeCN/NH4OH 8/1) afforded 125 (99 mg, 95 %) as a brown oil after 
lyophilisation.  
 
 
For atom numbering, see page 162. 
 
[α] 58925  = 0, [α] 25577  = -1, [α] 43525  = -3, [α] 40525  = -5 (c = 0.56, MeOH). 
 
UV (MeCN): 213 (4500). 
 
IR (film): 3410, 1680, 1455, 1205, 1140, 840, 800, 725 cm-1. 
 
1H-NMR (400 MHz, MeOD): 
7.44-7.39 (m, 4Harom); 7.33 (m, 1Harom); 4.26 (m, 3H, H-C(4’’’) and 2H-C(1’)); 4.07 (t, 1H, 
3J(H-C(2’), H-C(1’)) = 6.1, H-C(2’)); 3.98 (dd, 1H, 3J(H-C(3’’’), H-C(4’’’)) = 8.3, 3J(H-
C(3’’’), H-C(2’’’)) = 4.1, H-C(3’’’)); 3.52 (ddd ,1H, 3J(H-C(2’’’), H-C(3’’’)) = 4.1, 3J(H-
C(2’’’), H-C(1’’)) = 4.2, 3J(H-C(2’’’), H-C(1’’)) = 9.0, H-C(2’’’)); 3.47 (dd, 1H, 3J(H-C(5’’’), 
H-C(4’’’)) = 4.2, 2Jgem = 12.6, H-C(5’’’)); 3.27 (dd, 1H, 3J(H-C(5’’’), H-C(4’’’)) = 2.0, 2Jgem 
= 12.6, H-C(5’’’)); 2.97 (dd, 1H, 3J(H-C(1’’), H-C(2’’’)) = 4.2, 2Jgem = 13.3, H-C(1’’)); 2.84 
(dd, 1H, 3J(H-C(1’’), H-C(2’’’)) = 9.0, 2Jgem = 13.3, H-C(1’’)); 2.29 (t, 2H, 3J(H-C(2), H-
C(3)) = 7.4, H-C(2)); 1.58 (m, 2H, 3J(H-C(3), H-C(2)) = 7.4, 3J(H-C(3), H-C(4)) = 7.4, H-
C(3)); 0.89 (t, 3H, 3J(H-C(4), H-C(3)) = 7.4, H-C(4)). 
 
13C-NMR (101 MHz, MeOD):  
175.0 (s, C=O); 140.4 (s, 1Carom); 129.8 (d, 1J(C,H) = 160, 2Carom); 129.2 (d, 1J(C,H) = 160, 
1Carom); 128.7 (d, 1J(C,H) = 158, 2Carom); 74.7 (d, 1J(C,H) = 145, C(3’’’)); 70.9 (d, 1J(C,H) = 
153, C(4’’’)); 68.4 (t, 1J(C,H) =147, C(1’)); 63.2 (d, 1J(C,H) =137, C(2’)); 62.2 (d, 1J(C,H) 
=146, C(2’’’)); 50.7 (t, 1J(C,H) =149, C(5’’’)); 47.3 (t, 1J(C,H) =134, C(1’’)); 36.7 (t, 1J(C,H) 
=130, C(2)); 19.3 (t, 1J(C,H) =126, C(3)); 13.8 (q, 1J(C,H) =125, C(4)). 
 
 
MALDI-TOF: 323.40 (M+H)+. 
HRMS (C17H26N2O4 + H): calc. 323.1971; found 323.1972. 
Experimental Part 
 
 
169
(2R)-2-({[(2R,3R,4S)-3,4-Dihydroxypyrrolidin-2-yl]methyl}amino)-2-phenylethyl 
pentanoate ((-)-126) 
 
 
N
H
NH O
OHO OH
 
 
Procedure 1. Amine 115 (170 mg, 0.77 mmol, 1.4 eq), 87 (150 mg, 0.55 mmol, 1.0 eq), 
NaBH(OAc)3 (164 mg, 0.77 mmol, 1.4 eq), Cl(CH2)2Cl (7 ml). Flash chromatography 
(pentane/EtOAc 4/1) afforded 130 mg (0.27 mmol, 35 %, colourless oil) of the fully protected 
compound which was directly engaged in procedure 2b. Purification by flash 
chromatography (MeCN/NH4OH 6/1) afforded 126 (83 mg, 91 %) as a brown oil after 
lyophilisation.  
 
 
For atom numbering, see page 162. 
 
[α] 58925  = -3, [α] 25577  = -4, [α] 43525  = -11, [α] 40525  = -15 (c = 0.32, MeOH). 
 
UV (MeCN): 210 (5500). 
 
IR (film): 3020, 1670, 1455, 1215, 1140, 840, 800, 765 cm-1. 
 
1H-NMR (400 MHz, MeOD): 
7.36-7.30 (m, 5Harom); 4.33-4.12 (m, 3H, H-C(4’’’) and 2H-C(1’)); 4.02 (t, 1H, 3J(H-C(2’), H-
C(1’)) = 6.3, H-C(2’)); 3.95 (dd, 1H, 3J(H-C(3’’’), H-C(4’’’)) = 8.1, 3J(H-C(3’’’), H-C(2’’’)) 
= 4.0, H-C(3’’’)); 3.45 (m , 1H, H-C(2’’’)); 3.42 (dd, 1H, 3J(H-C(5’’’), H-C(4’’’)) = 4.1, 2Jgem 
= 12.6, H-C(5’’’)); 3.27 (dd, 1H, 3J(H-C(5’’’), H-C(4’’’)) = 2.1, 2Jgem = 12.6, H-C(5’’’)); 2.96 
(dd, 1H, 3J(H-C(1’’), H-C(2’’’)) = 4.3, 2Jgem = 13.3, H-C(1’’)); 2.72 (dd, 1H, 3J(H-C(1’’), H-
C(2’’’)) = 9.0, 2Jgem = 13.3, H-C(1’’)); 2.31 (t, 2H, 3J(H-C(2), H-C(3)) = 7.4, H-C(2)); 1.54 
(tt, 2H, 3J(H-C(3), H-C(2)) = 7.4, 3J(H-C(3), H-C(4)) = 7.4, H-C(3)); 1.29 (qt, 2H, 3J(H-C(4), 
H-C(3)) = 7.4, 3J(H-C(4), H-C(5)) = 7.4, H-C(4)); 0.89 (t, 3H, 3J(H-C(5), H-C(4)) = 7.4, H-
C(5)). 
 
13C-NMR (101 MHz, MeOD):  
174.9 (s, C=O); 130.1 (d, 1J(C,H) = 161, 2Carom); 129.8 (d, 1J(C,H) = 158, 1Carom); 129.0 (d, 
1J(C,H) = 161, 2Carom); 128.0 (s, 1Carom); 75.0 (d, 1J(C,H) = 145, C(3’’’)); 70.7 (d, 1J(C,H) = 
154, C(4’’’)); 67.3 (t, 1J(C,H) =148, C(1’)); 63.2 (d, 1J(C,H) =141, C(2’)); 61.0 (d, 1J(C,H) 
=148, C(2’’’)); 51.0 (t, 1J(C,H) =145, C(5’’’)); 47.2 (t, 1J(C,H) =138, C(1’’)); 34.5 (t, 1J(C,H) 
=128, C(2)); 27.9 (t, 1J(C,H) =127, C(3)); 23.1 (t, 1J(C,H) =127, C(4)); 14.0 (q, 1J(C,H) =124, 
C(5)). 
 
MALDI-TOF: 337.46 (M+H)+. 
HRMS (C18H28N2O4 + H): calc. 337.2127; found 337.2129. 
Experimental Part 
 
 
170 
1H-NMR spectrum of 125 
 
 
 
 
1H-NMR spectrum of 126 
 
Experimental Part 
 
 
171
(2R)-2-({[(2R,3R,4S)-3,4-Dihydroxypyrrolidin-2-yl]methyl}amino)-2-phenylethyl 2-
methylpropanoate ((+)-127) 
 
 
N
H
NH O
OHO OH
1 2
1'''
1''
2''
3
1'
1iv
2iv
3iv4iv
5iv
 
 
 
Procedure 1. Amine 116 (131 mg, 0.63 mmol, 1.0 eq), 87 (172 mg, 0.63 mmol, 1.0 eq), 
NaBH(OAc)3 (188 mg, 0.89 mmol, 1.4 eq), Cl(CH2)2Cl (7 ml). Flash chromatography 
(pentane/EtOAc 7/3) afforded 60 mg (0.13 mmol, 20 %, brown oil) of the fully protected 
compound which was directly engaged in procedure 2b. Purification by flash 
chromatography (MeCN/NH4OH 10/1) afforded 127 (39 mg, 94 %) as a brown oil.  
 
 
[α] 58925  = +11, [α] 25577  = +18, [α] 40525  = +25 (c = 0.26, MeOH). 
 
UV (MeCN): 209 (5500). 
 
IR (film): 3315, 2975, 1675, 1455, 1390, 1345, 1200, 1140, 840, 800, 760, 700 cm-1. 
 
1H-NMR (400 MHz, MeOD): 
7.46-7.37 (m, 4Harom); 7.35 (m, 1Harom); 4.31 (m, 2H, 2H-C(1’’)); 4.24 (ddd, 1H, 3J(H-C(4iv), 
H-C(5iv)) = 1.9, 3J(H-C(4iv), H-C(5iv)) = 4.1, 3J(H-C(4iv), H-C(3iv)) = 8.3 , H-C(4iv)); 4.11 (dd, 
1H, 3J(H-C(2’’), H-C(1’’)) = 5.8, 3J(H-C(2’’), H-C(1’’)) = 6.5, H-C(2’’)); 3.97 (dd, 1H, 3J(H-
C(3iv), H-C(2iv)) = 4.0, 3J(H-C(3iv), H-C(4iv)) = 8.3, H-C(3iv)); 3.52 (ddd, 1H, 3J(H-C(2iv), H-
C(3iv)) = 4.0, 3J(H-C(2iv), H-C(1’’’)) = 4.2, 3J(H-C(2iv), H-C(1’’’)) = 9.1, H-C(2iv)); 3.46 (dd, 
1H, 3J(H-C(5iv), H-C(4iv)) = 4.1, 2Jgem = 12.5, H-C(5iv)); 3.27 (dd, 1H, 3J(H-C(5iv), H-C(4iv)) 
= 1.9, 2Jgem = 12.5, H-C(5iv)); 3.00 (dd, 1H, 3J(H-C(1’’’), H-C(2iv)) = 4.2, 2Jgem = 13.3, H-
C(1’’’));; 2.87 (dd, 1H, 3J(H-C(1’’’), H-C(2iv)) = 9.1, 2Jgem = 13.3, H-C(1’’’)); 2.55 (qq, 1H, 
3J(H-C(2), H-C(3)) = 7.0, 3J(H-C(2), H-C(1’)) = 7.0, H-C(2)); 1.10 (d, 3H, 3J(H-C(3), H-
C(2)) = 7.0, H-C(3)); 1.09 (d, 3H, 3J(H-C(1’), H-C(2)) = 7.0, H-C(1’)). 
 
13C-NMR (101 MHz, MeOD):  
178.3 (s, C=O); 140.1 (s, 1Carom); 129.9 (d, 1J(C,H) = 160, 2Carom); 129.3 (d, 1J(C,H) = 161, 
1Carom); 128.8 (d, 1J(C,H) = 158, 2Carom); 74.8 (d, 1J(C,H) = 145, C(3iv)); 70.9 (d, 1J(C,H) = 
153, C(4iv)); 68.1 (t, 1J(C,H) =147, C(1’’)); 63.2 (d, 1J(C,H) =135, C(2’’)); 61.9 (d, 1J(C,H) 
=139, C(2iv)); 50.8 (t, 1J(C,H) =145, C(5iv)); 47.4 (t, 1J(C,H) =137, C(1’’’)); 35.0 (d, 1J(C,H) 
=130, C(2)); 19.2 (q, 1J(C,H) =128, C(3)); 19.1 (q, 1J(C,H) =128, C(1')). 
 
MALDI-TOF: 323.44 (M+H)+. 
HRMS (C17H26N2O4 + H): calc. 323.1971; found 323.1973. 
 
Experimental Part 
 
 
172 
(2R)-2-({[(2R,3R,4S)-3,4-Dihydroxypyrrolidin-2-yl]methyl}amino)-2-phenylethyl 3-
methylbutanoate ((+)-128) 
 
 
N
H
NH O
OHO OH
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1'''
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1iv
2iv
3iv4iv
5iv
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Procedure 1. Amine 117 (170 mg, 0.77 mmol, 1.4 eq), 87 (150 mg, 0.55 mmol, 1.0 eq), 
NaBH(OAc)3 (164 mg, 0.77 mmol, 1.4 eq), Cl(CH2)2Cl (6 ml). Flash chromatography 
(pentane/EtOAc 7/3) afforded 95 mg (0.20 mmol, 36 %, colourless oil) of the fully protected 
compound which was directly engaged in procedure 2b. Purification by flash 
chromatography (MeCN/NH4OH 12/1) afforded 128 (66 mg, 99 %) as a brown oil.  
 
 
[α] 58925  = +6, [α] 25577  = +9, [α] 43525  = +11, [α] 40525  = +12 (c = 0.57, MeOH). 
 
UV (MeCN): 260 (500), 229 (500), 208 (250). 
 
IR (film): 2960, 1680, 1455, 1200, 835, 800, 720, 700 cm-1. 
 
1H-NMR (400 MHz, MeOD): 
7.41 (m, 4Harom); 7.33 (m, 1Harom); 4.30-4.23 (m, 3H, 2H-C(1’’) and H-C(4iv)); 3.99 (t, 1H, 
3J(H-C(2’’), H-C(1’’)) = 6.2, H-C(2’’)); 3.94 (dd, 1H, 3J(H-C(3iv), H-C(4iv)) = 8.0, 3J(H-
C(3iv), H-C(2iv)) = 4.0, H-C(3iv)); 3.46-3.39 (dd and m, 2H, 3J(H-C(5iv), H-C(4iv)) = 4.0, 2Jgem 
= 12.4, H-C(5iv) and H-C(2iv)); 3.23 (dd, 1H, 3J(H-C(5iv), H-C(4iv)) = 2.1, 2Jgem = 12.4, H-
C(5iv)); 2.91 (dd, 1H, 3J(H-C(1’’’), H-C(2iv)) = 4.3, 2Jgem = 13.2, H-C(1’’’)); 2.70 (dd, 1H, 
3J(H-C(1’’’), H-C(2iv)) = 9.0, 2Jgem = 13.2, H-C(1’’’)); 2.18 (d, 2H, 3J(H-C(2), H-C(3)) = 7.1, 
H-C(2)); 2.00 (m, 1H, H-C(3)); 0.90 (d, 6H, 3J= 6.7, 3H-C(4) and 3H-C(1’)). 
 
13C-NMR (101 MHz, MeOD):  
174.4 (s, C=O); 141.3 (s, 1Carom); 129.7 (d, 1J(C,H) = 160, 2Carom); 128.9 (d, 1J(C,H) = 160, 
1Carom); 128.6 (d, 1J(C,H) = 153, 2Carom); 74.7 (d, 1J(C,H) = 145, C(3iv)); 71.1 (d, 1J(C,H) = 
153, C(4iv)); 68.7 (t, 1J(C,H) =148, C(1’’)); 63.2 (d, 1J(C,H) =137, C(2’’)); 62.6 (d, 1J(C,H) 
=147, C(2iv)); 50.7 (t, 1J(C,H) =145, C(5iv)); 47.5 (t, 1J(C,H) =135, C(1’’’)); 44.0 (t, 1J(C,H) 
=124, C(2)); 26.7 (d, 1J(C,H) =126, C(3)); 22.6 (q, 1J(C,H) =125, 2xMe(iPr)). 
 
MALDI-TOF: 337.60 (M+H)+. 
HRMS (C18H28N2O4 + H): calc. 337.2127; found 337.2129. 
 
Experimental Part 
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1H-NMR spectrum of 127 
 
 
1H-NMR spectrum of 128 
 
Experimental Part 
 
 
174 
(2R)-2-({[(2R,3S,4S)-3,4-Dihydroxypyrrolidin-2-yl]methyl}amino)-2-phenylethyl 2-
fluorobenzoate ((-)-129) 
 
N
OHHO
H
NH O
F
O
 
 
Procedure 1. Amine 118 (191 mg, 0.74 mmol, 1.0 eq), 87 (200 mg, 0.74 mmol, 1.0 eq), 
NaBH(OAc)3 (219 mg, 1.03 mmol, 1.4 eq), Cl(CH2)2Cl (7.5 ml). Flash chromatography 
(pentane/EtOAc 4/1) afforded 186 mg (0.36 mmol, 49 %, pale yellow solid) of the fully 
protected compound which was directly engaged in procedure 2b. Purification by flash 
chromatography (CH2Cl2/MeOH 8/1) afforded 129 (100 mg, 74 %) as a brown solid after 
lyophilisation.  
 
 
For atom numbering, see page 162. 
 
[α] 58925  = -5, [α] 43525  = -9, [α] 40525  = -14 (c = 0.45, MeOH). 
 
UV (MeCN): 225 (6000), 210 (5000), 206 (5500), 203 (6000).  
 
IR (film): 3390, 2360, 2340, 1680, 1455, 1210, 1140, 845, 800, 755, 725 cm-1. 
 
1H-NMR (400 MHz, MeOD):  
7.88 (m, 1Harom); 7.66-7.62 (m, 1Harom); 7.48-7.22 (m, 7Harom); 4.50 (m, 2H, 2H-C(1’); 4.22 
(ddd, 1H, 3J(H-C(4’’’), H-C(5’’’)) = 2.1, 3J(H-C(4’’’), H-C(5’’’)) = 4.2, 3J(H-C(4’’’), H-
C(3’’’)) = 4.0, H-C(4’’’)); 4.14 (t, 1H, 3J(H-C(2’), H-C(1’)) = 6.1, H-C(2’)); 3.96 (dd, 1H, 
3J(H-C(3’’’), H-C(4’’’)) = 4.0, 3J(H-C(3’’’), H-C(2’’’)) = 8.0, H-C(3’’’)); 3.48-3.38 (m and 
dd, 2H, 3J(H-C(5’’’), H-C(4’’’)) = 4.2, 2Jgem = 12.5, H-C(5’’’) and H-C(2’’’)); 3.23 (dd, 1H, 
3J(H-C(5’’’), H-C(4’’’)) = 2.1, 2Jgem = 12.5, H-C(5’’’)); 2.98 (dd, 1H, 3J(H-C(1’’), H-C(2’’’)) 
= 4.2, 2Jgem = 13.3, H-C(1’’)); 2.75 (dd, 1H, 3J(H-C(1’’), H-C(2’’’)) = 8.75, 2Jgem = 13.3, H-
C(1’’)). 
 
13C-NMR (101 MHz, MeOD):  
 167.1 (s, OC(O)Ar); 141.2 (s, 1Carom); 136.3, 136.2, 133.1, 129.8, 129.1, 128.6, 125.4, 118.1, 
117.9 (11Carom); 74.8 (d, 1J(C,H) = 146, C(3’’’)); 71.2 (d, 1J(C,H) = 158, C(4’’’)); 69.7 (t, 
1J(C,H) = 150, C(1’)); 63.3 (d, 1J(C,H) = 134, C(2’)); 62.7 (d, 1J(C,H) = 145, C(2’’’)); 50.8 (t, 
1J(C,H) = 147, C(5’’’)); 47.5 (t, 1J(C,H) = 138, C(1’’)). 
 
MALDI-TOF: 374.99 (M+H)+. 
HRMS (C20H23FN2O4 + H): calc. 375.1720; found 375.1716. 
Purity measured by HPLC (C18, C4 columns): 100%, 100%.  
M.P: 99-103°C. 
Experimental Part 
 
 
175
(2R)-2-({[(2R,3S,4S)-3,4-Dihydroxypyrrolidin-2-yl]methyl}amino)-2-phenylethyl 4-
fluorobenzoate ((+)-130) 
 
N
H
NH O
O
F
HO OH
 
 
Procedure 1. Amine 119 (185 mg, 0.72 mmol, 1.0 eq), 87 (194 mg, 0.72 mmol, 1.0 eq), 
NaBH(OAc)3 (212 mg, 1.0 mmol, 1.4 eq), Cl(CH2)2Cl (10 ml). Flash chromatography 
(pentane/EtOAc 7/3) afforded 218 mg (0.42 mmol, 60 %, white foam) of the fully protected 
compound which was directly engaged in procedure 2b. Purification by flash 
chromatography (CH2Cl2/MeOH 9/1) afforded 130 (131 mg, 83 %) as a pale yellow solid 
after lyophilisation.  
 
For atom numbering, see page 162. 
 
[α] 58925  = +2 (c = 0.37, MeOH). 
 
UV (MeCN): 230 (7500), 205 (7000), 196 (2500). 
 
IR (film): 3415, 2360, 2340, 1680, 1280, 1205, 1140, 845, 800, 725, 670 cm-1. 
 
1H-NMR (400 MHz, MeOD):  
8.05 (m, 2Harom); 7.48-7.33 (m, 5Harom); 7.22 (m, 2Harom); 4.53 (dd, 1H, 3J(H-C(1’), H-C(2’)) 
= 6.8, 2Jgem = 10.9, H-C(1’)); 4.45 (dd, 1H, 3J(H-C(1’), H-C(2’)) = 5.6, 2Jgem = 10.9, H-C(1’)); 
4.22 (m, 1H, H-C(4’’’)); 4.15 (dd, 1H, 3J(H-C(2’), H-C(1’)) = 5.6, 3J(H-C(2’), H-C(1’)) = 6.8, 
H-C(2’)); 3.95 (dd, 1H, 3J(H-C(3’’’), H-C(4’’’)) = 4.0, 3J(H-C(3’’’), H-C(2’’’)) = 8.1, H-
C(3’’’)); 3.48 (ddd, 1H, 3J(H-C(2’’’), H-C(1’’)) = 4.2, 3J(H-C(2’’’), H-C(3’’’)) = 8.1, 3J(H-
C(2’’’), H-C(1’’)) = 9.0, H-C(2’’’)); 3.41 (dd, 1H, 3J(H-C(5’’’), H-C(4’’’)) = 4.1, 2Jgem = 
12.5, H-C(5’’’)); 3.24 (dd, 1H, 3J(H-C(5’’’), H-C(4’’’)) = 2.1, 2Jgem = 12.5, H-C(5’’’)); 2.99 
(dd, 1H, 3J(H-C(1’’), H-C(2’’’)) = 4.2, 2Jgem = 13.2, H-C(1’’)); 2.74 (dd, 1H, 3J(H-C(1’’), H-
C(2’’’)) = 9.0, 2Jgem = 13.2, H-C(1’’)).  
 
13C-NMR (101 MHz, MeOD):  
173.0 (s, OC(O)Ar); 141.3 (s, 1Carom); 133.4 (d, 1J(C,H) = 166, 2Carom); 130.0 (s, 1Carom); 
129.8 (d, 1J(C,H) = 160, 2Carom); 129.4 (s, 1Carom); 129.0 (d, 1J(C,H) = 161, 1Carom); 128.6 (d, 
1J(C,H) = 162, 2Carom); 116.7 (d, 1J(C,H) = 166, 2Carom); 74.8 (d, 1J(C,H) = 145, C(3’’’)); 
71.1 (d, 1J(C,H) = 148, C(4’’’)); 69.5 (t, 1J(C,H) = 147, C(1’)); 63.4 (d, 1J(C,H) = 136, C(2’)); 
62.7 (d, 1J(C,H) = 146, C(2’’’)); 50.7 (t, 1J(C,H) = 145 , C(5’’’)); 47.6 (t, 1J(C,H) = 132, 
C(1’’)). 
 
MALDI-TOF: 375.08 (M+H)+. 
HRMS (C20H23FN2O4 + H): calc. 375.1720; found 375.1716. 
Purity measured by HPLC (C18, C8 columns): 100%, 100%.  
M.P: 85-90°C. 
Experimental Part 
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1H-NMR spectrum of 129 
 
 
1H-NMR spectrum of 130 
 
Experimental Part 
 
 
177
(2R)-2-({[(2R,3S,4S)-3,4-Dihydroxypyrrolidin-2-yl]methyl}amino)-2-phenylethyl 3-
bromobenzoate ((-)-131) 
 
N
H
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O
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HO OH
 
 
Procedure 1. Amine 120 (180 mg, 0.56 mmol, 1.0 eq), 87 (152 mg, 0.56 mmol, 1.0 eq), 
NaBH(OAc)3 (166 mg, 0.78 mmol, 1.4 eq), Cl(CH2)2Cl (8 ml). Flash chromatography 
(pentane/EtOAc 4/1) afforded 118 mg (0.21 mmol, 37 %, colourless oil) of the fully protected 
compound which was directly engaged in procedure 2b. Purification by flash 
chromatography (CH2Cl2/MeOH 9/1) afforded 131 (70 mg, 78 %) as a pale yellow solid after 
lyophilisation.  
 
For atom numbering, see page 162. 
 
[α] 58925  = 0, [α] 43525  = -16, [α] 40525  = -28 (c = 0.21, MeOH). 
 
UV (MeCN): 229 (2500), 205 (7000), 194 (1000). 
 
IR (film): 3415, 2350, 1435, 1205, 1140, 840, 800, 725, 670 cm-1. 
 
1H-NMR (400 MHz, MeOD):  
8.11 (s, 1Harom); 7.97 (d, 3J = 7.8, 1Harom); 7.80 (d, 3J = 7.9, 1Harom); 7.49-7.41 (m, 5Harom); 
7.35 (d, 3J = 7.1, 1Harom); 4.55 (dd, 1H, 3J(H-C(1’), H-C(2’)) = 6.8, 2Jgem = 11.0, H-C(1’)); 
4.46 (dd, 1H, 3J(H-C(1’), H-C(2’)) = 5.6, 2Jgem = 11.0, H-C(1’)); 4.21 (ddd, 1H, 3J(H-C(4’’’), 
H-C(5’’’)) = 2.1, 3J(H-C(4’’’), H-C(5’’’)) = 4.0, 3J(H-C(4’’’), H-C(3’’’)) = 4.1, H-C(4’’’)); 
4.14 (dd, 1H, 3J(H-C(2’), H-C(1’)) = 5.6, 3J(H-C(2’), H-C(1’)) = 6.8, H-C(2’)); 3.95 (dd, 1H, 
3J(H-C(3’’’), H-C(4’’’)) = 4.1, 3J(H-C(3’’’), H-C(2’’’)) = 8.0, H-C(3’’’)); 3.48-3.42 (ddd, 1H, 
3J(H-C(2’’’), H-C(1’’)) = 4.2, 3J(H-C(2’’’), H-C(3’’’)) = 8.0, 3J(H-C(2’’’), H-C(1’’)) = 8.9, 
H-C(2’’’)); 3.41-3.34 (m, 1H, H-C(5’’’)); 3.22 (dd, 1H, 3J(H-C(5’’’), H-C(4’’’)) = 2.1, 2Jgem = 
12.5, H-C(5’’’)); 2.98 (dd, 1H, 3J(H-C(1’’), H-C(2’’’)) = 4.2, 2Jgem = 13.2, H-C(1’’)); 2.72 
(dd, 1H, 3J(H-C(1’’), H-C(2’’’)) = 8.9, 2Jgem = 13.2, H-C(1’’)).  
 
13C-NMR (101 MHz, MeOD):  
163.3 (s, OC(O)Ar); 144.4, 141.3, 138.8 (3s, 3Carom); 137.2, 133.4, 131.5, 129.9, 129.3, 129.1, 
128.6 (7d, 9Carom); 74.9 (d, 1J(C,H) = 142, C(3’’’)); 71.2 (d, 1J(C,H) = 153, C(4’’’)); 69.7 (t, 
1J(C,H) = 145, C(1’)); 63.4 (d, 1J(C,H) = 137, C(2’)); 62.7 (d, 1J(C,H) = 150, C(2’’’)); 50.8 (t, 
C(5)); 47.7 (t, C(1’’)). 
 
MALDI-TOF: 437.07 (M+2)+, 435.07 (M)+. 
HRMS (C20H23BrN2O4 + H): calc. 435.0919; found 435.0919. 
Purity measured by HPLC (C18, C8 columns): 94%, 100%.  
M.P: 114-117°C. 
Experimental Part 
 
 
178 
(2R)-2-({[(2R,3R,4S)-3,4-Dihydroxypyrrolidin-2-yl]methyl}amino)-2-phenylethyl 4-
bromobenzoate ((-)-132) 
 
N
H
NH O
O
Br
HO OH
 
 
Procedure 1. Amine 121 (132 mg, 0.41 mmol, 1.0 eq), 87 (112 mg, 0.41 mmol, 1.0 eq), 
NaBH(OAc)3 (122 mg, 0.58 mmol, 1.4 eq), Cl(CH2)2Cl (5 ml). Flash chromatography 
(pentane/EtOAc 7/3) afforded 109 mg (0.25 mmol, 61 %, white foam) of the fully protected 
compound which was directly engaged in procedure 2b. Purification by flash 
chromatography (CH2Cl2/MeOH 9/1) afforded 132 (109 mg, quantitative) as a brown solid 
after lyophilisation.  
 
For atom numbering, see page 162. 
 
[α] 58925  = -3, [α] 43525  = -7, (c = 0.35, MeOH). 
 
UV (MeCN): 244 (12500), 211 (8000), 203 (7000), 193 (1500), 189 (1500).  
 
IR (film): 3265, 2355, 2340, 1680, 1455, 1205, 1140, 1010, 845, 800, 755, 725, 670 cm-1. 
 
1H-NMR (400 MHz, MeOD):  
7.90 (d, 3J = 8.5 , 2Harom); 7.68 (d, 3J = 8.5 , 2Harom); 7.48-7.40 (m, 4Harom); 7.34 (dd, 3J = 7.2, 
1Harom); 4.54 (dd, 1H, 3J(H-C(1’), H-C(2’)) = 6.8, 2Jgem = 11.0, H-C(1’)); 4.46 (dd, 1H, 3J(H-
C(1’), H-C(2’)) = 5.6, 2Jgem = 11.0, H-C(1’)); 4.22 (m, 1H, H-C(4’’’)); 4.14 (dd, 1H, 3J(H-
C(2’), H-C(1’)) = 5.6, 3J(H-C(2’), H-C(1’)) = 6.8, H-C(2’)); 3.95 (dd, 1H, 3J(H-C(3’’’), H-
C(4’’’)) = 8.0, 3J(H-C(3’’’), H-C(2’’’)) = 4.0, H-C(3’’’)); 3.46 (ddd, 1H, 3J(H-C(2’’’), H-
C(1’’)) = 4.2, 3J(H-C(2’’’), H-C(3’’’)) = 4.0, 3J(H-C(2’’’), H-C(1’’)) = 8.9, H-C(2’’’)); 3.41 
(m, 1H, H-C(5’’’)); 3.23 (dd, 1H, 3J(H-C(5’’’), H-C(4’’’)) = 1.9, 2Jgem = 12.5, H-C(5’’’)); 
2.99 (dd, 1H, 3J(H-C(1’’), H-C(2’’’)) = 4.2, 2Jgem = 13.2, H-C(1’’)); 2.73 (dd, 1H, 3J(H-
C(1’’), H-C(2’’’)) = 8.9, 2Jgem = 13.2, H-C(1’’)). 
 
13C-NMR (101 MHz, MeOD):  
170.0 (s, OC(O)Ar); 141.3 (s, 1Carom); 133.0 (d, 1J(C,H) = 169, 2Carom); 132.3 (d, 1J(C,H) = 
164, 2Carom); 130.3 (s, 1Carom); 129.9 (d, 1J(C,H) = 160, 2Carom); 129.2 (s, 1Carom); 129.1 (d, 
1J(C,H) = 161, 1Carom); 128.6 (d, 1J(C,H) = 157, 2Carom); 74.8 (d, 1J(C,H) = 145, C(3’’’)); 
71.1 (d, 1J(C,H) = 153, C(4’’’)); 69.6 (t, 1J(C,H) = 147, C(1’)); 63.4 (d, 1J(C,H) = 136, C(2’)); 
62.7 (d, 1J(C,H) = 146, C(2’’’)); 50.7 (t, 1J(C,H) = 148, C(5’’’)); 47.7 (t, 1J(C,H) = 137, 
C(1’’)). 
 
MALDI-TOF: 437.18 (M+2)+, 435.18 (M)+. 
MALDI-HRMS (C20H23BrN2O4 + H): calc. 435.0919; found 435.0919.  
Purity measured by HPLC (C18, C8 columns): 100%, 100%.  
M.P: 125-130°C. 
Experimental Part 
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1H-NMR spectrum of 131 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H-NMR spectrum of 132 
 
 
Experimental Part 
 
 
180 
(2R)-2-({[(2R,3R,4S)-3,4-Dihydroxypyrrolidin-2-yl]methyl}amino)-2-phenylethyl 4-
trifluoromethylbenzoate ((+)-133) 
 
 
N
H
NH O
O
CF3
HO OH
 
 
Procedure 1. Amine 122 (200 mg, 0.65 mmol, 1.0 eq), 87 (175 mg, 0.65 mmol, 1.0 eq), 
NaBH(OAc)3 (192 mg, 0.91 mmol, 1.4 eq), Cl(CH2)2Cl (9 ml). Flash chromatography 
(pentane/EtOAc 7/3) afforded 206 mg (0.36 mmol, 56 %, white foam) of the fully protected 
compound which was directly engaged in procedure 2b. Purification by flash 
chromatography (CH2Cl2/MeOH 9/1) afforded 133 (155 mg, quantitative) as a pale yellow 
solid after lyophilisation.  
 
For atom numbering, see page 162. 
 
[α] 58925  = 0, [α] 25577  = +3, [α] 43525  = +9, [α] 40525  = +11 (c = 0.39, MeOH). 
 
UV (MeCN): 230 (1000), 206 (500), 187 (500). 
 
IR (film): 3395, 1675, 1280, 1205, 1140, 760 cm-1. 
 
1H-NMR (400 MHz, MeOD):  
8.17 (d, 3J = 8.0, 2Harom); 7.82 (d, 3J = 8.0, 2Harom); 7.49-7.40 (m, 4Harom); 7.34 (m, 1Harom); 
4.58 (dd, 1H, 3J(H-C(1’), H-C(2’)) = 6.7, 2Jgem = 11.0, H-C(1’)); 4.50 (dd, 1H, 3J(H-C(1’), H-
C(2’)) = 5.7, 2Jgem = 11.0, H-C(1’)); 4.23 (m, 1H, H-C(4’’’)); 4.17 (dd, 1H, 3J(H-C(2’), H-
C(1’)) = 5.7, 3J(H-C(2’), H-C(1’)) = 6.7, H-C(2’)); 3.97 (dd, 1H, 3J(H-C(3’’’), H-C(4’’’)) = 
8.1, 3J(H-C(3’’’), H-C(2’’’)) = 4.0, H-C(3’’’)); 3.48 (ddd, 1H, 3J(H-C(2’’’), H-C(1’’)) = 4.2, 
3J(H-C(2’’’), H-C(3’’’)) = 4.0, 3J(H-C(2’’’), H-C(1’’)) = 9.0, H-C(2’’’)); 3.42 (dd, 1H, 3J(H-
C(5’’’), H-C(4’’’)) = 4.2, 2Jgem = 12.5, H-C(5’’’)); 3.23 (dd, 1H, 3J(H-C(5’’’), H-C(4’’’)) = 
1.7, 2Jgem = 12.5, H-C(5’’’)); 3.00 (dd, 1H, 3J(H-C(1’’), H-C(2’’’)) = 4.2, 2Jgem = 13.2, H-
C(1’’)); 2.74 (dd, 1H, 3J(H-C(1’’), H-C(2’’’)) = 9.0, 2Jgem = 13.2, H-C(1’’)).  
 
13C-NMR (101 MHz, MeOD):  
163.6 (s, OC(O)Ar); 141.2 (s, 1Carom); 131.3 (d, 1J(C,H) = 166, 2Carom); 129.9 (d, 1J(C,H) = 
159, 2Carom); 129.5 (s, 1Carom); 129.1 (d, 1J(C,H) = 161, 1Carom); 128.7 (s, 1Carom); 128.9 (d, 
1J(C,H) = 159, 2Carom); 126.6 (d, 1J(C,H) = 163, 2Carom); 74.8 (d, 1J(C,H) = 138, C(3’’’)); 
71.1 (d, 1J(C,H) = 153, C(4’’’)); 69.9 (t, 1J(C,H) = 150, C(1’)); 63.3 (d, 1J(C,H) = 139, C(2’)); 
62.7 (d, 1J(C,H) = 144, C(2’’’)); 50.7 (t, 1J(C,H) = 149 , C(5’’’)); 47.6 (t, 1J(C,H) = 138, 
C(1’’)). 
 
MALDI-TOF: 425.60 (M+H)+. 
HRMS (C21H23F3N2O4 + H): calc. 425.1688; found 425.1684. 
M.P: 125-130°C. 
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1H-NMR spectrum of 133 
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182 
(2S)-2-({[(2R,3R,4S)-3,4-Dihydroxypyrrolidin-2-yl]methyl}amino)-2-phenylethyl 4-
bromobenzoate ((+)-134) 
 
 
N
H
NH O
O
Br
HO OH
 
 
 
To a solution of L-(+)-α-phenylglycinol (5.0 g, 36.5 mmol, 1.0 eq) in anhydrous CH2Cl2 
(350 ml) were added pyridine (5.9 ml, 73 mmol, 2.0 eq), (Boc)2O (8.0 g, 36.5 mmol, 1.0 eq) 
and a catalytic amount of DMAP. The mixture was stirred at 0°C for 2 hours and poured into 
a saturated aqueous solution of NaHCO3 (150 ml). The aqueous layer was extracted with 
CH2Cl2 (80 ml, 2 times). The combined organic extracts were dried over MgSO4 and 
evaporated in vacuo. The residue was purified by flash chromatography (CH2Cl2/MeOH 20/1) 
to afford the corresponding carbamate (7.3 g, 86 %) as a pale yellow solid. 
 
To a solution of this carbamate (300 mg, 1.26 mmol, 1.0 eq) in anhydrous CH2Cl2 (4 ml), at 
0°C, were added NEt3 (705 μl, 5.06 mmol, 4.0 eq), 4-bromobenzoyl chloride (388 mg, 1.77 
mmol, 1.4 eq) and a catalytic amount of DMAP. The mixture was allowed to warm up to 
25°C and was stirred for 3 hours. The resulting mixture was poured into a saturated aqueous 
solution of NaHCO3 (10 ml). The aqueous layer was extracted with EtOAc (15 ml, 3 times). 
The combined organic extracts were washed with a saturated aqueous solution of NH4Cl (5 
ml) and brine (5 ml), dried over MgSO4, filtered and concentrated in vacuo. Purification by 
flash chromatography on silica gel (Pentane/EtOAc 7/3) afforded 505  mg of a pale yellow 
solid (1.20 mmol, 95 %) which was directly engaged in Procedure 2b to afford the 
corresponding amine (365 mg, 95 %) as a white solid. 
 
Procedure 1. Amine (365 mg, 0.11 mmol, 1.1 eq), 87 (281 mg, 1.04 mmol, 1.0 eq), 
NaBH(OAc)3 (309 mg, 1.46 mmol, 1.4 eq), Cl(CH2)2Cl (11 ml). Flash chromatography 
(pentane/EtOAc 7/3) afforded 420 mg (0.72 mmol, 70 %, white foam) of the fully protected 
compound which was directly engaged in procedure 2b. Purification by flash 
chromatography (CH2Cl2/MeOH 9/1) afforded 134 (234 mg, 74 %) as a pale yellow solid. 
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For atom numbering, see page 162. 
 
[α] 58925  = +25, [α] 25577  = +26, [α] 43525  = +50, [α] 40525  = +58 (c = 0.38, MeOH). 
 
IR (film): 3270, 2345, 1680, 1460, 1210, 1145, 1010, 840, 795, 755, 725 cm-1. 
 
1H-NMR (400 MHz, MeOD):  
7.94 (d, 3J = 8.4 , 2Harom); 7.64 (d, 3J = 8.6 , 2Harom); 7.55 (d, 3J = 7.0 , 2Harom); 7.43 (m, 
3Harom); 4.68 (m, 2H, 2H-C(1’)); 4.60 (m, 1H, H-C(2’)); 4.20 (m, 1H, H-C(4’’’)); 3.97 (dd, 
1H, 3J(H-C(3’’’), H-C(2’’’)) = 3.8, 3J(H-C(3’’’), H-C(4’’’)) = 9.2, H-C(3’’’)); 3.78 (ddd, 1H, 
3J(H-C(2’’’), H-C(1’’)) = 3.2, 3J(H-C(2’’’), H-C(3’’’)) = 3.8, 3J(H-C(2’’’), H-C(1’’)) = 8.9, 
H-C(2’’’)); 3.44 (dd, 1H, 3J(H-C(5’’’), H-C(4’’’)) = 3.8, 2Jgem = 12.7, H-C(5’’’)); 3.28 (m, 
2H, H-C(5’’’), H-C(1’’)); 3.14 (dd, 1H, 3J(H-C(1’’), H-C(2’’’)) = 8.9, 2Jgem = 13.2, H-C(1’’)). 
 
13C-NMR (101 MHz, MeOD):  
166.7 (s, OC(O)Ar); 135.7 (s, 1Carom); 133.0 (d, 1J(C,H) = 168, 2Carom); 132.5 (d, 1J(C,H) = 
166, 2Carom); 130.5 (s, 1Carom); 130.4 (d, 1J(C,H) = 161, 2Carom); 129.8 (s, 1Carom); 129.4 (d, 
1J(C,H) = 160, 1Carom); 129.3 (d, 1J(C,H) = 158, 2Carom); 75.2 (d, 1J(C,H) = 140, C(3’’’)); 
70.3 (d, 1J(C,H) = 154, C(4’’’)); 67.2 (t, 1J(C,H) = 151, C(1’)); 63.0 (d, 1J(C,H) = 143, C(2’)); 
59.4 (d, 1J(C,H) = 145, C(2’’’)); 51.4 (t, 1J(C,H) = 147, C(5’’’)); 46.9 (t, 1J(C,H) = 141, 
C(1’’)). 
 
MALDI-TOF: 437.57 (M+2)+, 435.57 (M)+. 
MALDI-HRMS (C20H23BrN2O4 + H): calc. 435.0919; found 435.0920.  
M.P: 70-75°C. 
 
1H-NMR spectrum of 134 
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Tert-butyl ((1R)-2-amino-1-phenylethyl) carbamate ((-)-135) 
 
 
Boc
NH NH2
 
 
To a solution of primary alcohol 111 (5.7 g, 24 mmol, 1.0 eq) in anhydrous CH2Cl2 (200 ml) 
was added NEt3 (8.4 ml, 60 mmol, 2.5 eq) and methanesulfonyl chloride (2.3 ml, 28.8 mmol, 
1.2 eq). The mixture was stirred at 0°C for 3 hours and then poured into water (200 ml). The 
aqueous layer was extracted with CH2Cl2 (100 ml, 3 times). The combined organic extracts 
were washed with a saturated aqueous solution of NH4Cl (150 ml) dried over MgSO4 and 
evaporated in vacuo. 
 
To a solution of crude (2R)-2-[(Tert-butoxycarbonyl)amino]-2-phenylethyl methanesulfonate 
(7.3 g, 23.2 mmol, 1.0 eq) in anhydrous THF (200 ml) was added sodium azide (7.6 g, 116 
mmol, 5.0 eq). The mixture was warmed at 60°C and stirred for 14 hours. The mixture was 
poured into a saturated aqueous solution of NaHCO3 (60 ml) and the aqueous layer was 
extracted with EtOAc (40 ml, 3 times). The combined organic extracts were dried over 
MgSO4 and evaporated in vacuo. The yellow residue was purified by flash chromatography 
(pentane/EtOAc 8/1) to afford a white solid (4.4g, 71 %, 2 steps). 
 
A solution of Tert-butyl [(1R)-2-azido-1-phenylethyl]carbamate (2.0 g, 7,7 mmol, 1.0 eq) in 
anhydrous methanol (50 ml) was stirred vigorously at 25°C under one atmosphere of 
hydrogen in the presence of a catalytic amount of 10 % Pd(OH)2/C for 7 hours. The mixture 
was filtered through a pad of Celite and concentrated in vacuo. The yellow residue was 
purified by flash chromatography (CH2Cl2/MeOH 9/1) to afford amine 135 (1.1 g, 60 %) as a 
waxy solid.  
 
 
[α] 58925  = -50, [α] 43525  = -109, [α] 40525  = -137 (c = 0.43, CH2Cl2). 
 
UV (MeCN): 216 (3000). 
 
IR (film): 3580, 3430, 3055, 2980, 2530, 1705, 1495, 1455, 1390, 1265, 1170, 825 cm-1. 
 
1H-NMR (400 MHz, CDCl3):  
7.34-7.23 (m, 5Harom); 4.67 (m, 1H, H-C(1)); 2.98 (m, 2H, H-C(2)); 2.22 (s, 2H, NH2); 1.41 
(s, 9H, Me3C). 
 
13C-NMR (101 MHz, CDCl3):  
155.6 (s, NC(O)O); 140.5 (s, 1Carom); 128.6 (d, 1J(C,H) = 160, 2Carom); 127.3 (d, 1J(C,H) = 
161, 1Carom); 126.3 (d, 1J(C,H) = 157, 2Carom); 79.5 (s, OCMe3); 56.3 (d, 1J(C,H) = 144, 
C(1)); 46.8 (t, 1J(C,H) = 137, C(2)); 28.3 (q, 1J(C,H) = 127, Me3C). 
 
MALDI-TOF: 275.42 (M+K)+, 259.45 (M+Na)+, 237.52 (M+H)+. 
HRMS (C13H20N2O2 + H): calc. 237.1603; found 237.1604. 
Experimental Part 
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N-((2R)-2-Amino-2-phenylethyl)-3-bromobenzamide ((-)-136) 
 
 
 
 
 
 
 
 
 
 
 
To a solution of amine 135 (100 mg, 0.42 mmol, 1.0 eq) in anhydrous CH2Cl2 (4 ml) at 0°C 
were added NEt3 (236 μl, 1.69 mmol, 4.0 eq), 3-bromobenzoyl chloride (111 μl, 0.85 mmol, 
1.2 eq) and a catalytic amount of DMAP. The mixture was allowed to warm up to 25°C and 
was stirred for 2 hours. The resulting mixture was poured into a saturated aqueous solution of 
NaHCO3 (10 ml). The aqueous layer was extracted with EtOAc (5 ml, 3 times). The 
combined organic extracts were washed with a saturated aqueous solution of NH4Cl (5 ml) 
and brine (5 ml), dried over MgSO4, filtered and concentrated in vacuo. Purification by flash 
chromatography on silica gel (CH2Cl2/MeOH 9/1) afforded 180  mg of a yellow solid (0.40 
mmol, 95 %) which was directly engaged in Procedure 2b to afford 136 (140 mg, 
quantitative) as a pale yellow solid. 
 
 
[α] 58925  = -30, [α] 25577  = -42, [α] 43525  = -78, [α] 40525  = -85 (c = 0.2, CH2Cl2). 
 
1H-NMR (400 MHz, CDCl3):  
7.70-7.48 (m, 3Harom); 7.28 (m, 6Harom); 4.58 (dd, 1H, H-C(2’)); 3.93 (dd, 1H, H-C(1’)); 3.70 
(dd, 1H, H-C(1’)). 
 
13C-NMR (101 MHz, CDCl3):  
168.9 (s, NC(O)Ar); 135.9 (s, 1Carom); 135.5 (s, 1Carom); 134.2, 133.3, 132.6, 129.5, 128.1, 
126.6, 125.5 (7d, 9Carom); 122.8 (s, 1Carom); 55.9 (d, 1J(C,H) = 147, C(2’)); 43.9 (t, 1J(C,H) = 
143, C(1’)). 
 
MALDI-TOF: 321.14 (M+2)+, 319.13 (M)+. 
HRMS (C15H15BrN2O + H): calc. 319.0446; found 319.0453. 
 
H2N
NH
O
Br
Experimental Part 
 
 
186 
N-[(2R)-2-({[(2R,3R,4S)-3,4-Dihydroxypyrrolidin-2-yl]methyl}amino)-2-phenylethyl]-3-
bromobenzamide ((+)-137) 
 
 
N
H
NH NH
O
Br
HO OH
 
 
 
Procedure 1. Amine 136 (100 mg, 0.31 mmol, 1.0 eq), 87 (85 mg, 0.31 mmol, 1.0 eq), 
NaBH(OAc)3 (93 mg, 0.44 mmol, 1.4 eq), Cl(CH2)2Cl (5 ml). Flash chromatography 
(pentane/EtOAc 3/7) afforded 135 mg (0.23 mmol, 75 %, yellow oil) of the fully protected 
compound which was directly engaged in procedure 2b. Purification by flash 
chromatography (CH2Cl2/MeOH 9/1) afforded 137 (101 mg, 99 %) as a pale yellow solid 
after lyophilisation.  
 
 
For atom numbering, see page 162. 
 
[α] 58925  = +5, [α] 43525  = +15, [α] 40525  = +16 (c = 0.31, MeOH). 
 
UV (MeCN): 260 (1500), 213 (8500), 187 (1000). 
 
IR (film): 3615, 3580, 3425, 3055, 2360, 1675, 1465, 1265, 1190, 1140, 845, 815, 730 cm-1. 
 
1H-NMR (400 MHz, MeOD):  
7.93 (s, 1Harom); 7.72 (dd, 3J = 8.0, 3J = 15.2 , 2Harom); 7.41-7.31 (m, 6Harom); 4.25 (m, 1H, H-
C(4’’’)); 3.99 (m, 2H, H-C(2’), H-C(3’’’)); 3.67 (dd, 1H, 3J(H-C(1’), H-C(2’)) = 7.1, 2Jgem = 
13.5, H-C(1’)); 3.59 (dd, 1H, 3J(H-C(1’), H-C(2’)) = 7.1, 2Jgem = 13.5, H-C(1’)); 3.51-3.43 
(m, 2H, H-C(2’’’), H-C(5’’’)); 3.28 (dd, 1H, 3J(H-C(5’’’), H-C(4’’’)) = 2.1, 2Jgem = 12.5, H-
C(5’’’)); 2.96 (dd, 1H, 3J(H-C(1’’), H-C(2’’’)) = 4.1, 2Jgem = 13.2, H-C(1’’)); 2.73 (dd, 1H, 
3J(H-C(1’’), H-C(2’’’)) = 9.1, 2Jgem = 13.2, H-C(1’’)).  
 
13C-NMR (101 MHz, MeOD):  
169.0 (s, NC(O)Ar); 142.4 (s, 1Carom); 137.7 (s, 1Carom); 135.6, 131.4, 129.8, 128.9, 128.4, 
127.1 (6d, 9Carom); 123.5 (s, 1Carom); 74.7 (d, 1J(C,H) = 145, C(3’’’)); 71.1 (d, 1J(C,H) = 148, 
C(4’’’)); 64.1 (d, 1J(C,H) = 135, C(2’)); 62.7 (d, 1J(C,H) = 147, C(2’’’)); 50.6 (t, 1J(C,H) = 
146, C(1’)); 47.4 (t, 1J(C,H) = 132 , C(1’’)); 46.8 (t, 1J(C,H) = 144, C(5’’’)). 
 
MALDI-TOF: 436.24 (M+2)+, 434.23 (M)+. 
MALDI-HRMS (C20H25BrN3O3 + H): calc. 434.1080, found 434.1078. 
Purity measured by HPLC (C18, C8 columns): 100%, 100%.  
 
M.P: 162-164°C. 
Experimental Part 
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1H-NMR spectrum of 137 
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(2R)-2-({[(2R,3R,4R)-3,4-Dihydroxy-5-oxopyrrolidin-2-yl]methyl}amino)-2- phenylethyl 
4-bromobenzoate ((+)-138) 
 
 
N
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5'''
1''
 
 
 
Procedure 1. Amine 121 (115 mg, 0.36 mmol, 1.0 eq), aldehyde 79 (102 mg, 0.36 mmol, 1.0 
eq), NaBH(OAc)3 (107 mg, 0.50 mmol, 1.4 eq), Cl(CH2)2Cl (4 ml). Flash chromatography 
(pentane/AcOEt 7/3) afforded 70 mg (0.12 mmol, 33 %, 2 steps, brown oil) of the fully 
protected compound which was directly engaged in procedure 2b. Purification by flash 
chromatography (MeCN/NH4OH 9/1) afforded 138 (34 mg, 78 %) as a brown oil.  
 
 
[α] 58925  = 3, [α] 25577  = 5, [α] 43525  = 10, [α] 40525  = 11 (c = 0.50, MeOH). 
 
IR (film): 3395, 1695, 1590, 1450, 1275, 1200, 1135, 1110, 845, 755, 700 cm-1. 
 
1H-NMR (400 MHz, MeOD):  
7.91 (d, 3J=8.6, 2Harom); 7.68 (d, 3J=8.6, 2Harom); 7.50-7.35 (m, 5Harom); 4.53 (m, 2H, 2H-
C(1)); 4.26-4.23 (m and d, 2H, 3J(H-C(4’’’), H-C(3’’’)) = 5.4, H-C(2’) and H-C(4’’’)); 4.24 
(dd, 1H, 3J(H-C(3’’’), H-C(2’’’)) = 1.6, 3J(H-C(3’’’), H-C(4’’’)) = 5.4, H-C(3’’’)); 3.58 (m, 
1H, H-C(2’’’)); 2.76 (m, 2H, 2H-C(1’’)). 
 
13C-NMR (101 MHz, MeOD):  
177.9 (s, C(5’’’)); 166.9 (s, OC(O)Ar); 133.0 (d, 1J(C,H) = 167, 2Carom); 132.3 (d, 1J(C,H) = 
164, 2Carom); 132.2 (s, 1Carom); 130.2 (s, 1Carom); 130.0 (d, 1J(C,H) = 160, 2Carom); 129.5 (d, 
1J(C,H) = 161, 1Carom); 129.3 (s, 1Carom); 128.9 (d, 1J(C,H) = 157, 2Carom); 72.3 (d, 1J(C,H) = 
153, C(3’’’)); 71.2 (d, 1J(C,H) = 145, C(4’’’)); 68.8 (t, 1J(C,H) = 147, C(1’)); 63.2 (d, 1J(C,H) 
= 137, C(2’)); 60.8 (d, 1J(C,H) = 142, C(2’’’)); 50.3 (t, 1J(C,H) = 137, C(1’’)). 
 
ESI-MS: 451.29 (M+2)+, 449.31 (M)+. 
HRMS (C20H21BrN2O5 + H): calc. 449.0712; found 449.0713.  
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(2R)-2-({[(2R,3R,4R)-3,4-Dihydroxy-1-methyl-5-oxopyrrolidin-2-yl]methyl}amino)-2-
phenylethyl 4-bromobenzoate ((-)-139) 
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Procedure 1. Amine 121 (160 mg, 0.50 mmol, 1.0 eq), aldehyde 85 (100 mg, 0.50 mmol, 1.0 
eq), NaBH(OAc)3 (148 mg, 0.70 mmol, 1.4 eq), Cl(CH2)2Cl (5 ml). Flash chromatography 
(CH2Cl2/MeOH 97/3) afforded 226 mg (0.45 mmol, 89 %, 2 steps) of the fully protected 
compound which was directly engaged in procedure 2b. Purification by flash 
chromatography (MeCN/NH4OH 15/1) afforded 139 (88 mg, 42 %) as a white foam.  
 
 
[α] 58925  = -11 (c = 0.38, MeOH). 
 
IR (film): 3290, 2930, 1715, 1590, 1545, 1450, 1400, 1270, 1120, 1110, 845, 755, 695 cm-1. 
 
1H-NMR (400 MHz, MeOD):  
7.89 (d, 3J=8.5, 2Harom); 7.66 (d, 3J=8.5, 2Harom); 7.44-7.31 (m, 5Harom); 4.48 (dd, 1H, 3J(H-
C(1’), H-C(2’)) = 7.5, 2Jgem = 11.2, H-C(1’)); 4.42 (dd, 1H, 3J(H-C(1’), H-C(2’)) = 5.4, 2Jgem 
= 11.2, H-C(1’)); 4.40 (d, 1H, , 3J(H-C(4’’’), H-C(3’’’)) = 5.4, H-C(4’’’)); 4.25 (d, 1H, , 3J(H-
C(3’’’), H-C(4’’’)) = 5.4, H-C(3’’’)); 4.13 (dd, 1H, , 3J(H-C(2’), H-C(1’)) = 5.4, 3J(H-C(2’), 
H-C(1’)) = 7.5, H-C(2’)); 3.41 (dd, 1H, 3J(H-C(2’’’), H-C(1’’)) = 3.4, 3J(H-C(2’’’), H-C(1’’)) 
= 6.1, H-C(2’’’)); 2.84 (dd, 1H, 3J(H-C(1’’), H-C(2’’’)) = 3.4, 2Jgem = 12.9, H-C(1’’)); 2.71 (s, 
3H, Me-N);. 2.65 (dd, 1H, 3J(H-C(1’’), H-C(2’’’)) = 6.1, 2Jgem = 12.9, H-C(1’’)). 
 
13C-NMR (101 MHz, MeOD):  
175.4 (s, C(5’’’)); 167.0 (s, OC(O)Ar); 133.0 (d, 1J(C,H) = 166, 2Carom); 132.3 (d, 1J(C,H) = 
163, 2Carom); 130.3 (s, 1Carom); 129.8 (d, 1J(C,H) = 160, 2Carom); 129.5 (s, 1Carom); 129.2 (s, 
1Carom); 129.1 (d, 1J(C,H) = 161, 1Carom); 128.8 (d, 1J(C,H) = 158, 2Carom); 71.6 (d, 1J(C,H) = 
145, C(4’’’)); 71.0 (d, 1J(C,H) = 154, C(3’’’)); 69.4 (t, 1J(C,H) = 149, C(1’)); 68.0 (d, 1J(C,H) 
= 145, C(2’)); 63.3 (d, 1J(C,H) = 135, C(2’’’)); 46.6 (t, 1J(C,H) = 135, C(1’’)); 28.8 (q, 
1J(C,H) = 138, Me-N). 
 
ESI-MS: 465.30 (M+2)+; 463.30 (M)+. 
HRMS (C21H23BrN2O5 + H): calc. 463.0869; found 463.0872. 
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1H-NMR spectrum of 138 
 
 
 
1H-NMR spectrum of 139 
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1995 - 2001  Diplôme en Biologie (eq. Master in Biology), UNIL 
• Certificate in cellular and molecular biology 
• Certificate in pharmacology and toxicology 
• Certificate in pharmaceutical sciences (I and II) 
1991 - 1995  Scientific Matura, Gymnasium CESSOUEST, Nyon (CH) 
PROFESSIONAL ACTIVITES: 
2003 -     EPFL, Lausanne (CH):  
• Synthesis of organic compounds and their evaluation on cancer cells 
• Supervision of advanced practical work and diploma projects 
• Exercises and corrections of exams in organic chemistry (1st year) 
2005 (4 months)   University McGill, Montreal (Canada), Department of Chemistry: 
• Programmation and Docking Studies on Unix Software (sgi) 
2003 (8 months)  NOVARTIS, Basel (CH), Department of Research and Development: 
• Physicochemistry profiling, laboratory robotics and data analysis 
2002 (1 month) Hôpital Cantonal Fribourg (CH), Pharmacy:  
• Development and validation of two systems of steril tests 
• Control analyses and preparation of medicine 
2001 (1-2months)  Collège du Château d’Aubonne (CH): 
• Teaching 
1999 (2 months)  Ares SERONO, Aubonne (CH), Department of metrology: 
• Development of statistic calculations 
1995 - 1998 (4x 2months) Ares SERONO, Aubonne (CH), Department of Quality Control: 
• Various Quality Control analyses 
• Biochemistry, Immunology and Microbiology assays 
PRIZES AND DISTINCTIONS: 
• Prize Metler Toledo for the Best oral presentation in Medicinal Chemistry, Fall Meeting of the Swiss 
Chemical Society (SCS), 2005  
• Grant of Excellence for the first year of PhD, EPFL, 2004 
• Prize of Faculty of Sciences for results obtained during the Licence ès Science en Chimie, UNIL, 2002 
 
